id	drug_S	action	cyp	drug_T	ic_class	atc5_S	atc5_T	atc4_S	atc4_T	atc3_S	atc3_T	NThR	ProD	ade	thf	patient	atc4_S_code	atc3_S_code	atc4_T_code	atc3_T_code
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			1401	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			2224	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			2582	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			3585	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			4163	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			4188	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			4529	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			4894	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			5866	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			5932	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			5968	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			5998	C01BD	C01B	N02BE	N02B
80	amiodarone	enhances	1A2	acetaminophen		C01BD01	N02BE01	Antiarrhythmics, class III (C01BD)	Anilides (N02BE)	Antiarrhythmics, class i and iii (C01B)	Other analgesics and antipyretics (N02B)	0	0			7093	C01BD	C01B	N02BE	N02B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	689	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1212	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2408	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2751	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3239	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4333	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4517	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5265	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5454	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5998	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7104	C01BD	C01B	N05BA	N05B
83	amiodarone	enhances	3A457	alprazolam		C01BD01	N05BA12	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7686	C01BD	C01B	N05BA	N05B
86	amiodarone	enhances	1A2,2C9,2D6,3A457	amitriptyline	D	C01BD01	N06AA09	Antiarrhythmics, class III (C01BD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01BD	C01B	N06AA	N06A
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	154	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	203	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	645	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	732	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	752	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	929	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1060	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1066	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1143	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1195	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2046	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2075	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2154	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2435	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2582	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2844	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2849	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3015	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3029	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3304	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3459	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4078	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4126	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4165	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4247	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4267	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4478	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4550	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4675	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4676	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4677	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4743	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4891	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5380	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5454	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5492	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5934	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5998	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6014	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6221	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6258	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7443	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7519	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7596	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7606	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7625	C01BD	C01B	C08CA	C08C
87	amiodarone	enhances	3A457	amlodipine	B	C01BD01	C08CA01	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7670	C01BD	C01B	C08CA	C08C
88	amiodarone	enhances	3A457	apixaban		C01BD01	B01AF02	Antiarrhythmics, class III (C01BD)	Direct factor Xa inhibitors (B01AF)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0				5549	C01BD	C01B	B01AF	B01A
88	amiodarone	enhances	3A457	apixaban		C01BD01	B01AF02	Antiarrhythmics, class III (C01BD)	Direct factor Xa inhibitors (B01AF)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0				7402	C01BD	C01B	B01AF	B01A
88	amiodarone	enhances	3A457	apixaban		C01BD01	B01AF02	Antiarrhythmics, class III (C01BD)	Direct factor Xa inhibitors (B01AF)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0				7642	C01BD	C01B	B01AF	B01A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		27	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		65	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		101	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		185	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		273	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		356	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		584	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		645	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		663	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		849	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		896	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1195	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1369	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1598	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2048	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2107	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2192	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2262	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2435	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2511	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2650	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2669	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2921	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3029	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3030	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3463	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3529	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3539	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3585	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3642	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3662	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3699	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3727	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3805	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4065	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4075	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4078	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4126	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4172	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4202	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4304	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4470	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4471	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4474	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4503	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4566	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4657	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4715	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4801	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4891	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5156	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5205	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5345	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5395	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5492	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5527	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5632	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5700	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5858	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5866	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5934	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5998	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6189	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6229	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7092	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7094	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7160	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7217	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7402	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7443	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7484	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7612	C01BD	C01B	C10AA	C10A
94	amiodarone	enhances	3A457	atorvastatin	B	C01BD01	C10AA05	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7625	C01BD	C01B	C10AA	C10A
104	amiodarone	enhances	2C9	capecitabine		C01BD01	L01BC06	Antiarrhythmics, class III (C01BD)	Pyrimidine analogues (L01BC)	Antiarrhythmics, class i and iii (C01B)	Antimetabolites (L01B)	1					C01BD	C01B	L01BC	L01B
105	amiodarone	enhances	3A457	carbamazepine		C01BD01	N03AF01	Antiarrhythmics, class III (C01BD)	Carboxamide derivatives (N03AF)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	752	C01BD	C01B	N03AF	N03A
105	amiodarone	enhances	3A457	carbamazepine		C01BD01	N03AF01	Antiarrhythmics, class III (C01BD)	Carboxamide derivatives (N03AF)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2003	C01BD	C01B	N03AF	N03A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	39	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	101	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	368	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	663	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1155	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1180	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1195	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1261	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1371	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1459	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1571	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2003	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2048	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2300	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2389	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2390	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2392	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2417	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2541	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2743	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3036	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3367	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3727	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3930	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4124	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4172	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4202	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4331	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4471	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4474	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4715	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4801	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4944	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5632	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5932	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6014	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6138	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6229	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7402	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7492	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7612	C01BD	C01B	C07AG	C07A
107	amiodarone	enhances	2D6	carvedilol	C	C01BD01	C07AG02	Antiarrhythmics, class III (C01BD)	Alpha and beta blocking agents (C07AG)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7642	C01BD	C01B	C07AG	C07A
108	amiodarone	enhances	2C9	celecoxib		C01BD01	M01AH01	Antiarrhythmics, class III (C01BD)	Coxibs (M01AH)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			4247	C01BD	C01B	M01AH	M01A
111	amiodarone	enhances	2D6,3A457	chlorpheniramine		C01BD01	R06AB04	Antiarrhythmics, class III (C01BD)	Substituted alkylamines (R06AB)	Antiarrhythmics, class i and iii (C01B)	Antihistamines for systemic use (R06A)	0	0				C01BD	C01B	R06AB	R06A
112	amiodarone	enhances	2D6	chlorpromazine	D	C01BD01	N05AA01	Antiarrhythmics, class III (C01BD)	Phenothiazines with aliphatic side-chain (N05AA)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				4265	C01BD	C01B	N05AA	N05A
113	amiodarone	enhances	3A457	cilostazol	D	C01BD01	B01AC23	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0					C01BD	C01B	B01AC	B01A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			727	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			1407	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			2186	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			2362	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			3304	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			3483	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			3968	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			6014	C01BD	C01B	N06AB	N06A
115	amiodarone	enhances	2D6,3A457	citalopram	D	C01BD01	N06AB04	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0			7721	C01BD	C01B	N06AB	N06A
116	amiodarone	enhances	3A457	clarithromycin	D	C01BD01	J01FA09	Antiarrhythmics, class III (C01BD)	Macrolides (J01FA)	Antiarrhythmics, class i and iii (C01B)	Macrolides, lincosamides and streptogramins (J01F)	0	0				C01BD	C01B	J01FA	J01F
117	amiodarone	enhances	3A457	clobazam		C01BD01	N05BA09	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0					C01BD	C01B	N05BA	N05B
118	amiodarone	enhances	1A2,2D6	clomipramine	D	C01BD01	N06AA04	Antiarrhythmics, class III (C01BD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01BD	C01B	N06AA	N06A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				925	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				992	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				1060	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				1129	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				1553	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				2145	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				2300	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				2435	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				2921	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				3526	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				4233	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				4502	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				4676	C01BD	C01B	C02AC	C02A
119	amiodarone	enhances	2D6	clonidine		C01BD01	C02AC01	Antiarrhythmics, class III (C01BD)	Imidazoline receptor agonists (C02AC)	Antiarrhythmics, class i and iii (C01B)	Antiadrenergic agents, centrally acting (C02A)	1				5380	C01BD	C01B	C02AC	C02A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	39	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	65	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	101	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	121	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	184	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	714	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	896	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1564	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1598	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2390	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3367	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3463	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3483	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3504	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4128	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4874	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5154	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5205	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5266	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5423	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5628	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5890	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6091	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6189	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7145	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7172	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7217	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7377	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7484	C01BD	C01B	B01AC	B01A
120	amiodarone	enhances	2C9,3A457	clopidogrel	B	C01BD01	B01AC04	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7721	C01BD	C01B	B01AC	B01A
121	amiodarone	enhances	1A2	clozapine	D	C01BD01	N05AH02	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		C01BD	C01B	N05AH	N05A
125	amiodarone	enhances	3A457	colchicine	B	C01BD01	M04AC01	Antiarrhythmics, class III (C01BD)	Preparations with no effect on uric acid metabolism (M04AC)	Antiarrhythmics, class i and iii (C01B)	Antigout preparations (M04A)	0					C01BD	C01B	M04AC	M04A
129	amiodarone	enhances	3A457	cyclosporine	C	C01BD01	L04AD01	Antiarrhythmics, class III (C01BD)	Calcineurin inhibitors (L04AD)	Antiarrhythmics, class i and iii (C01B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		7145	C01BD	C01B	L04AD	L04A
134	amiodarone	enhances	3A457	deflazacort		C01BD01	H02AB13	Antiarrhythmics, class III (C01BD)	Glucocorticoids (H02AB)	Antiarrhythmics, class i and iii (C01B)	Corticosteroids for systemic use, plain (H02A)	0					C01BD	C01B	H02AB	H02A
136	amiodarone	enhances	3A457	dexamethasone		C01BD01	H02AB02	Antiarrhythmics, class III (C01BD)	Glucocorticoids (H02AB)	Antiarrhythmics, class i and iii (C01B)	Corticosteroids for systemic use, plain (H02A)	0				2390	C01BD	C01B	H02AB	H02A
136	amiodarone	enhances	3A457	dexamethasone		C01BD01	H02AB02	Antiarrhythmics, class III (C01BD)	Glucocorticoids (H02AB)	Antiarrhythmics, class i and iii (C01B)	Corticosteroids for systemic use, plain (H02A)	0				2716	C01BD	C01B	H02AB	H02A
138	amiodarone	enhances	2D6,3A457	dextromethorphan		C01BD01	R05DA09	Antiarrhythmics, class III (C01BD)	Opium alkaloids and derivatives (R05DA)	Antiarrhythmics, class i and iii (C01B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				C01BD	C01B	R05DA	R05D
139	amiodarone	enhances	3A457	diazepam		C01BD01	N05BA01	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class i and iii (C01B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5628	C01BD	C01B	N05BA	N05B
140	amiodarone	enhances	2C9	diclofenac		C01BD01	M01AB05	Antiarrhythmics, class III (C01BD)	Acetic acid derivatives and related substances (M01AB)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			4676	C01BD	C01B	M01AB	M01A
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		732	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1369	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2071	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2278	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2389	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2695	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3504	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4233	C01BD	C01B	C08DB	C08D
141	amiodarone	enhances	3A457	diltiazem	D	C01BD01	C08DB01	Antiarrhythmics, class III (C01BD)	Benzothiazepine derivatives (C08DB)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4503	C01BD	C01B	C08DB	C08D
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				821	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				2071	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				3304	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				3606	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				3685	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				3932	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				3968	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				4165	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				4517	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				4751	C01BD	C01B	A03FA	A03F
144	amiodarone	enhances	3A457	domperidone	D	C01BD01	A03FA03	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				6247	C01BD	C01B	A03FA	A03F
145	amiodarone	enhances	2D6	donepezil	D	C01BD01	N06DA02	Antiarrhythmics, class III (C01BD)	Anticholinesterases (N06DA)	Antiarrhythmics, class i and iii (C01B)	Anti-dementia drugs (N06D)	0				2053	C01BD	C01B	N06DA	N06D
147	amiodarone	enhances	1A2,2D6	duloxetine		C01BD01	N06AX21	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4321	C01BD	C01B	N06AX	N06A
147	amiodarone	enhances	1A2,2D6	duloxetine		C01BD01	N06AX21	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4566	C01BD	C01B	N06AX	N06A
147	amiodarone	enhances	1A2,2D6	duloxetine		C01BD01	N06AX21	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5968	C01BD	C01B	N06AX	N06A
153	amiodarone	enhances	3A457	eplerenone	C	C01BD01	C03DA04	Antiarrhythmics, class III (C01BD)	Aldosterone antagonists (C03DA)	Antiarrhythmics, class i and iii (C01B)	Potassium-sparing agents (C03D)	0					C01BD	C01B	C03DA	C03D
156	amiodarone	enhances	2D6,3A457	escitalopram	D	C01BD01	N06AB10	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0				2224	C01BD	C01B	N06AB	N06A
156	amiodarone	enhances	2D6,3A457	escitalopram	D	C01BD01	N06AB10	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0				5379	C01BD	C01B	N06AB	N06A
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				154	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				356	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				645	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				664	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				759	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				896	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1212	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1459	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1571	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2115	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2417	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2872	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3727	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3778	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4172	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4300	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4517	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4683	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4770	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5205	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5306	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5345	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5549	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5628	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5698	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5934	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7092	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7176	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7300	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7612	C01BD	C01B	A02BC	A02B
157	amiodarone	enhances	3A457	esomeprazole		C01BD01	A02BC05	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7686	C01BD	C01B	A02BC	A02B
159	amiodarone	enhances	3A457	felodipine	D	C01BD01	C08CA02	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	907	C01BD	C01B	C08CA	C08C
159	amiodarone	enhances	3A457	felodipine	D	C01BD01	C08CA02	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1564	C01BD	C01B	C08CA	C08C
162	amiodarone	enhances	2D6	flecainide	D	C01BD01	C01BC04	Antiarrhythmics, class III (C01BD)	Antiarrhythmics, class Ic (C01BC)	Antiarrhythmics, class i and iii (C01B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			C01BD	C01B	C01BC	C01B
164	amiodarone	enhances	2C9,2D6	fluoxetine	D	C01BD01	N06AB03	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01BD	C01B	N06AB	N06A
165	amiodarone	enhances	2C9	fluvastatin	B	C01BD01	C10AA04	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			C01BD	C01B	C10AA	C10A
166	amiodarone	enhances	1A2,2D6	fluvoxamine		C01BD01	N06AB08	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01BD	C01B	N06AB	N06A
167	amiodarone	enhances	2C9	glimepiride	B	C01BD01	A10BB12	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0				1401	C01BD	C01B	A10BB	A10B
167	amiodarone	enhances	2C9	glimepiride	B	C01BD01	A10BB12	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0				2650	C01BD	C01B	A10BB	A10B
167	amiodarone	enhances	2C9	glimepiride	B	C01BD01	A10BB12	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0				2712	C01BD	C01B	A10BB	A10B
167	amiodarone	enhances	2C9	glimepiride	B	C01BD01	A10BB12	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0				4801	C01BD	C01B	A10BB	A10B
168	amiodarone	enhances	2C9	glipizide	B	C01BD01	A10BB07	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		121	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		1066	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		1598	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		2237	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		2390	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3092	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3743	C01BD	C01B	A10BB	A10B
169	amiodarone	enhances	2C9	glyburide	B	C01BD01	A10BB01	Antiarrhythmics, class III (C01BD)	Sulfonylureas (A10BB)	Antiarrhythmics, class i and iii (C01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4128	C01BD	C01B	A10BB	A10B
170	amiodarone	enhances	1A2,2D6,3A457	haloperidol	D	C01BD01	N05AD01	Antiarrhythmics, class III (C01BD)	Butyrophenone derivatives (N05AD)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5423	C01BD	C01B	N05AD	N05A
170	amiodarone	enhances	1A2,2D6,3A457	haloperidol	D	C01BD01	N05AD01	Antiarrhythmics, class III (C01BD)	Butyrophenone derivatives (N05AD)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5866	C01BD	C01B	N05AD	N05A
171	amiodarone	enhances	3A457	hydrocortisone	D	C01BD01	H02AB09	Antiarrhythmics, class III (C01BD)	Glucocorticoids (H02AB)	Antiarrhythmics, class i and iii (C01B)	Corticosteroids for systemic use, plain (H02A)	0					C01BD	C01B	H02AB	H02A
173	amiodarone	enhances	2C9	ibuprofen	B	C01BD01	M01AE01	Antiarrhythmics, class III (C01BD)	Propionic acid derivatives (M01AE)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			933	C01BD	C01B	M01AE	M01A
175	amiodarone	enhances	3A457	imatinib	B	C01BD01	L01XE01	Antiarrhythmics, class III (C01BD)	 (L01XE)	Antiarrhythmics, class i and iii (C01B)	Other antineoplastic agents (L01X)	0	0				C01BD	C01B	L01XE	L01X
176	amiodarone	enhances	1A2,2D6	imipramine	D	C01BD01	N06AA02	Antiarrhythmics, class III (C01BD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01BD	C01B	N06AA	N06A
177	amiodarone	enhances	3A457	indacaterol		C01BD01	R03AC18	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				4751	C01BD	C01B	R03AC	R03A
177	amiodarone	enhances	3A457	indacaterol		C01BD01	R03AC18	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				7160	C01BD	C01B	R03AC	R03A
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	142	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	154	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	663	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	689	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	1035	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	1369	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	1598	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	2048	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	2115	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	2712	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	2744	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3060	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3186	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3465	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3868	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3895	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3922	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3949	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4304	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4390	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4517	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4535	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4556	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4595	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4715	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	5932	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	7116	C01BD	C01B	C09CA	C09C
179	amiodarone	enhances	2C9	irbesartan	B	C01BD01	C09CA04	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	7139	C01BD	C01B	C09CA	C09C
182	amiodarone	enhances	3A457	ivabradine		C01BD01	C01EB17	Antiarrhythmics, class III (C01BD)	Other cardiac preparations (C01EB)	Antiarrhythmics, class i and iii (C01B)	Other cardiac preparations (C01E)	0				849	C01BD	C01B	C01EB	C01E
182	amiodarone	enhances	3A457	ivabradine		C01BD01	C01EB17	Antiarrhythmics, class III (C01BD)	Other cardiac preparations (C01EB)	Antiarrhythmics, class i and iii (C01B)	Other cardiac preparations (C01E)	0				4894	C01BD	C01B	C01EB	C01E
182	amiodarone	enhances	3A457	ivabradine		C01BD01	C01EB17	Antiarrhythmics, class III (C01BD)	Other cardiac preparations (C01EB)	Antiarrhythmics, class i and iii (C01B)	Other cardiac preparations (C01E)	0				5574	C01BD	C01B	C01EB	C01E
182	amiodarone	enhances	3A457	ivabradine		C01BD01	C01EB17	Antiarrhythmics, class III (C01BD)	Other cardiac preparations (C01EB)	Antiarrhythmics, class i and iii (C01B)	Other cardiac preparations (C01E)	0				7092	C01BD	C01B	C01EB	C01E
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			27	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			185	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			584	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			630	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			671	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			689	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			714	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			732	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			841	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1029	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1071	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1195	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1261	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1383	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1553	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2003	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2046	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2071	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2107	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2119	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2145	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2190	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2278	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2293	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2300	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2441	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2582	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2716	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2754	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2762	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2846	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2876	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3015	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3019	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3036	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3239	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3459	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3465	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3685	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3713	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3727	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3805	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3930	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4035	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4040	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4041	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4065	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4097	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4163	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4233	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4265	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4267	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4321	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4471	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4516	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4595	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4618	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4637	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4697	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4743	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4891	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5112	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5154	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5265	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5423	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5434	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5454	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5492	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5520	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5527	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5574	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5655	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5700	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5968	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6014	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6091	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6138	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7139	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7145	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7606	C01BD	C01B	A02BC	A02B
184	amiodarone	enhances	3A457	lansoprazole		C01BD01	A02BC03	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7741	C01BD	C01B	A02BC	A02B
186	amiodarone	enhances	3A457	lercanidipine	C	C01BD01	C08CA13	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1527	C01BD	C01B	C08CA	C08C
186	amiodarone	enhances	3A457	lercanidipine	C	C01BD01	C08CA13	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3465	C01BD	C01B	C08CA	C08C
186	amiodarone	enhances	3A457	lercanidipine	C	C01BD01	C08CA13	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4891	C01BD	C01B	C08CA	C08C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	89	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	185	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	295	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	356	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	862	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	1060	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	1407	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3089	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3263	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3583	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4172	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4300	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5266	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5700	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5849	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5890	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7104	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7160	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7172	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7625	C01BD	C01B	C09CA	C09C
193	amiodarone	enhances	2C9	losartan		C01BD01	C09CA01	Antiarrhythmics, class III (C01BD)	Angiotensin II receptor blockers, plain (C09CA)	Antiarrhythmics, class i and iii (C01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7725	C01BD	C01B	C09CA	C09C
194	amiodarone	enhances	3A457	lovastatin	C	C01BD01	C10AA02	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			C01BD	C01B	C10AA	C10A
196	amiodarone	enhances	2C9	meloxicam	B	C01BD01	M01AC06	Antiarrhythmics, class III (C01BD)	Oxicams (M01AC)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					C01BD	C01B	M01AC	M01A
197	amiodarone	enhances	3A457	methadone	D	C01BD01	N07BC02	Antiarrhythmics, class III (C01BD)	Drugs used in opioid dependence (N07BC)	Antiarrhythmics, class i and iii (C01B)	Drugs used in addictive disorders (N07B)	0	0				C01BD	C01B	N07BC	N07B
198	amiodarone	enhances	2D6	metoclopramide	D	C01BD01	A03FA01	Antiarrhythmics, class III (C01BD)	Propulsives (A03FA)	Antiarrhythmics, class i and iii (C01B)	Propulsives (A03F)	0				5265	C01BD	C01B	A03FA	A03F
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1029	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2262	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2511	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2846	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3029	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3030	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3036	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4536	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4891	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5112	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5423	C01BD	C01B	C07AB	C07A
199	amiodarone	enhances	2D6	metoprolol	B	C01BD01	C07AB02	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7217	C01BD	C01B	C07AB	C07A
201	amiodarone	enhances	3A457	midazolam		C01BD01	N05CD08	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05CD)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		C01BD	C01B	N05CD	N05C
206	amiodarone	enhances	1A2,2C9	naproxen	B	C01BD01	M01AE02	Antiarrhythmics, class III (C01BD)	Propionic acid derivatives (M01AE)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C01BD	C01B	M01AE	M01A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				1256	C01BD	C01B	C07AB	C07A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				1504	C01BD	C01B	C07AB	C07A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				2591	C01BD	C01B	C07AB	C07A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				3504	C01BD	C01B	C07AB	C07A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				4304	C01BD	C01B	C07AB	C07A
208	amiodarone	enhances	2D6	nebivolol	B	C01BD01	C07AB12	Antiarrhythmics, class III (C01BD)	Beta blocking agents, selective (C07AB)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				5492	C01BD	C01B	C07AB	C07A
211	amiodarone	enhances	3A457	nevirapine	C	C01BD01	J05AG01	Antiarrhythmics, class III (C01BD)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiarrhythmics, class i and iii (C01B)	Direct acting antivirals (J05A)	0	0				C01BD	C01B	J05AG	J05A
212	amiodarone	enhances	3A457	nifedipine	B	C01BD01	C08CA05	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2046	C01BD	C01B	C08CA	C08C
212	amiodarone	enhances	3A457	nifedipine	B	C01BD01	C08CA05	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2048	C01BD	C01B	C08CA	C08C
212	amiodarone	enhances	3A457	nifedipine	B	C01BD01	C08CA05	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4502	C01BD	C01B	C08CA	C08C
212	amiodarone	enhances	3A457	nifedipine	B	C01BD01	C08CA05	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7139	C01BD	C01B	C08CA	C08C
213	amiodarone	enhances	3A457	nisoldipine	D	C01BD01	C08CA07	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C01BD	C01B	C08CA	C08C
214	amiodarone	enhances	3A457	nitrendipine	D	C01BD01	C08CA08	Antiarrhythmics, class III (C01BD)	Dihydropyridine derivatives (C08CA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C01BD	C01B	C08CA	C08C
215	amiodarone	enhances	2D6	nortriptyline	D	C01BD01	N06AA10	Antiarrhythmics, class III (C01BD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	1					C01BD	C01B	N06AA	N06A
216	amiodarone	enhances	1A2	olanzapine	D	C01BD01	N05AH03	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2053	C01BD	C01B	N05AH	N05A
216	amiodarone	enhances	1A2	olanzapine	D	C01BD01	N05AH03	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	6247	C01BD	C01B	N05AH	N05A
216	amiodarone	enhances	1A2	olanzapine	D	C01BD01	N05AH03	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7443	C01BD	C01B	N05AH	N05A
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			39	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			65	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			203	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			368	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			821	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			822	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			913	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			922	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			925	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			933	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			969	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			992	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1064	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1097	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1527	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2049	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2075	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2082	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2093	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2277	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2365	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2373	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2390	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2541	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2580	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2744	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2831	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2980	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3029	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3030	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3186	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3241	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3263	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3503	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3504	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3529	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3545	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3606	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3616	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3689	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3724	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3728	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3803	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3870	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3895	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3897	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3949	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4078	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4139	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4153	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4165	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4188	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4202	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4247	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4331	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4550	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4556	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4657	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4874	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4963	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4970	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5267	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5344	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5517	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5527	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5757	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5858	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5890	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5932	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5998	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6221	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6258	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7054	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7615	C01BD	C01B	A02BC	A02B
219	amiodarone	enhances	3A457	omeprazole		C01BD01	A02BC01	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7721	C01BD	C01B	A02BC	A02B
220	amiodarone	enhances	1A2,2D6,3A457	ondansetron	D	C01BD01	A04AA01	Antiarrhythmics, class III (C01BD)	Serotonin (5HT3) antagonists (A04AA)	Antiarrhythmics, class i and iii (C01B)	Antiemetics and antinauseants (A04A)	0	0				C01BD	C01B	A04AA	A04A
223	amiodarone	enhances	2D6	oxycodone		C01BD01	N02AA05	Antiarrhythmics, class III (C01BD)	Natural opium alkaloids (N02AA)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4529	C01BD	C01B	N02AA	N02A
223	amiodarone	enhances	2D6	oxycodone		C01BD01	N02AA05	Antiarrhythmics, class III (C01BD)	Natural opium alkaloids (N02AA)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5866	C01BD	C01B	N02AA	N02A
223	amiodarone	enhances	2D6	oxycodone		C01BD01	N02AA05	Antiarrhythmics, class III (C01BD)	Natural opium alkaloids (N02AA)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7094	C01BD	C01B	N02AA	N02A
223	amiodarone	enhances	2D6	oxycodone		C01BD01	N02AA05	Antiarrhythmics, class III (C01BD)	Natural opium alkaloids (N02AA)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7104	C01BD	C01B	N02AA	N02A
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			121	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			147	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			184	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			663	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			823	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1060	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1070	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1108	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1127	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1256	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1401	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2224	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2412	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2849	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3092	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3235	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3483	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3662	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3743	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3868	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3932	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4116	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4264	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4333	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4470	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4478	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4502	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4675	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4677	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4749	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4891	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4903	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4944	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4988	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5156	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5179	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5205	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5236	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5266	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5380	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5595	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5655	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5846	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5866	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5926	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6189	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6229	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6237	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6247	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7093	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7104	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7217	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7443	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7484	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7596	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7625	C01BD	C01B	A02BC	A02B
228	amiodarone	enhances	3A457	pantoprazole		C01BD01	A02BC02	Antiarrhythmics, class III (C01BD)	Proton pump inhibitors (A02BC)	Antiarrhythmics, class i and iii (C01B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7642	C01BD	C01B	A02BC	A02B
229	amiodarone	enhances	2D6	paroxetine	D	C01BD01	N06AB05	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2949	C01BD	C01B	N06AB	N06A
229	amiodarone	enhances	2D6	paroxetine	D	C01BD01	N06AB05	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4265	C01BD	C01B	N06AB	N06A
229	amiodarone	enhances	2D6	paroxetine	D	C01BD01	N06AB05	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4550	C01BD	C01B	N06AB	N06A
229	amiodarone	enhances	2D6	paroxetine	D	C01BD01	N06AB05	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6091	C01BD	C01B	N06AB	N06A
229	amiodarone	enhances	2D6	paroxetine	D	C01BD01	N06AB05	Antiarrhythmics, class III (C01BD)	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7104	C01BD	C01B	N06AB	N06A
235	amiodarone	enhances	2C9	phenytoin	B	C01BD01	N03AB02	Antiarrhythmics, class III (C01BD)	Hydantoin derivatives (N03AB)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3092	C01BD	C01B	N03AB	N03A
235	amiodarone	enhances	2C9	phenytoin	B	C01BD01	N03AB02	Antiarrhythmics, class III (C01BD)	Hydantoin derivatives (N03AB)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	7407	C01BD	C01B	N03AB	N03A
239	amiodarone	enhances	2C9	piroxicam	B	C01BD01	M01AC01	Antiarrhythmics, class III (C01BD)	Oxicams (M01AC)	Antiarrhythmics, class i and iii (C01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C01BD	C01B	M01AC	M01A
243	amiodarone	enhances	2D6	promethazine	D	C01BD01	R06AD02	Antiarrhythmics, class III (C01BD)	Phenothiazine derivatives (R06AD)	Antiarrhythmics, class i and iii (C01B)	Antihistamines for systemic use (R06A)	0					C01BD	C01B	R06AD	R06A
244	amiodarone	enhances	2D6	propafenone	D	C01BD01	C01BC03	Antiarrhythmics, class III (C01BD)	Antiarrhythmics, class Ic (C01BC)	Antiarrhythmics, class i and iii (C01B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			C01BD	C01B	C01BC	C01B
245	amiodarone	enhances	1A2,2D6,3A457	propranolol	B	C01BD01	C07AA05	Antiarrhythmics, class III (C01BD)	Beta blocking agents, non-selective (C07AA)	Antiarrhythmics, class i and iii (C01B)	Beta blocking agents (C07A)	0				5968	C01BD	C01B	C07AA	C07A
246	amiodarone	enhances	3A457	quetiapine	D	C01BD01	N05AH04	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				273	C01BD	C01B	N05AH	N05A
246	amiodarone	enhances	3A457	quetiapine	D	C01BD01	N05AH04	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				2695	C01BD	C01B	N05AH	N05A
246	amiodarone	enhances	3A457	quetiapine	D	C01BD01	N05AH04	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				4321	C01BD	C01B	N05AH	N05A
246	amiodarone	enhances	3A457	quetiapine	D	C01BD01	N05AH04	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				5029	C01BD	C01B	N05AH	N05A
246	amiodarone	enhances	3A457	quetiapine	D	C01BD01	N05AH04	Antiarrhythmics, class III (C01BD)	Diazepines, oxazepines and thiazepines (N05AH)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0				5423	C01BD	C01B	N05AH	N05A
252	amiodarone	enhances	1A2	riluzole		C01BD01	N07XX02	Antiarrhythmics, class III (C01BD)	Other nervous system drugs (N07XX)	Antiarrhythmics, class i and iii (C01B)	Other nervous system drugs (N07X)	0	0				C01BD	C01B	N07XX	N07X
253	amiodarone	enhances	2D6,3A457	risperidone	D	C01BD01	N05AX08	Antiarrhythmics, class III (C01BD)	Other antipsychotics (N05AX)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		C01BD	C01B	N05AX	N05A
254	amiodarone	enhances	3A457	ritonavir	D	C01BD01	J05AE03	Antiarrhythmics, class III (C01BD)	Protease inhibitors (J05AE)	Antiarrhythmics, class i and iii (C01B)	Direct acting antivirals (J05A)	0	0				C01BD	C01B	J05AE	J05A
255	amiodarone	enhances	3A457	rivaroxaban		C01BD01	B01AF01	Antiarrhythmics, class III (C01BD)	Direct factor Xa inhibitors (B01AF)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0				5154	C01BD	C01B	B01AF	B01A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				306	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				732	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				1070	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				1261	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				1383	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				1504	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				1619	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				2186	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				2190	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				2695	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				2754	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				3015	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				3503	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				3539	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				3685	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				3805	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				4172	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				4202	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				4657	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				4683	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5344	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5379	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5454	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5574	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5632	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				5866	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				6221	C01BD	C01B	R03AC	R03A
263	amiodarone	enhances	3A457	salmeterol	D	C01BD01	R03AC12	Antiarrhythmics, class III (C01BD)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiarrhythmics, class i and iii (C01B)	Adrenergics, inhalants (R03A)	0				7104	C01BD	C01B	R03AC	R03A
264	amiodarone	enhances	3A457	saquinavir	D	C01BD01	J05AE01	Antiarrhythmics, class III (C01BD)	Protease inhibitors (J05AE)	Antiarrhythmics, class i and iii (C01B)	Direct acting antivirals (J05A)	0	0				C01BD	C01B	J05AE	J05A
266	amiodarone	enhances	3A457	sildenafil	C	C01BD01	G04BE03	Antiarrhythmics, class III (C01BD)	Drugs used in erectile dysfunction (G04BE)	Antiarrhythmics, class i and iii (C01B)	Urologicals (G04B)	0	0			4831	C01BD	C01B	G04BE	G04B
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		142	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		184	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		814	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		823	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		922	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1070	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1108	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1155	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1195	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1365	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1527	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2389	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3015	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3036	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3054	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3367	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3459	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3483	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3517	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3778	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3922	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3924	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4124	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4128	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4165	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4502	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4595	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4675	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4988	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5154	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5266	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5549	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5595	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5666	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5849	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5932	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5968	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6014	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6258	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7076	C01BD	C01B	C10AA	C10A
268	amiodarone	enhances	3A457	simvastatin	C	C01BD01	C10AA01	Antiarrhythmics, class III (C01BD)	HMG CoA reductase inhibitors (C10AA)	Antiarrhythmics, class i and iii (C01B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7146	C01BD	C01B	C10AA	C10A
269	amiodarone	enhances	3A457	sirolimus	C	C01BD01	L04AA10	Antiarrhythmics, class III (C01BD)	Selective immunosuppressants (L04AA)	Antiarrhythmics, class i and iii (C01B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C01BD	C01B	L04AA	L04A
271	amiodarone	enhances	3A457	sorafenib	D	C01BD01	L01XE05	Antiarrhythmics, class III (C01BD)	 (L01XE)	Antiarrhythmics, class i and iii (C01B)	Other antineoplastic agents (L01X)	1					C01BD	C01B	L01XE	L01X
273	amiodarone	enhances	3A457	sunitinib	D	C01BD01	L01XE04	Antiarrhythmics, class III (C01BD)	 (L01XE)	Antiarrhythmics, class i and iii (C01B)	Other antineoplastic agents (L01X)	1					C01BD	C01B	L01XE	L01X
277	amiodarone	enhances	3A457	tacrolimus	D	C01BD01	L04AD02	Antiarrhythmics, class III (C01BD)	Calcineurin inhibitors (L04AD)	Antiarrhythmics, class i and iii (C01B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C01BD	C01B	L04AD	L04A
278	amiodarone	enhances	3A457	tadalafil		C01BD01	G04BE08	Antiarrhythmics, class III (C01BD)	Drugs used in erectile dysfunction (G04BE)	Antiarrhythmics, class i and iii (C01B)	Urologicals (G04B)	0	0				C01BD	C01B	G04BE	G04B
279	amiodarone	enhances	2C9,2D6,3A457	tamoxifen	D	C01BD01	L02BA01	Antiarrhythmics, class III (C01BD)	Anti-estrogens (L02BA)	Antiarrhythmics, class i and iii (C01B)	Hormone antagonists and related agents (L02B)	1	1				C01BD	C01B	L02BA	L02B
285	amiodarone	enhances	3A457	testosterone		C01BD01	G03BA03	Antiarrhythmics, class III (C01BD)	3-oxoandrosten (4) derivatives (G03BA)	Antiarrhythmics, class i and iii (C01B)	Androgens (G03B)	0				7612	C01BD	C01B	G03BA	G03B
286	amiodarone	enhances	2D6	tetrabenazine	D	C01BD01	N07XX06	Antiarrhythmics, class III (C01BD)	Other nervous system drugs (N07XX)	Antiarrhythmics, class i and iii (C01B)	Other nervous system drugs (N07X)	0					C01BD	C01B	N07XX	N07X
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			117	C01BD	C01B	R03DA	R03D
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			1383	C01BD	C01B	R03DA	R03D
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2139	C01BD	C01B	R03DA	R03D
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2154	C01BD	C01B	R03DA	R03D
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			3186	C01BD	C01B	R03DA	R03D
287	amiodarone	enhances	1A2	theophylline	C	C01BD01	R03DA04	Antiarrhythmics, class III (C01BD)	Xanthines (R03DA)	Antiarrhythmics, class i and iii (C01B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			4683	C01BD	C01B	R03DA	R03D
289	amiodarone	enhances	3A457	ticagrelor		C01BD01	B01AC24	Antiarrhythmics, class III (C01BD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	0				5700	C01BD	C01B	B01AC	B01A
291	amiodarone	enhances	1A2	tizanidine	D	C01BD01	M03BX02	Antiarrhythmics, class III (C01BD)	Other centrally acting agents (M03BX)	Antiarrhythmics, class i and iii (C01B)	Muscle relaxants, centrally acting agents (M03B)	1	0				C01BD	C01B	M03BX	M03B
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			645	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			2277	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			2362	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			2650	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			2695	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			2743	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			3803	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			5423	C01BD	C01B	C03CA	C03C
295	amiodarone	enhances	2C9	torasemide	D	C01BD01	C03CA04	Antiarrhythmics, class III (C01BD)	Sulfonamides, plain (C03CA)	Antiarrhythmics, class i and iii (C01B)	High-ceiling diuretics (C03C)	0	0			7402	C01BD	C01B	C03CA	C03C
296	amiodarone	enhances	2D6,3A457	tramadol	B	C01BD01	N02AX02	Antiarrhythmics, class III (C01BD)	Other opioids (N02AX)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	1		Reduced analgesic effect	2277	C01BD	C01B	N02AX	N02A
296	amiodarone	enhances	2D6,3A457	tramadol	B	C01BD01	N02AX02	Antiarrhythmics, class III (C01BD)	Other opioids (N02AX)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	1		Reduced analgesic effect	4188	C01BD	C01B	N02AX	N02A
296	amiodarone	enhances	2D6,3A457	tramadol	B	C01BD01	N02AX02	Antiarrhythmics, class III (C01BD)	Other opioids (N02AX)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	1		Reduced analgesic effect	4304	C01BD	C01B	N02AX	N02A
296	amiodarone	enhances	2D6,3A457	tramadol	B	C01BD01	N02AX02	Antiarrhythmics, class III (C01BD)	Other opioids (N02AX)	Antiarrhythmics, class i and iii (C01B)	Opioids (N02A)	0	1		Reduced analgesic effect	7145	C01BD	C01B	N02AX	N02A
297	amiodarone	enhances	3A457	trazodone	D	C01BD01	N06AX05	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2695	C01BD	C01B	N06AX	N06A
297	amiodarone	enhances	3A457	trazodone	D	C01BD01	N06AX05	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3019	C01BD	C01B	N06AX	N06A
297	amiodarone	enhances	3A457	trazodone	D	C01BD01	N06AX05	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4516	C01BD	C01B	N06AX	N06A
297	amiodarone	enhances	3A457	trazodone	D	C01BD01	N06AX05	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5423	C01BD	C01B	N06AX	N06A
297	amiodarone	enhances	3A457	trazodone	D	C01BD01	N06AX05	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7519	C01BD	C01B	N06AX	N06A
298	amiodarone	enhances	1A2	triamterene		C01BD01	C03DB02	Antiarrhythmics, class III (C01BD)	Other potassium-sparing agents (C03DB)	Antiarrhythmics, class i and iii (C01B)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia		154	C01BD	C01B	C03DB	C03D
298	amiodarone	enhances	1A2	triamterene		C01BD01	C03DB02	Antiarrhythmics, class III (C01BD)	Other potassium-sparing agents (C03DB)	Antiarrhythmics, class i and iii (C01B)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia		4894	C01BD	C01B	C03DB	C03D
299	amiodarone	enhances	3A457	triazolam		C01BD01	N05CD05	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05CD)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1127	C01BD	C01B	N05CD	N05C
299	amiodarone	enhances	3A457	triazolam		C01BD01	N05CD05	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05CD)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2435	C01BD	C01B	N05CD	N05C
299	amiodarone	enhances	3A457	triazolam		C01BD01	N05CD05	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05CD)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3724	C01BD	C01B	N05CD	N05C
299	amiodarone	enhances	3A457	triazolam		C01BD01	N05CD05	Antiarrhythmics, class III (C01BD)	Benzodiazepine derivatives (N05CD)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5266	C01BD	C01B	N05CD	N05C
302	amiodarone	enhances	2C9	valproate		C01BD01	N03AG01	Antiarrhythmics, class III (C01BD)	Fatty acid derivatives (N03AG)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	759	C01BD	C01B	N03AG	N03A
302	amiodarone	enhances	2C9	valproate		C01BD01	N03AG01	Antiarrhythmics, class III (C01BD)	Fatty acid derivatives (N03AG)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	922	C01BD	C01B	N03AG	N03A
302	amiodarone	enhances	2C9	valproate		C01BD01	N03AG01	Antiarrhythmics, class III (C01BD)	Fatty acid derivatives (N03AG)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2192	C01BD	C01B	N03AG	N03A
302	amiodarone	enhances	2C9	valproate		C01BD01	N03AG01	Antiarrhythmics, class III (C01BD)	Fatty acid derivatives (N03AG)	Antiarrhythmics, class i and iii (C01B)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	6247	C01BD	C01B	N03AG	N03A
308	amiodarone	enhances	2C9,2D6,3A457	venlafaxine	D	C01BD01	N06AX16	Antiarrhythmics, class III (C01BD)	Other antidepressants (N06AX)	Antiarrhythmics, class i and iii (C01B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3465	C01BD	C01B	N06AX	N06A
309	amiodarone	enhances	1A2,3A457	verapamil	D	C01BD01	C08DA01	Antiarrhythmics, class III (C01BD)	Phenylalkylamine derivatives (C08DA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2750	C01BD	C01B	C08DA	C08D
309	amiodarone	enhances	1A2,3A457	verapamil	D	C01BD01	C08DA01	Antiarrhythmics, class III (C01BD)	Phenylalkylamine derivatives (C08DA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4128	C01BD	C01B	C08DA	C08D
309	amiodarone	enhances	1A2,3A457	verapamil	D	C01BD01	C08DA01	Antiarrhythmics, class III (C01BD)	Phenylalkylamine derivatives (C08DA)	Antiarrhythmics, class i and iii (C01B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7093	C01BD	C01B	C08DA	C08D
313	amiodarone	enhances	2C9,3A457	voriconazole	D	C01BD01	J02AC03	Antiarrhythmics, class III (C01BD)	Triazole derivatives (J02AC)	Antiarrhythmics, class i and iii (C01B)	Antimycotics for systemic use (J02A)	0	0				C01BD	C01B	J02AC	J02A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		89	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		117	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		147	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		185	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		223	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		273	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		664	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		714	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		769	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		814	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		862	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		896	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		913	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		969	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1029	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1066	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1108	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1129	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1155	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1256	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1346	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1369	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1371	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		1404	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2046	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2093	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2145	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2190	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2237	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2262	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2277	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2365	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2435	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2441	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2511	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2611	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2633	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2650	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2695	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2751	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2831	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2844	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2846	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2849	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2921	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		2980	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3036	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3092	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3235	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3239	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3249	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3263	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3304	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3503	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3662	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3685	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3724	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3728	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3803	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3861	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3870	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3895	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3922	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		3932	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4075	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4078	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4097	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4139	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4233	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4247	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4331	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4333	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4354	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4364	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4390	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4470	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4536	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4576	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4657	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4683	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4715	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4743	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4831	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4891	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4894	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		4944	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5112	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5156	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5205	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5265	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5306	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5380	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5492	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5632	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5666	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5757	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5846	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5849	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5858	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5866	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5932	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5968	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		5998	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6014	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6091	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6189	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6221	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6237	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		6247	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		7145	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		7146	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		7670	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		7725	C01BD	C01B	B01AA	B01A
314	amiodarone	enhances	1A2,2C9	warfarin	C	C01BD01	B01AA03	Antiarrhythmics, class III (C01BD)	Vitamin K antagonists (B01AA)	Antiarrhythmics, class i and iii (C01B)	Antithrombotic agents (B01A)	1	0	Bleeding		7741	C01BD	C01B	B01AA	B01A
316	amiodarone	enhances	3A457	zaleplon		C01BD01	N05CF03	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0					C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				356	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				3263	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				3968	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				4267	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				4331	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				5698	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				5998	C01BD	C01B	N05CF	N05C
320	amiodarone	enhances	3A457	zolpidem		C01BD01	N05CF02	Antiarrhythmics, class III (C01BD)	Benzodiazepine related drugs (N05CF)	Antiarrhythmics, class i and iii (C01B)	Hypnotics and sedatives (N05C)	0				7596	C01BD	C01B	N05CF	N05C
321	amiodarone	enhances	2D6	zuclopenthixol		C01BD01	N05AF05	Antiarrhythmics, class III (C01BD)	Thioxanthene derivatives (N05AF)	Antiarrhythmics, class i and iii (C01B)	Antipsychotics (N05A)	0					C01BD	C01B	N05AF	N05A
1142	buprenorphine	enhances	3A457	alprazolam	D	N02AE01	N05BA12	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05BA)	Opioids (N02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2386	N02AE	N02A	N05BA	N05B
1142	buprenorphine	enhances	3A457	alprazolam	D	N02AE01	N05BA12	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05BA)	Opioids (N02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3482	N02AE	N02A	N05BA	N05B
1143	buprenorphine	enhances	3A457	amitriptyline		N02AE01	N06AA09	Oripavine derivatives (N02AE)	Non-selective monoamine reuptake inhibitors (N06AA)	Opioids (N02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N02AE	N02A	N06AA	N06A
1144	buprenorphine	enhances	3A457	amlodipine		N02AE01	C08CA01	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N02AE	N02A	C08CA	C08C
1145	buprenorphine	enhances	3A457	apixaban		N02AE01	B01AF02	Oripavine derivatives (N02AE)	Direct factor Xa inhibitors (B01AF)	Opioids (N02A)	Antithrombotic agents (B01A)	0					N02AE	N02A	B01AF	B01A
1149	buprenorphine	enhances	3A457	atorvastatin		N02AE01	C10AA05	Oripavine derivatives (N02AE)	HMG CoA reductase inhibitors (C10AA)	Opioids (N02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2037	N02AE	N02A	C10AA	C10A
1149	buprenorphine	enhances	3A457	atorvastatin		N02AE01	C10AA05	Oripavine derivatives (N02AE)	HMG CoA reductase inhibitors (C10AA)	Opioids (N02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2386	N02AE	N02A	C10AA	C10A
1158	buprenorphine	enhances	3A457	carbamazepine	B	N02AE01	N03AF01	Oripavine derivatives (N02AE)	Carboxamide derivatives (N03AF)	Opioids (N02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N02AE	N02A	N03AF	N03A
1162	buprenorphine	enhances	3A457	chlorpheniramine	B	N02AE01	R06AB04	Oripavine derivatives (N02AE)	Substituted alkylamines (R06AB)	Opioids (N02A)	Antihistamines for systemic use (R06A)	0	0				N02AE	N02A	R06AB	R06A
1163	buprenorphine	enhances	3A457	cilostazol		N02AE01	B01AC23	Oripavine derivatives (N02AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Opioids (N02A)	Antithrombotic agents (B01A)	0					N02AE	N02A	B01AC	B01A
1165	buprenorphine	enhances	3A457	citalopram		N02AE01	N06AB04	Oripavine derivatives (N02AE)	Selective serotonin reuptake inhibitors (N06AB)	Opioids (N02A)	Antidepressants (N06A)	0	0				N02AE	N02A	N06AB	N06A
1166	buprenorphine	enhances	3A457	clarithromycin		N02AE01	J01FA09	Oripavine derivatives (N02AE)	Macrolides (J01FA)	Opioids (N02A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				N02AE	N02A	J01FA	J01F
1167	buprenorphine	enhances	3A457	clobazam		N02AE01	N05BA09	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05BA)	Opioids (N02A)	Anxiolytics (N05B)	0					N02AE	N02A	N05BA	N05B
1168	buprenorphine	enhances	3A457	clopidogrel		N02AE01	B01AC04	Oripavine derivatives (N02AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Opioids (N02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2386	N02AE	N02A	B01AC	B01A
1168	buprenorphine	enhances	3A457	clopidogrel		N02AE01	B01AC04	Oripavine derivatives (N02AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Opioids (N02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5442	N02AE	N02A	B01AC	B01A
1172	buprenorphine	enhances	3A457	colchicine		N02AE01	M04AC01	Oripavine derivatives (N02AE)	Preparations with no effect on uric acid metabolism (M04AC)	Opioids (N02A)	Antigout preparations (M04A)	0				1196	N02AE	N02A	M04AC	M04A
1175	buprenorphine	enhances	3A457	cyclosporine		N02AE01	L04AD01	Oripavine derivatives (N02AE)	Calcineurin inhibitors (L04AD)	Opioids (N02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N02AE	N02A	L04AD	L04A
1179	buprenorphine	enhances	3A457	deflazacort		N02AE01	H02AB13	Oripavine derivatives (N02AE)	Glucocorticoids (H02AB)	Opioids (N02A)	Corticosteroids for systemic use, plain (H02A)	0					N02AE	N02A	H02AB	H02A
1180	buprenorphine	enhances	3A457	dexamethasone		N02AE01	H02AB02	Oripavine derivatives (N02AE)	Glucocorticoids (H02AB)	Opioids (N02A)	Corticosteroids for systemic use, plain (H02A)	0				2132	N02AE	N02A	H02AB	H02A
1180	buprenorphine	enhances	3A457	dexamethasone		N02AE01	H02AB02	Oripavine derivatives (N02AE)	Glucocorticoids (H02AB)	Opioids (N02A)	Corticosteroids for systemic use, plain (H02A)	0				3995	N02AE	N02A	H02AB	H02A
1181	buprenorphine	enhances	3A457	dextromethorphan		N02AE01	R05DA09	Oripavine derivatives (N02AE)	Opium alkaloids and derivatives (R05DA)	Opioids (N02A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N02AE	N02A	R05DA	R05D
1182	buprenorphine	enhances	3A457	diazepam	D	N02AE01	N05BA01	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05BA)	Opioids (N02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N02AE	N02A	N05BA	N05B
1183	buprenorphine	enhances	3A457	diltiazem		N02AE01	C08DB01	Oripavine derivatives (N02AE)	Benzothiazepine derivatives (C08DB)	Opioids (N02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4233	N02AE	N02A	C08DB	C08D
1186	buprenorphine	enhances	3A457	domperidone		N02AE01	A03FA03	Oripavine derivatives (N02AE)	Propulsives (A03FA)	Opioids (N02A)	Propulsives (A03F)	0					N02AE	N02A	A03FA	A03F
1192	buprenorphine	enhances	3A457	eplerenone		N02AE01	C03DA04	Oripavine derivatives (N02AE)	Aldosterone antagonists (C03DA)	Opioids (N02A)	Potassium-sparing agents (C03D)	0					N02AE	N02A	C03DA	C03D
1195	buprenorphine	enhances	3A457	escitalopram		N02AE01	N06AB10	Oripavine derivatives (N02AE)	Selective serotonin reuptake inhibitors (N06AB)	Opioids (N02A)	Antidepressants (N06A)	0				2651	N02AE	N02A	N06AB	N06A
1196	buprenorphine	enhances	3A457	esomeprazole		N02AE01	A02BC05	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				357	N02AE	N02A	A02BC	A02B
1196	buprenorphine	enhances	3A457	esomeprazole		N02AE01	A02BC05	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3668	N02AE	N02A	A02BC	A02B
1198	buprenorphine	enhances	3A457	felodipine		N02AE01	C08CA02	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N02AE	N02A	C08CA	C08C
1202	buprenorphine	enhances	3A457	haloperidol		N02AE01	N05AD01	Oripavine derivatives (N02AE)	Butyrophenone derivatives (N05AD)	Opioids (N02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N02AE	N02A	N05AD	N05A
1203	buprenorphine	enhances	3A457	hydrocortisone		N02AE01	H02AB09	Oripavine derivatives (N02AE)	Glucocorticoids (H02AB)	Opioids (N02A)	Corticosteroids for systemic use, plain (H02A)	0					N02AE	N02A	H02AB	H02A
1206	buprenorphine	enhances	3A457	imatinib		N02AE01	L01XE01	Oripavine derivatives (N02AE)	 (L01XE)	Opioids (N02A)	Other antineoplastic agents (L01X)	0	0				N02AE	N02A	L01XE	L01X
1207	buprenorphine	enhances	3A457	indacaterol		N02AE01	R03AC18	Oripavine derivatives (N02AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Opioids (N02A)	Adrenergics, inhalants (R03A)	0					N02AE	N02A	R03AC	R03A
1211	buprenorphine	enhances	3A457	ivabradine		N02AE01	C01EB17	Oripavine derivatives (N02AE)	Other cardiac preparations (C01EB)	Opioids (N02A)	Other cardiac preparations (C01E)	0					N02AE	N02A	C01EB	C01E
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1196	N02AE	N02A	A02BC	A02B
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2037	N02AE	N02A	A02BC	A02B
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2651	N02AE	N02A	A02BC	A02B
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2880	N02AE	N02A	A02BC	A02B
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4233	N02AE	N02A	A02BC	A02B
1213	buprenorphine	enhances	3A457	lansoprazole		N02AE01	A02BC03	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5506	N02AE	N02A	A02BC	A02B
1215	buprenorphine	enhances	3A457	lercanidipine		N02AE01	C08CA13	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N02AE	N02A	C08CA	C08C
1219	buprenorphine	enhances	3A457	lovastatin		N02AE01	C10AA02	Oripavine derivatives (N02AE)	HMG CoA reductase inhibitors (C10AA)	Opioids (N02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N02AE	N02A	C10AA	C10A
1221	buprenorphine	enhances	3A457	methadone	D	N02AE01	N07BC02	Oripavine derivatives (N02AE)	Drugs used in opioid dependence (N07BC)	Opioids (N02A)	Drugs used in addictive disorders (N07B)	0	0				N02AE	N02A	N07BC	N07B
1222	buprenorphine	enhances	3A457	midazolam	D	N02AE01	N05CD08	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05CD)	Opioids (N02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N02AE	N02A	N05CD	N05C
1228	buprenorphine	enhances	3A457	nevirapine		N02AE01	J05AG01	Oripavine derivatives (N02AE)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Opioids (N02A)	Direct acting antivirals (J05A)	0	0				N02AE	N02A	J05AG	J05A
1229	buprenorphine	enhances	3A457	nifedipine		N02AE01	C08CA05	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N02AE	N02A	C08CA	C08C
1230	buprenorphine	enhances	3A457	nisoldipine		N02AE01	C08CA07	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N02AE	N02A	C08CA	C08C
1231	buprenorphine	enhances	3A457	nitrendipine		N02AE01	C08CA08	Oripavine derivatives (N02AE)	Dihydropyridine derivatives (C08CA)	Opioids (N02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N02AE	N02A	C08CA	C08C
1233	buprenorphine	enhances	3A457	omeprazole		N02AE01	A02BC01	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			248	N02AE	N02A	A02BC	A02B
1233	buprenorphine	enhances	3A457	omeprazole		N02AE01	A02BC01	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2132	N02AE	N02A	A02BC	A02B
1233	buprenorphine	enhances	3A457	omeprazole		N02AE01	A02BC01	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2291	N02AE	N02A	A02BC	A02B
1233	buprenorphine	enhances	3A457	omeprazole		N02AE01	A02BC01	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2386	N02AE	N02A	A02BC	A02B
1233	buprenorphine	enhances	3A457	omeprazole		N02AE01	A02BC01	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2829	N02AE	N02A	A02BC	A02B
1234	buprenorphine	enhances	3A457	ondansetron		N02AE01	A04AA01	Oripavine derivatives (N02AE)	Serotonin (5HT3) antagonists (A04AA)	Opioids (N02A)	Antiemetics and antinauseants (A04A)	0	0				N02AE	N02A	A04AA	A04A
1241	buprenorphine	enhances	3A457	pantoprazole		N02AE01	A02BC02	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3482	N02AE	N02A	A02BC	A02B
1241	buprenorphine	enhances	3A457	pantoprazole		N02AE01	A02BC02	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3995	N02AE	N02A	A02BC	A02B
1241	buprenorphine	enhances	3A457	pantoprazole		N02AE01	A02BC02	Oripavine derivatives (N02AE)	Proton pump inhibitors (A02BC)	Opioids (N02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5442	N02AE	N02A	A02BC	A02B
1248	buprenorphine	enhances	3A457	propranolol		N02AE01	C07AA05	Oripavine derivatives (N02AE)	Beta blocking agents, non-selective (C07AA)	Opioids (N02A)	Beta blocking agents (C07A)	0					N02AE	N02A	C07AA	C07A
1249	buprenorphine	enhances	3A457	quetiapine		N02AE01	N05AH04	Oripavine derivatives (N02AE)	Diazepines, oxazepines and thiazepines (N05AH)	Opioids (N02A)	Antipsychotics (N05A)	0					N02AE	N02A	N05AH	N05A
1255	buprenorphine	enhances	3A457	risperidone		N02AE01	N05AX08	Oripavine derivatives (N02AE)	Other antipsychotics (N05AX)	Opioids (N02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N02AE	N02A	N05AX	N05A
1256	buprenorphine	enhances	3A457	ritonavir	B	N02AE01	J05AE03	Oripavine derivatives (N02AE)	Protease inhibitors (J05AE)	Opioids (N02A)	Direct acting antivirals (J05A)	0	0				N02AE	N02A	J05AE	J05A
1257	buprenorphine	enhances	3A457	rivaroxaban		N02AE01	B01AF01	Oripavine derivatives (N02AE)	Direct factor Xa inhibitors (B01AF)	Opioids (N02A)	Antithrombotic agents (B01A)	0					N02AE	N02A	B01AF	B01A
1263	buprenorphine	enhances	3A457	salmeterol		N02AE01	R03AC12	Oripavine derivatives (N02AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Opioids (N02A)	Adrenergics, inhalants (R03A)	0				5506	N02AE	N02A	R03AC	R03A
1264	buprenorphine	enhances	3A457	saquinavir	B	N02AE01	J05AE01	Oripavine derivatives (N02AE)	Protease inhibitors (J05AE)	Opioids (N02A)	Direct acting antivirals (J05A)	0	0				N02AE	N02A	J05AE	J05A
1266	buprenorphine	enhances	3A457	sildenafil		N02AE01	G04BE03	Oripavine derivatives (N02AE)	Drugs used in erectile dysfunction (G04BE)	Opioids (N02A)	Urologicals (G04B)	0	0				N02AE	N02A	G04BE	G04B
1268	buprenorphine	enhances	3A457	simvastatin		N02AE01	C10AA01	Oripavine derivatives (N02AE)	HMG CoA reductase inhibitors (C10AA)	Opioids (N02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N02AE	N02A	C10AA	C10A
1269	buprenorphine	enhances	3A457	sirolimus		N02AE01	L04AA10	Oripavine derivatives (N02AE)	Selective immunosuppressants (L04AA)	Opioids (N02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N02AE	N02A	L04AA	L04A
1271	buprenorphine	enhances	3A457	sorafenib		N02AE01	L01XE05	Oripavine derivatives (N02AE)	 (L01XE)	Opioids (N02A)	Other antineoplastic agents (L01X)	1					N02AE	N02A	L01XE	L01X
1272	buprenorphine	enhances	3A457	sunitinib		N02AE01	L01XE04	Oripavine derivatives (N02AE)	 (L01XE)	Opioids (N02A)	Other antineoplastic agents (L01X)	1					N02AE	N02A	L01XE	L01X
1274	buprenorphine	enhances	3A457	tacrolimus		N02AE01	L04AD02	Oripavine derivatives (N02AE)	Calcineurin inhibitors (L04AD)	Opioids (N02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N02AE	N02A	L04AD	L04A
1275	buprenorphine	enhances	3A457	tadalafil		N02AE01	G04BE08	Oripavine derivatives (N02AE)	Drugs used in erectile dysfunction (G04BE)	Opioids (N02A)	Urologicals (G04B)	0	0				N02AE	N02A	G04BE	G04B
1276	buprenorphine	enhances	3A457	tamoxifen		N02AE01	L02BA01	Oripavine derivatives (N02AE)	Anti-estrogens (L02BA)	Opioids (N02A)	Hormone antagonists and related agents (L02B)	1	1				N02AE	N02A	L02BA	L02B
1282	buprenorphine	enhances	3A457	testosterone		N02AE01	G03BA03	Oripavine derivatives (N02AE)	3-oxoandrosten (4) derivatives (G03BA)	Opioids (N02A)	Androgens (G03B)	0					N02AE	N02A	G03BA	G03B
1283	buprenorphine	enhances	3A457	ticagrelor		N02AE01	B01AC24	Oripavine derivatives (N02AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Opioids (N02A)	Antithrombotic agents (B01A)	0					N02AE	N02A	B01AC	B01A
1286	buprenorphine	enhances	3A457	tramadol		N02AE01	N02AX02	Oripavine derivatives (N02AE)	Other opioids (N02AX)	Opioids (N02A)	Opioids (N02A)	0	1		Reduced analgesic effect	2651	N02AE	N02A	N02AX	N02A
1287	buprenorphine	enhances	3A457	trazodone		N02AE01	N06AX05	Oripavine derivatives (N02AE)	Other antidepressants (N06AX)	Opioids (N02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N02AE	N02A	N06AX	N06A
1288	buprenorphine	enhances	3A457	triazolam	D	N02AE01	N05CD05	Oripavine derivatives (N02AE)	Benzodiazepine derivatives (N05CD)	Opioids (N02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	105	N02AE	N02A	N05CD	N05C
1295	buprenorphine	enhances	3A457	venlafaxine		N02AE01	N06AX16	Oripavine derivatives (N02AE)	Other antidepressants (N06AX)	Opioids (N02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2386	N02AE	N02A	N06AX	N06A
1296	buprenorphine	enhances	3A457	verapamil		N02AE01	C08DA01	Oripavine derivatives (N02AE)	Phenylalkylamine derivatives (C08DA)	Opioids (N02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N02AE	N02A	C08DA	C08D
1300	buprenorphine	enhances	3A457	voriconazole		N02AE01	J02AC03	Oripavine derivatives (N02AE)	Triazole derivatives (J02AC)	Opioids (N02A)	Antimycotics for systemic use (J02A)	0	0				N02AE	N02A	J02AC	J02A
1301	buprenorphine	enhances	3A457	zaleplon		N02AE01	N05CF03	Oripavine derivatives (N02AE)	Benzodiazepine related drugs (N05CF)	Opioids (N02A)	Hypnotics and sedatives (N05C)	0					N02AE	N02A	N05CF	N05C
1303	buprenorphine	enhances	3A457	zolpidem		N02AE01	N05CF02	Oripavine derivatives (N02AE)	Benzodiazepine related drugs (N05CF)	Opioids (N02A)	Hypnotics and sedatives (N05C)	0				2132	N02AE	N02A	N05CF	N05C
1306	bupropion	enhances	2D6	amitriptyline		N06AX12	N06AA09	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AX	N06A	N06AA	N06A
1311	bupropion	enhances	2D6	carvedilol		N06AX12	C07AG02	Other antidepressants (N06AX)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N06AX	N06A	C07AG	C07A
1312	bupropion	enhances	2D6	chlorpheniramine	D	N06AX12	R06AB04	Other antidepressants (N06AX)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AX	N06A	R06AB	R06A
1313	bupropion	enhances	2D6	chlorpromazine		N06AX12	N05AA01	Other antidepressants (N06AX)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AX	N06A	N05AA	N05A
1314	bupropion	enhances	2D6	citalopram	B	N06AX12	N06AB04	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AX	N06A	N06AB	N06A
1315	bupropion	enhances	2D6	clomipramine	B	N06AX12	N06AA04	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AX	N06A	N06AA	N06A
1316	bupropion	enhances	2D6	clonidine		N06AX12	C02AC01	Other antidepressants (N06AX)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1					N06AX	N06A	C02AC	C02A
1321	bupropion	enhances	2D6	dextromethorphan		N06AX12	R05DA09	Other antidepressants (N06AX)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AX	N06A	R05DA	R05D
1322	bupropion	enhances	2D6	donepezil	B	N06AX12	N06DA02	Other antidepressants (N06AX)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0					N06AX	N06A	N06DA	N06D
1324	bupropion	enhances	2D6	duloxetine		N06AX12	N06AX21	Other antidepressants (N06AX)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AX	N06A
1327	bupropion	enhances	2D6	escitalopram	B	N06AX12	N06AB10	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AX	N06A	N06AB	N06A
1328	bupropion	enhances	2D6	flecainide	C	N06AX12	C01BC04	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N06AX	N06A	C01BC	C01B
1329	bupropion	enhances	2D6	fluoxetine	C	N06AX12	N06AB03	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AB	N06A
1330	bupropion	enhances	2D6	fluvoxamine	B	N06AX12	N06AB08	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4692	N06AX	N06A	N06AB	N06A
1331	bupropion	enhances	2D6	haloperidol	C	N06AX12	N05AD01	Other antidepressants (N06AX)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AX	N06A	N05AD	N05A
1333	bupropion	enhances	2D6	imipramine	B	N06AX12	N06AA02	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AX	N06A	N06AA	N06A
1336	bupropion	enhances	2D6	metoclopramide	D	N06AX12	A03FA01	Other antidepressants (N06AX)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AX	N06A	A03FA	A03F
1337	bupropion	enhances	2D6	metoprolol	D	N06AX12	C07AB02	Other antidepressants (N06AX)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N06AX	N06A	C07AB	C07A
1340	bupropion	enhances	2D6	nebivolol		N06AX12	C07AB12	Other antidepressants (N06AX)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AX	N06A	C07AB	C07A
1341	bupropion	enhances	2D6	nortriptyline	D	N06AX12	N06AA10	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AX	N06A	N06AA	N06A
1342	bupropion	enhances	2D6	ondansetron		N06AX12	A04AA01	Other antidepressants (N06AX)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AX	N06A	A04AA	A04A
1343	bupropion	enhances	2D6	oxycodone		N06AX12	N02AA05	Other antidepressants (N06AX)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N06AX	N06A	N02AA	N02A
1345	bupropion	enhances	2D6	paroxetine	C	N06AX12	N06AB05	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AB	N06A
1353	bupropion	enhances	2D6	promethazine		N06AX12	R06AD02	Other antidepressants (N06AX)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AX	N06A	R06AD	R06A
1354	bupropion	enhances	2D6	propafenone	C	N06AX12	C01BC03	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N06AX	N06A	C01BC	C01B
1355	bupropion	enhances	2D6	propranolol		N06AX12	C07AA05	Other antidepressants (N06AX)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AX	N06A	C07AA	C07A
1356	bupropion	enhances	2D6	risperidone	C	N06AX12	N05AX08	Other antidepressants (N06AX)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AX	N06A	N05AX	N05A
1359	bupropion	enhances	2D6	tamoxifen	D	N06AX12	L02BA01	Other antidepressants (N06AX)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AX	N06A	L02BA	L02B
1360	bupropion	enhances	2D6	tetrabenazine	D	N06AX12	N07XX06	Other antidepressants (N06AX)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AX	N06A	N07XX	N07X
1363	bupropion	enhances	2D6	tramadol		N06AX12	N02AX02	Other antidepressants (N06AX)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect		N06AX	N06A	N02AX	N02A
1366	bupropion	enhances	2D6	venlafaxine	D	N06AX12	N06AX16	Other antidepressants (N06AX)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AX	N06A
1368	bupropion	enhances	2D6	zuclopenthixol		N06AX12	N05AF05	Other antidepressants (N06AX)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AX	N06A	N05AF	N05A
1369	capecitabine	enhances	2C9	amitriptyline		L01BC06	N06AA09	Pyrimidine analogues (L01BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimetabolites (L01B)	Antidepressants (N06A)	1	0	Serotonin toxicity			L01BC	L01B	N06AA	N06A
1371	capecitabine	enhances	2C9	celecoxib		L01BC06	M01AH01	Pyrimidine analogues (L01BC)	Coxibs (M01AH)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				L01BC	L01B	M01AH	M01A
1372	capecitabine	enhances	2C9	clopidogrel		L01BC06	B01AC04	Pyrimidine analogues (L01BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimetabolites (L01B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		L01BC	L01B	B01AC	B01A
1373	capecitabine	enhances	2C9	diclofenac	B	L01BC06	M01AB05	Pyrimidine analogues (L01BC)	Acetic acid derivatives and related substances (M01AB)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				L01BC	L01B	M01AB	M01A
1375	capecitabine	enhances	2C9	fluoxetine		L01BC06	N06AB03	Pyrimidine analogues (L01BC)	Selective serotonin reuptake inhibitors (N06AB)	Antimetabolites (L01B)	Antidepressants (N06A)	0	0	Serotonin toxicity			L01BC	L01B	N06AB	N06A
1376	capecitabine	enhances	2C9	fluvastatin		L01BC06	C10AA04	Pyrimidine analogues (L01BC)	HMG CoA reductase inhibitors (C10AA)	Antimetabolites (L01B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			L01BC	L01B	C10AA	C10A
1377	capecitabine	enhances	2C9	glimepiride		L01BC06	A10BB12	Pyrimidine analogues (L01BC)	Sulfonylureas (A10BB)	Antimetabolites (L01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0					L01BC	L01B	A10BB	A10B
1378	capecitabine	enhances	2C9	glipizide		L01BC06	A10BB07	Pyrimidine analogues (L01BC)	Sulfonylureas (A10BB)	Antimetabolites (L01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			L01BC	L01B	A10BB	A10B
1379	capecitabine	enhances	2C9	glyburide		L01BC06	A10BB01	Pyrimidine analogues (L01BC)	Sulfonylureas (A10BB)	Antimetabolites (L01B)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			L01BC	L01B	A10BB	A10B
1380	capecitabine	enhances	2C9	ibuprofen		L01BC06	M01AE01	Pyrimidine analogues (L01BC)	Propionic acid derivatives (M01AE)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				L01BC	L01B	M01AE	M01A
1381	capecitabine	enhances	2C9	irbesartan		L01BC06	C09CA04	Pyrimidine analogues (L01BC)	Angiotensin II receptor blockers, plain (C09CA)	Antimetabolites (L01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		L01BC	L01B	C09CA	C09C
1384	capecitabine	enhances	2C9	losartan		L01BC06	C09CA01	Pyrimidine analogues (L01BC)	Angiotensin II receptor blockers, plain (C09CA)	Antimetabolites (L01B)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		L01BC	L01B	C09CA	C09C
1385	capecitabine	enhances	2C9	meloxicam		L01BC06	M01AC06	Pyrimidine analogues (L01BC)	Oxicams (M01AC)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					L01BC	L01B	M01AC	M01A
1386	capecitabine	enhances	2C9	naproxen		L01BC06	M01AE02	Pyrimidine analogues (L01BC)	Propionic acid derivatives (M01AE)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				L01BC	L01B	M01AE	M01A
1390	capecitabine	enhances	2C9	phenytoin	B	L01BC06	N03AB02	Pyrimidine analogues (L01BC)	Hydantoin derivatives (N03AB)	Antimetabolites (L01B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		L01BC	L01B	N03AB	N03A
1391	capecitabine	enhances	2C9	piroxicam		L01BC06	M01AC01	Pyrimidine analogues (L01BC)	Oxicams (M01AC)	Antimetabolites (L01B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				L01BC	L01B	M01AC	M01A
1395	capecitabine	enhances	2C9	tamoxifen		L01BC06	L02BA01	Pyrimidine analogues (L01BC)	Anti-estrogens (L02BA)	Antimetabolites (L01B)	Hormone antagonists and related agents (L02B)	1	1				L01BC	L01B	L02BA	L02B
1397	capecitabine	enhances	2C9	torasemide		L01BC06	C03CA04	Pyrimidine analogues (L01BC)	Sulfonamides, plain (C03CA)	Antimetabolites (L01B)	High-ceiling diuretics (C03C)	0	0				L01BC	L01B	C03CA	C03C
1398	capecitabine	enhances	2C9	valproate		L01BC06	N03AG01	Pyrimidine analogues (L01BC)	Fatty acid derivatives (N03AG)	Antimetabolites (L01B)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		L01BC	L01B	N03AG	N03A
1399	capecitabine	enhances	2C9	venlafaxine		L01BC06	N06AX16	Pyrimidine analogues (L01BC)	Other antidepressants (N06AX)	Antimetabolites (L01B)	Antidepressants (N06A)	0	0	Serotonin toxicity			L01BC	L01B	N06AX	N06A
1400	capecitabine	enhances	2C9	voriconazole		L01BC06	J02AC03	Pyrimidine analogues (L01BC)	Triazole derivatives (J02AC)	Antimetabolites (L01B)	Antimycotics for systemic use (J02A)	0	0				L01BC	L01B	J02AC	J02A
1401	capecitabine	enhances	2C9	warfarin	C	L01BC06	B01AA03	Pyrimidine analogues (L01BC)	Vitamin K antagonists (B01AA)	Antimetabolites (L01B)	Antithrombotic agents (B01A)	1	0	Bleeding			L01BC	L01B	B01AA	B01A
1406	carbamazepine	reduces	1A2	acetaminophen	B	N03AF01	N02BE01	Carboxamide derivatives (N03AF)	Anilides (N02BE)	Antiepileptics (N03A)	Other analgesics and antipyretics (N02B)	0	0			7197	N03AF	N03A	N02BE	N02B
1409	carbamazepine	reduces	3A457	alprazolam	C	N03AF01	N05BA12	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05BA	N05B
1410	carbamazepine	reduces	1A2,2C19,2C9,3A457	amitriptyline	B	N03AF01	N06AA09	Carboxamide derivatives (N03AF)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AF	N03A	N06AA	N06A
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	752	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2002	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2585	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2720	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3350	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3462	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4630	N03AF	N03A	C08CA	C08C
1411	carbamazepine	reduces	3A457	amlodipine		N03AF01	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5906	N03AF	N03A	C08CA	C08C
1412	carbamazepine	reduces	3A457	apixaban	B	N03AF01	B01AF02	Carboxamide derivatives (N03AF)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AF	B01A
1418	carbamazepine	reduces	3A457	atorvastatin	B	N03AF01	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		930	N03AF	N03A	C10AA	C10A
1418	carbamazepine	reduces	3A457	atorvastatin	B	N03AF01	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1292	N03AF	N03A	C10AA	C10A
1418	carbamazepine	reduces	3A457	atorvastatin	B	N03AF01	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1646	N03AF	N03A	C10AA	C10A
1418	carbamazepine	reduces	3A457	atorvastatin	B	N03AF01	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3350	N03AF	N03A	C10AA	C10A
1418	carbamazepine	reduces	3A457	atorvastatin	B	N03AF01	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3972	N03AF	N03A	C10AA	C10A
1426	carbamazepine	reduces	2B6	bupropion	A	N03AF01	N06AX12	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AF	N03A	N06AX	N06A
1429	carbamazepine	reduces	2C9	capecitabine		N03AF01	L01BC06	Carboxamide derivatives (N03AF)	Pyrimidine analogues (L01BC)	Antiepileptics (N03A)	Antimetabolites (L01B)	1					N03AF	N03A	L01BC	L01B
1432	carbamazepine	reduces	2C9	celecoxib		N03AF01	M01AH01	Carboxamide derivatives (N03AF)	Coxibs (M01AH)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AF	N03A	M01AH	M01A
1435	carbamazepine	reduces	3A457	chlorpheniramine	B	N03AF01	R06AB04	Carboxamide derivatives (N03AF)	Substituted alkylamines (R06AB)	Antiepileptics (N03A)	Antihistamines for systemic use (R06A)	0	0				N03AF	N03A	R06AB	R06A
1436	carbamazepine	reduces	3A457	cilostazol		N03AF01	B01AC23	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AC	B01A
1438	carbamazepine	reduces	2C19,3A457	citalopram		N03AF01	N06AB04	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0			3462	N03AF	N03A	N06AB	N06A
1439	carbamazepine	reduces	2B6,2C19,3A457	clobazam	B	N03AF01	N05BA09	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0				2585	N03AF	N03A	N05BA	N05B
1440	carbamazepine	reduces	1A2,2C19	clomipramine		N03AF01	N06AA04	Carboxamide derivatives (N03AF)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AF	N03A	N06AA	N06A
1441	carbamazepine	reduces	2C19,2C9,3A457	clopidogrel		N03AF01	B01AC04	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	782	N03AF	N03A	B01AC	B01A
1441	carbamazepine	reduces	2C19,2C9,3A457	clopidogrel		N03AF01	B01AC04	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2653	N03AF	N03A	B01AC	B01A
1441	carbamazepine	reduces	2C19,2C9,3A457	clopidogrel		N03AF01	B01AC04	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3701	N03AF	N03A	B01AC	B01A
1442	carbamazepine	reduces	1A2	clozapine	D	N03AF01	N05AH02	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1447	N03AF	N03A	N05AH	N05A
1446	carbamazepine	reduces	3A457	colchicine		N03AF01	M04AC01	Carboxamide derivatives (N03AF)	Preparations with no effect on uric acid metabolism (M04AC)	Antiepileptics (N03A)	Antigout preparations (M04A)	0					N03AF	N03A	M04AC	M04A
1449	carbamazepine	reduces	2B6,2C19	cyclophosphamide	C	N03AF01	L01AA01	Carboxamide derivatives (N03AF)	Nitrogen mustard analogues (L01AA)	Antiepileptics (N03A)	Alkylating agents (L01A)	1	1				N03AF	N03A	L01AA	L01A
1450	carbamazepine	reduces	3A457	cyclosporine	C	N03AF01	L04AD01	Carboxamide derivatives (N03AF)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AD	L04A
1454	carbamazepine	reduces	3A457	deflazacort	B	N03AF01	H02AB13	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AF	N03A	H02AB	H02A
1455	carbamazepine	reduces	3A457	dexamethasone	B	N03AF01	H02AB02	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0				177	N03AF	N03A	H02AB	H02A
1455	carbamazepine	reduces	3A457	dexamethasone	B	N03AF01	H02AB02	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0				2002	N03AF	N03A	H02AB	H02A
1456	carbamazepine	reduces	3A457	dextromethorphan		N03AF01	R05DA09	Carboxamide derivatives (N03AF)	Opium alkaloids and derivatives (R05DA)	Antiepileptics (N03A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N03AF	N03A	R05DA	R05D
1457	carbamazepine	reduces	2C19,3A457	diazepam	B	N03AF01	N05BA01	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2975	N03AF	N03A	N05BA	N05B
1458	carbamazepine	reduces	2C9	diclofenac	B	N03AF01	M01AB05	Carboxamide derivatives (N03AF)	Acetic acid derivatives and related substances (M01AB)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AF	N03A	M01AB	M01A
1461	carbamazepine	reduces	3A457	domperidone		N03AF01	A03FA03	Carboxamide derivatives (N03AF)	Propulsives (A03FA)	Antiepileptics (N03A)	Propulsives (A03F)	0					N03AF	N03A	A03FA	A03F
1463	carbamazepine	reduces	1A2	duloxetine		N03AF01	N06AX21	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AF	N03A	N06AX	N06A
1464	carbamazepine	reduces	2B6	efavirenz	D	N03AF01	J05AG03	Carboxamide derivatives (N03AF)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AF	N03A	J05AG	J05A
1469	carbamazepine	reduces	3A457	eplerenone	D	N03AF01	C03DA04	Carboxamide derivatives (N03AF)	Aldosterone antagonists (C03DA)	Antiepileptics (N03A)	Potassium-sparing agents (C03D)	0					N03AF	N03A	C03DA	C03D
1471	carbamazepine	reduces	2C19,3A457	escitalopram		N03AF01	N06AB10	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				1292	N03AF	N03A	N06AB	N06A
1471	carbamazepine	reduces	2C19,3A457	escitalopram		N03AF01	N06AB10	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				1496	N03AF	N03A	N06AB	N06A
1471	carbamazepine	reduces	2C19,3A457	escitalopram		N03AF01	N06AB10	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				2653	N03AF	N03A	N06AB	N06A
1471	carbamazepine	reduces	2C19,3A457	escitalopram		N03AF01	N06AB10	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				7197	N03AF	N03A	N06AB	N06A
1472	carbamazepine	reduces	2C19	esomeprazole		N03AF01	A02BC05	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2002	N03AF	N03A	A02BC	A02B
1472	carbamazepine	reduces	2C19	esomeprazole		N03AF01	A02BC05	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2127	N03AF	N03A	A02BC	A02B
1472	carbamazepine	reduces	2C19	esomeprazole		N03AF01	A02BC05	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3972	N03AF	N03A	A02BC	A02B
1474	carbamazepine	reduces	3A457	felodipine	B	N03AF01	C08CA02	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
1478	carbamazepine	reduces	2C9	fluoxetine	B	N03AF01	N06AB03	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AF	N03A	N06AB	N06A
1479	carbamazepine	reduces	2C9	fluvastatin		N03AF01	C10AA04	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N03AF	N03A	C10AA	C10A
1480	carbamazepine	reduces	1A2	fluvoxamine	B	N03AF01	N06AB08	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AF	N03A	N06AB	N06A
1481	carbamazepine	reduces	2C9	glimepiride		N03AF01	A10BB12	Carboxamide derivatives (N03AF)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					N03AF	N03A	A10BB	A10B
1482	carbamazepine	reduces	2C9	glipizide		N03AF01	A10BB07	Carboxamide derivatives (N03AF)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N03AF	N03A	A10BB	A10B
1483	carbamazepine	reduces	2C9	glyburide		N03AF01	A10BB01	Carboxamide derivatives (N03AF)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N03AF	N03A	A10BB	A10B
1484	carbamazepine	reduces	1A2,3A457	haloperidol	B	N03AF01	N05AD01	Carboxamide derivatives (N03AF)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2975	N03AF	N03A	N05AD	N05A
1486	carbamazepine	reduces	3A457	hydrocortisone	B	N03AF01	H02AB09	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AF	N03A	H02AB	H02A
1488	carbamazepine	reduces	2C9	ibuprofen		N03AF01	M01AE01	Carboxamide derivatives (N03AF)	Propionic acid derivatives (M01AE)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AF	N03A	M01AE	M01A
1490	carbamazepine	reduces	1A2,2C19	imipramine	B	N03AF01	N06AA02	Carboxamide derivatives (N03AF)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AF	N03A	N06AA	N06A
1491	carbamazepine	reduces	3A457	indacaterol		N03AF01	R03AC18	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				7647	N03AF	N03A	R03AC	R03A
1492	carbamazepine	reduces	2C19	indometacin		N03AF01	M01AB01	Carboxamide derivatives (N03AF)	Acetic acid derivatives and related substances (M01AB)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N03AF	N03A	M01AB	M01A
1493	carbamazepine	reduces	2C9	irbesartan		N03AF01	C09CA04	Carboxamide derivatives (N03AF)	Angiotensin II receptor blockers, plain (C09CA)	Antiepileptics (N03A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	1496	N03AF	N03A	C09CA	C09C
1493	carbamazepine	reduces	2C9	irbesartan		N03AF01	C09CA04	Carboxamide derivatives (N03AF)	Angiotensin II receptor blockers, plain (C09CA)	Antiepileptics (N03A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3701	N03AF	N03A	C09CA	C09C
1496	carbamazepine	reduces	3A457	ivabradine		N03AF01	C01EB17	Carboxamide derivatives (N03AF)	Other cardiac preparations (C01EB)	Antiepileptics (N03A)	Other cardiac preparations (C01E)	0					N03AF	N03A	C01EB	C01E
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			177	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			772	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1089	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1292	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2003	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2375	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2452	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4317	N03AF	N03A	A02BC	A02B
1500	carbamazepine	reduces	2C19,3A457	lansoprazole		N03AF01	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4442	N03AF	N03A	A02BC	A02B
1502	carbamazepine	reduces	3A457	lercanidipine		N03AF01	C08CA13	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2720	N03AF	N03A	C08CA	C08C
1508	carbamazepine	reduces	2C9	losartan		N03AF01	C09CA01	Carboxamide derivatives (N03AF)	Angiotensin II receptor blockers, plain (C09CA)	Antiepileptics (N03A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5663	N03AF	N03A	C09CA	C09C
1509	carbamazepine	reduces	3A457	lovastatin	D	N03AF01	C10AA02	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N03AF	N03A	C10AA	C10A
1511	carbamazepine	reduces	2C9	meloxicam		N03AF01	M01AC06	Carboxamide derivatives (N03AF)	Oxicams (M01AC)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N03AF	N03A	M01AC	M01A
1514	carbamazepine	reduces	2B6,3A457	methadone	C	N03AF01	N07BC02	Carboxamide derivatives (N03AF)	Drugs used in opioid dependence (N07BC)	Antiepileptics (N03A)	Drugs used in addictive disorders (N07B)	0	0				N03AF	N03A	N07BC	N07B
1517	carbamazepine	reduces	3A457	midazolam	C	N03AF01	N05CD08	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05CD	N05C
1522	carbamazepine	reduces	1A2,2C9	naproxen	C	N03AF01	M01AE02	Carboxamide derivatives (N03AF)	Propionic acid derivatives (M01AE)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AF	N03A	M01AE	M01A
1526	carbamazepine	reduces	2B6,3A457	nevirapine	B	N03AF01	J05AG01	Carboxamide derivatives (N03AF)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AF	N03A	J05AG	J05A
1527	carbamazepine	reduces	3A457	nifedipine	D	N03AF01	C08CA05	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
1529	carbamazepine	reduces	3A457	nisoldipine		N03AF01	C08CA07	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
1530	carbamazepine	reduces	3A457	nitrendipine		N03AF01	C08CA08	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
1531	carbamazepine	reduces	1A2	olanzapine	B	N03AF01	N05AH03	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N03AF	N03A	N05AH	N05A
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			782	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2002	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2505	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2585	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2653	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2720	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3350	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4634	N03AF	N03A	A02BC	A02B
1534	carbamazepine	reduces	2C19	omeprazole	B	N03AF01	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5663	N03AF	N03A	A02BC	A02B
1535	carbamazepine	reduces	1A2,3A457	ondansetron		N03AF01	A04AA01	Carboxamide derivatives (N03AF)	Serotonin (5HT3) antagonists (A04AA)	Antiepileptics (N03A)	Antiemetics and antinauseants (A04A)	0	0				N03AF	N03A	A04AA	A04A
1541	carbamazepine	reduces	2C19	pantoprazole		N03AF01	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1496	N03AF	N03A	A02BC	A02B
1541	carbamazepine	reduces	2C19	pantoprazole		N03AF01	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4230	N03AF	N03A	A02BC	A02B
1541	carbamazepine	reduces	2C19	pantoprazole		N03AF01	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4330	N03AF	N03A	A02BC	A02B
1541	carbamazepine	reduces	2C19	pantoprazole		N03AF01	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7197	N03AF	N03A	A02BC	A02B
1541	carbamazepine	reduces	2C19	pantoprazole		N03AF01	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7647	N03AF	N03A	A02BC	A02B
1543	carbamazepine	reduces	2C19	phenobarbital	B	N03AF01	N03AA02	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	192	N03AF	N03A	N03AA	N03A
1543	carbamazepine	reduces	2C19	phenobarbital	B	N03AF01	N03AA02	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	776	N03AF	N03A	N03AA	N03A
1543	carbamazepine	reduces	2C19	phenobarbital	B	N03AF01	N03AA02	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2003	N03AF	N03A	N03AA	N03A
1543	carbamazepine	reduces	2C19	phenobarbital	B	N03AF01	N03AA02	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4317	N03AF	N03A	N03AA	N03A
1543	carbamazepine	reduces	2C19	phenobarbital	B	N03AF01	N03AA02	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4667	N03AF	N03A	N03AA	N03A
1544	carbamazepine	reduces	2C19,2C9	phenytoin	B	N03AF01	N03AB02	Carboxamide derivatives (N03AF)	Hydantoin derivatives (N03AB)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	930	N03AF	N03A	N03AB	N03A
1548	carbamazepine	reduces	2C9	piroxicam		N03AF01	M01AC01	Carboxamide derivatives (N03AF)	Oxicams (M01AC)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AF	N03A	M01AC	M01A
1551	carbamazepine	reduces	2C19	primidone	B	N03AF01	N03AA03	Carboxamide derivatives (N03AF)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	0				2585	N03AF	N03A	N03AA	N03A
1555	carbamazepine	reduces	1A2,2C19,3A457	propranolol		N03AF01	C07AA05	Carboxamide derivatives (N03AF)	Beta blocking agents, non-selective (C07AA)	Antiepileptics (N03A)	Beta blocking agents (C07A)	0					N03AF	N03A	C07AA	C07A
1556	carbamazepine	reduces	3A457	quetiapine	C	N03AF01	N05AH04	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				589	N03AF	N03A	N05AH	N05A
1556	carbamazepine	reduces	3A457	quetiapine	C	N03AF01	N05AH04	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				2505	N03AF	N03A	N05AH	N05A
1556	carbamazepine	reduces	3A457	quetiapine	C	N03AF01	N05AH04	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				5906	N03AF	N03A	N05AH	N05A
1560	carbamazepine	reduces	1A2	riluzole		N03AF01	N07XX02	Carboxamide derivatives (N03AF)	Other nervous system drugs (N07XX)	Antiepileptics (N03A)	Other nervous system drugs (N07X)	0	0				N03AF	N03A	N07XX	N07X
1561	carbamazepine	reduces	3A457	risperidone	B	N03AF01	N05AX08	Carboxamide derivatives (N03AF)	Other antipsychotics (N05AX)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N03AF	N03A	N05AX	N05A
1562	carbamazepine	reduces	3A457	rivaroxaban	C	N03AF01	B01AF01	Carboxamide derivatives (N03AF)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AF	B01A
1570	carbamazepine	reduces	3A457	salmeterol		N03AF01	R03AC12	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				2753	N03AF	N03A	R03AC	R03A
1570	carbamazepine	reduces	3A457	salmeterol		N03AF01	R03AC12	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				4634	N03AF	N03A	R03AC	R03A
1570	carbamazepine	reduces	3A457	salmeterol		N03AF01	R03AC12	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				7342	N03AF	N03A	R03AC	R03A
1570	carbamazepine	reduces	3A457	salmeterol		N03AF01	R03AC12	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				7647	N03AF	N03A	R03AC	R03A
1571	carbamazepine	reduces	2B6	selegiline	D	N03AF01	N04BD01	Carboxamide derivatives (N03AF)	Monoamine oxidase B inhibitors (N04BD)	Antiepileptics (N03A)	Dopaminergic agents (N04B)	0	0				N03AF	N03A	N04BD	N04B
1573	carbamazepine	reduces	3A457	sildenafil	D	N03AF01	G04BE03	Carboxamide derivatives (N03AF)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AF	N03A	G04BE	G04B
1574	carbamazepine	reduces	3A457	simvastatin	B	N03AF01	C10AA01	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2452	N03AF	N03A	C10AA	C10A
1574	carbamazepine	reduces	3A457	simvastatin	B	N03AF01	C10AA01	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4230	N03AF	N03A	C10AA	C10A
1574	carbamazepine	reduces	3A457	simvastatin	B	N03AF01	C10AA01	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5906	N03AF	N03A	C10AA	C10A
1575	carbamazepine	reduces	3A457	sirolimus	D	N03AF01	L04AA10	Carboxamide derivatives (N03AF)	Selective immunosuppressants (L04AA)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AA	L04A
1577	carbamazepine	reduces	2B6,3A457	sorafenib	B	N03AF01	L01XE05	Carboxamide derivatives (N03AF)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AF	N03A	L01XE	L01X
1578	carbamazepine	reduces	3A457	sunitinib	D	N03AF01	L01XE04	Carboxamide derivatives (N03AF)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AF	N03A	L01XE	L01X
1582	carbamazepine	reduces	3A457	tacrolimus	C	N03AF01	L04AD02	Carboxamide derivatives (N03AF)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AD	L04A
1583	carbamazepine	reduces	3A457	tadalafil		N03AF01	G04BE08	Carboxamide derivatives (N03AF)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AF	N03A	G04BE	G04B
1584	carbamazepine	reduces	2C9,3A457	tamoxifen		N03AF01	L02BA01	Carboxamide derivatives (N03AF)	Anti-estrogens (L02BA)	Antiepileptics (N03A)	Hormone antagonists and related agents (L02B)	1	1				N03AF	N03A	L02BA	L02B
1589	carbamazepine	reduces	3A457	testosterone		N03AF01	G03BA03	Carboxamide derivatives (N03AF)	3-oxoandrosten (4) derivatives (G03BA)	Antiepileptics (N03A)	Androgens (G03B)	0					N03AF	N03A	G03BA	G03B
1590	carbamazepine	reduces	1A2	theophylline	B	N03AF01	R03DA04	Carboxamide derivatives (N03AF)	Xanthines (R03DA)	Antiepileptics (N03A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				N03AF	N03A	R03DA	R03D
1591	carbamazepine	reduces	3A457	ticagrelor		N03AF01	B01AC24	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AC	B01A
1592	carbamazepine	reduces	1A2	tizanidine	B	N03AF01	M03BX02	Carboxamide derivatives (N03AF)	Other centrally acting agents (M03BX)	Antiepileptics (N03A)	Muscle relaxants, centrally acting agents (M03B)	1	0				N03AF	N03A	M03BX	M03B
1596	carbamazepine	reduces	2C9	torasemide		N03AF01	C03CA04	Carboxamide derivatives (N03AF)	Sulfonamides, plain (C03CA)	Antiepileptics (N03A)	High-ceiling diuretics (C03C)	0	0			2653	N03AF	N03A	C03CA	C03C
1597	carbamazepine	reduces	2B6,3A457	tramadol	D	N03AF01	N02AX02	Carboxamide derivatives (N03AF)	Other opioids (N02AX)	Antiepileptics (N03A)	Opioids (N02A)	0	1		Reduced analgesic effect	7197	N03AF	N03A	N02AX	N02A
1598	carbamazepine	reduces	3A457	trazodone	B	N03AF01	N06AX05	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4630	N03AF	N03A	N06AX	N06A
1598	carbamazepine	reduces	3A457	trazodone	B	N03AF01	N06AX05	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		5906	N03AF	N03A	N06AX	N06A
1599	carbamazepine	reduces	1A2	triamterene		N03AF01	C03DB02	Carboxamide derivatives (N03AF)	Other potassium-sparing agents (C03DB)	Antiepileptics (N03A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			N03AF	N03A	C03DB	C03D
1600	carbamazepine	reduces	3A457	triazolam	C	N03AF01	N05CD05	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05CD	N05C
1602	carbamazepine	reduces	2C9	valproate	B	N03AF01	N03AG01	Carboxamide derivatives (N03AF)	Fatty acid derivatives (N03AG)	Antiepileptics (N03A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	772	N03AF	N03A	N03AG	N03A
1608	carbamazepine	reduces	2C19,2C9,3A457	venlafaxine		N03AF01	N06AX16	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AF	N03A	N06AX	N06A
1609	carbamazepine	reduces	1A2	verapamil	B	N03AF01	C08DA01	Carboxamide derivatives (N03AF)	Phenylalkylamine derivatives (C08DA)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N03AF	N03A	C08DA	C08D
1613	carbamazepine	reduces	2C19,2C9	voriconazole	D	N03AF01	J02AC03	Carboxamide derivatives (N03AF)	Triazole derivatives (J02AC)	Antiepileptics (N03A)	Antimycotics for systemic use (J02A)	0	0				N03AF	N03A	J02AC	J02A
1614	carbamazepine	reduces	1A2,2C19,2C9	warfarin	C	N03AF01	B01AA03	Carboxamide derivatives (N03AF)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		2127	N03AF	N03A	B01AA	B01A
1614	carbamazepine	reduces	1A2,2C19,2C9	warfarin	C	N03AF01	B01AA03	Carboxamide derivatives (N03AF)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		2653	N03AF	N03A	B01AA	B01A
1614	carbamazepine	reduces	1A2,2C19,2C9	warfarin	C	N03AF01	B01AA03	Carboxamide derivatives (N03AF)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		3350	N03AF	N03A	B01AA	B01A
1614	carbamazepine	reduces	1A2,2C19,2C9	warfarin	C	N03AF01	B01AA03	Carboxamide derivatives (N03AF)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		4442	N03AF	N03A	B01AA	B01A
1616	carbamazepine	reduces	3A457	zaleplon	D	N03AF01	N05CF03	Carboxamide derivatives (N03AF)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AF	N03A	N05CF	N05C
1620	carbamazepine	reduces	3A457	zolpidem	B	N03AF01	N05CF02	Carboxamide derivatives (N03AF)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0				5906	N03AF	N03A	N05CF	N05C
1623	celecoxib	enhances	2D6	amitriptyline		M01AH01	N06AA09	Coxibs (M01AH)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	1	0	Serotonin toxicity		3794	M01AH	M01A	N06AA	N06A
1628	celecoxib	enhances	2D6	carvedilol	B	M01AH01	C07AG02	Coxibs (M01AH)	Alpha and beta blocking agents (C07AG)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3738	M01AH	M01A	C07AG	C07A
1629	celecoxib	enhances	2D6	chlorpheniramine		M01AH01	R06AB04	Coxibs (M01AH)	Substituted alkylamines (R06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antihistamines for systemic use (R06A)	0	0				M01AH	M01A	R06AB	R06A
1630	celecoxib	enhances	2D6	chlorpromazine		M01AH01	N05AA01	Coxibs (M01AH)	Phenothiazines with aliphatic side-chain (N05AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antipsychotics (N05A)	0					M01AH	M01A	N05AA	N05A
1631	celecoxib	enhances	2D6	citalopram	C	M01AH01	N06AB04	Coxibs (M01AH)	Selective serotonin reuptake inhibitors (N06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0			2092	M01AH	M01A	N06AB	N06A
1632	celecoxib	enhances	2D6	clomipramine		M01AH01	N06AA04	Coxibs (M01AH)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	1	0	Serotonin toxicity			M01AH	M01A	N06AA	N06A
1633	celecoxib	enhances	2D6	clonidine		M01AH01	C02AC01	Coxibs (M01AH)	Imidazoline receptor agonists (C02AC)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antiadrenergic agents, centrally acting (C02A)	1					M01AH	M01A	C02AC	C02A
1638	celecoxib	enhances	2D6	dextromethorphan		M01AH01	R05DA09	Coxibs (M01AH)	Opium alkaloids and derivatives (R05DA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				M01AH	M01A	R05DA	R05D
1639	celecoxib	enhances	2D6	donepezil		M01AH01	N06DA02	Coxibs (M01AH)	Anticholinesterases (N06DA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Anti-dementia drugs (N06D)	0					M01AH	M01A	N06DA	N06D
1641	celecoxib	enhances	2D6	duloxetine	B	M01AH01	N06AX21	Coxibs (M01AH)	Other antidepressants (N06AX)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			M01AH	M01A	N06AX	N06A
1644	celecoxib	enhances	2D6	escitalopram	C	M01AH01	N06AB10	Coxibs (M01AH)	Selective serotonin reuptake inhibitors (N06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0					M01AH	M01A	N06AB	N06A
1645	celecoxib	enhances	2D6	flecainide		M01AH01	C01BC04	Coxibs (M01AH)	Antiarrhythmics, class Ic (C01BC)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			M01AH	M01A	C01BC	C01B
1646	celecoxib	enhances	2D6	fluoxetine	C	M01AH01	N06AB03	Coxibs (M01AH)	Selective serotonin reuptake inhibitors (N06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			M01AH	M01A	N06AB	N06A
1647	celecoxib	enhances	2D6	fluvoxamine	C	M01AH01	N06AB08	Coxibs (M01AH)	Selective serotonin reuptake inhibitors (N06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			M01AH	M01A	N06AB	N06A
1648	celecoxib	enhances	2D6	haloperidol		M01AH01	N05AD01	Coxibs (M01AH)	Butyrophenone derivatives (N05AD)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		M01AH	M01A	N05AD	N05A
1650	celecoxib	enhances	2D6	imipramine		M01AH01	N06AA02	Coxibs (M01AH)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	1	0	Serotonin toxicity			M01AH	M01A	N06AA	N06A
1653	celecoxib	enhances	2D6	metoclopramide		M01AH01	A03FA01	Coxibs (M01AH)	Propulsives (A03FA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Propulsives (A03F)	0					M01AH	M01A	A03FA	A03F
1654	celecoxib	enhances	2D6	metoprolol	B	M01AH01	C07AB02	Coxibs (M01AH)	Beta blocking agents, selective (C07AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		M01AH	M01A	C07AB	C07A
1657	celecoxib	enhances	2D6	nebivolol		M01AH01	C07AB12	Coxibs (M01AH)	Beta blocking agents, selective (C07AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Beta blocking agents (C07A)	0					M01AH	M01A	C07AB	C07A
1658	celecoxib	enhances	2D6	nortriptyline		M01AH01	N06AA10	Coxibs (M01AH)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	1					M01AH	M01A	N06AA	N06A
1659	celecoxib	enhances	2D6	ondansetron		M01AH01	A04AA01	Coxibs (M01AH)	Serotonin (5HT3) antagonists (A04AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antiemetics and antinauseants (A04A)	0	0				M01AH	M01A	A04AA	A04A
1660	celecoxib	enhances	2D6	oxycodone		M01AH01	N02AA05	Coxibs (M01AH)	Natural opium alkaloids (N02AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		M01AH	M01A	N02AA	N02A
1662	celecoxib	enhances	2D6	paroxetine	C	M01AH01	N06AB05	Coxibs (M01AH)	Selective serotonin reuptake inhibitors (N06AB)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			M01AH	M01A	N06AB	N06A
1670	celecoxib	enhances	2D6	promethazine		M01AH01	R06AD02	Coxibs (M01AH)	Phenothiazine derivatives (R06AD)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antihistamines for systemic use (R06A)	0					M01AH	M01A	R06AD	R06A
1671	celecoxib	enhances	2D6	propafenone		M01AH01	C01BC03	Coxibs (M01AH)	Antiarrhythmics, class Ic (C01BC)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			M01AH	M01A	C01BC	C01B
1672	celecoxib	enhances	2D6	propranolol	B	M01AH01	C07AA05	Coxibs (M01AH)	Beta blocking agents, non-selective (C07AA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Beta blocking agents (C07A)	0					M01AH	M01A	C07AA	C07A
1673	celecoxib	enhances	2D6	risperidone		M01AH01	N05AX08	Coxibs (M01AH)	Other antipsychotics (N05AX)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		M01AH	M01A	N05AX	N05A
1676	celecoxib	enhances	2D6	tamoxifen		M01AH01	L02BA01	Coxibs (M01AH)	Anti-estrogens (L02BA)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Hormone antagonists and related agents (L02B)	1	1				M01AH	M01A	L02BA	L02B
1677	celecoxib	enhances	2D6	tetrabenazine		M01AH01	N07XX06	Coxibs (M01AH)	Other nervous system drugs (N07XX)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Other nervous system drugs (N07X)	0					M01AH	M01A	N07XX	N07X
1680	celecoxib	enhances	2D6	tramadol		M01AH01	N02AX02	Coxibs (M01AH)	Other opioids (N02AX)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Opioids (N02A)	0	1		Reduced analgesic effect	4533	M01AH	M01A	N02AX	N02A
1683	celecoxib	enhances	2D6	venlafaxine	C	M01AH01	N06AX16	Coxibs (M01AH)	Other antidepressants (N06AX)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			M01AH	M01A	N06AX	N06A
1685	celecoxib	enhances	2D6	zuclopenthixol		M01AH01	N05AF05	Coxibs (M01AH)	Thioxanthene derivatives (N05AF)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	Antipsychotics (N05A)	0					M01AH	M01A	N05AF	N05A
2094	chlorpheniramine	enhances	2D6	amitriptyline		R06AB04	N06AA09	Substituted alkylamines (R06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AB	R06A	N06AA	N06A
2099	chlorpheniramine	enhances	2D6	carvedilol		R06AB04	C07AG02	Substituted alkylamines (R06AB)	Alpha and beta blocking agents (C07AG)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3798	R06AB	R06A	C07AG	C07A
2100	chlorpheniramine	enhances	2D6	chlorpromazine		R06AB04	N05AA01	Substituted alkylamines (R06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0					R06AB	R06A	N05AA	N05A
2101	chlorpheniramine	enhances	2D6	citalopram	B	R06AB04	N06AB04	Substituted alkylamines (R06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0				R06AB	R06A	N06AB	N06A
2102	chlorpheniramine	enhances	2D6	clomipramine		R06AB04	N06AA04	Substituted alkylamines (R06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AB	R06A	N06AA	N06A
2103	chlorpheniramine	enhances	2D6	clonidine	B	R06AB04	C02AC01	Substituted alkylamines (R06AB)	Imidazoline receptor agonists (C02AC)	Antihistamines for systemic use (R06A)	Antiadrenergic agents, centrally acting (C02A)	1					R06AB	R06A	C02AC	C02A
2108	chlorpheniramine	enhances	2D6	dextromethorphan		R06AB04	R05DA09	Substituted alkylamines (R06AB)	Opium alkaloids and derivatives (R05DA)	Antihistamines for systemic use (R06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				R06AB	R06A	R05DA	R05D
2109	chlorpheniramine	enhances	2D6	donepezil		R06AB04	N06DA02	Substituted alkylamines (R06AB)	Anticholinesterases (N06DA)	Antihistamines for systemic use (R06A)	Anti-dementia drugs (N06D)	0					R06AB	R06A	N06DA	N06D
2111	chlorpheniramine	enhances	2D6	duloxetine	C	R06AB04	N06AX21	Substituted alkylamines (R06AB)	Other antidepressants (N06AX)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AB	R06A	N06AX	N06A
2114	chlorpheniramine	enhances	2D6	escitalopram	B	R06AB04	N06AB10	Substituted alkylamines (R06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0					R06AB	R06A	N06AB	N06A
2115	chlorpheniramine	enhances	2D6	flecainide		R06AB04	C01BC04	Substituted alkylamines (R06AB)	Antiarrhythmics, class Ic (C01BC)	Antihistamines for systemic use (R06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		5026	R06AB	R06A	C01BC	C01B
2116	chlorpheniramine	enhances	2D6	fluoxetine	D	R06AB04	N06AB03	Substituted alkylamines (R06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AB	R06A	N06AB	N06A
2117	chlorpheniramine	enhances	2D6	fluvoxamine	B	R06AB04	N06AB08	Substituted alkylamines (R06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AB	R06A	N06AB	N06A
2118	chlorpheniramine	enhances	2D6	haloperidol	B	R06AB04	N05AD01	Substituted alkylamines (R06AB)	Butyrophenone derivatives (N05AD)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		R06AB	R06A	N05AD	N05A
2120	chlorpheniramine	enhances	2D6	imipramine		R06AB04	N06AA02	Substituted alkylamines (R06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AB	R06A	N06AA	N06A
2123	chlorpheniramine	enhances	2D6	metoclopramide		R06AB04	A03FA01	Substituted alkylamines (R06AB)	Propulsives (A03FA)	Antihistamines for systemic use (R06A)	Propulsives (A03F)	0				2784	R06AB	R06A	A03FA	A03F
2124	chlorpheniramine	enhances	2D6	metoprolol		R06AB04	C07AB02	Substituted alkylamines (R06AB)	Beta blocking agents, selective (C07AB)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3760	R06AB	R06A	C07AB	C07A
2127	chlorpheniramine	enhances	2D6	nebivolol		R06AB04	C07AB12	Substituted alkylamines (R06AB)	Beta blocking agents, selective (C07AB)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0					R06AB	R06A	C07AB	C07A
2128	chlorpheniramine	enhances	2D6	nortriptyline		R06AB04	N06AA10	Substituted alkylamines (R06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1					R06AB	R06A	N06AA	N06A
2129	chlorpheniramine	enhances	2D6	ondansetron		R06AB04	A04AA01	Substituted alkylamines (R06AB)	Serotonin (5HT3) antagonists (A04AA)	Antihistamines for systemic use (R06A)	Antiemetics and antinauseants (A04A)	0	0				R06AB	R06A	A04AA	A04A
2130	chlorpheniramine	enhances	2D6	oxycodone	B	R06AB04	N02AA05	Substituted alkylamines (R06AB)	Natural opium alkaloids (N02AA)	Antihistamines for systemic use (R06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		R06AB	R06A	N02AA	N02A
2132	chlorpheniramine	enhances	2D6	paroxetine		R06AB04	N06AB05	Substituted alkylamines (R06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AB	R06A	N06AB	N06A
2140	chlorpheniramine	enhances	2D6	promethazine		R06AB04	R06AD02	Substituted alkylamines (R06AB)	Phenothiazine derivatives (R06AD)	Antihistamines for systemic use (R06A)	Antihistamines for systemic use (R06A)	0					R06AB	R06A	R06AD	R06A
2141	chlorpheniramine	enhances	2D6	propafenone		R06AB04	C01BC03	Substituted alkylamines (R06AB)	Antiarrhythmics, class Ic (C01BC)	Antihistamines for systemic use (R06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			R06AB	R06A	C01BC	C01B
2142	chlorpheniramine	enhances	2D6	propranolol		R06AB04	C07AA05	Substituted alkylamines (R06AB)	Beta blocking agents, non-selective (C07AA)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0				2242	R06AB	R06A	C07AA	C07A
2143	chlorpheniramine	enhances	2D6	risperidone		R06AB04	N05AX08	Substituted alkylamines (R06AB)	Other antipsychotics (N05AX)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		R06AB	R06A	N05AX	N05A
2146	chlorpheniramine	enhances	2D6	tamoxifen		R06AB04	L02BA01	Substituted alkylamines (R06AB)	Anti-estrogens (L02BA)	Antihistamines for systemic use (R06A)	Hormone antagonists and related agents (L02B)	1	1				R06AB	R06A	L02BA	L02B
2147	chlorpheniramine	enhances	2D6	tetrabenazine		R06AB04	N07XX06	Substituted alkylamines (R06AB)	Other nervous system drugs (N07XX)	Antihistamines for systemic use (R06A)	Other nervous system drugs (N07X)	0					R06AB	R06A	N07XX	N07X
2150	chlorpheniramine	enhances	2D6	tramadol		R06AB04	N02AX02	Substituted alkylamines (R06AB)	Other opioids (N02AX)	Antihistamines for systemic use (R06A)	Opioids (N02A)	0	1		Reduced analgesic effect		R06AB	R06A	N02AX	N02A
2153	chlorpheniramine	enhances	2D6	venlafaxine		R06AB04	N06AX16	Substituted alkylamines (R06AB)	Other antidepressants (N06AX)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AB	R06A	N06AX	N06A
2155	chlorpheniramine	enhances	2D6	zuclopenthixol		R06AB04	N05AF05	Substituted alkylamines (R06AB)	Thioxanthene derivatives (N05AF)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0					R06AB	R06A	N05AF	N05A
2158	chlorpromazine	enhances	2D6	amitriptyline	D	N05AA01	N06AA09	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AA	N05A	N06AA	N06A
2163	chlorpromazine	enhances	2D6	carvedilol		N05AA01	C07AG02	Phenothiazines with aliphatic side-chain (N05AA)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3669	N05AA	N05A	C07AG	C07A
2164	chlorpromazine	enhances	2D6	chlorpheniramine		N05AA01	R06AB04	Phenothiazines with aliphatic side-chain (N05AA)	Substituted alkylamines (R06AB)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0	0				N05AA	N05A	R06AB	R06A
2165	chlorpromazine	enhances	2D6	citalopram	D	N05AA01	N06AB04	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0				N05AA	N05A	N06AB	N06A
2166	chlorpromazine	enhances	2D6	clomipramine	D	N05AA01	N06AA04	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AA	N05A	N06AA	N06A
2167	chlorpromazine	enhances	2D6	clonidine		N05AA01	C02AC01	Phenothiazines with aliphatic side-chain (N05AA)	Imidazoline receptor agonists (C02AC)	Antipsychotics (N05A)	Antiadrenergic agents, centrally acting (C02A)	1					N05AA	N05A	C02AC	C02A
2172	chlorpromazine	enhances	2D6	dextromethorphan	B	N05AA01	R05DA09	Phenothiazines with aliphatic side-chain (N05AA)	Opium alkaloids and derivatives (R05DA)	Antipsychotics (N05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N05AA	N05A	R05DA	R05D
2173	chlorpromazine	enhances	2D6	donepezil	D	N05AA01	N06DA02	Phenothiazines with aliphatic side-chain (N05AA)	Anticholinesterases (N06DA)	Antipsychotics (N05A)	Anti-dementia drugs (N06D)	0					N05AA	N05A	N06DA	N06D
2175	chlorpromazine	enhances	2D6	duloxetine	B	N05AA01	N06AX21	Phenothiazines with aliphatic side-chain (N05AA)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AX	N06A
2178	chlorpromazine	enhances	2D6	escitalopram	D	N05AA01	N06AB10	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0					N05AA	N05A	N06AB	N06A
2179	chlorpromazine	enhances	2D6	flecainide	D	N05AA01	C01BC04	Phenothiazines with aliphatic side-chain (N05AA)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N05AA	N05A	C01BC	C01B
2180	chlorpromazine	enhances	2D6	fluoxetine	D	N05AA01	N06AB03	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AB	N06A
2181	chlorpromazine	enhances	2D6	fluvoxamine		N05AA01	N06AB08	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity		96	N05AA	N05A	N06AB	N06A
2182	chlorpromazine	enhances	2D6	haloperidol	D	N05AA01	N05AD01	Phenothiazines with aliphatic side-chain (N05AA)	Butyrophenone derivatives (N05AD)	Antipsychotics (N05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N05AA	N05A	N05AD	N05A
2184	chlorpromazine	enhances	2D6	imipramine	D	N05AA01	N06AA02	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AA	N05A	N06AA	N06A
2187	chlorpromazine	enhances	2D6	metoclopramide	D	N05AA01	A03FA01	Phenothiazines with aliphatic side-chain (N05AA)	Propulsives (A03FA)	Antipsychotics (N05A)	Propulsives (A03F)	0					N05AA	N05A	A03FA	A03F
2188	chlorpromazine	enhances	2D6	metoprolol	B	N05AA01	C07AB02	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N05AA	N05A	C07AB	C07A
2191	chlorpromazine	enhances	2D6	nebivolol		N05AA01	C07AB12	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0					N05AA	N05A	C07AB	C07A
2192	chlorpromazine	enhances	2D6	nortriptyline	D	N05AA01	N06AA10	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1					N05AA	N05A	N06AA	N06A
2193	chlorpromazine	enhances	2D6	ondansetron	D	N05AA01	A04AA01	Phenothiazines with aliphatic side-chain (N05AA)	Serotonin (5HT3) antagonists (A04AA)	Antipsychotics (N05A)	Antiemetics and antinauseants (A04A)	0	0			3520	N05AA	N05A	A04AA	A04A
2194	chlorpromazine	enhances	2D6	oxycodone	C	N05AA01	N02AA05	Phenothiazines with aliphatic side-chain (N05AA)	Natural opium alkaloids (N02AA)	Antipsychotics (N05A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N05AA	N05A	N02AA	N02A
2196	chlorpromazine	enhances	2D6	paroxetine	D	N05AA01	N06AB05	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4265	N05AA	N05A	N06AB	N06A
2204	chlorpromazine	enhances	2D6	promethazine	D	N05AA01	R06AD02	Phenothiazines with aliphatic side-chain (N05AA)	Phenothiazine derivatives (R06AD)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0				96	N05AA	N05A	R06AD	R06A
2205	chlorpromazine	enhances	2D6	propafenone	D	N05AA01	C01BC03	Phenothiazines with aliphatic side-chain (N05AA)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N05AA	N05A	C01BC	C01B
2206	chlorpromazine	enhances	2D6	propranolol	B	N05AA01	C07AA05	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, non-selective (C07AA)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0					N05AA	N05A	C07AA	C07A
2207	chlorpromazine	enhances	2D6	risperidone	D	N05AA01	N05AX08	Phenothiazines with aliphatic side-chain (N05AA)	Other antipsychotics (N05AX)	Antipsychotics (N05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N05AA	N05A	N05AX	N05A
2210	chlorpromazine	enhances	2D6	tamoxifen	D	N05AA01	L02BA01	Phenothiazines with aliphatic side-chain (N05AA)	Anti-estrogens (L02BA)	Antipsychotics (N05A)	Hormone antagonists and related agents (L02B)	1	1				N05AA	N05A	L02BA	L02B
2211	chlorpromazine	enhances	2D6	tetrabenazine	D	N05AA01	N07XX06	Phenothiazines with aliphatic side-chain (N05AA)	Other nervous system drugs (N07XX)	Antipsychotics (N05A)	Other nervous system drugs (N07X)	0					N05AA	N05A	N07XX	N07X
2214	chlorpromazine	enhances	2D6	tramadol	C	N05AA01	N02AX02	Phenothiazines with aliphatic side-chain (N05AA)	Other opioids (N02AX)	Antipsychotics (N05A)	Opioids (N02A)	0	1		Reduced analgesic effect	163	N05AA	N05A	N02AX	N02A
2217	chlorpromazine	enhances	2D6	venlafaxine	D	N05AA01	N06AX16	Phenothiazines with aliphatic side-chain (N05AA)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AX	N06A
2219	chlorpromazine	enhances	2D6	zuclopenthixol		N05AA01	N05AF05	Phenothiazines with aliphatic side-chain (N05AA)	Thioxanthene derivatives (N05AF)	Antipsychotics (N05A)	Antipsychotics (N05A)	0					N05AA	N05A	N05AF	N05A
2460	cinacalcet	enhances	2D6	amitriptyline	B	H05BX01	N06AA09	Other anti-parathyroid agents (H05BX)	Non-selective monoamine reuptake inhibitors (N06AA)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			H05BX	H05B	N06AA	N06A
2465	cinacalcet	enhances	2D6	carvedilol		H05BX01	C07AG02	Other anti-parathyroid agents (H05BX)	Alpha and beta blocking agents (C07AG)	Anti-parathyroid agents (H05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		H05BX	H05B	C07AG	C07A
2466	cinacalcet	enhances	2D6	chlorpheniramine		H05BX01	R06AB04	Other anti-parathyroid agents (H05BX)	Substituted alkylamines (R06AB)	Anti-parathyroid agents (H05B)	Antihistamines for systemic use (R06A)	0	0				H05BX	H05B	R06AB	R06A
2467	cinacalcet	enhances	2D6	chlorpromazine		H05BX01	N05AA01	Other anti-parathyroid agents (H05BX)	Phenothiazines with aliphatic side-chain (N05AA)	Anti-parathyroid agents (H05B)	Antipsychotics (N05A)	0					H05BX	H05B	N05AA	N05A
2468	cinacalcet	enhances	2D6	citalopram		H05BX01	N06AB04	Other anti-parathyroid agents (H05BX)	Selective serotonin reuptake inhibitors (N06AB)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0				H05BX	H05B	N06AB	N06A
2469	cinacalcet	enhances	2D6	clomipramine		H05BX01	N06AA04	Other anti-parathyroid agents (H05BX)	Non-selective monoamine reuptake inhibitors (N06AA)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			H05BX	H05B	N06AA	N06A
2470	cinacalcet	enhances	2D6	clonidine		H05BX01	C02AC01	Other anti-parathyroid agents (H05BX)	Imidazoline receptor agonists (C02AC)	Anti-parathyroid agents (H05B)	Antiadrenergic agents, centrally acting (C02A)	1					H05BX	H05B	C02AC	C02A
2475	cinacalcet	enhances	2D6	dextromethorphan		H05BX01	R05DA09	Other anti-parathyroid agents (H05BX)	Opium alkaloids and derivatives (R05DA)	Anti-parathyroid agents (H05B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				H05BX	H05B	R05DA	R05D
2476	cinacalcet	enhances	2D6	donepezil		H05BX01	N06DA02	Other anti-parathyroid agents (H05BX)	Anticholinesterases (N06DA)	Anti-parathyroid agents (H05B)	Anti-dementia drugs (N06D)	0					H05BX	H05B	N06DA	N06D
2478	cinacalcet	enhances	2D6	duloxetine		H05BX01	N06AX21	Other anti-parathyroid agents (H05BX)	Other antidepressants (N06AX)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			H05BX	H05B	N06AX	N06A
2481	cinacalcet	enhances	2D6	escitalopram		H05BX01	N06AB10	Other anti-parathyroid agents (H05BX)	Selective serotonin reuptake inhibitors (N06AB)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0					H05BX	H05B	N06AB	N06A
2482	cinacalcet	enhances	2D6	flecainide		H05BX01	C01BC04	Other anti-parathyroid agents (H05BX)	Antiarrhythmics, class Ic (C01BC)	Anti-parathyroid agents (H05B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			H05BX	H05B	C01BC	C01B
2483	cinacalcet	enhances	2D6	fluoxetine		H05BX01	N06AB03	Other anti-parathyroid agents (H05BX)	Selective serotonin reuptake inhibitors (N06AB)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			H05BX	H05B	N06AB	N06A
2484	cinacalcet	enhances	2D6	fluvoxamine		H05BX01	N06AB08	Other anti-parathyroid agents (H05BX)	Selective serotonin reuptake inhibitors (N06AB)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			H05BX	H05B	N06AB	N06A
2485	cinacalcet	enhances	2D6	haloperidol		H05BX01	N05AD01	Other anti-parathyroid agents (H05BX)	Butyrophenone derivatives (N05AD)	Anti-parathyroid agents (H05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		H05BX	H05B	N05AD	N05A
2487	cinacalcet	enhances	2D6	imipramine	C	H05BX01	N06AA02	Other anti-parathyroid agents (H05BX)	Non-selective monoamine reuptake inhibitors (N06AA)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			H05BX	H05B	N06AA	N06A
2490	cinacalcet	enhances	2D6	metoclopramide		H05BX01	A03FA01	Other anti-parathyroid agents (H05BX)	Propulsives (A03FA)	Anti-parathyroid agents (H05B)	Propulsives (A03F)	0					H05BX	H05B	A03FA	A03F
2491	cinacalcet	enhances	2D6	metoprolol		H05BX01	C07AB02	Other anti-parathyroid agents (H05BX)	Beta blocking agents, selective (C07AB)	Anti-parathyroid agents (H05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		H05BX	H05B	C07AB	C07A
2494	cinacalcet	enhances	2D6	nebivolol		H05BX01	C07AB12	Other anti-parathyroid agents (H05BX)	Beta blocking agents, selective (C07AB)	Anti-parathyroid agents (H05B)	Beta blocking agents (C07A)	0					H05BX	H05B	C07AB	C07A
2495	cinacalcet	enhances	2D6	nortriptyline	B	H05BX01	N06AA10	Other anti-parathyroid agents (H05BX)	Non-selective monoamine reuptake inhibitors (N06AA)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	1					H05BX	H05B	N06AA	N06A
2496	cinacalcet	enhances	2D6	ondansetron		H05BX01	A04AA01	Other anti-parathyroid agents (H05BX)	Serotonin (5HT3) antagonists (A04AA)	Anti-parathyroid agents (H05B)	Antiemetics and antinauseants (A04A)	0	0				H05BX	H05B	A04AA	A04A
2497	cinacalcet	enhances	2D6	oxycodone		H05BX01	N02AA05	Other anti-parathyroid agents (H05BX)	Natural opium alkaloids (N02AA)	Anti-parathyroid agents (H05B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		H05BX	H05B	N02AA	N02A
2499	cinacalcet	enhances	2D6	paroxetine		H05BX01	N06AB05	Other anti-parathyroid agents (H05BX)	Selective serotonin reuptake inhibitors (N06AB)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			H05BX	H05B	N06AB	N06A
2507	cinacalcet	enhances	2D6	promethazine		H05BX01	R06AD02	Other anti-parathyroid agents (H05BX)	Phenothiazine derivatives (R06AD)	Anti-parathyroid agents (H05B)	Antihistamines for systemic use (R06A)	0					H05BX	H05B	R06AD	R06A
2508	cinacalcet	enhances	2D6	propafenone		H05BX01	C01BC03	Other anti-parathyroid agents (H05BX)	Antiarrhythmics, class Ic (C01BC)	Anti-parathyroid agents (H05B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			H05BX	H05B	C01BC	C01B
2509	cinacalcet	enhances	2D6	propranolol		H05BX01	C07AA05	Other anti-parathyroid agents (H05BX)	Beta blocking agents, non-selective (C07AA)	Anti-parathyroid agents (H05B)	Beta blocking agents (C07A)	0					H05BX	H05B	C07AA	C07A
2510	cinacalcet	enhances	2D6	risperidone		H05BX01	N05AX08	Other anti-parathyroid agents (H05BX)	Other antipsychotics (N05AX)	Anti-parathyroid agents (H05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		H05BX	H05B	N05AX	N05A
2513	cinacalcet	enhances	2D6	tamoxifen		H05BX01	L02BA01	Other anti-parathyroid agents (H05BX)	Anti-estrogens (L02BA)	Anti-parathyroid agents (H05B)	Hormone antagonists and related agents (L02B)	1	1				H05BX	H05B	L02BA	L02B
2514	cinacalcet	enhances	2D6	tetrabenazine	C	H05BX01	N07XX06	Other anti-parathyroid agents (H05BX)	Other nervous system drugs (N07XX)	Anti-parathyroid agents (H05B)	Other nervous system drugs (N07X)	0					H05BX	H05B	N07XX	N07X
2517	cinacalcet	enhances	2D6	tramadol		H05BX01	N02AX02	Other anti-parathyroid agents (H05BX)	Other opioids (N02AX)	Anti-parathyroid agents (H05B)	Opioids (N02A)	0	1		Reduced analgesic effect		H05BX	H05B	N02AX	N02A
2520	cinacalcet	enhances	2D6	venlafaxine		H05BX01	N06AX16	Other anti-parathyroid agents (H05BX)	Other antidepressants (N06AX)	Anti-parathyroid agents (H05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			H05BX	H05B	N06AX	N06A
2522	cinacalcet	enhances	2D6	zuclopenthixol		H05BX01	N05AF05	Other anti-parathyroid agents (H05BX)	Thioxanthene derivatives (N05AF)	Anti-parathyroid agents (H05B)	Antipsychotics (N05A)	0					H05BX	H05B	N05AF	N05A
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			8	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			21	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			2342	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			2386	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			4049	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			4374	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			4548	J01MA	J01M	N02BE	N02B
2526	ciprofloxacin	enhances	1A2	acetaminophen		J01MA02	N02BE01	Fluoroquinolones (J01MA)	Anilides (N02BE)	Quinolone antibacterials (J01M)	Other analgesics and antipyretics (N02B)	0	0			4713	J01MA	J01M	N02BE	N02B
2529	ciprofloxacin	enhances	3A457	alprazolam	C	J01MA02	N05BA12	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2386	J01MA	J01M	N05BA	N05B
2530	ciprofloxacin	enhances	1A2,3A457	amitriptyline	D	J01MA02	N06AA09	Fluoroquinolones (J01MA)	Non-selective monoamine reuptake inhibitors (N06AA)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01MA	J01M	N06AA	N06A
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	340	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	652	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	898	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2021	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2064	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2279	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3296	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3304	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3372	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4011	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4682	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4724	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5285	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5330	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5544	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7040	J01MA	J01M	C08CA	C08C
2531	ciprofloxacin	enhances	3A457	amlodipine		J01MA02	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7705	J01MA	J01M	C08CA	C08C
2532	ciprofloxacin	enhances	3A457	apixaban		J01MA02	B01AF02	Fluoroquinolones (J01MA)	Direct factor Xa inhibitors (B01AF)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AF	B01A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		166	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		354	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2386	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3438	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4664	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4783	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5711	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5922	J01MA	J01M	C10AA	C10A
2537	ciprofloxacin	enhances	3A457	atorvastatin	C	J01MA02	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7612	J01MA	J01M	C10AA	C10A
2546	ciprofloxacin	enhances	3A457	carbamazepine		J01MA02	N03AF01	Fluoroquinolones (J01MA)	Carboxamide derivatives (N03AF)	Quinolone antibacterials (J01M)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J01MA	J01M	N03AF	N03A
2550	ciprofloxacin	enhances	3A457	chlorpheniramine		J01MA02	R06AB04	Fluoroquinolones (J01MA)	Substituted alkylamines (R06AB)	Quinolone antibacterials (J01M)	Antihistamines for systemic use (R06A)	0	0				J01MA	J01M	R06AB	R06A
2551	ciprofloxacin	enhances	3A457	cilostazol	D	J01MA02	B01AC23	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AC	B01A
2553	ciprofloxacin	enhances	3A457	citalopram	D	J01MA02	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0			3004	J01MA	J01M	N06AB	N06A
2553	ciprofloxacin	enhances	3A457	citalopram	D	J01MA02	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0			3304	J01MA	J01M	N06AB	N06A
2553	ciprofloxacin	enhances	3A457	citalopram	D	J01MA02	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0			3536	J01MA	J01M	N06AB	N06A
2553	ciprofloxacin	enhances	3A457	citalopram	D	J01MA02	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0			3968	J01MA	J01M	N06AB	N06A
2553	ciprofloxacin	enhances	3A457	citalopram	D	J01MA02	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0			5814	J01MA	J01M	N06AB	N06A
2554	ciprofloxacin	enhances	3A457	clarithromycin	D	J01MA02	J01FA09	Fluoroquinolones (J01MA)	Macrolides (J01FA)	Quinolone antibacterials (J01M)	Macrolides, lincosamides and streptogramins (J01F)	0	0			2496	J01MA	J01M	J01FA	J01F
2554	ciprofloxacin	enhances	3A457	clarithromycin	D	J01MA02	J01FA09	Fluoroquinolones (J01MA)	Macrolides (J01FA)	Quinolone antibacterials (J01M)	Macrolides, lincosamides and streptogramins (J01F)	0	0			3699	J01MA	J01M	J01FA	J01F
2555	ciprofloxacin	enhances	3A457	clobazam		J01MA02	N05BA09	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0					J01MA	J01M	N05BA	N05B
2556	ciprofloxacin	enhances	1A2	clomipramine	D	J01MA02	N06AA04	Fluoroquinolones (J01MA)	Non-selective monoamine reuptake inhibitors (N06AA)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01MA	J01M	N06AA	N06A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2386	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3004	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3437	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4352	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5240	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5241	J01MA	J01M	B01AC	B01A
2557	ciprofloxacin	enhances	3A457	clopidogrel		J01MA02	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5990	J01MA	J01M	B01AC	B01A
2558	ciprofloxacin	enhances	1A2	clozapine	D	J01MA02	N05AH02	Fluoroquinolones (J01MA)	Diazepines, oxazepines and thiazepines (N05AH)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J01MA	J01M	N05AH	N05A
2562	ciprofloxacin	enhances	3A457	colchicine		J01MA02	M04AC01	Fluoroquinolones (J01MA)	Preparations with no effect on uric acid metabolism (M04AC)	Quinolone antibacterials (J01M)	Antigout preparations (M04A)	0				1272	J01MA	J01M	M04AC	M04A
2562	ciprofloxacin	enhances	3A457	colchicine		J01MA02	M04AC01	Fluoroquinolones (J01MA)	Preparations with no effect on uric acid metabolism (M04AC)	Quinolone antibacterials (J01M)	Antigout preparations (M04A)	0				2058	J01MA	J01M	M04AC	M04A
2566	ciprofloxacin	enhances	3A457	cyclosporine	B	J01MA02	L04AD01	Fluoroquinolones (J01MA)	Calcineurin inhibitors (L04AD)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01MA	J01M	L04AD	L04A
2570	ciprofloxacin	enhances	3A457	deflazacort	C	J01MA02	H02AB13	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0					J01MA	J01M	H02AB	H02A
2571	ciprofloxacin	enhances	3A457	dexamethasone	B	J01MA02	H02AB02	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0				2841	J01MA	J01M	H02AB	H02A
2572	ciprofloxacin	enhances	3A457	dextromethorphan		J01MA02	R05DA09	Fluoroquinolones (J01MA)	Opium alkaloids and derivatives (R05DA)	Quinolone antibacterials (J01M)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J01MA	J01M	R05DA	R05D
2573	ciprofloxacin	enhances	3A457	diazepam		J01MA02	N05BA01	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05BA	N05B
2574	ciprofloxacin	enhances	3A457	diltiazem		J01MA02	C08DB01	Fluoroquinolones (J01MA)	Benzothiazepine derivatives (C08DB)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2662	J01MA	J01M	C08DB	C08D
2574	ciprofloxacin	enhances	3A457	diltiazem		J01MA02	C08DB01	Fluoroquinolones (J01MA)	Benzothiazepine derivatives (C08DB)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2957	J01MA	J01M	C08DB	C08D
2577	ciprofloxacin	enhances	3A457	domperidone	D	J01MA02	A03FA03	Fluoroquinolones (J01MA)	Propulsives (A03FA)	Quinolone antibacterials (J01M)	Propulsives (A03F)	0				3304	J01MA	J01M	A03FA	A03F
2577	ciprofloxacin	enhances	3A457	domperidone	D	J01MA02	A03FA03	Fluoroquinolones (J01MA)	Propulsives (A03FA)	Quinolone antibacterials (J01M)	Propulsives (A03F)	0				3475	J01MA	J01M	A03FA	A03F
2577	ciprofloxacin	enhances	3A457	domperidone	D	J01MA02	A03FA03	Fluoroquinolones (J01MA)	Propulsives (A03FA)	Quinolone antibacterials (J01M)	Propulsives (A03F)	0				3492	J01MA	J01M	A03FA	A03F
2577	ciprofloxacin	enhances	3A457	domperidone	D	J01MA02	A03FA03	Fluoroquinolones (J01MA)	Propulsives (A03FA)	Quinolone antibacterials (J01M)	Propulsives (A03F)	0				4574	J01MA	J01M	A03FA	A03F
2579	ciprofloxacin	enhances	1A2	duloxetine	D	J01MA02	N06AX21	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01MA	J01M	N06AX	N06A
2584	ciprofloxacin	enhances	3A457	eplerenone	C	J01MA02	C03DA04	Fluoroquinolones (J01MA)	Aldosterone antagonists (C03DA)	Quinolone antibacterials (J01M)	Potassium-sparing agents (C03D)	0					J01MA	J01M	C03DA	C03D
2587	ciprofloxacin	enhances	3A457	escitalopram	D	J01MA02	N06AB10	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0				3782	J01MA	J01M	N06AB	N06A
2587	ciprofloxacin	enhances	3A457	escitalopram	D	J01MA02	N06AB10	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0				5970	J01MA	J01M	N06AB	N06A
2587	ciprofloxacin	enhances	3A457	escitalopram	D	J01MA02	N06AB10	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0				7555	J01MA	J01M	N06AB	N06A
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				21	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				354	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				805	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1418	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2058	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2376	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3536	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3699	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4521	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4548	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4574	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4770	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7176	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7300	J01MA	J01M	A02BC	A02B
2588	ciprofloxacin	enhances	3A457	esomeprazole		J01MA02	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7612	J01MA	J01M	A02BC	A02B
2590	ciprofloxacin	enhances	3A457	felodipine		J01MA02	C08CA02	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
2594	ciprofloxacin	enhances	1A2	fluvoxamine		J01MA02	N06AB08	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01MA	J01M	N06AB	N06A
2595	ciprofloxacin	enhances	1A2,3A457	haloperidol	D	J01MA02	N05AD01	Fluoroquinolones (J01MA)	Butyrophenone derivatives (N05AD)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2856	J01MA	J01M	N05AD	N05A
2595	ciprofloxacin	enhances	1A2,3A457	haloperidol	D	J01MA02	N05AD01	Fluoroquinolones (J01MA)	Butyrophenone derivatives (N05AD)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	6058	J01MA	J01M	N05AD	N05A
2596	ciprofloxacin	enhances	3A457	hydrocortisone	C	J01MA02	H02AB09	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0					J01MA	J01M	H02AB	H02A
2599	ciprofloxacin	enhances	3A457	imatinib		J01MA02	L01XE01	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	0	0				J01MA	J01M	L01XE	L01X
2600	ciprofloxacin	enhances	1A2	imipramine	D	J01MA02	N06AA02	Fluoroquinolones (J01MA)	Non-selective monoamine reuptake inhibitors (N06AA)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01MA	J01M	N06AA	N06A
2601	ciprofloxacin	enhances	3A457	indacaterol		J01MA02	R03AC18	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				4926	J01MA	J01M	R03AC	R03A
2605	ciprofloxacin	enhances	3A457	ivabradine		J01MA02	C01EB17	Fluoroquinolones (J01MA)	Other cardiac preparations (C01EB)	Quinolone antibacterials (J01M)	Other cardiac preparations (C01E)	0					J01MA	J01M	C01EB	C01E
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			299	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			340	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			671	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1137	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1642	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2064	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2258	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2424	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2548	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2711	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2729	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2841	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2858	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2868	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2933	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3004	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3034	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3179	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3437	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3740	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3743	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3782	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4062	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4724	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4926	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5241	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5285	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5330	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5924	J01MA	J01M	A02BC	A02B
2607	ciprofloxacin	enhances	3A457	lansoprazole		J01MA02	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7555	J01MA	J01M	A02BC	A02B
2609	ciprofloxacin	enhances	3A457	lercanidipine		J01MA02	C08CA13	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4532	J01MA	J01M	C08CA	C08C
2609	ciprofloxacin	enhances	3A457	lercanidipine		J01MA02	C08CA13	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4664	J01MA	J01M	C08CA	C08C
2609	ciprofloxacin	enhances	3A457	lercanidipine		J01MA02	C08CA13	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5990	J01MA	J01M	C08CA	C08C
2613	ciprofloxacin	enhances	3A457	lovastatin	C	J01MA02	C10AA02	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2884	J01MA	J01M	C10AA	C10A
2615	ciprofloxacin	enhances	3A457	methadone	D	J01MA02	N07BC02	Fluoroquinolones (J01MA)	Drugs used in opioid dependence (N07BC)	Quinolone antibacterials (J01M)	Drugs used in addictive disorders (N07B)	0	0				J01MA	J01M	N07BC	N07B
2617	ciprofloxacin	enhances	3A457	midazolam	C	J01MA02	N05CD08	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05CD)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05CD	N05C
2621	ciprofloxacin	enhances	1A2	naproxen		J01MA02	M01AE02	Fluoroquinolones (J01MA)	Propionic acid derivatives (M01AE)	Quinolone antibacterials (J01M)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01MA	J01M	M01AE	M01A
2625	ciprofloxacin	enhances	3A457	nevirapine		J01MA02	J05AG01	Fluoroquinolones (J01MA)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AG	J05A
2626	ciprofloxacin	enhances	3A457	nifedipine		J01MA02	C08CA05	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1137	J01MA	J01M	C08CA	C08C
2626	ciprofloxacin	enhances	3A457	nifedipine		J01MA02	C08CA05	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2761	J01MA	J01M	C08CA	C08C
2626	ciprofloxacin	enhances	3A457	nifedipine		J01MA02	C08CA05	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3543	J01MA	J01M	C08CA	C08C
2626	ciprofloxacin	enhances	3A457	nifedipine		J01MA02	C08CA05	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5924	J01MA	J01M	C08CA	C08C
2627	ciprofloxacin	enhances	3A457	nisoldipine		J01MA02	C08CA07	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
2628	ciprofloxacin	enhances	3A457	nitrendipine		J01MA02	C08CA08	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
2629	ciprofloxacin	enhances	1A2	olanzapine	D	J01MA02	N05AH03	Fluoroquinolones (J01MA)	Diazepines, oxazepines and thiazepines (N05AH)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3068	J01MA	J01M	N05AH	N05A
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			119	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			203	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			631	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			720	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1064	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1065	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1379	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2131	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2138	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2386	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2778	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2825	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2980	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3058	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3296	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3303	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3308	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3438	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3475	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3492	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3543	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3688	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3958	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4011	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4125	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4251	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4368	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4664	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5196	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5544	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5990	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6146	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6169	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7585	J01MA	J01M	A02BC	A02B
2631	ciprofloxacin	enhances	3A457	omeprazole		J01MA02	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7705	J01MA	J01M	A02BC	A02B
2632	ciprofloxacin	enhances	1A2,3A457	ondansetron	D	J01MA02	A04AA01	Fluoroquinolones (J01MA)	Serotonin (5HT3) antagonists (A04AA)	Quinolone antibacterials (J01M)	Antiemetics and antinauseants (A04A)	0	0				J01MA	J01M	A04AA	A04A
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1505	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3518	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3816	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4250	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4352	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4374	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4429	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4508	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5321	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5970	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6072	J01MA	J01M	A02BC	A02B
2639	ciprofloxacin	enhances	3A457	pantoprazole		J01MA02	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7425	J01MA	J01M	A02BC	A02B
2648	ciprofloxacin	enhances	1A2,3A457	propranolol	B	J01MA02	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				649	J01MA	J01M	C07AA	C07A
2648	ciprofloxacin	enhances	1A2,3A457	propranolol	B	J01MA02	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				2825	J01MA	J01M	C07AA	C07A
2648	ciprofloxacin	enhances	1A2,3A457	propranolol	B	J01MA02	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				2938	J01MA	J01M	C07AA	C07A
2648	ciprofloxacin	enhances	1A2,3A457	propranolol	B	J01MA02	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				3475	J01MA	J01M	C07AA	C07A
2649	ciprofloxacin	enhances	3A457	quetiapine	D	J01MA02	N05AH04	Fluoroquinolones (J01MA)	Diazepines, oxazepines and thiazepines (N05AH)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0				2552	J01MA	J01M	N05AH	N05A
2649	ciprofloxacin	enhances	3A457	quetiapine	D	J01MA02	N05AH04	Fluoroquinolones (J01MA)	Diazepines, oxazepines and thiazepines (N05AH)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0				3816	J01MA	J01M	N05AH	N05A
2655	ciprofloxacin	enhances	1A2	riluzole	B	J01MA02	N07XX02	Fluoroquinolones (J01MA)	Other nervous system drugs (N07XX)	Quinolone antibacterials (J01M)	Other nervous system drugs (N07X)	0	0				J01MA	J01M	N07XX	N07X
2656	ciprofloxacin	enhances	3A457	risperidone	D	J01MA02	N05AX08	Fluoroquinolones (J01MA)	Other antipsychotics (N05AX)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5330	J01MA	J01M	N05AX	N05A
2657	ciprofloxacin	enhances	3A457	ritonavir	D	J01MA02	J05AE03	Fluoroquinolones (J01MA)	Protease inhibitors (J05AE)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AE	J05A
2658	ciprofloxacin	enhances	3A457	rivaroxaban		J01MA02	B01AF01	Fluoroquinolones (J01MA)	Direct factor Xa inhibitors (B01AF)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AF	B01A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				631	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				1137	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				1505	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				1619	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				2535	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				3004	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				4031	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				4532	J01MA	J01M	R03AC	R03A
2665	ciprofloxacin	enhances	3A457	salmeterol	D	J01MA02	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0				6146	J01MA	J01M	R03AC	R03A
2666	ciprofloxacin	enhances	3A457	saquinavir	D	J01MA02	J05AE01	Fluoroquinolones (J01MA)	Protease inhibitors (J05AE)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AE	J05A
2668	ciprofloxacin	enhances	3A457	sildenafil	B	J01MA02	G04BE03	Fluoroquinolones (J01MA)	Drugs used in erectile dysfunction (G04BE)	Quinolone antibacterials (J01M)	Urologicals (G04B)	0	0				J01MA	J01M	G04BE	G04B
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3068	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3537	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3696	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3816	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4125	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4429	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5238	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5240	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5241	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5544	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5990	J01MA	J01M	C10AA	C10A
2670	ciprofloxacin	enhances	3A457	simvastatin	C	J01MA02	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7705	J01MA	J01M	C10AA	C10A
2671	ciprofloxacin	enhances	3A457	sirolimus		J01MA02	L04AA10	Fluoroquinolones (J01MA)	Selective immunosuppressants (L04AA)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01MA	J01M	L04AA	L04A
2673	ciprofloxacin	enhances	3A457	sorafenib	D	J01MA02	L01XE05	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	1					J01MA	J01M	L01XE	L01X
2674	ciprofloxacin	enhances	3A457	sunitinib	D	J01MA02	L01XE04	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	1					J01MA	J01M	L01XE	L01X
2677	ciprofloxacin	enhances	3A457	tacrolimus	D	J01MA02	L04AD02	Fluoroquinolones (J01MA)	Calcineurin inhibitors (L04AD)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		5321	J01MA	J01M	L04AD	L04A
2678	ciprofloxacin	enhances	3A457	tadalafil		J01MA02	G04BE08	Fluoroquinolones (J01MA)	Drugs used in erectile dysfunction (G04BE)	Quinolone antibacterials (J01M)	Urologicals (G04B)	0	0				J01MA	J01M	G04BE	G04B
2679	ciprofloxacin	enhances	3A457	tamoxifen	D	J01MA02	L02BA01	Fluoroquinolones (J01MA)	Anti-estrogens (L02BA)	Quinolone antibacterials (J01M)	Hormone antagonists and related agents (L02B)	1	1			2938	J01MA	J01M	L02BA	L02B
2685	ciprofloxacin	enhances	3A457	testosterone		J01MA02	G03BA03	Fluoroquinolones (J01MA)	3-oxoandrosten (4) derivatives (G03BA)	Quinolone antibacterials (J01M)	Androgens (G03B)	0				7612	J01MA	J01M	G03BA	G03B
2686	ciprofloxacin	enhances	1A2	theophylline	D	J01MA02	R03DA04	Fluoroquinolones (J01MA)	Xanthines (R03DA)	Quinolone antibacterials (J01M)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2154	J01MA	J01M	R03DA	R03D
2686	ciprofloxacin	enhances	1A2	theophylline	D	J01MA02	R03DA04	Fluoroquinolones (J01MA)	Xanthines (R03DA)	Quinolone antibacterials (J01M)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			4352	J01MA	J01M	R03DA	R03D
2687	ciprofloxacin	enhances	3A457	ticagrelor		J01MA02	B01AC24	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AC	B01A
2688	ciprofloxacin	enhances	1A2	tizanidine	D	J01MA02	M03BX02	Fluoroquinolones (J01MA)	Other centrally acting agents (M03BX)	Quinolone antibacterials (J01M)	Muscle relaxants, centrally acting agents (M03B)	1	0				J01MA	J01M	M03BX	M03B
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	8	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	21	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	299	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	2064	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	2778	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	2841	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	4548	J01MA	J01M	N02AX	N02A
2691	ciprofloxacin	enhances	3A457	tramadol		J01MA02	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect	5814	J01MA	J01M	N02AX	N02A
2692	ciprofloxacin	enhances	3A457	trazodone	D	J01MA02	N06AX05	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		1368	J01MA	J01M	N06AX	N06A
2692	ciprofloxacin	enhances	3A457	trazodone	D	J01MA02	N06AX05	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		2868	J01MA	J01M	N06AX	N06A
2692	ciprofloxacin	enhances	3A457	trazodone	D	J01MA02	N06AX05	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		4532	J01MA	J01M	N06AX	N06A
2692	ciprofloxacin	enhances	3A457	trazodone	D	J01MA02	N06AX05	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		4548	J01MA	J01M	N06AX	N06A
2693	ciprofloxacin	enhances	1A2	triamterene		J01MA02	C03DB02	Fluoroquinolones (J01MA)	Other potassium-sparing agents (C03DB)	Quinolone antibacterials (J01M)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			J01MA	J01M	C03DB	C03D
2694	ciprofloxacin	enhances	3A457	triazolam	C	J01MA02	N05CD05	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05CD)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05CD	N05C
2701	ciprofloxacin	enhances	3A457	venlafaxine	D	J01MA02	N06AX16	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		2386	J01MA	J01M	N06AX	N06A
2701	ciprofloxacin	enhances	3A457	venlafaxine	D	J01MA02	N06AX16	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity		7705	J01MA	J01M	N06AX	N06A
2702	ciprofloxacin	enhances	1A2,3A457	verapamil		J01MA02	C08DA01	Fluoroquinolones (J01MA)	Phenylalkylamine derivatives (C08DA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2258	J01MA	J01M	C08DA	C08D
2702	ciprofloxacin	enhances	1A2,3A457	verapamil		J01MA02	C08DA01	Fluoroquinolones (J01MA)	Phenylalkylamine derivatives (C08DA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2981	J01MA	J01M	C08DA	C08D
2702	ciprofloxacin	enhances	1A2,3A457	verapamil		J01MA02	C08DA01	Fluoroquinolones (J01MA)	Phenylalkylamine derivatives (C08DA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3058	J01MA	J01M	C08DA	C08D
2702	ciprofloxacin	enhances	1A2,3A457	verapamil		J01MA02	C08DA01	Fluoroquinolones (J01MA)	Phenylalkylamine derivatives (C08DA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3711	J01MA	J01M	C08DA	C08D
2706	ciprofloxacin	enhances	3A457	voriconazole	D	J01MA02	J02AC03	Fluoroquinolones (J01MA)	Triazole derivatives (J02AC)	Quinolone antibacterials (J01M)	Antimycotics for systemic use (J02A)	0	0				J01MA	J01M	J02AC	J02A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		862	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		1272	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		2011	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		2058	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		2548	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		2761	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		2980	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		3179	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		3537	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		3622	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		4660	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		5238	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		5241	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		5316	J01MA	J01M	B01AA	B01A
2707	ciprofloxacin	enhances	1A2	warfarin	C	J01MA02	B01AA03	Fluoroquinolones (J01MA)	Vitamin K antagonists (B01AA)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	1	0	Bleeding		6146	J01MA	J01M	B01AA	B01A
2708	ciprofloxacin	enhances	3A457	zaleplon		J01MA02	N05CF03	Fluoroquinolones (J01MA)	Benzodiazepine related drugs (N05CF)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0					J01MA	J01M	N05CF	N05C
2712	ciprofloxacin	enhances	3A457	zolpidem		J01MA02	N05CF02	Fluoroquinolones (J01MA)	Benzodiazepine related drugs (N05CF)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0				3058	J01MA	J01M	N05CF	N05C
2712	ciprofloxacin	enhances	3A457	zolpidem		J01MA02	N05CF02	Fluoroquinolones (J01MA)	Benzodiazepine related drugs (N05CF)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0				3968	J01MA	J01M	N05CF	N05C
2713	citalopram	enhances	1A2	acetaminophen		N06AB04	N02BE01	Selective serotonin reuptake inhibitors (N06AB)	Anilides (N02BE)	Antidepressants (N06A)	Other analgesics and antipyretics (N02B)	0	0			728	N06AB	N06A	N02BE	N02B
2713	citalopram	enhances	1A2	acetaminophen		N06AB04	N02BE01	Selective serotonin reuptake inhibitors (N06AB)	Anilides (N02BE)	Antidepressants (N06A)	Other analgesics and antipyretics (N02B)	0	0			3142	N06AB	N06A	N02BE	N02B
2713	citalopram	enhances	1A2	acetaminophen		N06AB04	N02BE01	Selective serotonin reuptake inhibitors (N06AB)	Anilides (N02BE)	Antidepressants (N06A)	Other analgesics and antipyretics (N02B)	0	0			4209	N06AB	N06A	N02BE	N02B
2713	citalopram	enhances	1A2	acetaminophen		N06AB04	N02BE01	Selective serotonin reuptake inhibitors (N06AB)	Anilides (N02BE)	Antidepressants (N06A)	Other analgesics and antipyretics (N02B)	0	0			6243	N06AB	N06A	N02BE	N02B
2716	citalopram	enhances	1A2,2C19,2D6	amitriptyline	D	N06AB04	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity		4209	N06AB	N06A	N06AA	N06A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	600	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	770	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1537	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2294	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2361	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2503	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3824	N06AB	N06A	C07AG	C07A
2725	citalopram	enhances	2D6	carvedilol		N06AB04	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6014	N06AB	N06A	C07AG	C07A
2727	citalopram	enhances	2D6	chlorpheniramine	B	N06AB04	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
2728	citalopram	enhances	2D6	chlorpromazine	D	N06AB04	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AA	N05A
2729	citalopram	enhances	2C19	clobazam		N06AB04	N05BA09	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0					N06AB	N06A	N05BA	N05B
2730	citalopram	enhances	1A2,2C19,2D6	clomipramine	D	N06AB04	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
2731	citalopram	enhances	2D6	clonidine		N06AB04	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				2294	N06AB	N06A	C02AC	C02A
2731	citalopram	enhances	2D6	clonidine		N06AB04	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				2813	N06AB	N06A	C02AC	C02A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	353	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	994	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2436	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3004	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3477	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3483	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5242	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7084	N06AB	N06A	B01AC	B01A
2732	citalopram	enhances	2C19	clopidogrel	B	N06AB04	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7721	N06AB	N06A	B01AC	B01A
2733	citalopram	enhances	1A2	clozapine	D	N06AB04	N05AH02	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AH	N05A
2736	citalopram	enhances	2C19	cyclophosphamide		N06AB04	L01AA01	Selective serotonin reuptake inhibitors (N06AB)	Nitrogen mustard analogues (L01AA)	Antidepressants (N06A)	Alkylating agents (L01A)	1	1				N06AB	N06A	L01AA	L01A
2740	citalopram	enhances	2D6	dextromethorphan	C	N06AB04	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
2741	citalopram	enhances	2C19	diazepam	B	N06AB04	N05BA01	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2456	N06AB	N06A	N05BA	N05B
2742	citalopram	enhances	2D6	donepezil	D	N06AB04	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				7251	N06AB	N06A	N06DA	N06D
2744	citalopram	enhances	1A2,2D6	duloxetine	D	N06AB04	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
2747	citalopram	enhances	2C19,2D6	escitalopram	D	N06AB04	N06AB10	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AB	N06A	N06AB	N06A
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				278	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				353	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2251	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3526	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3536	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3982	N06AB	N06A	A02BC	A02B
2748	citalopram	enhances	2C19	esomeprazole		N06AB04	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5007	N06AB	N06A	A02BC	A02B
2750	citalopram	enhances	2D6	flecainide	D	N06AB04	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N06AB	N06A	C01BC	C01B
2752	citalopram	enhances	2D6	fluoxetine	D	N06AB04	N06AB03	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
2753	citalopram	enhances	1A2,2D6	fluvoxamine	D	N06AB04	N06AB08	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
2754	citalopram	enhances	1A2,2D6	haloperidol	D	N06AB04	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3047	N06AB	N06A	N05AD	N05A
2757	citalopram	enhances	1A2,2C19,2D6	imipramine	D	N06AB04	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
2758	citalopram	enhances	2C19	indometacin	C	N06AB04	M01AB01	Selective serotonin reuptake inhibitors (N06AB)	Acetic acid derivatives and related substances (M01AB)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N06AB	N06A	M01AB	M01A
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			107	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			278	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			608	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			672	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			994	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1082	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1107	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1286	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1366	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1537	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1560	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2289	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2456	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2567	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2813	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2861	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2899	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3004	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3069	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3075	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3108	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3204	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4135	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5242	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5486	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6014	N06AB	N06A	A02BC	A02B
2760	citalopram	enhances	2C19	lansoprazole		N06AB04	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6239	N06AB	N06A	A02BC	A02B
2765	citalopram	enhances	2D6	metoclopramide	D	N06AB04	A03FA01	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0				3004	N06AB	N06A	A03FA	A03F
2766	citalopram	enhances	2D6	metoprolol	B	N06AB04	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1082	N06AB	N06A	C07AB	C07A
2766	citalopram	enhances	2D6	metoprolol	B	N06AB04	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2456	N06AB	N06A	C07AB	C07A
2766	citalopram	enhances	2D6	metoprolol	B	N06AB04	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2861	N06AB	N06A	C07AB	C07A
2766	citalopram	enhances	2D6	metoprolol	B	N06AB04	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3004	N06AB	N06A	C07AB	C07A
2766	citalopram	enhances	2D6	metoprolol	B	N06AB04	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3142	N06AB	N06A	C07AB	C07A
2771	citalopram	enhances	1A2	naproxen	C	N06AB04	M01AE02	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AE	M01A
2772	citalopram	enhances	2D6	nebivolol		N06AB04	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1006	N06AB	N06A	C07AB	C07A
2772	citalopram	enhances	2D6	nebivolol		N06AB04	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1515	N06AB	N06A	C07AB	C07A
2772	citalopram	enhances	2D6	nebivolol		N06AB04	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				7084	N06AB	N06A	C07AB	C07A
2775	citalopram	enhances	2D6	nortriptyline	D	N06AB04	N06AA10	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AB	N06A	N06AA	N06A
2776	citalopram	enhances	1A2	olanzapine	D	N06AB04	N05AH03	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2798	N06AB	N06A	N05AH	N05A
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			336	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			600	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			728	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			902	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1009	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1026	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1164	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1267	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1378	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1581	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2521	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2899	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3298	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3477	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3503	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3656	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4209	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5462	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5902	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5925	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6006	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6244	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7251	N06AB	N06A	A02BC	A02B
2777	citalopram	enhances	2C19	omeprazole		N06AB04	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7721	N06AB	N06A	A02BC	A02B
2778	citalopram	enhances	1A2,2D6	ondansetron	D	N06AB04	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AB	N06A	A04AA	A04A
2780	citalopram	enhances	2D6	oxycodone		N06AB04	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	278	N06AB	N06A	N02AA	N02A
2780	citalopram	enhances	2D6	oxycodone		N06AB04	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	1378	N06AB	N06A	N02AA	N02A
2780	citalopram	enhances	2D6	oxycodone		N06AB04	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7118	N06AB	N06A	N02AA	N02A
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			260	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			353	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2436	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3483	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3490	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5033	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7044	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7118	N06AB	N06A	A02BC	A02B
2782	citalopram	enhances	2C19	pantoprazole		N06AB04	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7513	N06AB	N06A	A02BC	A02B
2783	citalopram	enhances	2D6	paroxetine	D	N06AB04	N06AB05	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
2788	citalopram	enhances	2C19	phenobarbital		N06AB04	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	336	N06AB	N06A	N03AA	N03A
2788	citalopram	enhances	2C19	phenobarbital		N06AB04	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1163	N06AB	N06A	N03AA	N03A
2788	citalopram	enhances	2C19	phenobarbital		N06AB04	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1378	N06AB	N06A	N03AA	N03A
2788	citalopram	enhances	2C19	phenobarbital		N06AB04	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3324	N06AB	N06A	N03AA	N03A
2789	citalopram	enhances	2C19	phenytoin		N06AB04	N03AB02	Selective serotonin reuptake inhibitors (N06AB)	Hydantoin derivatives (N03AB)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AB	N03A
2794	citalopram	enhances	2C19	primidone		N06AB04	N03AA03	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	0				1006	N06AB	N06A	N03AA	N03A
2797	citalopram	enhances	2D6	promethazine	D	N06AB04	R06AD02	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0				2173	N06AB	N06A	R06AD	R06A
2798	citalopram	enhances	2D6	propafenone	D	N06AB04	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3503	N06AB	N06A	C01BC	C01B
2799	citalopram	enhances	1A2,2C19,2D6	propranolol		N06AB04	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1006	N06AB	N06A	C07AA	C07A
2799	citalopram	enhances	1A2,2C19,2D6	propranolol		N06AB04	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2363	N06AB	N06A	C07AA	C07A
2800	citalopram	enhances	1A2	riluzole		N06AB04	N07XX02	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0	0				N06AB	N06A	N07XX	N07X
2801	citalopram	enhances	2D6	risperidone	D	N06AB04	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1286	N06AB	N06A	N05AX	N05A
2801	citalopram	enhances	2D6	risperidone	D	N06AB04	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2567	N06AB	N06A	N05AX	N05A
2808	citalopram	enhances	2D6	tamoxifen	D	N06AB04	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AB	N06A	L02BA	L02B
2811	citalopram	enhances	2D6	tetrabenazine	D	N06AB04	N07XX06	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AB	N06A	N07XX	N07X
2812	citalopram	enhances	1A2	theophylline		N06AB04	R03DA04	Selective serotonin reuptake inhibitors (N06AB)	Xanthines (R03DA)	Antidepressants (N06A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				N06AB	N06A	R03DA	R03D
2815	citalopram	enhances	1A2	tizanidine	D	N06AB04	M03BX02	Selective serotonin reuptake inhibitors (N06AB)	Other centrally acting agents (M03BX)	Antidepressants (N06A)	Muscle relaxants, centrally acting agents (M03B)	1	0				N06AB	N06A	M03BX	M03B
2817	citalopram	enhances	2D6	tramadol	D	N06AB04	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	728	N06AB	N06A	N02AX	N02A
2817	citalopram	enhances	2D6	tramadol	D	N06AB04	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	1515	N06AB	N06A	N02AX	N02A
2817	citalopram	enhances	2D6	tramadol	D	N06AB04	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	2251	N06AB	N06A	N02AX	N02A
2817	citalopram	enhances	2D6	tramadol	D	N06AB04	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	2540	N06AB	N06A	N02AX	N02A
2817	citalopram	enhances	2D6	tramadol	D	N06AB04	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	5814	N06AB	N06A	N02AX	N02A
2818	citalopram	enhances	1A2	triamterene		N06AB04	C03DB02	Selective serotonin reuptake inhibitors (N06AB)	Other potassium-sparing agents (C03DB)	Antidepressants (N06A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			N06AB	N06A	C03DB	C03D
2821	citalopram	enhances	2C19,2D6	venlafaxine	D	N06AB04	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
2822	citalopram	enhances	1A2	verapamil		N06AB04	C08DA01	Selective serotonin reuptake inhibitors (N06AB)	Phenylalkylamine derivatives (C08DA)	Antidepressants (N06A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5638	N06AB	N06A	C08DA	C08D
2824	citalopram	enhances	2C19	voriconazole	D	N06AB04	J02AC03	Selective serotonin reuptake inhibitors (N06AB)	Triazole derivatives (J02AC)	Antidepressants (N06A)	Antimycotics for systemic use (J02A)	0	0				N06AB	N06A	J02AC	J02A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		278	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		1046	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		1163	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		1378	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		1515	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		2311	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		2861	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		3108	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		3304	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		4135	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		4154	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		5902	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		6014	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		6243	N06AB	N06A	B01AA	B01A
2825	citalopram	enhances	1A2,2C19	warfarin	B	N06AB04	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		7513	N06AB	N06A	B01AA	B01A
2828	citalopram	enhances	2D6	zuclopenthixol		N06AB04	N05AF05	Selective serotonin reuptake inhibitors (N06AB)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AF	N05A
2834	clarithromycin	enhances	3A457	alprazolam	D	J01FA09	N05BA12	Macrolides (J01FA)	Benzodiazepine derivatives (N05BA)	Macrolides, lincosamides and streptogramins (J01F)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1550	J01FA	J01F	N05BA	N05B
2834	clarithromycin	enhances	3A457	alprazolam	D	J01FA09	N05BA12	Macrolides (J01FA)	Benzodiazepine derivatives (N05BA)	Macrolides, lincosamides and streptogramins (J01F)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2597	J01FA	J01F	N05BA	N05B
2834	clarithromycin	enhances	3A457	alprazolam	D	J01FA09	N05BA12	Macrolides (J01FA)	Benzodiazepine derivatives (N05BA)	Macrolides, lincosamides and streptogramins (J01F)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4583	J01FA	J01F	N05BA	N05B
2835	clarithromycin	enhances	3A457	amitriptyline	D	J01FA09	N06AA09	Macrolides (J01FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01FA	J01F	N06AA	N06A
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2152	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2439	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2614	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3819	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4371	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4640	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6048	J01FA	J01F	C08CA	C08C
2836	clarithromycin	enhances	3A457	amlodipine	C	J01FA09	C08CA01	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7040	J01FA	J01F	C08CA	C08C
2837	clarithromycin	enhances	3A457	apixaban	D	J01FA09	B01AF02	Macrolides (J01FA)	Direct factor Xa inhibitors (B01AF)	Macrolides, lincosamides and streptogramins (J01F)	Antithrombotic agents (B01A)	0					J01FA	J01F	B01AF	B01A
2841	clarithromycin	enhances	3A457	atorvastatin	C	J01FA09	C10AA05	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1004	J01FA	J01F	C10AA	C10A
2841	clarithromycin	enhances	3A457	atorvastatin	C	J01FA09	C10AA05	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1455	J01FA	J01F	C10AA	C10A
2841	clarithromycin	enhances	3A457	atorvastatin	C	J01FA09	C10AA05	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3819	J01FA	J01F	C10AA	C10A
2841	clarithromycin	enhances	3A457	atorvastatin	C	J01FA09	C10AA05	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3972	J01FA	J01F	C10AA	C10A
2852	clarithromycin	enhances	3A457	chlorpheniramine		J01FA09	R06AB04	Macrolides (J01FA)	Substituted alkylamines (R06AB)	Macrolides, lincosamides and streptogramins (J01F)	Antihistamines for systemic use (R06A)	0	0				J01FA	J01F	R06AB	R06A
2853	clarithromycin	enhances	3A457	cilostazol	D	J01FA09	B01AC23	Macrolides (J01FA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Macrolides, lincosamides and streptogramins (J01F)	Antithrombotic agents (B01A)	0					J01FA	J01F	B01AC	B01A
2855	clarithromycin	enhances	3A457	citalopram	D	J01FA09	N06AB04	Macrolides (J01FA)	Selective serotonin reuptake inhibitors (N06AB)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	0	0			260	J01FA	J01F	N06AB	N06A
2856	clarithromycin	enhances	3A457	clopidogrel		J01FA09	B01AC04	Macrolides (J01FA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Macrolides, lincosamides and streptogramins (J01F)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J01FA	J01F	B01AC	B01A
2860	clarithromycin	enhances	3A457	colchicine	C	J01FA09	M04AC01	Macrolides (J01FA)	Preparations with no effect on uric acid metabolism (M04AC)	Macrolides, lincosamides and streptogramins (J01F)	Antigout preparations (M04A)	0					J01FA	J01F	M04AC	M04A
2863	clarithromycin	enhances	3A457	cyclosporine	D	J01FA09	L04AD01	Macrolides (J01FA)	Calcineurin inhibitors (L04AD)	Macrolides, lincosamides and streptogramins (J01F)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01FA	J01F	L04AD	L04A
2866	clarithromycin	enhances	3A457	deflazacort		J01FA09	H02AB13	Macrolides (J01FA)	Glucocorticoids (H02AB)	Macrolides, lincosamides and streptogramins (J01F)	Corticosteroids for systemic use, plain (H02A)	0				5273	J01FA	J01F	H02AB	H02A
2867	clarithromycin	enhances	3A457	dexamethasone		J01FA09	H02AB02	Macrolides (J01FA)	Glucocorticoids (H02AB)	Macrolides, lincosamides and streptogramins (J01F)	Corticosteroids for systemic use, plain (H02A)	0				1004	J01FA	J01F	H02AB	H02A
2868	clarithromycin	enhances	3A457	dextromethorphan	B	J01FA09	R05DA09	Macrolides (J01FA)	Opium alkaloids and derivatives (R05DA)	Macrolides, lincosamides and streptogramins (J01F)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J01FA	J01F	R05DA	R05D
2869	clarithromycin	enhances	3A457	diazepam	B	J01FA09	N05BA01	Macrolides (J01FA)	Benzodiazepine derivatives (N05BA)	Macrolides, lincosamides and streptogramins (J01F)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01FA	J01F	N05BA	N05B
2870	clarithromycin	enhances	3A457	diltiazem	C	J01FA09	C08DB01	Macrolides (J01FA)	Benzothiazepine derivatives (C08DB)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5206	J01FA	J01F	C08DB	C08D
2870	clarithromycin	enhances	3A457	diltiazem	C	J01FA09	C08DB01	Macrolides (J01FA)	Benzothiazepine derivatives (C08DB)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5654	J01FA	J01F	C08DB	C08D
2873	clarithromycin	enhances	3A457	domperidone	D	J01FA09	A03FA03	Macrolides (J01FA)	Propulsives (A03FA)	Macrolides, lincosamides and streptogramins (J01F)	Propulsives (A03F)	0					J01FA	J01F	A03FA	A03F
2877	clarithromycin	enhances	3A457	eplerenone	D	J01FA09	C03DA04	Macrolides (J01FA)	Aldosterone antagonists (C03DA)	Macrolides, lincosamides and streptogramins (J01F)	Potassium-sparing agents (C03D)	0					J01FA	J01F	C03DA	C03D
2880	clarithromycin	enhances	3A457	escitalopram	D	J01FA09	N06AB10	Macrolides (J01FA)	Selective serotonin reuptake inhibitors (N06AB)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	0				1481	J01FA	J01F	N06AB	N06A
2880	clarithromycin	enhances	3A457	escitalopram	D	J01FA09	N06AB10	Macrolides (J01FA)	Selective serotonin reuptake inhibitors (N06AB)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	0				5771	J01FA	J01F	N06AB	N06A
2881	clarithromycin	enhances	3A457	esomeprazole		J01FA09	A02BC05	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1459	J01FA	J01F	A02BC	A02B
2881	clarithromycin	enhances	3A457	esomeprazole		J01FA09	A02BC05	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3699	J01FA	J01F	A02BC	A02B
2881	clarithromycin	enhances	3A457	esomeprazole		J01FA09	A02BC05	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3972	J01FA	J01F	A02BC	A02B
2883	clarithromycin	enhances	3A457	felodipine	C	J01FA09	C08CA02	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01FA	J01F	C08CA	C08C
2887	clarithromycin	enhances	3A457	haloperidol	D	J01FA09	N05AD01	Macrolides (J01FA)	Butyrophenone derivatives (N05AD)	Macrolides, lincosamides and streptogramins (J01F)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J01FA	J01F	N05AD	N05A
2888	clarithromycin	enhances	3A457	hydrocortisone		J01FA09	H02AB09	Macrolides (J01FA)	Glucocorticoids (H02AB)	Macrolides, lincosamides and streptogramins (J01F)	Corticosteroids for systemic use, plain (H02A)	0					J01FA	J01F	H02AB	H02A
2891	clarithromycin	enhances	3A457	imatinib	D	J01FA09	L01XE01	Macrolides (J01FA)	 (L01XE)	Macrolides, lincosamides and streptogramins (J01F)	Other antineoplastic agents (L01X)	0	0				J01FA	J01F	L01XE	L01X
2892	clarithromycin	enhances	3A457	indacaterol		J01FA09	R03AC18	Macrolides (J01FA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Macrolides, lincosamides and streptogramins (J01F)	Adrenergics, inhalants (R03A)	0					J01FA	J01F	R03AC	R03A
2896	clarithromycin	enhances	3A457	ivabradine		J01FA09	C01EB17	Macrolides (J01FA)	Other cardiac preparations (C01EB)	Macrolides, lincosamides and streptogramins (J01F)	Other cardiac preparations (C01E)	0					J01FA	J01F	C01EB	C01E
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			341	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1481	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1550	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2016	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2439	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3614	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4213	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4317	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5654	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5847	J01FA	J01F	A02BC	A02B
2898	clarithromycin	enhances	3A457	lansoprazole	D	J01FA09	A02BC03	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5860	J01FA	J01F	A02BC	A02B
2900	clarithromycin	enhances	3A457	lercanidipine		J01FA09	C08CA13	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3815	J01FA	J01F	C08CA	C08C
2904	clarithromycin	enhances	3A457	lovastatin	C	J01FA09	C10AA02	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J01FA	J01F	C10AA	C10A
2906	clarithromycin	enhances	3A457	methadone	D	J01FA09	N07BC02	Macrolides (J01FA)	Drugs used in opioid dependence (N07BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs used in addictive disorders (N07B)	0	0				J01FA	J01F	N07BC	N07B
2907	clarithromycin	enhances	3A457	midazolam	D	J01FA09	N05CD08	Macrolides (J01FA)	Benzodiazepine derivatives (N05CD)	Macrolides, lincosamides and streptogramins (J01F)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01FA	J01F	N05CD	N05C
2913	clarithromycin	enhances	3A457	nifedipine	C	J01FA09	C08CA05	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2166	J01FA	J01F	C08CA	C08C
2914	clarithromycin	enhances	3A457	nisoldipine		J01FA09	C08CA07	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01FA	J01F	C08CA	C08C
2915	clarithromycin	enhances	3A457	nitrendipine		J01FA09	C08CA08	Macrolides (J01FA)	Dihydropyridine derivatives (C08CA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01FA	J01F	C08CA	C08C
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			952	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1455	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2357	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3819	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4208	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5099	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5138	J01FA	J01F	A02BC	A02B
2917	clarithromycin	enhances	3A457	omeprazole		J01FA09	A02BC01	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5805	J01FA	J01F	A02BC	A02B
2918	clarithromycin	enhances	3A457	ondansetron	D	J01FA09	A04AA01	Macrolides (J01FA)	Serotonin (5HT3) antagonists (A04AA)	Macrolides, lincosamides and streptogramins (J01F)	Antiemetics and antinauseants (A04A)	0	0				J01FA	J01F	A04AA	A04A
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			260	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1147	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2597	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3815	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4371	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5206	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5771	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6046	J01FA	J01F	A02BC	A02B
2925	clarithromycin	enhances	3A457	pantoprazole		J01FA09	A02BC02	Macrolides (J01FA)	Proton pump inhibitors (A02BC)	Macrolides, lincosamides and streptogramins (J01F)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6048	J01FA	J01F	A02BC	A02B
2932	clarithromycin	enhances	3A457	propranolol		J01FA09	C07AA05	Macrolides (J01FA)	Beta blocking agents, non-selective (C07AA)	Macrolides, lincosamides and streptogramins (J01F)	Beta blocking agents (C07A)	0					J01FA	J01F	C07AA	C07A
2933	clarithromycin	enhances	3A457	quetiapine	D	J01FA09	N05AH04	Macrolides (J01FA)	Diazepines, oxazepines and thiazepines (N05AH)	Macrolides, lincosamides and streptogramins (J01F)	Antipsychotics (N05A)	0					J01FA	J01F	N05AH	N05A
2939	clarithromycin	enhances	3A457	risperidone	D	J01FA09	N05AX08	Macrolides (J01FA)	Other antipsychotics (N05AX)	Macrolides, lincosamides and streptogramins (J01F)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J01FA	J01F	N05AX	N05A
2940	clarithromycin	enhances	3A457	ritonavir	D	J01FA09	J05AE03	Macrolides (J01FA)	Protease inhibitors (J05AE)	Macrolides, lincosamides and streptogramins (J01F)	Direct acting antivirals (J05A)	0	0				J01FA	J01F	J05AE	J05A
2941	clarithromycin	enhances	3A457	rivaroxaban	C	J01FA09	B01AF01	Macrolides (J01FA)	Direct factor Xa inhibitors (B01AF)	Macrolides, lincosamides and streptogramins (J01F)	Antithrombotic agents (B01A)	0				5273	J01FA	J01F	B01AF	B01A
2947	clarithromycin	enhances	3A457	salmeterol	D	J01FA09	R03AC12	Macrolides (J01FA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Macrolides, lincosamides and streptogramins (J01F)	Adrenergics, inhalants (R03A)	0				2671	J01FA	J01F	R03AC	R03A
2947	clarithromycin	enhances	3A457	salmeterol	D	J01FA09	R03AC12	Macrolides (J01FA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Macrolides, lincosamides and streptogramins (J01F)	Adrenergics, inhalants (R03A)	0				4748	J01FA	J01F	R03AC	R03A
2948	clarithromycin	enhances	3A457	saquinavir	D	J01FA09	J05AE01	Macrolides (J01FA)	Protease inhibitors (J05AE)	Macrolides, lincosamides and streptogramins (J01F)	Direct acting antivirals (J05A)	0	0				J01FA	J01F	J05AE	J05A
2950	clarithromycin	enhances	3A457	sildenafil	C	J01FA09	G04BE03	Macrolides (J01FA)	Drugs used in erectile dysfunction (G04BE)	Macrolides, lincosamides and streptogramins (J01F)	Urologicals (G04B)	0	0				J01FA	J01F	G04BE	G04B
2952	clarithromycin	enhances	3A457	simvastatin	C	J01FA09	C10AA01	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1481	J01FA	J01F	C10AA	C10A
2952	clarithromycin	enhances	3A457	simvastatin	C	J01FA09	C10AA01	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2439	J01FA	J01F	C10AA	C10A
2952	clarithromycin	enhances	3A457	simvastatin	C	J01FA09	C10AA01	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4748	J01FA	J01F	C10AA	C10A
2952	clarithromycin	enhances	3A457	simvastatin	C	J01FA09	C10AA01	Macrolides (J01FA)	HMG CoA reductase inhibitors (C10AA)	Macrolides, lincosamides and streptogramins (J01F)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5860	J01FA	J01F	C10AA	C10A
2953	clarithromycin	enhances	3A457	sirolimus	D	J01FA09	L04AA10	Macrolides (J01FA)	Selective immunosuppressants (L04AA)	Macrolides, lincosamides and streptogramins (J01F)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01FA	J01F	L04AA	L04A
2955	clarithromycin	enhances	3A457	sorafenib	D	J01FA09	L01XE05	Macrolides (J01FA)	 (L01XE)	Macrolides, lincosamides and streptogramins (J01F)	Other antineoplastic agents (L01X)	1					J01FA	J01F	L01XE	L01X
2956	clarithromycin	enhances	3A457	sunitinib	D	J01FA09	L01XE04	Macrolides (J01FA)	 (L01XE)	Macrolides, lincosamides and streptogramins (J01F)	Other antineoplastic agents (L01X)	1					J01FA	J01F	L01XE	L01X
2958	clarithromycin	enhances	3A457	tacrolimus	D	J01FA09	L04AD02	Macrolides (J01FA)	Calcineurin inhibitors (L04AD)	Macrolides, lincosamides and streptogramins (J01F)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		1455	J01FA	J01F	L04AD	L04A
2959	clarithromycin	enhances	3A457	tadalafil		J01FA09	G04BE08	Macrolides (J01FA)	Drugs used in erectile dysfunction (G04BE)	Macrolides, lincosamides and streptogramins (J01F)	Urologicals (G04B)	0	0				J01FA	J01F	G04BE	G04B
2960	clarithromycin	enhances	3A457	tamoxifen	D	J01FA09	L02BA01	Macrolides (J01FA)	Anti-estrogens (L02BA)	Macrolides, lincosamides and streptogramins (J01F)	Hormone antagonists and related agents (L02B)	1	1				J01FA	J01F	L02BA	L02B
2966	clarithromycin	enhances	3A457	testosterone		J01FA09	G03BA03	Macrolides (J01FA)	3-oxoandrosten (4) derivatives (G03BA)	Macrolides, lincosamides and streptogramins (J01F)	Androgens (G03B)	0					J01FA	J01F	G03BA	G03B
2967	clarithromycin	enhances	3A457	ticagrelor		J01FA09	B01AC24	Macrolides (J01FA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Macrolides, lincosamides and streptogramins (J01F)	Antithrombotic agents (B01A)	0					J01FA	J01F	B01AC	B01A
2970	clarithromycin	enhances	3A457	tramadol		J01FA09	N02AX02	Macrolides (J01FA)	Other opioids (N02AX)	Macrolides, lincosamides and streptogramins (J01F)	Opioids (N02A)	0	1		Reduced analgesic effect		J01FA	J01F	N02AX	N02A
2971	clarithromycin	enhances	3A457	trazodone	D	J01FA09	N06AX05	Macrolides (J01FA)	Other antidepressants (N06AX)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	0	0	Serotonin toxicity		1481	J01FA	J01F	N06AX	N06A
2972	clarithromycin	enhances	3A457	triazolam	D	J01FA09	N05CD05	Macrolides (J01FA)	Benzodiazepine derivatives (N05CD)	Macrolides, lincosamides and streptogramins (J01F)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3819	J01FA	J01F	N05CD	N05C
2979	clarithromycin	enhances	3A457	venlafaxine	D	J01FA09	N06AX16	Macrolides (J01FA)	Other antidepressants (N06AX)	Macrolides, lincosamides and streptogramins (J01F)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01FA	J01F	N06AX	N06A
2980	clarithromycin	enhances	3A457	verapamil	C	J01FA09	C08DA01	Macrolides (J01FA)	Phenylalkylamine derivatives (C08DA)	Macrolides, lincosamides and streptogramins (J01F)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4748	J01FA	J01F	C08DA	C08D
2984	clarithromycin	enhances	3A457	voriconazole	D	J01FA09	J02AC03	Macrolides (J01FA)	Triazole derivatives (J02AC)	Macrolides, lincosamides and streptogramins (J01F)	Antimycotics for systemic use (J02A)	0	0				J01FA	J01F	J02AC	J02A
2985	clarithromycin	enhances	3A457	zaleplon		J01FA09	N05CF03	Macrolides (J01FA)	Benzodiazepine related drugs (N05CF)	Macrolides, lincosamides and streptogramins (J01F)	Hypnotics and sedatives (N05C)	0					J01FA	J01F	N05CF	N05C
2987	clarithromycin	enhances	3A457	zolpidem		J01FA09	N05CF02	Macrolides (J01FA)	Benzodiazepine related drugs (N05CF)	Macrolides, lincosamides and streptogramins (J01F)	Hypnotics and sedatives (N05C)	0				2439	J01FA	J01F	N05CF	N05C
3056	clobazam	enhances	2D6	carvedilol	B	N05BA09	C07AG02	Benzodiazepine derivatives (N05BA)	Alpha and beta blocking agents (C07AG)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N05BA	N05B	C07AG	C07A
3057	clobazam	enhances	2D6	chlorpromazine		N05BA09	N05AA01	Benzodiazepine derivatives (N05BA)	Phenothiazines with aliphatic side-chain (N05AA)	Anxiolytics (N05B)	Antipsychotics (N05A)	0					N05BA	N05B	N05AA	N05A
3058	clobazam	enhances	2D6	clomipramine	B	N05BA09	N06AA04	Benzodiazepine derivatives (N05BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05BA	N05B	N06AA	N06A
3059	clobazam	enhances	2D6	clonidine		N05BA09	C02AC01	Benzodiazepine derivatives (N05BA)	Imidazoline receptor agonists (C02AC)	Anxiolytics (N05B)	Antiadrenergic agents, centrally acting (C02A)	1					N05BA	N05B	C02AC	C02A
3063	clobazam	enhances	2D6	donepezil		N05BA09	N06DA02	Benzodiazepine derivatives (N05BA)	Anticholinesterases (N06DA)	Anxiolytics (N05B)	Anti-dementia drugs (N06D)	0					N05BA	N05B	N06DA	N06D
3064	clobazam	enhances	2D6	duloxetine	B	N05BA09	N06AX21	Benzodiazepine derivatives (N05BA)	Other antidepressants (N06AX)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BA	N05B	N06AX	N06A
3066	clobazam	enhances	2D6	flecainide		N05BA09	C01BC04	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class Ic (C01BC)	Anxiolytics (N05B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N05BA	N05B	C01BC	C01B
3067	clobazam	enhances	2D6	fluoxetine		N05BA09	N06AB03	Benzodiazepine derivatives (N05BA)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BA	N05B	N06AB	N06A
3068	clobazam	enhances	2D6	fluvoxamine	C	N05BA09	N06AB08	Benzodiazepine derivatives (N05BA)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BA	N05B	N06AB	N06A
3069	clobazam	enhances	2D6	imipramine	B	N05BA09	N06AA02	Benzodiazepine derivatives (N05BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05BA	N05B	N06AA	N06A
3071	clobazam	enhances	2D6	metoclopramide		N05BA09	A03FA01	Benzodiazepine derivatives (N05BA)	Propulsives (A03FA)	Anxiolytics (N05B)	Propulsives (A03F)	0					N05BA	N05B	A03FA	A03F
3072	clobazam	enhances	2D6	metoprolol	B	N05BA09	C07AB02	Benzodiazepine derivatives (N05BA)	Beta blocking agents, selective (C07AB)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N05BA	N05B	C07AB	C07A
3075	clobazam	enhances	2D6	nebivolol		N05BA09	C07AB12	Benzodiazepine derivatives (N05BA)	Beta blocking agents, selective (C07AB)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0					N05BA	N05B	C07AB	C07A
3076	clobazam	enhances	2D6	nortriptyline	B	N05BA09	N06AA10	Benzodiazepine derivatives (N05BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1					N05BA	N05B	N06AA	N06A
3077	clobazam	enhances	2D6	oxycodone	C	N05BA09	N02AA05	Benzodiazepine derivatives (N05BA)	Natural opium alkaloids (N02AA)	Anxiolytics (N05B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4598	N05BA	N05B	N02AA	N02A
3078	clobazam	enhances	2D6	paroxetine		N05BA09	N06AB05	Benzodiazepine derivatives (N05BA)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BA	N05B	N06AB	N06A
3083	clobazam	enhances	2D6	promethazine		N05BA09	R06AD02	Benzodiazepine derivatives (N05BA)	Phenothiazine derivatives (R06AD)	Anxiolytics (N05B)	Antihistamines for systemic use (R06A)	0					N05BA	N05B	R06AD	R06A
3084	clobazam	enhances	2D6	propafenone	C	N05BA09	C01BC03	Benzodiazepine derivatives (N05BA)	Antiarrhythmics, class Ic (C01BC)	Anxiolytics (N05B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N05BA	N05B	C01BC	C01B
3086	clobazam	enhances	2D6	tetrabenazine	B	N05BA09	N07XX06	Benzodiazepine derivatives (N05BA)	Other nervous system drugs (N07XX)	Anxiolytics (N05B)	Other nervous system drugs (N07X)	0					N05BA	N05B	N07XX	N07X
3090	clobazam	enhances	2D6	zuclopenthixol		N05BA09	N05AF05	Benzodiazepine derivatives (N05BA)	Thioxanthene derivatives (N05AF)	Anxiolytics (N05B)	Antipsychotics (N05A)	0					N05BA	N05B	N05AF	N05A
3096	clobazam	reduces	3A457	alprazolam		N05BA09	N05BA12	Benzodiazepine derivatives (N05BA)	Benzodiazepine derivatives (N05BA)	Anxiolytics (N05B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N05BA	N05B	N05BA	N05B
3097	clobazam	reduces	3A457	amlodipine		N05BA09	C08CA01	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N05BA	N05B	C08CA	C08C
3098	clobazam	reduces	3A457	apixaban		N05BA09	B01AF02	Benzodiazepine derivatives (N05BA)	Direct factor Xa inhibitors (B01AF)	Anxiolytics (N05B)	Antithrombotic agents (B01A)	0					N05BA	N05B	B01AF	B01A
3100	clobazam	reduces	3A457	atorvastatin		N05BA09	C10AA05	Benzodiazepine derivatives (N05BA)	HMG CoA reductase inhibitors (C10AA)	Anxiolytics (N05B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N05BA	N05B	C10AA	C10A
3107	clobazam	reduces	3A457	carbamazepine	B	N05BA09	N03AF01	Benzodiazepine derivatives (N05BA)	Carboxamide derivatives (N03AF)	Anxiolytics (N05B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2585	N05BA	N05B	N03AF	N03A
3109	clobazam	reduces	3A457	cilostazol		N05BA09	B01AC23	Benzodiazepine derivatives (N05BA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Anxiolytics (N05B)	Antithrombotic agents (B01A)	0					N05BA	N05B	B01AC	B01A
3111	clobazam	reduces	3A457	clopidogrel		N05BA09	B01AC04	Benzodiazepine derivatives (N05BA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Anxiolytics (N05B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		N05BA	N05B	B01AC	B01A
3114	clobazam	reduces	3A457	colchicine		N05BA09	M04AC01	Benzodiazepine derivatives (N05BA)	Preparations with no effect on uric acid metabolism (M04AC)	Anxiolytics (N05B)	Antigout preparations (M04A)	0					N05BA	N05B	M04AC	M04A
3116	clobazam	reduces	3A457	cyclosporine		N05BA09	L04AD01	Benzodiazepine derivatives (N05BA)	Calcineurin inhibitors (L04AD)	Anxiolytics (N05B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N05BA	N05B	L04AD	L04A
3120	clobazam	reduces	3A457	deflazacort		N05BA09	H02AB13	Benzodiazepine derivatives (N05BA)	Glucocorticoids (H02AB)	Anxiolytics (N05B)	Corticosteroids for systemic use, plain (H02A)	0					N05BA	N05B	H02AB	H02A
3121	clobazam	reduces	3A457	dexamethasone		N05BA09	H02AB02	Benzodiazepine derivatives (N05BA)	Glucocorticoids (H02AB)	Anxiolytics (N05B)	Corticosteroids for systemic use, plain (H02A)	0				4598	N05BA	N05B	H02AB	H02A
3122	clobazam	reduces	3A457	diazepam		N05BA09	N05BA01	Benzodiazepine derivatives (N05BA)	Benzodiazepine derivatives (N05BA)	Anxiolytics (N05B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N05BA	N05B	N05BA	N05B
3125	clobazam	reduces	3A457	domperidone		N05BA09	A03FA03	Benzodiazepine derivatives (N05BA)	Propulsives (A03FA)	Anxiolytics (N05B)	Propulsives (A03F)	0					N05BA	N05B	A03FA	A03F
3129	clobazam	reduces	3A457	eplerenone		N05BA09	C03DA04	Benzodiazepine derivatives (N05BA)	Aldosterone antagonists (C03DA)	Anxiolytics (N05B)	Potassium-sparing agents (C03D)	0					N05BA	N05B	C03DA	C03D
3132	clobazam	reduces	3A457	felodipine		N05BA09	C08CA02	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N05BA	N05B	C08CA	C08C
3136	clobazam	reduces	3A457	hydrocortisone		N05BA09	H02AB09	Benzodiazepine derivatives (N05BA)	Glucocorticoids (H02AB)	Anxiolytics (N05B)	Corticosteroids for systemic use, plain (H02A)	0					N05BA	N05B	H02AB	H02A
3137	clobazam	reduces	3A457	indacaterol		N05BA09	R03AC18	Benzodiazepine derivatives (N05BA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Anxiolytics (N05B)	Adrenergics, inhalants (R03A)	0					N05BA	N05B	R03AC	R03A
3140	clobazam	reduces	3A457	ivabradine		N05BA09	C01EB17	Benzodiazepine derivatives (N05BA)	Other cardiac preparations (C01EB)	Anxiolytics (N05B)	Other cardiac preparations (C01E)	0					N05BA	N05B	C01EB	C01E
3142	clobazam	reduces	3A457	lansoprazole		N05BA09	A02BC03	Benzodiazepine derivatives (N05BA)	Proton pump inhibitors (A02BC)	Anxiolytics (N05B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4598	N05BA	N05B	A02BC	A02B
3144	clobazam	reduces	3A457	lercanidipine		N05BA09	C08CA13	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N05BA	N05B	C08CA	C08C
3147	clobazam	reduces	3A457	lovastatin		N05BA09	C10AA02	Benzodiazepine derivatives (N05BA)	HMG CoA reductase inhibitors (C10AA)	Anxiolytics (N05B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N05BA	N05B	C10AA	C10A
3149	clobazam	reduces	3A457	methadone		N05BA09	N07BC02	Benzodiazepine derivatives (N05BA)	Drugs used in opioid dependence (N07BC)	Anxiolytics (N05B)	Drugs used in addictive disorders (N07B)	0	0				N05BA	N05B	N07BC	N07B
3150	clobazam	reduces	3A457	midazolam		N05BA09	N05CD08	Benzodiazepine derivatives (N05BA)	Benzodiazepine derivatives (N05CD)	Anxiolytics (N05B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N05BA	N05B	N05CD	N05C
3155	clobazam	reduces	3A457	nevirapine		N05BA09	J05AG01	Benzodiazepine derivatives (N05BA)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Anxiolytics (N05B)	Direct acting antivirals (J05A)	0	0				N05BA	N05B	J05AG	J05A
3156	clobazam	reduces	3A457	nifedipine		N05BA09	C08CA05	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N05BA	N05B	C08CA	C08C
3157	clobazam	reduces	3A457	nisoldipine		N05BA09	C08CA07	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N05BA	N05B	C08CA	C08C
3158	clobazam	reduces	3A457	nitrendipine		N05BA09	C08CA08	Benzodiazepine derivatives (N05BA)	Dihydropyridine derivatives (C08CA)	Anxiolytics (N05B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N05BA	N05B	C08CA	C08C
3167	clobazam	reduces	3A457	quetiapine		N05BA09	N05AH04	Benzodiazepine derivatives (N05BA)	Diazepines, oxazepines and thiazepines (N05AH)	Anxiolytics (N05B)	Antipsychotics (N05A)	0					N05BA	N05B	N05AH	N05A
3171	clobazam	reduces	3A457	rivaroxaban		N05BA09	B01AF01	Benzodiazepine derivatives (N05BA)	Direct factor Xa inhibitors (B01AF)	Anxiolytics (N05B)	Antithrombotic agents (B01A)	0					N05BA	N05B	B01AF	B01A
3176	clobazam	reduces	3A457	salmeterol		N05BA09	R03AC12	Benzodiazepine derivatives (N05BA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Anxiolytics (N05B)	Adrenergics, inhalants (R03A)	0					N05BA	N05B	R03AC	R03A
3178	clobazam	reduces	3A457	sildenafil		N05BA09	G04BE03	Benzodiazepine derivatives (N05BA)	Drugs used in erectile dysfunction (G04BE)	Anxiolytics (N05B)	Urologicals (G04B)	0	0				N05BA	N05B	G04BE	G04B
3179	clobazam	reduces	3A457	simvastatin		N05BA09	C10AA01	Benzodiazepine derivatives (N05BA)	HMG CoA reductase inhibitors (C10AA)	Anxiolytics (N05B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N05BA	N05B	C10AA	C10A
3180	clobazam	reduces	3A457	sirolimus		N05BA09	L04AA10	Benzodiazepine derivatives (N05BA)	Selective immunosuppressants (L04AA)	Anxiolytics (N05B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N05BA	N05B	L04AA	L04A
3182	clobazam	reduces	3A457	sorafenib		N05BA09	L01XE05	Benzodiazepine derivatives (N05BA)	 (L01XE)	Anxiolytics (N05B)	Other antineoplastic agents (L01X)	1					N05BA	N05B	L01XE	L01X
3183	clobazam	reduces	3A457	sunitinib		N05BA09	L01XE04	Benzodiazepine derivatives (N05BA)	 (L01XE)	Anxiolytics (N05B)	Other antineoplastic agents (L01X)	1					N05BA	N05B	L01XE	L01X
3185	clobazam	reduces	3A457	tacrolimus		N05BA09	L04AD02	Benzodiazepine derivatives (N05BA)	Calcineurin inhibitors (L04AD)	Anxiolytics (N05B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N05BA	N05B	L04AD	L04A
3186	clobazam	reduces	3A457	tadalafil		N05BA09	G04BE08	Benzodiazepine derivatives (N05BA)	Drugs used in erectile dysfunction (G04BE)	Anxiolytics (N05B)	Urologicals (G04B)	0	0				N05BA	N05B	G04BE	G04B
3190	clobazam	reduces	3A457	testosterone		N05BA09	G03BA03	Benzodiazepine derivatives (N05BA)	3-oxoandrosten (4) derivatives (G03BA)	Anxiolytics (N05B)	Androgens (G03B)	0					N05BA	N05B	G03BA	G03B
3191	clobazam	reduces	3A457	ticagrelor		N05BA09	B01AC24	Benzodiazepine derivatives (N05BA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Anxiolytics (N05B)	Antithrombotic agents (B01A)	0					N05BA	N05B	B01AC	B01A
3194	clobazam	reduces	3A457	trazodone		N05BA09	N06AX05	Benzodiazepine derivatives (N05BA)	Other antidepressants (N06AX)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BA	N05B	N06AX	N06A
3195	clobazam	reduces	3A457	triazolam		N05BA09	N05CD05	Benzodiazepine derivatives (N05BA)	Benzodiazepine derivatives (N05CD)	Anxiolytics (N05B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N05BA	N05B	N05CD	N05C
3203	clobazam	reduces	3A457	zaleplon		N05BA09	N05CF03	Benzodiazepine derivatives (N05BA)	Benzodiazepine related drugs (N05CF)	Anxiolytics (N05B)	Hypnotics and sedatives (N05C)	0					N05BA	N05B	N05CF	N05C
3205	clobazam	reduces	3A457	zolpidem		N05BA09	N05CF02	Benzodiazepine derivatives (N05BA)	Benzodiazepine related drugs (N05CF)	Anxiolytics (N05B)	Hypnotics and sedatives (N05C)	0					N05BA	N05B	N05CF	N05C
3208	clomipramine	enhances	2D6	amitriptyline	D	N06AA04	N06AA09	Non-selective monoamine reuptake inhibitors (N06AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AA	N06A	N06AA	N06A
3213	clomipramine	enhances	2D6	carvedilol	B	N06AA04	C07AG02	Non-selective monoamine reuptake inhibitors (N06AA)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N06AA	N06A	C07AG	C07A
3214	clomipramine	enhances	2D6	chlorpheniramine		N06AA04	R06AB04	Non-selective monoamine reuptake inhibitors (N06AA)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AA	N06A	R06AB	R06A
3215	clomipramine	enhances	2D6	chlorpromazine	D	N06AA04	N05AA01	Non-selective monoamine reuptake inhibitors (N06AA)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AA	N06A	N05AA	N05A
3216	clomipramine	enhances	2D6	citalopram	D	N06AA04	N06AB04	Non-selective monoamine reuptake inhibitors (N06AA)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AA	N06A	N06AB	N06A
3217	clomipramine	enhances	2D6	clonidine	C	N06AA04	C02AC01	Non-selective monoamine reuptake inhibitors (N06AA)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1					N06AA	N06A	C02AC	C02A
3222	clomipramine	enhances	2D6	dextromethorphan	D	N06AA04	R05DA09	Non-selective monoamine reuptake inhibitors (N06AA)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AA	N06A	R05DA	R05D
3223	clomipramine	enhances	2D6	donepezil	D	N06AA04	N06DA02	Non-selective monoamine reuptake inhibitors (N06AA)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0					N06AA	N06A	N06DA	N06D
3225	clomipramine	enhances	2D6	duloxetine	B	N06AA04	N06AX21	Non-selective monoamine reuptake inhibitors (N06AA)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AA	N06A	N06AX	N06A
3228	clomipramine	enhances	2D6	escitalopram	D	N06AA04	N06AB10	Non-selective monoamine reuptake inhibitors (N06AA)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AA	N06A	N06AB	N06A
3229	clomipramine	enhances	2D6	flecainide	D	N06AA04	C01BC04	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N06AA	N06A	C01BC	C01B
3230	clomipramine	enhances	2D6	fluoxetine	D	N06AA04	N06AB03	Non-selective monoamine reuptake inhibitors (N06AA)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AA	N06A	N06AB	N06A
3231	clomipramine	enhances	2D6	fluvoxamine	B	N06AA04	N06AB08	Non-selective monoamine reuptake inhibitors (N06AA)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AA	N06A	N06AB	N06A
3232	clomipramine	enhances	2D6	haloperidol	D	N06AA04	N05AD01	Non-selective monoamine reuptake inhibitors (N06AA)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AA	N06A	N05AD	N05A
3234	clomipramine	enhances	2D6	imipramine	D	N06AA04	N06AA02	Non-selective monoamine reuptake inhibitors (N06AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AA	N06A	N06AA	N06A
3237	clomipramine	enhances	2D6	metoclopramide	D	N06AA04	A03FA01	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0				2030	N06AA	N06A	A03FA	A03F
3237	clomipramine	enhances	2D6	metoclopramide	D	N06AA04	A03FA01	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0				2576	N06AA	N06A	A03FA	A03F
3238	clomipramine	enhances	2D6	metoprolol	B	N06AA04	C07AB02	Non-selective monoamine reuptake inhibitors (N06AA)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N06AA	N06A	C07AB	C07A
3241	clomipramine	enhances	2D6	nebivolol	B	N06AA04	C07AB12	Non-selective monoamine reuptake inhibitors (N06AA)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AA	N06A	C07AB	C07A
3242	clomipramine	enhances	2D6	nortriptyline	D	N06AA04	N06AA10	Non-selective monoamine reuptake inhibitors (N06AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AA	N06A	N06AA	N06A
3243	clomipramine	enhances	2D6	ondansetron	D	N06AA04	A04AA01	Non-selective monoamine reuptake inhibitors (N06AA)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AA	N06A	A04AA	A04A
3244	clomipramine	enhances	2D6	oxycodone		N06AA04	N02AA05	Non-selective monoamine reuptake inhibitors (N06AA)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N06AA	N06A	N02AA	N02A
3246	clomipramine	enhances	2D6	paroxetine	D	N06AA04	N06AB05	Non-selective monoamine reuptake inhibitors (N06AA)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AA	N06A	N06AB	N06A
3254	clomipramine	enhances	2D6	promethazine	D	N06AA04	R06AD02	Non-selective monoamine reuptake inhibitors (N06AA)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AA	N06A	R06AD	R06A
3255	clomipramine	enhances	2D6	propafenone	D	N06AA04	C01BC03	Non-selective monoamine reuptake inhibitors (N06AA)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N06AA	N06A	C01BC	C01B
3256	clomipramine	enhances	2D6	propranolol	B	N06AA04	C07AA05	Non-selective monoamine reuptake inhibitors (N06AA)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AA	N06A	C07AA	C07A
3257	clomipramine	enhances	2D6	risperidone	D	N06AA04	N05AX08	Non-selective monoamine reuptake inhibitors (N06AA)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AA	N06A	N05AX	N05A
3260	clomipramine	enhances	2D6	tamoxifen	D	N06AA04	L02BA01	Non-selective monoamine reuptake inhibitors (N06AA)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AA	N06A	L02BA	L02B
3261	clomipramine	enhances	2D6	tetrabenazine	D	N06AA04	N07XX06	Non-selective monoamine reuptake inhibitors (N06AA)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AA	N06A	N07XX	N07X
3264	clomipramine	enhances	2D6	tramadol	D	N06AA04	N02AX02	Non-selective monoamine reuptake inhibitors (N06AA)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	2030	N06AA	N06A	N02AX	N02A
3267	clomipramine	enhances	2D6	venlafaxine	D	N06AA04	N06AX16	Non-selective monoamine reuptake inhibitors (N06AA)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2030	N06AA	N06A	N06AX	N06A
3269	clomipramine	enhances	2D6	zuclopenthixol		N06AA04	N05AF05	Non-selective monoamine reuptake inhibitors (N06AA)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AA	N06A	N05AF	N05A
3272	clopidogrel	enhances	2B6	bupropion		B01AC04	N06AX12	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			B01AC	B01A	N06AX	N06A
3274	clopidogrel	enhances	2B6	clobazam		B01AC04	N05BA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Benzodiazepine derivatives (N05BA)	Antithrombotic agents (B01A)	Anxiolytics (N05B)	0					B01AC	B01A	N05BA	N05B
3275	clopidogrel	enhances	2B6	cyclophosphamide	B	B01AC04	L01AA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Nitrogen mustard analogues (L01AA)	Antithrombotic agents (B01A)	Alkylating agents (L01A)	1	1				B01AC	B01A	L01AA	L01A
3277	clopidogrel	enhances	2B6	efavirenz		B01AC04	J05AG03	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antithrombotic agents (B01A)	Direct acting antivirals (J05A)	0	0				B01AC	B01A	J05AG	J05A
3282	clopidogrel	enhances	2B6	methadone		B01AC04	N07BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs used in opioid dependence (N07BC)	Antithrombotic agents (B01A)	Drugs used in addictive disorders (N07B)	0	0				B01AC	B01A	N07BC	N07B
3283	clopidogrel	enhances	2B6	nevirapine		B01AC04	J05AG01	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antithrombotic agents (B01A)	Direct acting antivirals (J05A)	0	0				B01AC	B01A	J05AG	J05A
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		127	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		564	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		619	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		959	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		1162	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		1488	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3181	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3196	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3461	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3635	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3701	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3800	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3852	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4376	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4492	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4668	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4721	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		5120	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		5349	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		6054	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		6088	B01AC	B01A	A10BX	A10B
3288	clopidogrel	enhances	2C8	repaglinide		B01AC04	A10BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Antithrombotic agents (B01A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		6189	B01AC	B01A	A10BX	A10B
3289	clopidogrel	enhances	2B6	selegiline		B01AC04	N04BD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Monoamine oxidase B inhibitors (N04BD)	Antithrombotic agents (B01A)	Dopaminergic agents (N04B)	0	0				B01AC	B01A	N04BD	N04B
3291	clopidogrel	enhances	2B6,2C8	sorafenib		B01AC04	L01XE05	Platelet aggregation inhibitors excl. heparin (B01AC)	 (L01XE)	Antithrombotic agents (B01A)	Other antineoplastic agents (L01X)	1					B01AC	B01A	L01XE	L01X
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			1198	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			1360	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			2436	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			2653	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			2664	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			4013	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			5134	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			5423	B01AC	B01A	C03CA	C03C
3292	clopidogrel	enhances	2C8	torasemide		B01AC04	C03CA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Sulfonamides, plain (C03CA)	Antithrombotic agents (B01A)	High-ceiling diuretics (C03C)	0	0			5780	B01AC	B01A	C03CA	C03C
3293	clopidogrel	enhances	2B6	tramadol		B01AC04	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	2442	B01AC	B01A	N02AX	N02A
3293	clopidogrel	enhances	2B6	tramadol		B01AC04	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	3597	B01AC	B01A	N02AX	N02A
3293	clopidogrel	enhances	2B6	tramadol		B01AC04	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	4541	B01AC	B01A	N02AX	N02A
3293	clopidogrel	enhances	2B6	tramadol		B01AC04	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	4778	B01AC	B01A	N02AX	N02A
3293	clopidogrel	enhances	2B6	tramadol		B01AC04	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	7145	B01AC	B01A	N02AX	N02A
3877	dexamethasone	reduces	2D6	amitriptyline		H02AB02	N06AA09	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity		3574	H02AB	H02A	N06AA	N06A
3882	dexamethasone	reduces	2D6	carvedilol		H02AB02	C07AG02	Glucocorticoids (H02AB)	Alpha and beta blocking agents (C07AG)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2390	H02AB	H02A	C07AG	C07A
3882	dexamethasone	reduces	2D6	carvedilol		H02AB02	C07AG02	Glucocorticoids (H02AB)	Alpha and beta blocking agents (C07AG)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6255	H02AB	H02A	C07AG	C07A
3883	dexamethasone	reduces	2D6	chlorpheniramine		H02AB02	R06AB04	Glucocorticoids (H02AB)	Substituted alkylamines (R06AB)	Corticosteroids for systemic use, plain (H02A)	Antihistamines for systemic use (R06A)	0	0				H02AB	H02A	R06AB	R06A
3884	dexamethasone	reduces	2D6	chlorpromazine		H02AB02	N05AA01	Glucocorticoids (H02AB)	Phenothiazines with aliphatic side-chain (N05AA)	Corticosteroids for systemic use, plain (H02A)	Antipsychotics (N05A)	0					H02AB	H02A	N05AA	N05A
3885	dexamethasone	reduces	2D6	citalopram		H02AB02	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			1378	H02AB	H02A	N06AB	N06A
3886	dexamethasone	reduces	2D6	clomipramine		H02AB02	N06AA04	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			H02AB	H02A	N06AA	N06A
3887	dexamethasone	reduces	2D6	clonidine		H02AB02	C02AC01	Glucocorticoids (H02AB)	Imidazoline receptor agonists (C02AC)	Corticosteroids for systemic use, plain (H02A)	Antiadrenergic agents, centrally acting (C02A)	1				3758	H02AB	H02A	C02AC	C02A
3892	dexamethasone	reduces	2D6	dextromethorphan		H02AB02	R05DA09	Glucocorticoids (H02AB)	Opium alkaloids and derivatives (R05DA)	Corticosteroids for systemic use, plain (H02A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				H02AB	H02A	R05DA	R05D
3893	dexamethasone	reduces	2D6	donepezil		H02AB02	N06DA02	Glucocorticoids (H02AB)	Anticholinesterases (N06DA)	Corticosteroids for systemic use, plain (H02A)	Anti-dementia drugs (N06D)	0					H02AB	H02A	N06DA	N06D
3895	dexamethasone	reduces	2D6	duloxetine		H02AB02	N06AX21	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		939	H02AB	H02A	N06AX	N06A
3898	dexamethasone	reduces	2D6	escitalopram		H02AB02	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				7149	H02AB	H02A	N06AB	N06A
3899	dexamethasone	reduces	2D6	flecainide		H02AB02	C01BC04	Glucocorticoids (H02AB)	Antiarrhythmics, class Ic (C01BC)	Corticosteroids for systemic use, plain (H02A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		1004	H02AB	H02A	C01BC	C01B
3900	dexamethasone	reduces	2D6	fluoxetine		H02AB02	N06AB03	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			H02AB	H02A	N06AB	N06A
3901	dexamethasone	reduces	2D6	fluvoxamine		H02AB02	N06AB08	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			H02AB	H02A	N06AB	N06A
3902	dexamethasone	reduces	2D6	haloperidol		H02AB02	N05AD01	Glucocorticoids (H02AB)	Butyrophenone derivatives (N05AD)	Corticosteroids for systemic use, plain (H02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1408	H02AB	H02A	N05AD	N05A
3902	dexamethasone	reduces	2D6	haloperidol		H02AB02	N05AD01	Glucocorticoids (H02AB)	Butyrophenone derivatives (N05AD)	Corticosteroids for systemic use, plain (H02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5507	H02AB	H02A	N05AD	N05A
3904	dexamethasone	reduces	2D6	imipramine		H02AB02	N06AA02	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			H02AB	H02A	N06AA	N06A
3907	dexamethasone	reduces	2D6	metoclopramide		H02AB02	A03FA01	Glucocorticoids (H02AB)	Propulsives (A03FA)	Corticosteroids for systemic use, plain (H02A)	Propulsives (A03F)	0				3781	H02AB	H02A	A03FA	A03F
3908	dexamethasone	reduces	2D6	metoprolol	B	H02AB02	C07AB02	Glucocorticoids (H02AB)	Beta blocking agents, selective (C07AB)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	324	H02AB	H02A	C07AB	C07A
3908	dexamethasone	reduces	2D6	metoprolol	B	H02AB02	C07AB02	Glucocorticoids (H02AB)	Beta blocking agents, selective (C07AB)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1461	H02AB	H02A	C07AB	C07A
3908	dexamethasone	reduces	2D6	metoprolol	B	H02AB02	C07AB02	Glucocorticoids (H02AB)	Beta blocking agents, selective (C07AB)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5979	H02AB	H02A	C07AB	C07A
3911	dexamethasone	reduces	2D6	nebivolol	B	H02AB02	C07AB12	Glucocorticoids (H02AB)	Beta blocking agents, selective (C07AB)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0					H02AB	H02A	C07AB	C07A
3912	dexamethasone	reduces	2D6	nortriptyline		H02AB02	N06AA10	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1					H02AB	H02A	N06AA	N06A
3913	dexamethasone	reduces	2D6	ondansetron		H02AB02	A04AA01	Glucocorticoids (H02AB)	Serotonin (5HT3) antagonists (A04AA)	Corticosteroids for systemic use, plain (H02A)	Antiemetics and antinauseants (A04A)	0	0			7248	H02AB	H02A	A04AA	A04A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	1004	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	1378	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	3278	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	3781	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4598	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4691	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4977	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5178	H02AB	H02A	N02AA	N02A
3914	dexamethasone	reduces	2D6	oxycodone		H02AB02	N02AA05	Glucocorticoids (H02AB)	Natural opium alkaloids (N02AA)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5722	H02AB	H02A	N02AA	N02A
3916	dexamethasone	reduces	2D6	paroxetine		H02AB02	N06AB05	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			H02AB	H02A	N06AB	N06A
3924	dexamethasone	reduces	2D6	promethazine		H02AB02	R06AD02	Glucocorticoids (H02AB)	Phenothiazine derivatives (R06AD)	Corticosteroids for systemic use, plain (H02A)	Antihistamines for systemic use (R06A)	0					H02AB	H02A	R06AD	R06A
3925	dexamethasone	reduces	2D6	propafenone		H02AB02	C01BC03	Glucocorticoids (H02AB)	Antiarrhythmics, class Ic (C01BC)	Corticosteroids for systemic use, plain (H02A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			H02AB	H02A	C01BC	C01B
3926	dexamethasone	reduces	2D6	propranolol		H02AB02	C07AA05	Glucocorticoids (H02AB)	Beta blocking agents, non-selective (C07AA)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0				3042	H02AB	H02A	C07AA	C07A
3927	dexamethasone	reduces	2D6	risperidone		H02AB02	N05AX08	Glucocorticoids (H02AB)	Other antipsychotics (N05AX)	Corticosteroids for systemic use, plain (H02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		H02AB	H02A	N05AX	N05A
3930	dexamethasone	reduces	2D6	tamoxifen		H02AB02	L02BA01	Glucocorticoids (H02AB)	Anti-estrogens (L02BA)	Corticosteroids for systemic use, plain (H02A)	Hormone antagonists and related agents (L02B)	1	1				H02AB	H02A	L02BA	L02B
3931	dexamethasone	reduces	2D6	tetrabenazine		H02AB02	N07XX06	Glucocorticoids (H02AB)	Other nervous system drugs (N07XX)	Corticosteroids for systemic use, plain (H02A)	Other nervous system drugs (N07X)	0					H02AB	H02A	N07XX	N07X
3934	dexamethasone	reduces	2D6	tramadol		H02AB02	N02AX02	Glucocorticoids (H02AB)	Other opioids (N02AX)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	1		Reduced analgesic effect	662	H02AB	H02A	N02AX	N02A
3934	dexamethasone	reduces	2D6	tramadol		H02AB02	N02AX02	Glucocorticoids (H02AB)	Other opioids (N02AX)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	1		Reduced analgesic effect	2841	H02AB	H02A	N02AX	N02A
3934	dexamethasone	reduces	2D6	tramadol		H02AB02	N02AX02	Glucocorticoids (H02AB)	Other opioids (N02AX)	Corticosteroids for systemic use, plain (H02A)	Opioids (N02A)	0	1		Reduced analgesic effect	3995	H02AB	H02A	N02AX	N02A
3937	dexamethasone	reduces	2D6	venlafaxine		H02AB02	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			H02AB	H02A	N06AX	N06A
3939	dexamethasone	reduces	2D6	zuclopenthixol		H02AB02	N05AF05	Glucocorticoids (H02AB)	Thioxanthene derivatives (N05AF)	Corticosteroids for systemic use, plain (H02A)	Antipsychotics (N05A)	0					H02AB	H02A	N05AF	N05A
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	19	C08DB	C08D	N05BA	N05B
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2201	C08DB	C08D	N05BA	N05B
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2256	C08DB	C08D	N05BA	N05B
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3635	C08DB	C08D	N05BA	N05B
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3692	C08DB	C08D	N05BA	N05B
3945	diltiazem	enhances	3A457	alprazolam	C	C08DB01	N05BA12	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7679	C08DB	C08D	N05BA	N05B
3946	diltiazem	enhances	3A457	amitriptyline		C08DB01	N06AA09	Benzothiazepine derivatives (C08DB)	Non-selective monoamine reuptake inhibitors (N06AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	1	0	Serotonin toxicity		3081	C08DB	C08D	N06AA	N06A
3947	diltiazem	enhances	3A457	amlodipine		C08DB01	C08CA01	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	732	C08DB	C08D	C08CA	C08C
3947	diltiazem	enhances	3A457	amlodipine		C08DB01	C08CA01	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3111	C08DB	C08D	C08CA	C08C
3947	diltiazem	enhances	3A457	amlodipine		C08DB01	C08CA01	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3187	C08DB	C08D	C08CA	C08C
3947	diltiazem	enhances	3A457	amlodipine		C08DB01	C08CA01	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3644	C08DB	C08D	C08CA	C08C
3947	diltiazem	enhances	3A457	amlodipine		C08DB01	C08CA01	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7071	C08DB	C08D	C08CA	C08C
3948	diltiazem	enhances	3A457	apixaban	B	C08DB01	B01AF02	Benzothiazepine derivatives (C08DB)	Direct factor Xa inhibitors (B01AF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0					C08DB	C08D	B01AF	B01A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		201	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		284	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		963	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1162	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1369	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2024	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2081	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2665	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2862	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3035	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3187	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3386	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3501	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3611	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4182	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4503	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4641	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4655	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5134	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5610	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5828	C08DB	C08D	C10AA	C10A
3952	diltiazem	enhances	3A457	atorvastatin	C	C08DB01	C10AA05	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7208	C08DB	C08D	C10AA	C10A
3963	diltiazem	enhances	3A457	chlorpheniramine		C08DB01	R06AB04	Benzothiazepine derivatives (C08DB)	Substituted alkylamines (R06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antihistamines for systemic use (R06A)	0	0				C08DB	C08D	R06AB	R06A
3964	diltiazem	enhances	3A457	cilostazol		C08DB01	B01AC23	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0				4946	C08DB	C08D	B01AC	B01A
3966	diltiazem	enhances	3A457	citalopram		C08DB01	N06AB04	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			608	C08DB	C08D	N06AB	N06A
3966	diltiazem	enhances	3A457	citalopram		C08DB01	N06AB04	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			1378	C08DB	C08D	N06AB	N06A
3966	diltiazem	enhances	3A457	citalopram		C08DB01	N06AB04	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			2567	C08DB	C08D	N06AB	N06A
3966	diltiazem	enhances	3A457	citalopram		C08DB01	N06AB04	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			3046	C08DB	C08D	N06AB	N06A
3966	diltiazem	enhances	3A457	citalopram		C08DB01	N06AB04	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			5902	C08DB	C08D	N06AB	N06A
3967	diltiazem	enhances	3A457	clarithromycin	C	C08DB01	J01FA09	Benzothiazepine derivatives (C08DB)	Macrolides (J01FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5206	C08DB	C08D	J01FA	J01F
3967	diltiazem	enhances	3A457	clarithromycin	C	C08DB01	J01FA09	Benzothiazepine derivatives (C08DB)	Macrolides (J01FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5654	C08DB	C08D	J01FA	J01F
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	782	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	963	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1019	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1162	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2256	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3187	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3386	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3501	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3611	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3635	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3800	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4612	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5134	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5349	C08DB	C08D	B01AC	B01A
3968	diltiazem	enhances	3A457	clopidogrel		C08DB01	B01AC04	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5962	C08DB	C08D	B01AC	B01A
3972	diltiazem	enhances	3A457	colchicine		C08DB01	M04AC01	Benzothiazepine derivatives (C08DB)	Preparations with no effect on uric acid metabolism (M04AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antigout preparations (M04A)	0					C08DB	C08D	M04AC	M04A
3975	diltiazem	enhances	3A457	cyclosporine	B	C08DB01	L04AD01	Benzothiazepine derivatives (C08DB)	Calcineurin inhibitors (L04AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		2659	C08DB	C08D	L04AD	L04A
3978	diltiazem	enhances	3A457	deflazacort		C08DB01	H02AB13	Benzothiazepine derivatives (C08DB)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0					C08DB	C08D	H02AB	H02A
3979	diltiazem	enhances	3A457	dexamethasone		C08DB01	H02AB02	Benzothiazepine derivatives (C08DB)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0				5903	C08DB	C08D	H02AB	H02A
3980	diltiazem	enhances	3A457	dextromethorphan		C08DB01	R05DA09	Benzothiazepine derivatives (C08DB)	Opium alkaloids and derivatives (R05DA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				C08DB	C08D	R05DA	R05D
3981	diltiazem	enhances	3A457	diazepam		C08DB01	N05BA01	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		C08DB	C08D	N05BA	N05B
3984	diltiazem	enhances	3A457	domperidone		C08DB01	A03FA03	Benzothiazepine derivatives (C08DB)	Propulsives (A03FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Propulsives (A03F)	0				2071	C08DB	C08D	A03FA	A03F
3984	diltiazem	enhances	3A457	domperidone		C08DB01	A03FA03	Benzothiazepine derivatives (C08DB)	Propulsives (A03FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Propulsives (A03F)	0				2577	C08DB	C08D	A03FA	A03F
3984	diltiazem	enhances	3A457	domperidone		C08DB01	A03FA03	Benzothiazepine derivatives (C08DB)	Propulsives (A03FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Propulsives (A03F)	0				3693	C08DB	C08D	A03FA	A03F
3988	diltiazem	enhances	3A457	eplerenone	C	C08DB01	C03DA04	Benzothiazepine derivatives (C08DB)	Aldosterone antagonists (C03DA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Potassium-sparing agents (C03D)	0					C08DB	C08D	C03DA	C03D
3991	diltiazem	enhances	3A457	escitalopram		C08DB01	N06AB10	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0				2567	C08DB	C08D	N06AB	N06A
3991	diltiazem	enhances	3A457	escitalopram		C08DB01	N06AB10	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0				3104	C08DB	C08D	N06AB	N06A
3991	diltiazem	enhances	3A457	escitalopram		C08DB01	N06AB10	Benzothiazepine derivatives (C08DB)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0				5610	C08DB	C08D	N06AB	N06A
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				201	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				284	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				305	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				757	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1019	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1179	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2081	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2599	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3167	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4864	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4960	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5962	C08DB	C08D	A02BC	A02B
3992	diltiazem	enhances	3A457	esomeprazole		C08DB01	A02BC05	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7662	C08DB	C08D	A02BC	A02B
3994	diltiazem	enhances	3A457	felodipine		C08DB01	C08CA02	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DB	C08D	C08CA	C08C
3998	diltiazem	enhances	3A457	haloperidol		C08DB01	N05AD01	Benzothiazepine derivatives (C08DB)	Butyrophenone derivatives (N05AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7439	C08DB	C08D	N05AD	N05A
3999	diltiazem	enhances	3A457	hydrocortisone		C08DB01	H02AB09	Benzothiazepine derivatives (C08DB)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0					C08DB	C08D	H02AB	H02A
4002	diltiazem	enhances	3A457	imatinib	B	C08DB01	L01XE01	Benzothiazepine derivatives (C08DB)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	0	0				C08DB	C08D	L01XE	L01X
4003	diltiazem	enhances	3A457	indacaterol		C08DB01	R03AC18	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				7023	C08DB	C08D	R03AC	R03A
4007	diltiazem	enhances	3A457	ivabradine		C08DB01	C01EB17	Benzothiazepine derivatives (C08DB)	Other cardiac preparations (C01EB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other cardiac preparations (C01E)	0				1162	C08DB	C08D	C01EB	C01E
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			19	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			106	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			117	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			608	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			699	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			732	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			784	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1010	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1013	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1438	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2024	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2071	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2201	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2211	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2278	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2336	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2400	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2414	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2454	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2458	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2567	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2577	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2731	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2862	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2915	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3018	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3057	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3081	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3160	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3164	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3339	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3611	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3644	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3691	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3694	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4233	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4700	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4827	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4946	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5134	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5610	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5654	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5656	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5828	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5832	C08DB	C08D	A02BC	A02B
4009	diltiazem	enhances	3A457	lansoprazole		C08DB01	A02BC03	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7208	C08DB	C08D	A02BC	A02B
4011	diltiazem	enhances	3A457	lercanidipine		C08DB01	C08CA13	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3457	C08DB	C08D	C08CA	C08C
4015	diltiazem	enhances	3A457	lovastatin	C	C08DB01	C10AA02	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			C08DB	C08D	C10AA	C10A
4017	diltiazem	enhances	3A457	methadone		C08DB01	N07BC02	Benzothiazepine derivatives (C08DB)	Drugs used in opioid dependence (N07BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs used in addictive disorders (N07B)	0	0				C08DB	C08D	N07BC	N07B
4018	diltiazem	enhances	3A457	midazolam	B	C08DB01	N05CD08	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		C08DB	C08D	N05CD	N05C
4024	diltiazem	enhances	3A457	nifedipine	B	C08DB01	C08CA05	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2862	C08DB	C08D	C08CA	C08C
4025	diltiazem	enhances	3A457	nisoldipine		C08DB01	C08CA07	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DB	C08D	C08CA	C08C
4026	diltiazem	enhances	3A457	nitrendipine		C08DB01	C08CA08	Benzothiazepine derivatives (C08DB)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DB	C08D	C08CA	C08C
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			171	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			620	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			782	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			788	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1027	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1378	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1400	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1456	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2227	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2256	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2285	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2525	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2659	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2937	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2947	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3022	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3111	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3386	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3504	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3693	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4005	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4086	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4111	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4367	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4613	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4641	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4733	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4884	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5654	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5752	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5902	C08DB	C08D	A02BC	A02B
4028	diltiazem	enhances	3A457	omeprazole		C08DB01	A02BC01	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5903	C08DB	C08D	A02BC	A02B
4029	diltiazem	enhances	3A457	ondansetron		C08DB01	A04AA01	Benzothiazepine derivatives (C08DB)	Serotonin (5HT3) antagonists (A04AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antiemetics and antinauseants (A04A)	0	0				C08DB	C08D	A04AA	A04A
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			123	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			565	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			675	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			760	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1162	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3059	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3501	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3542	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3878	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4178	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4273	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4295	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4612	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4655	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5206	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5278	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5349	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5735	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5789	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5865	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7023	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7071	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7162	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7232	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7439	C08DB	C08D	A02BC	A02B
4036	diltiazem	enhances	3A457	pantoprazole		C08DB01	A02BC02	Benzothiazepine derivatives (C08DB)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7679	C08DB	C08D	A02BC	A02B
4043	diltiazem	enhances	3A457	propranolol	D	C08DB01	C07AA05	Benzothiazepine derivatives (C08DB)	Beta blocking agents, non-selective (C07AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Beta blocking agents (C07A)	0				124	C08DB	C08D	C07AA	C07A
4044	diltiazem	enhances	3A457	quetiapine		C08DB01	N05AH04	Benzothiazepine derivatives (C08DB)	Diazepines, oxazepines and thiazepines (N05AH)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0				608	C08DB	C08D	N05AH	N05A
4044	diltiazem	enhances	3A457	quetiapine		C08DB01	N05AH04	Benzothiazepine derivatives (C08DB)	Diazepines, oxazepines and thiazepines (N05AH)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0				2695	C08DB	C08D	N05AH	N05A
4050	diltiazem	enhances	3A457	risperidone		C08DB01	N05AX08	Benzothiazepine derivatives (C08DB)	Other antipsychotics (N05AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2567	C08DB	C08D	N05AX	N05A
4051	diltiazem	enhances	3A457	ritonavir	B	C08DB01	J05AE03	Benzothiazepine derivatives (C08DB)	Protease inhibitors (J05AE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Direct acting antivirals (J05A)	0	0				C08DB	C08D	J05AE	J05A
4052	diltiazem	enhances	3A457	rivaroxaban		C08DB01	B01AF01	Benzothiazepine derivatives (C08DB)	Direct factor Xa inhibitors (B01AF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0				7208	C08DB	C08D	B01AF	B01A
4052	diltiazem	enhances	3A457	rivaroxaban		C08DB01	B01AF01	Benzothiazepine derivatives (C08DB)	Direct factor Xa inhibitors (B01AF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0				7429	C08DB	C08D	B01AF	B01A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				106	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				284	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				562	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				732	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				1241	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				1456	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				2695	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3018	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3059	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3167	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3542	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3611	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3691	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3693	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3694	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3878	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				4655	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5610	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5656	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5865	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5902	C08DB	C08D	R03AC	R03A
4058	diltiazem	enhances	3A457	salmeterol		C08DB01	R03AC12	Benzothiazepine derivatives (C08DB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				7679	C08DB	C08D	R03AC	R03A
4059	diltiazem	enhances	3A457	saquinavir	B	C08DB01	J05AE01	Benzothiazepine derivatives (C08DB)	Protease inhibitors (J05AE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Direct acting antivirals (J05A)	0	0				C08DB	C08D	J05AE	J05A
4061	diltiazem	enhances	3A457	sildenafil		C08DB01	G04BE03	Benzothiazepine derivatives (C08DB)	Drugs used in erectile dysfunction (G04BE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Urologicals (G04B)	0	0				C08DB	C08D	G04BE	G04B
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		171	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		620	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1019	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1241	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1378	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2089	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2114	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2285	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2389	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2442	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2863	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3022	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3057	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3081	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3138	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3164	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3167	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3339	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3457	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3542	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3800	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4295	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4946	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5349	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5656	C08DB	C08D	C10AA	C10A
4063	diltiazem	enhances	3A457	simvastatin	C	C08DB01	C10AA01	Benzothiazepine derivatives (C08DB)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5809	C08DB	C08D	C10AA	C10A
4064	diltiazem	enhances	3A457	sirolimus	C	C08DB01	L04AA10	Benzothiazepine derivatives (C08DB)	Selective immunosuppressants (L04AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C08DB	C08D	L04AA	L04A
4066	diltiazem	enhances	3A457	sorafenib		C08DB01	L01XE05	Benzothiazepine derivatives (C08DB)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	1					C08DB	C08D	L01XE	L01X
4067	diltiazem	enhances	3A457	sunitinib		C08DB01	L01XE04	Benzothiazepine derivatives (C08DB)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	1					C08DB	C08D	L01XE	L01X
4069	diltiazem	enhances	3A457	tacrolimus	C	C08DB01	L04AD02	Benzothiazepine derivatives (C08DB)	Calcineurin inhibitors (L04AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C08DB	C08D	L04AD	L04A
4070	diltiazem	enhances	3A457	tadalafil		C08DB01	G04BE08	Benzothiazepine derivatives (C08DB)	Drugs used in erectile dysfunction (G04BE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Urologicals (G04B)	0	0				C08DB	C08D	G04BE	G04B
4071	diltiazem	enhances	3A457	tamoxifen		C08DB01	L02BA01	Benzothiazepine derivatives (C08DB)	Anti-estrogens (L02BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hormone antagonists and related agents (L02B)	1	1				C08DB	C08D	L02BA	L02B
4077	diltiazem	enhances	3A457	testosterone		C08DB01	G03BA03	Benzothiazepine derivatives (C08DB)	3-oxoandrosten (4) derivatives (G03BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Androgens (G03B)	0					C08DB	C08D	G03BA	G03B
4078	diltiazem	enhances	3A457	ticagrelor		C08DB01	B01AC24	Benzothiazepine derivatives (C08DB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0					C08DB	C08D	B01AC	B01A
4081	diltiazem	enhances	3A457	tramadol		C08DB01	N02AX02	Benzothiazepine derivatives (C08DB)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	124	C08DB	C08D	N02AX	N02A
4081	diltiazem	enhances	3A457	tramadol		C08DB01	N02AX02	Benzothiazepine derivatives (C08DB)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	760	C08DB	C08D	N02AX	N02A
4081	diltiazem	enhances	3A457	tramadol		C08DB01	N02AX02	Benzothiazepine derivatives (C08DB)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	2404	C08DB	C08D	N02AX	N02A
4081	diltiazem	enhances	3A457	tramadol		C08DB01	N02AX02	Benzothiazepine derivatives (C08DB)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	2525	C08DB	C08D	N02AX	N02A
4081	diltiazem	enhances	3A457	tramadol		C08DB01	N02AX02	Benzothiazepine derivatives (C08DB)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	3035	C08DB	C08D	N02AX	N02A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		565	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		608	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		1378	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		2695	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		4382	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		4613	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		5278	C08DB	C08D	N06AX	N06A
4082	diltiazem	enhances	3A457	trazodone		C08DB01	N06AX05	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		5865	C08DB	C08D	N06AX	N06A
4083	diltiazem	enhances	3A457	triazolam	C	C08DB01	N05CD05	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2442	C08DB	C08D	N05CD	N05C
4083	diltiazem	enhances	3A457	triazolam	C	C08DB01	N05CD05	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2454	C08DB	C08D	N05CD	N05C
4083	diltiazem	enhances	3A457	triazolam	C	C08DB01	N05CD05	Benzothiazepine derivatives (C08DB)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3565	C08DB	C08D	N05CD	N05C
4090	diltiazem	enhances	3A457	venlafaxine		C08DB01	N06AX16	Benzothiazepine derivatives (C08DB)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity			C08DB	C08D	N06AX	N06A
4091	diltiazem	enhances	3A457	verapamil	B	C08DB01	C08DA01	Benzothiazepine derivatives (C08DB)	Phenylalkylamine derivatives (C08DA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			C08DB	C08D	C08DA	C08D
4095	diltiazem	enhances	3A457	voriconazole	B	C08DB01	J02AC03	Benzothiazepine derivatives (C08DB)	Triazole derivatives (J02AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antimycotics for systemic use (J02A)	0	0				C08DB	C08D	J02AC	J02A
4096	diltiazem	enhances	3A457	zaleplon		C08DB01	N05CF03	Benzothiazepine derivatives (C08DB)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0					C08DB	C08D	N05CF	N05C
4098	diltiazem	enhances	3A457	zolpidem		C08DB01	N05CF02	Benzothiazepine derivatives (C08DB)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0				3644	C08DB	C08D	N05CF	N05C
4098	diltiazem	enhances	3A457	zolpidem		C08DB01	N05CF02	Benzothiazepine derivatives (C08DB)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0				4655	C08DB	C08D	N05CF	N05C
4098	diltiazem	enhances	3A457	zolpidem		C08DB01	N05CF02	Benzothiazepine derivatives (C08DB)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0				5865	C08DB	C08D	N05CF	N05C
4307	duloxetine	enhances	2D6	amitriptyline	B	N06AX21	N06AA09	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity		1271	N06AX	N06A	N06AA	N06A
4312	duloxetine	enhances	2D6	carvedilol		N06AX21	C07AG02	Other antidepressants (N06AX)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2283	N06AX	N06A	C07AG	C07A
4313	duloxetine	enhances	2D6	chlorpheniramine	C	N06AX21	R06AB04	Other antidepressants (N06AX)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AX	N06A	R06AB	R06A
4314	duloxetine	enhances	2D6	chlorpromazine	B	N06AX21	N05AA01	Other antidepressants (N06AX)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AX	N06A	N05AA	N05A
4315	duloxetine	enhances	2D6	citalopram	D	N06AX21	N06AB04	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AX	N06A	N06AB	N06A
4316	duloxetine	enhances	2D6	clomipramine	B	N06AX21	N06AA04	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AX	N06A	N06AA	N06A
4317	duloxetine	enhances	2D6	clonidine		N06AX21	C02AC01	Other antidepressants (N06AX)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				3635	N06AX	N06A	C02AC	C02A
4322	duloxetine	enhances	2D6	dextromethorphan	C	N06AX21	R05DA09	Other antidepressants (N06AX)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AX	N06A	R05DA	R05D
4323	duloxetine	enhances	2D6	donepezil		N06AX21	N06DA02	Other antidepressants (N06AX)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				3244	N06AX	N06A	N06DA	N06D
4327	duloxetine	enhances	2D6	escitalopram	D	N06AX21	N06AB10	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AX	N06A	N06AB	N06A
4328	duloxetine	enhances	2D6	flecainide	C	N06AX21	C01BC04	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		1048	N06AX	N06A	C01BC	C01B
4329	duloxetine	enhances	2D6	fluoxetine	D	N06AX21	N06AB03	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AB	N06A
4330	duloxetine	enhances	2D6	fluvoxamine	D	N06AX21	N06AB08	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AB	N06A
4331	duloxetine	enhances	2D6	haloperidol		N06AX21	N05AD01	Other antidepressants (N06AX)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4882	N06AX	N06A	N05AD	N05A
4333	duloxetine	enhances	2D6	imipramine	B	N06AX21	N06AA02	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity		3533	N06AX	N06A	N06AA	N06A
4336	duloxetine	enhances	2D6	metoclopramide	D	N06AX21	A03FA01	Other antidepressants (N06AX)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AX	N06A	A03FA	A03F
4337	duloxetine	enhances	2D6	metoprolol		N06AX21	C07AB02	Other antidepressants (N06AX)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5442	N06AX	N06A	C07AB	C07A
4340	duloxetine	enhances	2D6	nebivolol		N06AX21	C07AB12	Other antidepressants (N06AX)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				7317	N06AX	N06A	C07AB	C07A
4341	duloxetine	enhances	2D6	nortriptyline	C	N06AX21	N06AA10	Other antidepressants (N06AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AX	N06A	N06AA	N06A
4342	duloxetine	enhances	2D6	ondansetron		N06AX21	A04AA01	Other antidepressants (N06AX)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AX	N06A	A04AA	A04A
4343	duloxetine	enhances	2D6	oxycodone		N06AX21	N02AA05	Other antidepressants (N06AX)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5692	N06AX	N06A	N02AA	N02A
4343	duloxetine	enhances	2D6	oxycodone		N06AX21	N02AA05	Other antidepressants (N06AX)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7317	N06AX	N06A	N02AA	N02A
4345	duloxetine	enhances	2D6	paroxetine	C	N06AX21	N06AB05	Other antidepressants (N06AX)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AB	N06A
4353	duloxetine	enhances	2D6	promethazine	C	N06AX21	R06AD02	Other antidepressants (N06AX)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AX	N06A	R06AD	R06A
4354	duloxetine	enhances	2D6	propafenone	C	N06AX21	C01BC03	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3124	N06AX	N06A	C01BC	C01B
4354	duloxetine	enhances	2D6	propafenone	C	N06AX21	C01BC03	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3665	N06AX	N06A	C01BC	C01B
4354	duloxetine	enhances	2D6	propafenone	C	N06AX21	C01BC03	Other antidepressants (N06AX)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		4904	N06AX	N06A	C01BC	C01B
4355	duloxetine	enhances	2D6	propranolol		N06AX21	C07AA05	Other antidepressants (N06AX)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				5968	N06AX	N06A	C07AA	C07A
4356	duloxetine	enhances	2D6	risperidone		N06AX21	N05AX08	Other antidepressants (N06AX)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AX	N06A	N05AX	N05A
4359	duloxetine	enhances	2D6	tamoxifen	D	N06AX21	L02BA01	Other antidepressants (N06AX)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AX	N06A	L02BA	L02B
4360	duloxetine	enhances	2D6	tetrabenazine	D	N06AX21	N07XX06	Other antidepressants (N06AX)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AX	N06A	N07XX	N07X
4363	duloxetine	enhances	2D6	tramadol	C	N06AX21	N02AX02	Other antidepressants (N06AX)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	728	N06AX	N06A	N02AX	N02A
4363	duloxetine	enhances	2D6	tramadol	C	N06AX21	N02AX02	Other antidepressants (N06AX)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	4882	N06AX	N06A	N02AX	N02A
4366	duloxetine	enhances	2D6	venlafaxine	D	N06AX21	N06AX16	Other antidepressants (N06AX)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AX	N06A	N06AX	N06A
4368	duloxetine	enhances	2D6	zuclopenthixol	B	N06AX21	N05AF05	Other antidepressants (N06AX)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AX	N06A	N05AF	N05A
4369	efavirenz	enhances	1A2	acetaminophen	C	J05AG03	N02BE01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Anilides (N02BE)	Direct acting antivirals (J05A)	Other analgesics and antipyretics (N02B)	0	0				J05AG	J05A	N02BE	N02B
4372	efavirenz	enhances	2C9	capecitabine		J05AG03	L01BC06	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Pyrimidine analogues (L01BC)	Direct acting antivirals (J05A)	Antimetabolites (L01B)	1					J05AG	J05A	L01BC	L01B
4373	efavirenz	enhances	2C9	celecoxib		J05AG03	M01AH01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Coxibs (M01AH)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AH	M01A
4374	efavirenz	enhances	1A2	clozapine		J05AG03	N05AH02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AG	J05A	N05AH	N05A
4376	efavirenz	enhances	2C9	diclofenac		J05AG03	M01AB05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Acetic acid derivatives and related substances (M01AB)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			7335	J05AG	J05A	M01AB	M01A
4377	efavirenz	enhances	1A2	duloxetine		J05AG03	N06AX21	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
4378	efavirenz	enhances	2C9	fluoxetine		J05AG03	N06AB03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AB	N06A
4379	efavirenz	enhances	2C9	fluvastatin		J05AG03	C10AA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AG	J05A	C10AA	C10A
4380	efavirenz	enhances	1A2	fluvoxamine		J05AG03	N06AB08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AB	N06A
4381	efavirenz	enhances	2C9	glimepiride		J05AG03	A10BB12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J05AG	J05A	A10BB	A10B
4382	efavirenz	enhances	2C9	glipizide		J05AG03	A10BB07	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J05AG	J05A	A10BB	A10B
4383	efavirenz	enhances	2C9	glyburide		J05AG03	A10BB01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J05AG	J05A	A10BB	A10B
4384	efavirenz	enhances	2C9	ibuprofen		J05AG03	M01AE01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propionic acid derivatives (M01AE)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AE	M01A
4385	efavirenz	enhances	2C9	irbesartan		J05AG03	C09CA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Angiotensin II receptor blockers, plain (C09CA)	Direct acting antivirals (J05A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		J05AG	J05A	C09CA	C09C
4388	efavirenz	enhances	2C9	losartan		J05AG03	C09CA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Angiotensin II receptor blockers, plain (C09CA)	Direct acting antivirals (J05A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		J05AG	J05A	C09CA	C09C
4389	efavirenz	enhances	2C9	meloxicam		J05AG03	M01AC06	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Oxicams (M01AC)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J05AG	J05A	M01AC	M01A
4392	efavirenz	enhances	1A2,2C9	naproxen		J05AG03	M01AE02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propionic acid derivatives (M01AE)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AE	M01A
4393	efavirenz	enhances	1A2	olanzapine		J05AG03	N05AH03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AG	J05A	N05AH	N05A
4397	efavirenz	enhances	2C9	piroxicam		J05AG03	M01AC01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Oxicams (M01AC)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			7541	J05AG	J05A	M01AC	M01A
4398	efavirenz	enhances	1A2	riluzole		J05AG03	N07XX02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other nervous system drugs (N07XX)	Direct acting antivirals (J05A)	Other nervous system drugs (N07X)	0	0				J05AG	J05A	N07XX	N07X
4403	efavirenz	enhances	1A2	theophylline		J05AG03	R03DA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Xanthines (R03DA)	Direct acting antivirals (J05A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				J05AG	J05A	R03DA	R03D
4404	efavirenz	enhances	1A2	tizanidine		J05AG03	M03BX02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other centrally acting agents (M03BX)	Direct acting antivirals (J05A)	Muscle relaxants, centrally acting agents (M03B)	1	0				J05AG	J05A	M03BX	M03B
4406	efavirenz	enhances	2C9	torasemide		J05AG03	C03CA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonamides, plain (C03CA)	Direct acting antivirals (J05A)	High-ceiling diuretics (C03C)	0	0				J05AG	J05A	C03CA	C03C
4407	efavirenz	enhances	1A2	triamterene		J05AG03	C03DB02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other potassium-sparing agents (C03DB)	Direct acting antivirals (J05A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			J05AG	J05A	C03DB	C03D
4408	efavirenz	enhances	2C9	valproate		J05AG03	N03AG01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Fatty acid derivatives (N03AG)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AG	N03A
4417	efavirenz	reduces	3A457	alprazolam		J05AG03	N05BA12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05BA	N05B
4418	efavirenz	reduces	3A457	amlodipine		J05AG03	C08CA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
4419	efavirenz	reduces	3A457	apixaban		J05AG03	B01AF02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AF	B01A
4425	efavirenz	reduces	3A457	atorvastatin	B	J05AG03	C10AA05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AG	J05A	C10AA	C10A
4433	efavirenz	reduces	2B6	bupropion	B	J05AG03	N06AX12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
4435	efavirenz	reduces	3A457	carbamazepine	D	J05AG03	N03AF01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Carboxamide derivatives (N03AF)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AF	N03A
4441	efavirenz	reduces	3A457	chlorpheniramine		J05AG03	R06AB04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Substituted alkylamines (R06AB)	Direct acting antivirals (J05A)	Antihistamines for systemic use (R06A)	0	0				J05AG	J05A	R06AB	R06A
4442	efavirenz	reduces	3A457	cilostazol		J05AG03	B01AC23	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AC	B01A
4444	efavirenz	reduces	2C19,3A457	citalopram		J05AG03	N06AB04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0				J05AG	J05A	N06AB	N06A
4445	efavirenz	reduces	3A457	clarithromycin	B	J05AG03	J01FA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Macrolides (J01FA)	Direct acting antivirals (J05A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J05AG	J05A	J01FA	J01F
4446	efavirenz	reduces	2B6,2C19,3A457	clobazam		J05AG03	N05BA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0					J05AG	J05A	N05BA	N05B
4450	efavirenz	reduces	3A457	colchicine		J05AG03	M04AC01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Preparations with no effect on uric acid metabolism (M04AC)	Direct acting antivirals (J05A)	Antigout preparations (M04A)	0					J05AG	J05A	M04AC	M04A
4453	efavirenz	reduces	2B6,2C19	cyclophosphamide		J05AG03	L01AA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Nitrogen mustard analogues (L01AA)	Direct acting antivirals (J05A)	Alkylating agents (L01A)	1	1				J05AG	J05A	L01AA	L01A
4454	efavirenz	reduces	3A457	cyclosporine		J05AG03	L04AD01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AD	L04A
4458	efavirenz	reduces	3A457	deflazacort		J05AG03	H02AB13	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
4459	efavirenz	reduces	3A457	dexamethasone	C	J05AG03	H02AB02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
4460	efavirenz	reduces	3A457	dextromethorphan		J05AG03	R05DA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Opium alkaloids and derivatives (R05DA)	Direct acting antivirals (J05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J05AG	J05A	R05DA	R05D
4461	efavirenz	reduces	2C19,3A457	diazepam		J05AG03	N05BA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05BA	N05B
4462	efavirenz	reduces	3A457	diltiazem		J05AG03	C08DB01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzothiazepine derivatives (C08DB)	Direct acting antivirals (J05A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J05AG	J05A	C08DB	C08D
4465	efavirenz	reduces	3A457	domperidone		J05AG03	A03FA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propulsives (A03FA)	Direct acting antivirals (J05A)	Propulsives (A03F)	0					J05AG	J05A	A03FA	A03F
4470	efavirenz	reduces	3A457	eplerenone		J05AG03	C03DA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Aldosterone antagonists (C03DA)	Direct acting antivirals (J05A)	Potassium-sparing agents (C03D)	0					J05AG	J05A	C03DA	C03D
4473	efavirenz	reduces	2C19,3A457	escitalopram		J05AG03	N06AB10	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0					J05AG	J05A	N06AB	N06A
4474	efavirenz	reduces	2C19,3A457	esomeprazole		J05AG03	A02BC05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					J05AG	J05A	A02BC	A02B
4475	efavirenz	reduces	3A457	felodipine		J05AG03	C08CA02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
4480	efavirenz	reduces	3A457	hydrocortisone		J05AG03	H02AB09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
4484	efavirenz	reduces	3A457	imatinib	B	J05AG03	L01XE01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	0	0				J05AG	J05A	L01XE	L01X
4485	efavirenz	reduces	3A457	indacaterol		J05AG03	R03AC18	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AG	J05A	R03AC	R03A
4487	efavirenz	reduces	2C19	indometacin		J05AG03	M01AB01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Acetic acid derivatives and related substances (M01AB)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J05AG	J05A	M01AB	M01A
4490	efavirenz	reduces	3A457	ivabradine		J05AG03	C01EB17	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other cardiac preparations (C01EB)	Direct acting antivirals (J05A)	Other cardiac preparations (C01E)	0					J05AG	J05A	C01EB	C01E
4494	efavirenz	reduces	2C19,3A457	lansoprazole		J05AG03	A02BC03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AG	J05A	A02BC	A02B
4496	efavirenz	reduces	3A457	lercanidipine		J05AG03	C08CA13	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J05AG	J05A	C08CA	C08C
4500	efavirenz	reduces	3A457	lovastatin	B	J05AG03	C10AA02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AG	J05A	C10AA	C10A
4504	efavirenz	reduces	2B6,3A457	methadone	B	J05AG03	N07BC02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in opioid dependence (N07BC)	Direct acting antivirals (J05A)	Drugs used in addictive disorders (N07B)	0	0				J05AG	J05A	N07BC	N07B
4506	efavirenz	reduces	3A457	midazolam		J05AG03	N05CD08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05CD	N05C
4512	efavirenz	reduces	2B6,3A457	nevirapine	D	J05AG03	J05AG01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AG	J05A	J05AG	J05A
4513	efavirenz	reduces	3A457	nifedipine		J05AG03	C08CA05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
4515	efavirenz	reduces	3A457	nisoldipine		J05AG03	C08CA07	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
4516	efavirenz	reduces	3A457	nitrendipine		J05AG03	C08CA08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
4518	efavirenz	reduces	2C19,3A457	omeprazole		J05AG03	A02BC01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AG	J05A	A02BC	A02B
4524	efavirenz	reduces	2C19,3A457	pantoprazole		J05AG03	A02BC02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7322	J05AG	J05A	A02BC	A02B
4526	efavirenz	reduces	2C19	phenobarbital	B	J05AG03	N03AA02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Barbiturates and derivatives (N03AA)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AA	N03A
4530	efavirenz	reduces	2C19	primidone		J05AG03	N03AA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Barbiturates and derivatives (N03AA)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	0					J05AG	J05A	N03AA	N03A
4534	efavirenz	reduces	3A457	quetiapine		J05AG03	N05AH04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AG	J05A	N05AH	N05A
4540	efavirenz	reduces	3A457	risperidone		J05AG03	N05AX08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antipsychotics (N05AX)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AG	J05A	N05AX	N05A
4541	efavirenz	reduces	3A457	ritonavir	B	J05AG03	J05AE03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Protease inhibitors (J05AE)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AG	J05A	J05AE	J05A
4542	efavirenz	reduces	3A457	rivaroxaban		J05AG03	B01AF01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AF	B01A
4545	efavirenz	reduces	3A457	salmeterol		J05AG03	R03AC12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AG	J05A	R03AC	R03A
4546	efavirenz	reduces	3A457	saquinavir	B	J05AG03	J05AE01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Protease inhibitors (J05AE)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AG	J05A	J05AE	J05A
4547	efavirenz	reduces	2B6	selegiline		J05AG03	N04BD01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Monoamine oxidase B inhibitors (N04BD)	Direct acting antivirals (J05A)	Dopaminergic agents (N04B)	0	0				J05AG	J05A	N04BD	N04B
4549	efavirenz	reduces	3A457	sildenafil		J05AG03	G04BE03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AG	J05A	G04BE	G04B
4551	efavirenz	reduces	3A457	simvastatin	B	J05AG03	C10AA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AG	J05A	C10AA	C10A
4552	efavirenz	reduces	3A457	sirolimus	C	J05AG03	L04AA10	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective immunosuppressants (L04AA)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AA	L04A
4554	efavirenz	reduces	2B6,3A457	sorafenib		J05AG03	L01XE05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AG	J05A	L01XE	L01X
4555	efavirenz	reduces	3A457	sunitinib	B	J05AG03	L01XE04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AG	J05A	L01XE	L01X
4557	efavirenz	reduces	3A457	tacrolimus	C	J05AG03	L04AD02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AD	L04A
4558	efavirenz	reduces	3A457	tadalafil		J05AG03	G04BE08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AG	J05A	G04BE	G04B
4564	efavirenz	reduces	3A457	testosterone		J05AG03	G03BA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	3-oxoandrosten (4) derivatives (G03BA)	Direct acting antivirals (J05A)	Androgens (G03B)	0					J05AG	J05A	G03BA	G03B
4565	efavirenz	reduces	3A457	ticagrelor		J05AG03	B01AC24	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AC	B01A
4568	efavirenz	reduces	2B6,3A457	tramadol		J05AG03	N02AX02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other opioids (N02AX)	Direct acting antivirals (J05A)	Opioids (N02A)	0	1		Reduced analgesic effect		J05AG	J05A	N02AX	N02A
4569	efavirenz	reduces	3A457	trazodone		J05AG03	N06AX05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
4570	efavirenz	reduces	3A457	triazolam		J05AG03	N05CD05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05CD	N05C
4580	efavirenz	reduces	3A457	zaleplon		J05AG03	N05CF03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AG	J05A	N05CF	N05C
4582	efavirenz	reduces	3A457	zolpidem		J05AG03	N05CF02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AG	J05A	N05CF	N05C
5240	escitalopram	enhances	2D6	amitriptyline	D	N06AB10	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
5245	escitalopram	enhances	2D6	carvedilol		N06AB10	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1139	N06AB	N06A	C07AG	C07A
5245	escitalopram	enhances	2D6	carvedilol		N06AB10	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4335	N06AB	N06A	C07AG	C07A
5245	escitalopram	enhances	2D6	carvedilol		N06AB10	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4351	N06AB	N06A	C07AG	C07A
5245	escitalopram	enhances	2D6	carvedilol		N06AB10	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5404	N06AB	N06A	C07AG	C07A
5245	escitalopram	enhances	2D6	carvedilol		N06AB10	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5619	N06AB	N06A	C07AG	C07A
5246	escitalopram	enhances	2D6	chlorpheniramine	B	N06AB10	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
5247	escitalopram	enhances	2D6	chlorpromazine	D	N06AB10	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AA	N05A
5248	escitalopram	enhances	2D6	citalopram	D	N06AB10	N06AB04	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AB	N06A	N06AB	N06A
5249	escitalopram	enhances	2D6	clomipramine	D	N06AB10	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
5250	escitalopram	enhances	2D6	clonidine		N06AB10	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				2482	N06AB	N06A	C02AC	C02A
5250	escitalopram	enhances	2D6	clonidine		N06AB10	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				3286	N06AB	N06A	C02AC	C02A
5255	escitalopram	enhances	2D6	dextromethorphan	C	N06AB10	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
5256	escitalopram	enhances	2D6	donepezil	D	N06AB10	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				2043	N06AB	N06A	N06DA	N06D
5256	escitalopram	enhances	2D6	donepezil	D	N06AB10	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				2391	N06AB	N06A	N06DA	N06D
5256	escitalopram	enhances	2D6	donepezil	D	N06AB10	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				4102	N06AB	N06A	N06DA	N06D
5256	escitalopram	enhances	2D6	donepezil	D	N06AB10	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				4316	N06AB	N06A	N06DA	N06D
5258	escitalopram	enhances	2D6	duloxetine	D	N06AB10	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
5261	escitalopram	enhances	2D6	flecainide	D	N06AB10	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		1219	N06AB	N06A	C01BC	C01B
5262	escitalopram	enhances	2D6	fluoxetine	D	N06AB10	N06AB03	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
5263	escitalopram	enhances	2D6	fluvoxamine	D	N06AB10	N06AB08	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
5264	escitalopram	enhances	2D6	haloperidol	D	N06AB10	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	334	N06AB	N06A	N05AD	N05A
5264	escitalopram	enhances	2D6	haloperidol	D	N06AB10	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7445	N06AB	N06A	N05AD	N05A
5266	escitalopram	enhances	2D6	imipramine	D	N06AB10	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
5269	escitalopram	enhances	2D6	metoclopramide	D	N06AB10	A03FA01	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0				4738	N06AB	N06A	A03FA	A03F
5270	escitalopram	enhances	2D6	metoprolol	B	N06AB10	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3464	N06AB	N06A	C07AB	C07A
5270	escitalopram	enhances	2D6	metoprolol	B	N06AB10	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7557	N06AB	N06A	C07AB	C07A
5273	escitalopram	enhances	2D6	nebivolol		N06AB10	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1496	N06AB	N06A	C07AB	C07A
5273	escitalopram	enhances	2D6	nebivolol		N06AB10	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1532	N06AB	N06A	C07AB	C07A
5273	escitalopram	enhances	2D6	nebivolol		N06AB10	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2482	N06AB	N06A	C07AB	C07A
5274	escitalopram	enhances	2D6	nortriptyline	D	N06AB10	N06AA10	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AB	N06A	N06AA	N06A
5275	escitalopram	enhances	2D6	ondansetron	D	N06AB10	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AB	N06A	A04AA	A04A
5276	escitalopram	enhances	2D6	oxycodone		N06AB10	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4738	N06AB	N06A	N02AA	N02A
5276	escitalopram	enhances	2D6	oxycodone		N06AB10	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7557	N06AB	N06A	N02AA	N02A
5278	escitalopram	enhances	2D6	paroxetine	D	N06AB10	N06AB05	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
5286	escitalopram	enhances	2D6	promethazine	D	N06AB10	R06AD02	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AB	N06A	R06AD	R06A
5287	escitalopram	enhances	2D6	propafenone	D	N06AB10	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		133	N06AB	N06A	C01BC	C01B
5287	escitalopram	enhances	2D6	propafenone	D	N06AB10	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		351	N06AB	N06A	C01BC	C01B
5288	escitalopram	enhances	2D6	propranolol		N06AB10	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2276	N06AB	N06A	C07AA	C07A
5289	escitalopram	enhances	2D6	risperidone	D	N06AB10	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2567	N06AB	N06A	N05AX	N05A
5292	escitalopram	enhances	2D6	tamoxifen	D	N06AB10	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1			4873	N06AB	N06A	L02BA	L02B
5293	escitalopram	enhances	2D6	tetrabenazine	D	N06AB10	N07XX06	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AB	N06A	N07XX	N07X
5296	escitalopram	enhances	2D6	tramadol	D	N06AB10	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	2651	N06AB	N06A	N02AX	N02A
5296	escitalopram	enhances	2D6	tramadol	D	N06AB10	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	7197	N06AB	N06A	N02AX	N02A
5299	escitalopram	enhances	2D6	venlafaxine	D	N06AB10	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		5365	N06AB	N06A	N06AX	N06A
5301	escitalopram	enhances	2D6	zuclopenthixol		N06AB10	N05AF05	Selective serotonin reuptake inhibitors (N06AB)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AF	N05A
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	152	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	756	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1212	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2672	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4517	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4704	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5123	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5343	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5556	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6035	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7095	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7653	A02BC	A02B	N05BA	N05B
5474	esomeprazole	enhances	3A457	alprazolam		A02BC05	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7686	A02BC	A02B	N05BA	N05B
5475	esomeprazole	enhances	2C19,3A457	amitriptyline		A02BC05	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		833	A02BC	A02B	N06AA	N06A
5475	esomeprazole	enhances	2C19,3A457	amitriptyline		A02BC05	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		1271	A02BC	A02B	N06AA	N06A
5475	esomeprazole	enhances	2C19,3A457	amitriptyline		A02BC05	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		3765	A02BC	A02B	N06AA	N06A
5475	esomeprazole	enhances	2C19,3A457	amitriptyline		A02BC05	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		7095	A02BC	A02B	N06AA	N06A
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	35	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	130	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	154	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	300	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	645	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	679	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	767	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1360	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1452	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2002	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2039	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2396	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2416	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2439	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2649	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2679	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2728	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2776	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2960	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3009	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3171	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3179	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3196	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3472	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3766	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3777	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3791	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3829	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3875	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3954	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4013	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4107	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4144	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4145	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4224	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4335	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4418	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4438	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4458	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4558	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4636	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4754	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4942	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5007	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5013	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5019	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5194	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5556	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5934	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5957	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7305	A02BC	A02B	C08CA	C08C
5476	esomeprazole	enhances	3A457	amlodipine		A02BC05	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7601	A02BC	A02B	C08CA	C08C
5477	esomeprazole	enhances	3A457	apixaban		A02BC05	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5549	A02BC	A02B	B01AF	B01A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		49	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		130	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		201	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		213	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		284	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		288	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		335	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		351	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		354	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		356	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		645	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		870	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		877	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		896	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1208	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1244	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1360	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1362	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1473	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1546	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2081	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2117	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2172	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2197	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2251	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2259	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2396	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2664	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2728	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2776	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2787	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2910	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3765	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3829	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3838	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3972	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4027	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4107	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4120	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4172	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4438	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4602	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4718	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4843	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4862	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4872	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4883	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4942	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5019	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5194	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5197	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5205	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5291	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5343	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5345	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5721	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5730	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5747	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5848	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5865	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5887	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5934	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5984	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6003	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6104	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7024	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7092	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7095	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7113	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7174	A02BC	A02B	C10AA	C10A
5482	esomeprazole	enhances	3A457	atorvastatin		A02BC05	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7612	A02BC	A02B	C10AA	C10A
5496	esomeprazole	enhances	3A457	chlorpheniramine		A02BC05	R06AB04	Proton pump inhibitors (A02BC)	Substituted alkylamines (R06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antihistamines for systemic use (R06A)	0	0				A02BC	A02B	R06AB	R06A
5497	esomeprazole	enhances	3A457	cilostazol		A02BC05	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				1362	A02BC	A02B	B01AC	B01A
5497	esomeprazole	enhances	3A457	cilostazol		A02BC05	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5957	A02BC	A02B	B01AC	B01A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			278	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			353	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2251	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3526	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3536	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3982	A02BC	A02B	N06AB	N06A
5499	esomeprazole	enhances	2C19,3A457	citalopram		A02BC05	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5007	A02BC	A02B	N06AB	N06A
5500	esomeprazole	enhances	3A457	clarithromycin		A02BC05	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			1459	A02BC	A02B	J01FA	J01F
5500	esomeprazole	enhances	3A457	clarithromycin		A02BC05	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			3699	A02BC	A02B	J01FA	J01F
5500	esomeprazole	enhances	3A457	clarithromycin		A02BC05	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			3972	A02BC	A02B	J01FA	J01F
5501	esomeprazole	enhances	2C19	clobazam		A02BC05	N05BA09	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0					A02BC	A02B	N05BA	N05B
5502	esomeprazole	enhances	2C19	clomipramine		A02BC05	N06AA04	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		2576	A02BC	A02B	N06AA	N06A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	288	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	353	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	679	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1019	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1141	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1360	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1486	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2172	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2664	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2913	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3196	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3221	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3479	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3765	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4013	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4144	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4411	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4458	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4541	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4718	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4945	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5194	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5291	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5343	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5628	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5827	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5957	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5962	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7024	A02BC	A02B	B01AC	B01A
5503	esomeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC05	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7113	A02BC	A02B	B01AC	B01A
5507	esomeprazole	enhances	3A457	colchicine		A02BC05	M04AC01	Proton pump inhibitors (A02BC)	Preparations with no effect on uric acid metabolism (M04AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antigout preparations (M04A)	0				2058	A02BC	A02B	M04AC	M04A
5510	esomeprazole	enhances	2C19	cyclophosphamide		A02BC05	L01AA01	Proton pump inhibitors (A02BC)	Nitrogen mustard analogues (L01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Alkylating agents (L01A)	1	1				A02BC	A02B	L01AA	L01A
5511	esomeprazole	enhances	3A457	cyclosporine		A02BC05	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A02BC	A02B	L04AD	L04A
5514	esomeprazole	enhances	3A457	deflazacort		A02BC05	H02AB13	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0					A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				311	A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				324	A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				1235	A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2002	A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2757	A02BC	A02B	H02AB	H02A
5515	esomeprazole	enhances	3A457	dexamethasone		A02BC05	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				4691	A02BC	A02B	H02AB	H02A
5516	esomeprazole	enhances	3A457	dextromethorphan		A02BC05	R05DA09	Proton pump inhibitors (A02BC)	Opium alkaloids and derivatives (R05DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1			4145	A02BC	A02B	R05DA	R05D
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	235	A02BC	A02B	N05BA	N05B
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2172	A02BC	A02B	N05BA	N05B
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2823	A02BC	A02B	N05BA	N05B
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3973	A02BC	A02B	N05BA	N05B
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5628	A02BC	A02B	N05BA	N05B
5517	esomeprazole	enhances	2C19,3A457	diazepam		A02BC05	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7733	A02BC	A02B	N05BA	N05B
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		201	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		284	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		305	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		757	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1019	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1179	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2081	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2599	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3167	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4864	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4960	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5962	A02BC	A02B	C08DB	C08D
5518	esomeprazole	enhances	3A457	diltiazem		A02BC05	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7662	A02BC	A02B	C08DB	C08D
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2088	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2251	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2595	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3838	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4517	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4574	A02BC	A02B	A03FA	A03F
5521	esomeprazole	enhances	3A457	domperidone		A02BC05	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				5973	A02BC	A02B	A03FA	A03F
5525	esomeprazole	enhances	3A457	eplerenone		A02BC05	C03DA04	Proton pump inhibitors (A02BC)	Aldosterone antagonists (C03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Potassium-sparing agents (C03D)	0					A02BC	A02B	C03DA	C03D
5528	esomeprazole	enhances	2C19,3A457	escitalopram		A02BC05	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				351	A02BC	A02B	N06AB	N06A
5528	esomeprazole	enhances	2C19,3A457	escitalopram		A02BC05	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				897	A02BC	A02B	N06AB	N06A
5528	esomeprazole	enhances	2C19,3A457	escitalopram		A02BC05	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1452	A02BC	A02B	N06AB	N06A
5528	esomeprazole	enhances	2C19,3A457	escitalopram		A02BC05	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4335	A02BC	A02B	N06AB	N06A
5528	esomeprazole	enhances	2C19,3A457	escitalopram		A02BC05	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4873	A02BC	A02B	N06AB	N06A
5530	esomeprazole	enhances	3A457	felodipine		A02BC05	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	208	A02BC	A02B	C08CA	C08C
5534	esomeprazole	enhances	3A457	haloperidol		A02BC05	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	149	A02BC	A02B	N05AD	N05A
5534	esomeprazole	enhances	3A457	haloperidol		A02BC05	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4017	A02BC	A02B	N05AD	N05A
5534	esomeprazole	enhances	3A457	haloperidol		A02BC05	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4548	A02BC	A02B	N05AD	N05A
5534	esomeprazole	enhances	3A457	haloperidol		A02BC05	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7087	A02BC	A02B	N05AD	N05A
5536	esomeprazole	enhances	3A457	hydrocortisone		A02BC05	H02AB09	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2437	A02BC	A02B	H02AB	H02A
5536	esomeprazole	enhances	3A457	hydrocortisone		A02BC05	H02AB09	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2960	A02BC	A02B	H02AB	H02A
5539	esomeprazole	enhances	3A457	imatinib		A02BC05	L01XE01	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	0	0				A02BC	A02B	L01XE	L01X
5540	esomeprazole	enhances	2C19	imipramine		A02BC05	N06AA02	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BC	A02B	N06AA	N06A
5541	esomeprazole	enhances	3A457	indacaterol		A02BC05	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4107	A02BC	A02B	R03AC	R03A
5541	esomeprazole	enhances	3A457	indacaterol		A02BC05	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4862	A02BC	A02B	R03AC	R03A
5541	esomeprazole	enhances	3A457	indacaterol		A02BC05	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5032	A02BC	A02B	R03AC	R03A
5541	esomeprazole	enhances	3A457	indacaterol		A02BC05	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7381	A02BC	A02B	R03AC	R03A
5543	esomeprazole	enhances	2C19	indometacin		A02BC05	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				7	A02BC	A02B	M01AB	M01A
5546	esomeprazole	enhances	3A457	ivabradine		A02BC05	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				1381	A02BC	A02B	C01EB	C01E
5546	esomeprazole	enhances	3A457	ivabradine		A02BC05	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				4883	A02BC	A02B	C01EB	C01E
5546	esomeprazole	enhances	3A457	ivabradine		A02BC05	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				5747	A02BC	A02B	C01EB	C01E
5546	esomeprazole	enhances	3A457	ivabradine		A02BC05	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				7092	A02BC	A02B	C01EB	C01E
5549	esomeprazole	enhances	2C19,3A457	lansoprazole		A02BC05	A02BC03	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				A02BC	A02B	A02BC	A02B
5551	esomeprazole	enhances	3A457	lercanidipine		A02BC05	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3521	A02BC	A02B	C08CA	C08C
5551	esomeprazole	enhances	3A457	lercanidipine		A02BC05	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3975	A02BC	A02B	C08CA	C08C
5551	esomeprazole	enhances	3A457	lercanidipine		A02BC05	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				7478	A02BC	A02B	C08CA	C08C
5555	esomeprazole	enhances	3A457	lovastatin		A02BC05	C10AA02	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		252	A02BC	A02B	C10AA	C10A
5558	esomeprazole	enhances	3A457	methadone		A02BC05	N07BC02	Proton pump inhibitors (A02BC)	Drugs used in opioid dependence (N07BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs used in addictive disorders (N07B)	0	0				A02BC	A02B	N07BC	N07B
5560	esomeprazole	enhances	3A457	midazolam		A02BC05	N05CD08	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A02BC	A02B	N05CD	N05C
5567	esomeprazole	enhances	3A457	nifedipine		A02BC05	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1216	A02BC	A02B	C08CA	C08C
5567	esomeprazole	enhances	3A457	nifedipine		A02BC05	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1362	A02BC	A02B	C08CA	C08C
5567	esomeprazole	enhances	3A457	nifedipine		A02BC05	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3078	A02BC	A02B	C08CA	C08C
5567	esomeprazole	enhances	3A457	nifedipine		A02BC05	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4017	A02BC	A02B	C08CA	C08C
5567	esomeprazole	enhances	3A457	nifedipine		A02BC05	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6034	A02BC	A02B	C08CA	C08C
5569	esomeprazole	enhances	3A457	nisoldipine		A02BC05	C08CA07	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2348	A02BC	A02B	C08CA	C08C
5570	esomeprazole	enhances	3A457	nitrendipine		A02BC05	C08CA08	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A02BC	A02B	C08CA	C08C
5572	esomeprazole	enhances	2C19,3A457	omeprazole		A02BC05	A02BC01	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				A02BC	A02B	A02BC	A02B
5573	esomeprazole	enhances	3A457	ondansetron		A02BC05	A04AA01	Proton pump inhibitors (A02BC)	Serotonin (5HT3) antagonists (A04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiemetics and antinauseants (A04A)	0	0			2595	A02BC	A02B	A04AA	A04A
5580	esomeprazole	enhances	2C19,3A457	pantoprazole		A02BC05	A02BC02	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				A02BC	A02B	A02BC	A02B
5582	esomeprazole	enhances	2C19	phenobarbital		A02BC05	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2326	A02BC	A02B	N03AA	N03A
5582	esomeprazole	enhances	2C19	phenobarbital		A02BC05	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2787	A02BC	A02B	N03AA	N03A
5582	esomeprazole	enhances	2C19	phenobarbital		A02BC05	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3320	A02BC	A02B	N03AA	N03A
5582	esomeprazole	enhances	2C19	phenobarbital		A02BC05	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4947	A02BC	A02B	N03AA	N03A
5583	esomeprazole	enhances	2C19	phenytoin		A02BC05	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		A02BC	A02B	N03AB	N03A
5588	esomeprazole	enhances	2C19	primidone		A02BC05	N03AA03	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	0					A02BC	A02B	N03AA	N03A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				876	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1216	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1470	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2756	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3007	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3393	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3396	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3479	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4018	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4099	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4437	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4805	A02BC	A02B	C07AA	C07A
5591	esomeprazole	enhances	2C19,3A457	propranolol		A02BC05	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5693	A02BC	A02B	C07AA	C07A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				1152	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				2672	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3320	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3526	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3605	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4310	A02BC	A02B	N05AH	N05A
5592	esomeprazole	enhances	3A457	quetiapine		A02BC05	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4945	A02BC	A02B	N05AH	N05A
5598	esomeprazole	enhances	3A457	risperidone		A02BC05	N05AX08	Proton pump inhibitors (A02BC)	Other antipsychotics (N05AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A02BC	A02B	N05AX	N05A
5599	esomeprazole	enhances	3A457	ritonavir		A02BC05	J05AE03	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0			7357	A02BC	A02B	J05AE	J05A
5600	esomeprazole	enhances	3A457	rivaroxaban		A02BC05	B01AF01	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5931	A02BC	A02B	B01AF	B01A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				149	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				284	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				335	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				658	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				794	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				800	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2073	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2348	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3167	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3481	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3829	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4172	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4224	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4458	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4683	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4746	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4883	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5467	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5782	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5976	A02BC	A02B	R03AC	R03A
5606	esomeprazole	enhances	3A457	salmeterol		A02BC05	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7024	A02BC	A02B	R03AC	R03A
5607	esomeprazole	enhances	3A457	saquinavir	B	A02BC05	J05AE01	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0				A02BC	A02B	J05AE	J05A
5609	esomeprazole	enhances	3A457	sildenafil		A02BC05	G04BE03	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0			1362	A02BC	A02B	G04BE	G04B
5609	esomeprazole	enhances	3A457	sildenafil		A02BC05	G04BE03	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0			2648	A02BC	A02B	G04BE	G04B
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		34	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		206	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		208	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		800	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1019	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1161	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1452	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1617	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2439	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2648	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2913	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3078	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3167	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3171	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3442	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3472	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3514	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3526	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3778	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3954	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4310	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4335	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4541	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4553	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4615	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4689	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4846	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4857	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5218	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5549	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5551	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5827	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6206	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7403	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7416	A02BC	A02B	C10AA	C10A
5611	esomeprazole	enhances	3A457	simvastatin		A02BC05	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7478	A02BC	A02B	C10AA	C10A
5612	esomeprazole	enhances	3A457	sirolimus		A02BC05	L04AA10	Proton pump inhibitors (A02BC)	Selective immunosuppressants (L04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A02BC	A02B	L04AA	L04A
5614	esomeprazole	enhances	3A457	sorafenib		A02BC05	L01XE05	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1					A02BC	A02B	L01XE	L01X
5615	esomeprazole	enhances	3A457	sunitinib		A02BC05	L01XE04	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1					A02BC	A02B	L01XE	L01X
5617	esomeprazole	enhances	3A457	tacrolimus		A02BC05	L04AD02	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A02BC	A02B	L04AD	L04A
5618	esomeprazole	enhances	3A457	tadalafil		A02BC05	G04BE08	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0				A02BC	A02B	G04BE	G04B
5619	esomeprazole	enhances	3A457	tamoxifen		A02BC05	L02BA01	Proton pump inhibitors (A02BC)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1			4873	A02BC	A02B	L02BA	L02B
5626	esomeprazole	enhances	3A457	testosterone		A02BC05	G03BA03	Proton pump inhibitors (A02BC)	3-oxoandrosten (4) derivatives (G03BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Androgens (G03B)	0				7612	A02BC	A02B	G03BA	G03B
5627	esomeprazole	enhances	3A457	ticagrelor		A02BC05	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				4862	A02BC	A02B	B01AC	B01A
5627	esomeprazole	enhances	3A457	ticagrelor		A02BC05	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				4942	A02BC	A02B	B01AC	B01A
5627	esomeprazole	enhances	3A457	ticagrelor		A02BC05	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5747	A02BC	A02B	B01AC	B01A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	21	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	756	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	828	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2251	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2416	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3333	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3486	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3875	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3954	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4173	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4548	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4558	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	5013	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	5461	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	5857	A02BC	A02B	N02AX	N02A
5630	esomeprazole	enhances	3A457	tramadol		A02BC05	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	6206	A02BC	A02B	N02AX	N02A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		838	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		975	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1617	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2413	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3605	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4548	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5007	A02BC	A02B	N06AX	N06A
5631	esomeprazole	enhances	3A457	trazodone		A02BC05	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6067	A02BC	A02B	N06AX	N06A
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	353	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1452	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4303	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4394	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5742	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5848	A02BC	A02B	N05CD	N05C
5632	esomeprazole	enhances	3A457	triazolam		A02BC05	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6102	A02BC	A02B	N05CD	N05C
5639	esomeprazole	enhances	2C19,3A457	venlafaxine		A02BC05	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6075	A02BC	A02B	N06AX	N06A
5639	esomeprazole	enhances	2C19,3A457	venlafaxine		A02BC05	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7095	A02BC	A02B	N06AX	N06A
5639	esomeprazole	enhances	2C19,3A457	venlafaxine		A02BC05	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7416	A02BC	A02B	N06AX	N06A
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1579	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2039	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2123	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3481	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3549	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3777	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4746	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4873	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5556	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5601	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5730	A02BC	A02B	C08DA	C08D
5640	esomeprazole	enhances	3A457	verapamil		A02BC05	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7639	A02BC	A02B	C08DA	C08D
5644	esomeprazole	enhances	2C19,3A457	voriconazole	B	A02BC05	J02AC03	Proton pump inhibitors (A02BC)	Triazole derivatives (J02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antimycotics for systemic use (J02A)	0	0				A02BC	A02B	J02AC	J02A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		149	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		201	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		208	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		278	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		300	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		332	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		370	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		625	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		664	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		838	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1614	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2058	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2059	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2127	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2214	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2259	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2672	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2872	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2888	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2979	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3178	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3179	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3521	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3820	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3838	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4002	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4099	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4553	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4683	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4746	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4864	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4872	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4883	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4931	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4945	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5205	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5306	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5742	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5812	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5839	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5962	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5976	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6075	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6193	A02BC	A02B	B01AA	B01A
5645	esomeprazole	enhances	2C19	warfarin	B	A02BC05	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7639	A02BC	A02B	B01AA	B01A
5646	esomeprazole	enhances	3A457	zaleplon		A02BC05	N05CF03	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3393	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				152	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				356	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				828	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				1271	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				2439	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				2620	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3791	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4718	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5019	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5461	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5698	A02BC	A02B	N05CF	N05C
5648	esomeprazole	enhances	3A457	zolpidem		A02BC05	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5865	A02BC	A02B	N05CF	N05C
5744	fenofibrate	enhances	2C9	amitriptyline		C10AB05	N06AA09	Fibrates (C10AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	1	0	Serotonin toxicity			C10AB	C10A	N06AA	N06A
5746	fenofibrate	enhances	2C9	capecitabine		C10AB05	L01BC06	Fibrates (C10AB)	Pyrimidine analogues (L01BC)	Lipid modifying agents, plain (C10A)	Antimetabolites (L01B)	1					C10AB	C10A	L01BC	L01B
5747	fenofibrate	enhances	2C9	celecoxib		C10AB05	M01AH01	Fibrates (C10AB)	Coxibs (M01AH)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AB	C10A	M01AH	M01A
5748	fenofibrate	enhances	2C9	clopidogrel		C10AB05	B01AC04	Fibrates (C10AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Lipid modifying agents, plain (C10A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4721	C10AB	C10A	B01AC	B01A
5749	fenofibrate	enhances	2C9	diclofenac	B	C10AB05	M01AB05	Fibrates (C10AB)	Acetic acid derivatives and related substances (M01AB)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AB	C10A	M01AB	M01A
5751	fenofibrate	enhances	2C9	fluoxetine		C10AB05	N06AB03	Fibrates (C10AB)	Selective serotonin reuptake inhibitors (N06AB)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	0	0	Serotonin toxicity			C10AB	C10A	N06AB	N06A
5752	fenofibrate	enhances	2C9	fluvastatin	C	C10AB05	C10AA04	Fibrates (C10AB)	HMG CoA reductase inhibitors (C10AA)	Lipid modifying agents, plain (C10A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2667	C10AB	C10A	C10AA	C10A
5753	fenofibrate	enhances	2C9	glimepiride	B	C10AB05	A10BB12	Fibrates (C10AB)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				2043	C10AB	C10A	A10BB	A10B
5753	fenofibrate	enhances	2C9	glimepiride	B	C10AB05	A10BB12	Fibrates (C10AB)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				3001	C10AB	C10A	A10BB	A10B
5753	fenofibrate	enhances	2C9	glimepiride	B	C10AB05	A10BB12	Fibrates (C10AB)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				3596	C10AB	C10A	A10BB	A10B
5754	fenofibrate	enhances	2C9	glipizide		C10AB05	A10BB07	Fibrates (C10AB)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			C10AB	C10A	A10BB	A10B
5755	fenofibrate	enhances	2C9	glyburide	C	C10AB05	A10BB01	Fibrates (C10AB)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		158	C10AB	C10A	A10BB	A10B
5756	fenofibrate	enhances	2C9	ibuprofen		C10AB05	M01AE01	Fibrates (C10AB)	Propionic acid derivatives (M01AE)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AB	C10A	M01AE	M01A
5757	fenofibrate	enhances	2C9	irbesartan		C10AB05	C09CA04	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	25	C10AB	C10A	C09CA	C09C
5757	fenofibrate	enhances	2C9	irbesartan		C10AB05	C09CA04	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3596	C10AB	C10A	C09CA	C09C
5760	fenofibrate	enhances	2C9	losartan		C10AB05	C09CA01	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	2667	C10AB	C10A	C09CA	C09C
5760	fenofibrate	enhances	2C9	losartan		C10AB05	C09CA01	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3001	C10AB	C10A	C09CA	C09C
5760	fenofibrate	enhances	2C9	losartan		C10AB05	C09CA01	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4334	C10AB	C10A	C09CA	C09C
5760	fenofibrate	enhances	2C9	losartan		C10AB05	C09CA01	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4721	C10AB	C10A	C09CA	C09C
5760	fenofibrate	enhances	2C9	losartan		C10AB05	C09CA01	Fibrates (C10AB)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	5239	C10AB	C10A	C09CA	C09C
5761	fenofibrate	enhances	2C9	meloxicam		C10AB05	M01AC06	Fibrates (C10AB)	Oxicams (M01AC)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					C10AB	C10A	M01AC	M01A
5762	fenofibrate	enhances	2C9	naproxen		C10AB05	M01AE02	Fibrates (C10AB)	Propionic acid derivatives (M01AE)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AB	C10A	M01AE	M01A
5766	fenofibrate	enhances	2C9	phenytoin		C10AB05	N03AB02	Fibrates (C10AB)	Hydantoin derivatives (N03AB)	Lipid modifying agents, plain (C10A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		C10AB	C10A	N03AB	N03A
5767	fenofibrate	enhances	2C9	piroxicam		C10AB05	M01AC01	Fibrates (C10AB)	Oxicams (M01AC)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AB	C10A	M01AC	M01A
5771	fenofibrate	enhances	2C9	tamoxifen		C10AB05	L02BA01	Fibrates (C10AB)	Anti-estrogens (L02BA)	Lipid modifying agents, plain (C10A)	Hormone antagonists and related agents (L02B)	1	1				C10AB	C10A	L02BA	L02B
5773	fenofibrate	enhances	2C9	torasemide		C10AB05	C03CA04	Fibrates (C10AB)	Sulfonamides, plain (C03CA)	Lipid modifying agents, plain (C10A)	High-ceiling diuretics (C03C)	0	0			4650	C10AB	C10A	C03CA	C03C
5774	fenofibrate	enhances	2C9	valproate		C10AB05	N03AG01	Fibrates (C10AB)	Fatty acid derivatives (N03AG)	Lipid modifying agents, plain (C10A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		C10AB	C10A	N03AG	N03A
5775	fenofibrate	enhances	2C9	venlafaxine		C10AB05	N06AX16	Fibrates (C10AB)	Other antidepressants (N06AX)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	0	0	Serotonin toxicity			C10AB	C10A	N06AX	N06A
5776	fenofibrate	enhances	2C9	voriconazole		C10AB05	J02AC03	Fibrates (C10AB)	Triazole derivatives (J02AC)	Lipid modifying agents, plain (C10A)	Antimycotics for systemic use (J02A)	0	0				C10AB	C10A	J02AC	J02A
5777	fenofibrate	enhances	2C9	warfarin	C	C10AB05	B01AA03	Fibrates (C10AB)	Vitamin K antagonists (B01AA)	Lipid modifying agents, plain (C10A)	Antithrombotic agents (B01A)	1	0	Bleeding		3001	C10AB	C10A	B01AA	B01A
5777	fenofibrate	enhances	2C9	warfarin	C	C10AB05	B01AA03	Fibrates (C10AB)	Vitamin K antagonists (B01AA)	Lipid modifying agents, plain (C10A)	Antithrombotic agents (B01A)	1	0	Bleeding		4669	C10AB	C10A	B01AA	B01A
5784	fluconazole	enhances	3A457	alprazolam	B	J02AC01	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	895	J02AC	J02A	N05BA	N05B
5784	fluconazole	enhances	3A457	alprazolam	B	J02AC01	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3245	J02AC	J02A	N05BA	N05B
5784	fluconazole	enhances	3A457	alprazolam	B	J02AC01	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5836	J02AC	J02A	N05BA	N05B
5784	fluconazole	enhances	3A457	alprazolam	B	J02AC01	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6035	J02AC	J02A	N05BA	N05B
5785	fluconazole	enhances	2C9,3A457	amitriptyline	D	J02AC01	N06AA09	Triazole derivatives (J02AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J02AC	J02A	N06AA	N06A
5786	fluconazole	enhances	3A457	amlodipine	B	J02AC01	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	238	J02AC	J02A	C08CA	C08C
5786	fluconazole	enhances	3A457	amlodipine	B	J02AC01	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2129	J02AC	J02A	C08CA	C08C
5786	fluconazole	enhances	3A457	amlodipine	B	J02AC01	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2177	J02AC	J02A	C08CA	C08C
5786	fluconazole	enhances	3A457	amlodipine	B	J02AC01	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3619	J02AC	J02A	C08CA	C08C
5786	fluconazole	enhances	3A457	amlodipine	B	J02AC01	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4234	J02AC	J02A	C08CA	C08C
5787	fluconazole	enhances	3A457	apixaban		J02AC01	B01AF02	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
5791	fluconazole	enhances	3A457	atorvastatin	C	J02AC01	C10AA05	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5107	J02AC	J02A	C10AA	C10A
5801	fluconazole	enhances	2C9	capecitabine		J02AC01	L01BC06	Triazole derivatives (J02AC)	Pyrimidine analogues (L01BC)	Antimycotics for systemic use (J02A)	Antimetabolites (L01B)	1					J02AC	J02A	L01BC	L01B
5802	fluconazole	enhances	3A457	carbamazepine	B	J02AC01	N03AF01	Triazole derivatives (J02AC)	Carboxamide derivatives (N03AF)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5881	J02AC	J02A	N03AF	N03A
5804	fluconazole	enhances	2C9	celecoxib		J02AC01	M01AH01	Triazole derivatives (J02AC)	Coxibs (M01AH)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AH	M01A
5807	fluconazole	enhances	3A457	chlorpheniramine		J02AC01	R06AB04	Triazole derivatives (J02AC)	Substituted alkylamines (R06AB)	Antimycotics for systemic use (J02A)	Antihistamines for systemic use (R06A)	0	0				J02AC	J02A	R06AB	R06A
5808	fluconazole	enhances	3A457	cilostazol	D	J02AC01	B01AC23	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
5810	fluconazole	enhances	3A457	citalopram	D	J02AC01	N06AB04	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0			3075	J02AC	J02A	N06AB	N06A
5811	fluconazole	enhances	3A457	clarithromycin	D	J02AC01	J01FA09	Triazole derivatives (J02AC)	Macrolides (J01FA)	Antimycotics for systemic use (J02A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J02AC	J02A	J01FA	J01F
5812	fluconazole	enhances	3A457	clobazam	C	J02AC01	N05BA09	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0					J02AC	J02A	N05BA	N05B
5813	fluconazole	enhances	2C9,3A457	clopidogrel		J02AC01	B01AC04	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J02AC	J02A	B01AC	B01A
5817	fluconazole	enhances	3A457	colchicine	C	J02AC01	M04AC01	Triazole derivatives (J02AC)	Preparations with no effect on uric acid metabolism (M04AC)	Antimycotics for systemic use (J02A)	Antigout preparations (M04A)	0				1196	J02AC	J02A	M04AC	M04A
5817	fluconazole	enhances	3A457	colchicine	C	J02AC01	M04AC01	Triazole derivatives (J02AC)	Preparations with no effect on uric acid metabolism (M04AC)	Antimycotics for systemic use (J02A)	Antigout preparations (M04A)	0				3859	J02AC	J02A	M04AC	M04A
5820	fluconazole	enhances	3A457	cyclosporine	B	J02AC01	L04AD01	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
5824	fluconazole	enhances	3A457	deflazacort		J02AC01	H02AB13	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
5825	fluconazole	enhances	3A457	dexamethasone		J02AC01	H02AB02	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0				3042	J02AC	J02A	H02AB	H02A
5825	fluconazole	enhances	3A457	dexamethasone		J02AC01	H02AB02	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0				5903	J02AC	J02A	H02AB	H02A
5826	fluconazole	enhances	3A457	dextromethorphan		J02AC01	R05DA09	Triazole derivatives (J02AC)	Opium alkaloids and derivatives (R05DA)	Antimycotics for systemic use (J02A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J02AC	J02A	R05DA	R05D
5827	fluconazole	enhances	3A457	diazepam	D	J02AC01	N05BA01	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2547	J02AC	J02A	N05BA	N05B
5827	fluconazole	enhances	3A457	diazepam	D	J02AC01	N05BA01	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4234	J02AC	J02A	N05BA	N05B
5828	fluconazole	enhances	2C9	diclofenac	B	J02AC01	M01AB05	Triazole derivatives (J02AC)	Acetic acid derivatives and related substances (M01AB)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AB	M01A
5829	fluconazole	enhances	3A457	diltiazem		J02AC01	C08DB01	Triazole derivatives (J02AC)	Benzothiazepine derivatives (C08DB)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2695	J02AC	J02A	C08DB	C08D
5829	fluconazole	enhances	3A457	diltiazem		J02AC01	C08DB01	Triazole derivatives (J02AC)	Benzothiazepine derivatives (C08DB)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3692	J02AC	J02A	C08DB	C08D
5829	fluconazole	enhances	3A457	diltiazem		J02AC01	C08DB01	Triazole derivatives (J02AC)	Benzothiazepine derivatives (C08DB)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5903	J02AC	J02A	C08DB	C08D
5832	fluconazole	enhances	3A457	domperidone	D	J02AC01	A03FA03	Triazole derivatives (J02AC)	Propulsives (A03FA)	Antimycotics for systemic use (J02A)	Propulsives (A03F)	0					J02AC	J02A	A03FA	A03F
5838	fluconazole	enhances	3A457	eplerenone	C	J02AC01	C03DA04	Triazole derivatives (J02AC)	Aldosterone antagonists (C03DA)	Antimycotics for systemic use (J02A)	Potassium-sparing agents (C03D)	0					J02AC	J02A	C03DA	C03D
5841	fluconazole	enhances	3A457	escitalopram	D	J02AC01	N06AB10	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0				238	J02AC	J02A	N06AB	N06A
5842	fluconazole	enhances	3A457	esomeprazole	B	J02AC01	A02BC05	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2872	J02AC	J02A	A02BC	A02B
5842	fluconazole	enhances	3A457	esomeprazole	B	J02AC01	A02BC05	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2979	J02AC	J02A	A02BC	A02B
5842	fluconazole	enhances	3A457	esomeprazole	B	J02AC01	A02BC05	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				6035	J02AC	J02A	A02BC	A02B
5844	fluconazole	enhances	3A457	felodipine	B	J02AC01	C08CA02	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
5848	fluconazole	enhances	2C9	fluoxetine	D	J02AC01	N06AB03	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AB	N06A
5849	fluconazole	enhances	2C9	fluvastatin	C	J02AC01	C10AA04	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J02AC	J02A	C10AA	C10A
5850	fluconazole	enhances	2C9	glimepiride	B	J02AC01	A10BB12	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J02AC	J02A	A10BB	A10B
5851	fluconazole	enhances	2C9	glipizide	B	J02AC01	A10BB07	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J02AC	J02A	A10BB	A10B
5852	fluconazole	enhances	2C9	glyburide	B	J02AC01	A10BB01	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		2129	J02AC	J02A	A10BB	A10B
5853	fluconazole	enhances	3A457	haloperidol	D	J02AC01	N05AD01	Triazole derivatives (J02AC)	Butyrophenone derivatives (N05AD)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2547	J02AC	J02A	N05AD	N05A
5854	fluconazole	enhances	3A457	hydrocortisone		J02AC01	H02AB09	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
5856	fluconazole	enhances	2C9	ibuprofen	B	J02AC01	M01AE01	Triazole derivatives (J02AC)	Propionic acid derivatives (M01AE)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AE	M01A
5858	fluconazole	enhances	3A457	imatinib		J02AC01	L01XE01	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	0	0				J02AC	J02A	L01XE	L01X
5859	fluconazole	enhances	3A457	indacaterol		J02AC01	R03AC18	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				4926	J02AC	J02A	R03AC	R03A
5861	fluconazole	enhances	2C9	irbesartan	B	J02AC01	C09CA04	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3245	J02AC	J02A	C09CA	C09C
5861	fluconazole	enhances	2C9	irbesartan	B	J02AC01	C09CA04	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4374	J02AC	J02A	C09CA	C09C
5861	fluconazole	enhances	2C9	irbesartan	B	J02AC01	C09CA04	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	6252	J02AC	J02A	C09CA	C09C
5864	fluconazole	enhances	3A457	ivabradine		J02AC01	C01EB17	Triazole derivatives (J02AC)	Other cardiac preparations (C01EB)	Antimycotics for systemic use (J02A)	Other cardiac preparations (C01E)	0					J02AC	J02A	C01EB	C01E
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			156	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			214	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1062	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1196	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2394	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2754	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2891	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3075	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3609	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4926	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5840	J02AC	J02A	A02BC	A02B
5866	fluconazole	enhances	3A457	lansoprazole		J02AC01	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7498	J02AC	J02A	A02BC	A02B
5868	fluconazole	enhances	3A457	lercanidipine	B	J02AC01	C08CA13	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2932	J02AC	J02A	C08CA	C08C
5874	fluconazole	enhances	2C9	losartan	B	J02AC01	C09CA01	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	595	J02AC	J02A	C09CA	C09C
5874	fluconazole	enhances	2C9	losartan	B	J02AC01	C09CA01	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3609	J02AC	J02A	C09CA	C09C
5875	fluconazole	enhances	3A457	lovastatin	C	J02AC01	C10AA02	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J02AC	J02A	C10AA	C10A
5877	fluconazole	enhances	2C9	meloxicam	B	J02AC01	M01AC06	Triazole derivatives (J02AC)	Oxicams (M01AC)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J02AC	J02A	M01AC	M01A
5878	fluconazole	enhances	3A457	methadone	D	J02AC01	N07BC02	Triazole derivatives (J02AC)	Drugs used in opioid dependence (N07BC)	Antimycotics for systemic use (J02A)	Drugs used in addictive disorders (N07B)	0	0				J02AC	J02A	N07BC	N07B
5879	fluconazole	enhances	3A457	midazolam	C	J02AC01	N05CD08	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05CD	N05C
5882	fluconazole	enhances	2C9	naproxen		J02AC01	M01AE02	Triazole derivatives (J02AC)	Propionic acid derivatives (M01AE)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AE	M01A
5886	fluconazole	enhances	3A457	nevirapine	B	J02AC01	J05AG01	Triazole derivatives (J02AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AG	J05A
5887	fluconazole	enhances	3A457	nifedipine	B	J02AC01	C08CA05	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
5888	fluconazole	enhances	3A457	nisoldipine	B	J02AC01	C08CA07	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
5889	fluconazole	enhances	3A457	nitrendipine	B	J02AC01	C08CA08	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1104	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2049	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2177	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2584	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2853	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3197	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3313	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3752	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3859	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5107	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5836	J02AC	J02A	A02BC	A02B
5892	fluconazole	enhances	3A457	omeprazole	B	J02AC01	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5903	J02AC	J02A	A02BC	A02B
5893	fluconazole	enhances	3A457	ondansetron	D	J02AC01	A04AA01	Triazole derivatives (J02AC)	Serotonin (5HT3) antagonists (A04AA)	Antimycotics for systemic use (J02A)	Antiemetics and antinauseants (A04A)	0	0				J02AC	J02A	A04AA	A04A
5900	fluconazole	enhances	3A457	pantoprazole		J02AC01	A02BC02	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2932	J02AC	J02A	A02BC	A02B
5900	fluconazole	enhances	3A457	pantoprazole		J02AC01	A02BC02	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4374	J02AC	J02A	A02BC	A02B
5902	fluconazole	enhances	2C9	phenytoin	C	J02AC01	N03AB02	Triazole derivatives (J02AC)	Hydantoin derivatives (N03AB)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J02AC	J02A	N03AB	N03A
5905	fluconazole	enhances	2C9	piroxicam		J02AC01	M01AC01	Triazole derivatives (J02AC)	Oxicams (M01AC)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AC	M01A
5909	fluconazole	enhances	3A457	propranolol		J02AC01	C07AA05	Triazole derivatives (J02AC)	Beta blocking agents, non-selective (C07AA)	Antimycotics for systemic use (J02A)	Beta blocking agents (C07A)	0				3042	J02AC	J02A	C07AA	C07A
5910	fluconazole	enhances	3A457	quetiapine	D	J02AC01	N05AH04	Triazole derivatives (J02AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0				238	J02AC	J02A	N05AH	N05A
5910	fluconazole	enhances	3A457	quetiapine	D	J02AC01	N05AH04	Triazole derivatives (J02AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0				2695	J02AC	J02A	N05AH	N05A
5916	fluconazole	enhances	3A457	risperidone	D	J02AC01	N05AX08	Triazole derivatives (J02AC)	Other antipsychotics (N05AX)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J02AC	J02A	N05AX	N05A
5917	fluconazole	enhances	3A457	ritonavir	D	J02AC01	J05AE03	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
5918	fluconazole	enhances	3A457	rivaroxaban	B	J02AC01	B01AF01	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
5925	fluconazole	enhances	3A457	salmeterol	D	J02AC01	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				2695	J02AC	J02A	R03AC	R03A
5925	fluconazole	enhances	3A457	salmeterol	D	J02AC01	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				2754	J02AC	J02A	R03AC	R03A
5925	fluconazole	enhances	3A457	salmeterol	D	J02AC01	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				3042	J02AC	J02A	R03AC	R03A
5925	fluconazole	enhances	3A457	salmeterol	D	J02AC01	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				3752	J02AC	J02A	R03AC	R03A
5926	fluconazole	enhances	3A457	saquinavir	D	J02AC01	J05AE01	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
5928	fluconazole	enhances	3A457	sildenafil	B	J02AC01	G04BE03	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
5930	fluconazole	enhances	3A457	simvastatin	C	J02AC01	C10AA01	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3471	J02AC	J02A	C10AA	C10A
5931	fluconazole	enhances	3A457	sirolimus	D	J02AC01	L04AA10	Triazole derivatives (J02AC)	Selective immunosuppressants (L04AA)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AA	L04A
5933	fluconazole	enhances	3A457	sorafenib	D	J02AC01	L01XE05	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
5934	fluconazole	enhances	3A457	sunitinib	D	J02AC01	L01XE04	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
5937	fluconazole	enhances	3A457	tacrolimus	D	J02AC01	L04AD02	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
5938	fluconazole	enhances	3A457	tadalafil		J02AC01	G04BE08	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
5939	fluconazole	enhances	2C9,3A457	tamoxifen	D	J02AC01	L02BA01	Triazole derivatives (J02AC)	Anti-estrogens (L02BA)	Antimycotics for systemic use (J02A)	Hormone antagonists and related agents (L02B)	1	1				J02AC	J02A	L02BA	L02B
5945	fluconazole	enhances	3A457	testosterone		J02AC01	G03BA03	Triazole derivatives (J02AC)	3-oxoandrosten (4) derivatives (G03BA)	Antimycotics for systemic use (J02A)	Androgens (G03B)	0					J02AC	J02A	G03BA	G03B
5946	fluconazole	enhances	3A457	ticagrelor		J02AC01	B01AC24	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
5950	fluconazole	enhances	2C9	torasemide	D	J02AC01	C03CA04	Triazole derivatives (J02AC)	Sulfonamides, plain (C03CA)	Antimycotics for systemic use (J02A)	High-ceiling diuretics (C03C)	0	0			2695	J02AC	J02A	C03CA	C03C
5951	fluconazole	enhances	3A457	tramadol		J02AC01	N02AX02	Triazole derivatives (J02AC)	Other opioids (N02AX)	Antimycotics for systemic use (J02A)	Opioids (N02A)	0	1		Reduced analgesic effect	214	J02AC	J02A	N02AX	N02A
5952	fluconazole	enhances	3A457	trazodone	D	J02AC01	N06AX05	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2695	J02AC	J02A	N06AX	N06A
5953	fluconazole	enhances	3A457	triazolam	C	J02AC01	N05CD05	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05CD	N05C
5955	fluconazole	enhances	2C9	valproate		J02AC01	N03AG01	Triazole derivatives (J02AC)	Fatty acid derivatives (N03AG)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	595	J02AC	J02A	N03AG	N03A
5955	fluconazole	enhances	2C9	valproate		J02AC01	N03AG01	Triazole derivatives (J02AC)	Fatty acid derivatives (N03AG)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2129	J02AC	J02A	N03AG	N03A
5955	fluconazole	enhances	2C9	valproate		J02AC01	N03AG01	Triazole derivatives (J02AC)	Fatty acid derivatives (N03AG)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2440	J02AC	J02A	N03AG	N03A
5961	fluconazole	enhances	2C9,3A457	venlafaxine	D	J02AC01	N06AX16	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3245	J02AC	J02A	N06AX	N06A
5962	fluconazole	enhances	3A457	verapamil		J02AC01	C08DA01	Triazole derivatives (J02AC)	Phenylalkylamine derivatives (C08DA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J02AC	J02A	C08DA	C08D
5966	fluconazole	enhances	2C9,3A457	voriconazole	D	J02AC01	J02AC03	Triazole derivatives (J02AC)	Triazole derivatives (J02AC)	Antimycotics for systemic use (J02A)	Antimycotics for systemic use (J02A)	0	0				J02AC	J02A	J02AC	J02A
5967	fluconazole	enhances	2C9	warfarin	C	J02AC01	B01AA03	Triazole derivatives (J02AC)	Vitamin K antagonists (B01AA)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	1	0	Bleeding		664	J02AC	J02A	B01AA	B01A
5967	fluconazole	enhances	2C9	warfarin	C	J02AC01	B01AA03	Triazole derivatives (J02AC)	Vitamin K antagonists (B01AA)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2695	J02AC	J02A	B01AA	B01A
5967	fluconazole	enhances	2C9	warfarin	C	J02AC01	B01AA03	Triazole derivatives (J02AC)	Vitamin K antagonists (B01AA)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2979	J02AC	J02A	B01AA	B01A
5967	fluconazole	enhances	2C9	warfarin	C	J02AC01	B01AA03	Triazole derivatives (J02AC)	Vitamin K antagonists (B01AA)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	1	0	Bleeding		7498	J02AC	J02A	B01AA	B01A
5969	fluconazole	enhances	3A457	zaleplon		J02AC01	N05CF03	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0					J02AC	J02A	N05CF	N05C
5971	fluconazole	enhances	3A457	zolpidem	B	J02AC01	N05CF02	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0				3245	J02AC	J02A	N05CF	N05C
5977	fluoxetine	enhances	3A457	alprazolam	B	N06AB03	N05BA12	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05BA	N05B
5980	fluoxetine	enhances	2C19,2D6,3A457	amitriptyline	D	N06AB03	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
5981	fluoxetine	enhances	3A457	amlodipine		N06AB03	C08CA01	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5845	N06AB	N06A	C08CA	C08C
5981	fluoxetine	enhances	3A457	amlodipine		N06AB03	C08CA01	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7503	N06AB	N06A	C08CA	C08C
5982	fluoxetine	enhances	3A457	apixaban		N06AB03	B01AF02	Selective serotonin reuptake inhibitors (N06AB)	Direct factor Xa inhibitors (B01AF)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AF	B01A
5987	fluoxetine	enhances	3A457	atorvastatin		N06AB03	C10AA05	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N06AB	N06A	C10AA	C10A
5997	fluoxetine	enhances	3A457	carbamazepine	B	N06AB03	N03AF01	Selective serotonin reuptake inhibitors (N06AB)	Carboxamide derivatives (N03AF)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AF	N03A
6000	fluoxetine	enhances	2D6	carvedilol		N06AB03	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N06AB	N06A	C07AG	C07A
6004	fluoxetine	enhances	2D6,3A457	chlorpheniramine	D	N06AB03	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
6005	fluoxetine	enhances	2D6	chlorpromazine	D	N06AB03	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AA	N05A
6006	fluoxetine	enhances	3A457	cilostazol	D	N06AB03	B01AC23	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AC	B01A
6008	fluoxetine	enhances	2C19,2D6,3A457	citalopram	D	N06AB03	N06AB04	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AB	N06A	N06AB	N06A
6009	fluoxetine	enhances	3A457	clarithromycin	D	N06AB03	J01FA09	Selective serotonin reuptake inhibitors (N06AB)	Macrolides (J01FA)	Antidepressants (N06A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				N06AB	N06A	J01FA	J01F
6010	fluoxetine	enhances	2C19,3A457	clobazam		N06AB03	N05BA09	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0					N06AB	N06A	N05BA	N05B
6011	fluoxetine	enhances	2C19,2D6	clomipramine	D	N06AB03	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
6012	fluoxetine	enhances	2D6	clonidine		N06AB03	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1					N06AB	N06A	C02AC	C02A
6013	fluoxetine	enhances	2C19,3A457	clopidogrel	C	N06AB03	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		N06AB	N06A	B01AC	B01A
6017	fluoxetine	enhances	3A457	colchicine		N06AB03	M04AC01	Selective serotonin reuptake inhibitors (N06AB)	Preparations with no effect on uric acid metabolism (M04AC)	Antidepressants (N06A)	Antigout preparations (M04A)	0					N06AB	N06A	M04AC	M04A
6020	fluoxetine	enhances	2C19	cyclophosphamide		N06AB03	L01AA01	Selective serotonin reuptake inhibitors (N06AB)	Nitrogen mustard analogues (L01AA)	Antidepressants (N06A)	Alkylating agents (L01A)	1	1				N06AB	N06A	L01AA	L01A
6021	fluoxetine	enhances	3A457	cyclosporine		N06AB03	L04AD01	Selective serotonin reuptake inhibitors (N06AB)	Calcineurin inhibitors (L04AD)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AD	L04A
6026	fluoxetine	enhances	3A457	deflazacort		N06AB03	H02AB13	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6028	fluoxetine	enhances	3A457	dexamethasone		N06AB03	H02AB02	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6030	fluoxetine	enhances	2D6,3A457	dextromethorphan	D	N06AB03	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
6031	fluoxetine	enhances	2C19,3A457	diazepam	C	N06AB03	N05BA01	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05BA	N05B
6032	fluoxetine	enhances	3A457	diltiazem	B	N06AB03	C08DB01	Selective serotonin reuptake inhibitors (N06AB)	Benzothiazepine derivatives (C08DB)	Antidepressants (N06A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N06AB	N06A	C08DB	C08D
6035	fluoxetine	enhances	3A457	domperidone	D	N06AB03	A03FA03	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AB	N06A	A03FA	A03F
6036	fluoxetine	enhances	2D6	donepezil	D	N06AB03	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0					N06AB	N06A	N06DA	N06D
6038	fluoxetine	enhances	2D6	duloxetine	D	N06AB03	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
6044	fluoxetine	enhances	3A457	eplerenone	C	N06AB03	C03DA04	Selective serotonin reuptake inhibitors (N06AB)	Aldosterone antagonists (C03DA)	Antidepressants (N06A)	Potassium-sparing agents (C03D)	0					N06AB	N06A	C03DA	C03D
6047	fluoxetine	enhances	2C19,2D6,3A457	escitalopram	D	N06AB03	N06AB10	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AB	N06A	N06AB	N06A
6048	fluoxetine	enhances	2C19,3A457	esomeprazole		N06AB03	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					N06AB	N06A	A02BC	A02B
6050	fluoxetine	enhances	3A457	felodipine		N06AB03	C08CA02	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1336	N06AB	N06A	C08CA	C08C
6053	fluoxetine	enhances	2D6	flecainide	D	N06AB03	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N06AB	N06A	C01BC	C01B
6055	fluoxetine	enhances	2D6	fluvoxamine	D	N06AB03	N06AB08	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
6056	fluoxetine	enhances	2D6,3A457	haloperidol	D	N06AB03	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AD	N05A
6058	fluoxetine	enhances	3A457	hydrocortisone		N06AB03	H02AB09	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6061	fluoxetine	enhances	3A457	imatinib		N06AB03	L01XE01	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	0	0				N06AB	N06A	L01XE	L01X
6062	fluoxetine	enhances	2C19,2D6	imipramine	D	N06AB03	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
6063	fluoxetine	enhances	3A457	indacaterol		N06AB03	R03AC18	Selective serotonin reuptake inhibitors (N06AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antidepressants (N06A)	Adrenergics, inhalants (R03A)	0					N06AB	N06A	R03AC	R03A
6065	fluoxetine	enhances	2C19	indometacin	C	N06AB03	M01AB01	Selective serotonin reuptake inhibitors (N06AB)	Acetic acid derivatives and related substances (M01AB)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N06AB	N06A	M01AB	M01A
6068	fluoxetine	enhances	3A457	ivabradine		N06AB03	C01EB17	Selective serotonin reuptake inhibitors (N06AB)	Other cardiac preparations (C01EB)	Antidepressants (N06A)	Other cardiac preparations (C01E)	0					N06AB	N06A	C01EB	C01E
6071	fluoxetine	enhances	2C19,3A457	lansoprazole		N06AB03	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5845	N06AB	N06A	A02BC	A02B
6073	fluoxetine	enhances	3A457	lercanidipine		N06AB03	C08CA13	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N06AB	N06A	C08CA	C08C
6078	fluoxetine	enhances	3A457	lovastatin		N06AB03	C10AA02	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N06AB	N06A	C10AA	C10A
6081	fluoxetine	enhances	3A457	methadone	D	N06AB03	N07BC02	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in opioid dependence (N07BC)	Antidepressants (N06A)	Drugs used in addictive disorders (N07B)	0	0				N06AB	N06A	N07BC	N07B
6083	fluoxetine	enhances	2D6	metoclopramide	D	N06AB03	A03FA01	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AB	N06A	A03FA	A03F
6084	fluoxetine	enhances	2D6	metoprolol	D	N06AB03	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7503	N06AB	N06A	C07AB	C07A
6086	fluoxetine	enhances	3A457	midazolam	B	N06AB03	N05CD08	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05CD)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05CD	N05C
6092	fluoxetine	enhances	2D6	nebivolol	D	N06AB03	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AB	N06A	C07AB	C07A
6095	fluoxetine	enhances	3A457	nevirapine		N06AB03	J05AG01	Selective serotonin reuptake inhibitors (N06AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AG	J05A
6096	fluoxetine	enhances	3A457	nifedipine	B	N06AB03	C08CA05	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6098	fluoxetine	enhances	3A457	nisoldipine		N06AB03	C08CA07	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6099	fluoxetine	enhances	3A457	nitrendipine		N06AB03	C08CA08	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6100	fluoxetine	enhances	2D6	nortriptyline	D	N06AB03	N06AA10	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AB	N06A	N06AA	N06A
6102	fluoxetine	enhances	2C19,3A457	omeprazole		N06AB03	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N06AB	N06A	A02BC	A02B
6103	fluoxetine	enhances	2D6,3A457	ondansetron	D	N06AB03	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AB	N06A	A04AA	A04A
6106	fluoxetine	enhances	2D6	oxycodone		N06AB03	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N06AB	N06A	N02AA	N02A
6111	fluoxetine	enhances	2C19,3A457	pantoprazole		N06AB03	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N06AB	N06A	A02BC	A02B
6112	fluoxetine	enhances	2D6	paroxetine	D	N06AB03	N06AB05	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
6118	fluoxetine	enhances	2C19	phenobarbital		N06AB03	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AA	N03A
6119	fluoxetine	enhances	2C19	phenytoin	C	N06AB03	N03AB02	Selective serotonin reuptake inhibitors (N06AB)	Hydantoin derivatives (N03AB)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AB	N03A
6124	fluoxetine	enhances	2C19	primidone		N06AB03	N03AA03	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	0					N06AB	N06A	N03AA	N03A
6127	fluoxetine	enhances	2D6	promethazine	D	N06AB03	R06AD02	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AB	N06A	R06AD	R06A
6128	fluoxetine	enhances	2D6	propafenone	D	N06AB03	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N06AB	N06A	C01BC	C01B
6129	fluoxetine	enhances	2C19,2D6,3A457	propranolol	D	N06AB03	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AB	N06A	C07AA	C07A
6130	fluoxetine	enhances	3A457	quetiapine	D	N06AB03	N05AH04	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0				7547	N06AB	N06A	N05AH	N05A
6136	fluoxetine	enhances	2D6,3A457	risperidone	D	N06AB03	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AX	N05A
6137	fluoxetine	enhances	3A457	ritonavir	D	N06AB03	J05AE03	Selective serotonin reuptake inhibitors (N06AB)	Protease inhibitors (J05AE)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AE	J05A
6138	fluoxetine	enhances	3A457	rivaroxaban		N06AB03	B01AF01	Selective serotonin reuptake inhibitors (N06AB)	Direct factor Xa inhibitors (B01AF)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AF	B01A
6144	fluoxetine	enhances	3A457	salmeterol	D	N06AB03	R03AC12	Selective serotonin reuptake inhibitors (N06AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antidepressants (N06A)	Adrenergics, inhalants (R03A)	0					N06AB	N06A	R03AC	R03A
6145	fluoxetine	enhances	3A457	saquinavir	D	N06AB03	J05AE01	Selective serotonin reuptake inhibitors (N06AB)	Protease inhibitors (J05AE)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AE	J05A
6147	fluoxetine	enhances	3A457	sildenafil		N06AB03	G04BE03	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in erectile dysfunction (G04BE)	Antidepressants (N06A)	Urologicals (G04B)	0	0				N06AB	N06A	G04BE	G04B
6149	fluoxetine	enhances	3A457	simvastatin		N06AB03	C10AA01	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1336	N06AB	N06A	C10AA	C10A
6149	fluoxetine	enhances	3A457	simvastatin		N06AB03	C10AA01	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5443	N06AB	N06A	C10AA	C10A
6150	fluoxetine	enhances	3A457	sirolimus		N06AB03	L04AA10	Selective serotonin reuptake inhibitors (N06AB)	Selective immunosuppressants (L04AA)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AA	L04A
6152	fluoxetine	enhances	3A457	sorafenib	D	N06AB03	L01XE05	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	1					N06AB	N06A	L01XE	L01X
6154	fluoxetine	enhances	3A457	sunitinib	D	N06AB03	L01XE04	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	1					N06AB	N06A	L01XE	L01X
6156	fluoxetine	enhances	3A457	tacrolimus	D	N06AB03	L04AD02	Selective serotonin reuptake inhibitors (N06AB)	Calcineurin inhibitors (L04AD)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AD	L04A
6157	fluoxetine	enhances	3A457	tadalafil		N06AB03	G04BE08	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in erectile dysfunction (G04BE)	Antidepressants (N06A)	Urologicals (G04B)	0	0				N06AB	N06A	G04BE	G04B
6158	fluoxetine	enhances	2D6,3A457	tamoxifen	D	N06AB03	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AB	N06A	L02BA	L02B
6165	fluoxetine	enhances	3A457	testosterone		N06AB03	G03BA03	Selective serotonin reuptake inhibitors (N06AB)	3-oxoandrosten (4) derivatives (G03BA)	Antidepressants (N06A)	Androgens (G03B)	0					N06AB	N06A	G03BA	G03B
6166	fluoxetine	enhances	2D6	tetrabenazine	D	N06AB03	N07XX06	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AB	N06A	N07XX	N07X
6168	fluoxetine	enhances	3A457	ticagrelor		N06AB03	B01AC24	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AC	B01A
6172	fluoxetine	enhances	2D6,3A457	tramadol	D	N06AB03	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect		N06AB	N06A	N02AX	N02A
6173	fluoxetine	enhances	3A457	trazodone	D	N06AB03	N06AX05	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		1336	N06AB	N06A	N06AX	N06A
6174	fluoxetine	enhances	3A457	triazolam	B	N06AB03	N05CD05	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05CD)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05CD	N05C
6182	fluoxetine	enhances	2C19,2D6,3A457	venlafaxine	D	N06AB03	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
6183	fluoxetine	enhances	3A457	verapamil		N06AB03	C08DA01	Selective serotonin reuptake inhibitors (N06AB)	Phenylalkylamine derivatives (C08DA)	Antidepressants (N06A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N06AB	N06A	C08DA	C08D
6187	fluoxetine	enhances	2C19,3A457	voriconazole	D	N06AB03	J02AC03	Selective serotonin reuptake inhibitors (N06AB)	Triazole derivatives (J02AC)	Antidepressants (N06A)	Antimycotics for systemic use (J02A)	0	0				N06AB	N06A	J02AC	J02A
6188	fluoxetine	enhances	2C19	warfarin	B	N06AB03	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding			N06AB	N06A	B01AA	B01A
6189	fluoxetine	enhances	3A457	zaleplon		N06AB03	N05CF03	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine related drugs (N05CF)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0					N06AB	N06A	N05CF	N05C
6191	fluoxetine	enhances	3A457	zolpidem	B	N06AB03	N05CF02	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine related drugs (N05CF)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0					N06AB	N06A	N05CF	N05C
6192	fluoxetine	enhances	2D6	zuclopenthixol	B	N06AB03	N05AF05	Selective serotonin reuptake inhibitors (N06AB)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AF	N05A
6193	fluvastatin	enhances	2C9	amitriptyline		C10AA04	N06AA09	HMG CoA reductase inhibitors (C10AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	1	0	Serotonin toxicity			C10AA	C10A	N06AA	N06A
6195	fluvastatin	enhances	2C9	capecitabine		C10AA04	L01BC06	HMG CoA reductase inhibitors (C10AA)	Pyrimidine analogues (L01BC)	Lipid modifying agents, plain (C10A)	Antimetabolites (L01B)	1					C10AA	C10A	L01BC	L01B
6196	fluvastatin	enhances	2C9	celecoxib		C10AA04	M01AH01	HMG CoA reductase inhibitors (C10AA)	Coxibs (M01AH)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AA	C10A	M01AH	M01A
6197	fluvastatin	enhances	2C9	clopidogrel		C10AA04	B01AC04	HMG CoA reductase inhibitors (C10AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Lipid modifying agents, plain (C10A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		C10AA	C10A	B01AC	B01A
6198	fluvastatin	enhances	2C9	diclofenac	B	C10AA04	M01AB05	HMG CoA reductase inhibitors (C10AA)	Acetic acid derivatives and related substances (M01AB)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AA	C10A	M01AB	M01A
6200	fluvastatin	enhances	2C9	fluoxetine		C10AA04	N06AB03	HMG CoA reductase inhibitors (C10AA)	Selective serotonin reuptake inhibitors (N06AB)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	0	0	Serotonin toxicity			C10AA	C10A	N06AB	N06A
6201	fluvastatin	enhances	2C9	glimepiride		C10AA04	A10BB12	HMG CoA reductase inhibitors (C10AA)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				2025	C10AA	C10A	A10BB	A10B
6201	fluvastatin	enhances	2C9	glimepiride		C10AA04	A10BB12	HMG CoA reductase inhibitors (C10AA)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				3469	C10AA	C10A	A10BB	A10B
6202	fluvastatin	enhances	2C9	glipizide		C10AA04	A10BB07	HMG CoA reductase inhibitors (C10AA)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			C10AA	C10A	A10BB	A10B
6203	fluvastatin	enhances	2C9	glyburide		C10AA04	A10BB01	HMG CoA reductase inhibitors (C10AA)	Sulfonylureas (A10BB)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			C10AA	C10A	A10BB	A10B
6204	fluvastatin	enhances	2C9	ibuprofen		C10AA04	M01AE01	HMG CoA reductase inhibitors (C10AA)	Propionic acid derivatives (M01AE)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AA	C10A	M01AE	M01A
6205	fluvastatin	enhances	2C9	irbesartan		C10AA04	C09CA04	HMG CoA reductase inhibitors (C10AA)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3469	C10AA	C10A	C09CA	C09C
6208	fluvastatin	enhances	2C9	losartan		C10AA04	C09CA01	HMG CoA reductase inhibitors (C10AA)	Angiotensin II receptor blockers, plain (C09CA)	Lipid modifying agents, plain (C10A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	2667	C10AA	C10A	C09CA	C09C
6209	fluvastatin	enhances	2C9	meloxicam		C10AA04	M01AC06	HMG CoA reductase inhibitors (C10AA)	Oxicams (M01AC)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					C10AA	C10A	M01AC	M01A
6210	fluvastatin	enhances	2C9	naproxen	C	C10AA04	M01AE02	HMG CoA reductase inhibitors (C10AA)	Propionic acid derivatives (M01AE)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AA	C10A	M01AE	M01A
6214	fluvastatin	enhances	2C9	phenytoin	B	C10AA04	N03AB02	HMG CoA reductase inhibitors (C10AA)	Hydantoin derivatives (N03AB)	Lipid modifying agents, plain (C10A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		C10AA	C10A	N03AB	N03A
6215	fluvastatin	enhances	2C9	piroxicam		C10AA04	M01AC01	HMG CoA reductase inhibitors (C10AA)	Oxicams (M01AC)	Lipid modifying agents, plain (C10A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				C10AA	C10A	M01AC	M01A
6219	fluvastatin	enhances	2C9	tamoxifen		C10AA04	L02BA01	HMG CoA reductase inhibitors (C10AA)	Anti-estrogens (L02BA)	Lipid modifying agents, plain (C10A)	Hormone antagonists and related agents (L02B)	1	1				C10AA	C10A	L02BA	L02B
6221	fluvastatin	enhances	2C9	torasemide		C10AA04	C03CA04	HMG CoA reductase inhibitors (C10AA)	Sulfonamides, plain (C03CA)	Lipid modifying agents, plain (C10A)	High-ceiling diuretics (C03C)	0	0				C10AA	C10A	C03CA	C03C
6222	fluvastatin	enhances	2C9	valproate		C10AA04	N03AG01	HMG CoA reductase inhibitors (C10AA)	Fatty acid derivatives (N03AG)	Lipid modifying agents, plain (C10A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		C10AA	C10A	N03AG	N03A
6223	fluvastatin	enhances	2C9	venlafaxine		C10AA04	N06AX16	HMG CoA reductase inhibitors (C10AA)	Other antidepressants (N06AX)	Lipid modifying agents, plain (C10A)	Antidepressants (N06A)	0	0	Serotonin toxicity			C10AA	C10A	N06AX	N06A
6224	fluvastatin	enhances	2C9	voriconazole		C10AA04	J02AC03	HMG CoA reductase inhibitors (C10AA)	Triazole derivatives (J02AC)	Lipid modifying agents, plain (C10A)	Antimycotics for systemic use (J02A)	0	0				C10AA	C10A	J02AC	J02A
6225	fluvastatin	enhances	2C9	warfarin	B	C10AA04	B01AA03	HMG CoA reductase inhibitors (C10AA)	Vitamin K antagonists (B01AA)	Lipid modifying agents, plain (C10A)	Antithrombotic agents (B01A)	1	0	Bleeding			C10AA	C10A	B01AA	B01A
6230	fluvoxamine	enhances	1A2	acetaminophen		N06AB08	N02BE01	Selective serotonin reuptake inhibitors (N06AB)	Anilides (N02BE)	Antidepressants (N06A)	Other analgesics and antipyretics (N02B)	0	0				N06AB	N06A	N02BE	N02B
6233	fluvoxamine	enhances	3A457	alprazolam	B	N06AB08	N05BA12	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05BA	N05B
6234	fluvoxamine	enhances	1A2,2C19,2C9,3A457	amitriptyline	B	N06AB08	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
6235	fluvoxamine	enhances	3A457	amlodipine		N06AB08	C08CA01	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6236	fluvoxamine	enhances	3A457	apixaban		N06AB08	B01AF02	Selective serotonin reuptake inhibitors (N06AB)	Direct factor Xa inhibitors (B01AF)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AF	B01A
6242	fluvoxamine	enhances	3A457	atorvastatin		N06AB08	C10AA05	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2758	N06AB	N06A	C10AA	C10A
6253	fluvoxamine	enhances	2C9	capecitabine		N06AB08	L01BC06	Selective serotonin reuptake inhibitors (N06AB)	Pyrimidine analogues (L01BC)	Antidepressants (N06A)	Antimetabolites (L01B)	1					N06AB	N06A	L01BC	L01B
6254	fluvoxamine	enhances	3A457	carbamazepine	B	N06AB08	N03AF01	Selective serotonin reuptake inhibitors (N06AB)	Carboxamide derivatives (N03AF)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AF	N03A
6257	fluvoxamine	enhances	2C9	celecoxib	C	N06AB08	M01AH01	Selective serotonin reuptake inhibitors (N06AB)	Coxibs (M01AH)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AH	M01A
6261	fluvoxamine	enhances	3A457	chlorpheniramine	B	N06AB08	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
6262	fluvoxamine	enhances	3A457	cilostazol		N06AB08	B01AC23	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AC	B01A
6264	fluvoxamine	enhances	2C19,3A457	citalopram	D	N06AB08	N06AB04	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AB	N06A	N06AB	N06A
6265	fluvoxamine	enhances	3A457	clarithromycin		N06AB08	J01FA09	Selective serotonin reuptake inhibitors (N06AB)	Macrolides (J01FA)	Antidepressants (N06A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				N06AB	N06A	J01FA	J01F
6266	fluvoxamine	enhances	2C19,3A457	clobazam	C	N06AB08	N05BA09	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0					N06AB	N06A	N05BA	N05B
6267	fluvoxamine	enhances	1A2,2C19	clomipramine	B	N06AB08	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
6268	fluvoxamine	enhances	2C19,2C9,3A457	clopidogrel	C	N06AB08	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		N06AB	N06A	B01AC	B01A
6269	fluvoxamine	enhances	1A2	clozapine	D	N06AB08	N05AH02	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AH	N05A
6273	fluvoxamine	enhances	3A457	colchicine		N06AB08	M04AC01	Selective serotonin reuptake inhibitors (N06AB)	Preparations with no effect on uric acid metabolism (M04AC)	Antidepressants (N06A)	Antigout preparations (M04A)	0					N06AB	N06A	M04AC	M04A
6277	fluvoxamine	enhances	2C19	cyclophosphamide		N06AB08	L01AA01	Selective serotonin reuptake inhibitors (N06AB)	Nitrogen mustard analogues (L01AA)	Antidepressants (N06A)	Alkylating agents (L01A)	1	1				N06AB	N06A	L01AA	L01A
6278	fluvoxamine	enhances	3A457	cyclosporine	B	N06AB08	L04AD01	Selective serotonin reuptake inhibitors (N06AB)	Calcineurin inhibitors (L04AD)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AD	L04A
6282	fluvoxamine	enhances	3A457	deflazacort		N06AB08	H02AB13	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6283	fluvoxamine	enhances	3A457	dexamethasone		N06AB08	H02AB02	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6284	fluvoxamine	enhances	3A457	dextromethorphan		N06AB08	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
6285	fluvoxamine	enhances	2C19,3A457	diazepam	D	N06AB08	N05BA01	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05BA)	Antidepressants (N06A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05BA	N05B
6286	fluvoxamine	enhances	2C9	diclofenac	C	N06AB08	M01AB05	Selective serotonin reuptake inhibitors (N06AB)	Acetic acid derivatives and related substances (M01AB)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AB	M01A
6287	fluvoxamine	enhances	3A457	diltiazem	B	N06AB08	C08DB01	Selective serotonin reuptake inhibitors (N06AB)	Benzothiazepine derivatives (C08DB)	Antidepressants (N06A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N06AB	N06A	C08DB	C08D
6290	fluvoxamine	enhances	3A457	domperidone		N06AB08	A03FA03	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AB	N06A	A03FA	A03F
6292	fluvoxamine	enhances	1A2	duloxetine	D	N06AB08	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
6297	fluvoxamine	enhances	3A457	eplerenone		N06AB08	C03DA04	Selective serotonin reuptake inhibitors (N06AB)	Aldosterone antagonists (C03DA)	Antidepressants (N06A)	Potassium-sparing agents (C03D)	0					N06AB	N06A	C03DA	C03D
6300	fluvoxamine	enhances	2C19,3A457	escitalopram	D	N06AB08	N06AB10	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AB	N06A	N06AB	N06A
6301	fluvoxamine	enhances	2C19,3A457	esomeprazole		N06AB08	A02BC05	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					N06AB	N06A	A02BC	A02B
6303	fluvoxamine	enhances	3A457	felodipine		N06AB08	C08CA02	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6307	fluvoxamine	enhances	2C9	fluoxetine	D	N06AB08	N06AB03	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
6308	fluvoxamine	enhances	2C9	fluvastatin		N06AB08	C10AA04	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N06AB	N06A	C10AA	C10A
6309	fluvoxamine	enhances	2C9	glimepiride	B	N06AB08	A10BB12	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					N06AB	N06A	A10BB	A10B
6310	fluvoxamine	enhances	2C9	glipizide	B	N06AB08	A10BB07	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N06AB	N06A	A10BB	A10B
6311	fluvoxamine	enhances	2C9	glyburide	B	N06AB08	A10BB01	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		96	N06AB	N06A	A10BB	A10B
6312	fluvoxamine	enhances	1A2,3A457	haloperidol	B	N06AB08	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AD	N05A
6314	fluvoxamine	enhances	3A457	hydrocortisone		N06AB08	H02AB09	Selective serotonin reuptake inhibitors (N06AB)	Glucocorticoids (H02AB)	Antidepressants (N06A)	Corticosteroids for systemic use, plain (H02A)	0					N06AB	N06A	H02AB	H02A
6316	fluvoxamine	enhances	2C9	ibuprofen	C	N06AB08	M01AE01	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AE	M01A
6318	fluvoxamine	enhances	3A457	imatinib	B	N06AB08	L01XE01	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	0	0				N06AB	N06A	L01XE	L01X
6319	fluvoxamine	enhances	1A2,2C19	imipramine	B	N06AB08	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
6320	fluvoxamine	enhances	3A457	indacaterol		N06AB08	R03AC18	Selective serotonin reuptake inhibitors (N06AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antidepressants (N06A)	Adrenergics, inhalants (R03A)	0					N06AB	N06A	R03AC	R03A
6322	fluvoxamine	enhances	2C19	indometacin	C	N06AB08	M01AB01	Selective serotonin reuptake inhibitors (N06AB)	Acetic acid derivatives and related substances (M01AB)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N06AB	N06A	M01AB	M01A
6323	fluvoxamine	enhances	2C9	irbesartan		N06AB08	C09CA04	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		N06AB	N06A	C09CA	C09C
6326	fluvoxamine	enhances	3A457	ivabradine		N06AB08	C01EB17	Selective serotonin reuptake inhibitors (N06AB)	Other cardiac preparations (C01EB)	Antidepressants (N06A)	Other cardiac preparations (C01E)	0					N06AB	N06A	C01EB	C01E
6329	fluvoxamine	enhances	2C19,3A457	lansoprazole		N06AB08	A02BC03	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N06AB	N06A	A02BC	A02B
6331	fluvoxamine	enhances	3A457	lercanidipine		N06AB08	C08CA13	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N06AB	N06A	C08CA	C08C
6337	fluvoxamine	enhances	2C9	losartan		N06AB08	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		N06AB	N06A	C09CA	C09C
6338	fluvoxamine	enhances	3A457	lovastatin		N06AB08	C10AA02	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N06AB	N06A	C10AA	C10A
6340	fluvoxamine	enhances	2C9	meloxicam	C	N06AB08	M01AC06	Selective serotonin reuptake inhibitors (N06AB)	Oxicams (M01AC)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N06AB	N06A	M01AC	M01A
6342	fluvoxamine	enhances	3A457	methadone	C	N06AB08	N07BC02	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in opioid dependence (N07BC)	Antidepressants (N06A)	Drugs used in addictive disorders (N07B)	0	0				N06AB	N06A	N07BC	N07B
6345	fluvoxamine	enhances	3A457	midazolam	B	N06AB08	N05CD08	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05CD)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05CD	N05C
6350	fluvoxamine	enhances	1A2,2C9	naproxen	C	N06AB08	M01AE02	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AE	M01A
6354	fluvoxamine	enhances	3A457	nevirapine		N06AB08	J05AG01	Selective serotonin reuptake inhibitors (N06AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AG	J05A
6355	fluvoxamine	enhances	3A457	nifedipine		N06AB08	C08CA05	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6357	fluvoxamine	enhances	3A457	nisoldipine		N06AB08	C08CA07	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6358	fluvoxamine	enhances	3A457	nitrendipine		N06AB08	C08CA08	Selective serotonin reuptake inhibitors (N06AB)	Dihydropyridine derivatives (C08CA)	Antidepressants (N06A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N06AB	N06A	C08CA	C08C
6359	fluvoxamine	enhances	1A2	olanzapine	C	N06AB08	N05AH03	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AH	N05A
6362	fluvoxamine	enhances	2C19,3A457	omeprazole		N06AB08	A02BC01	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N06AB	N06A	A02BC	A02B
6363	fluvoxamine	enhances	1A2,3A457	ondansetron		N06AB08	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AB	N06A	A04AA	A04A
6370	fluvoxamine	enhances	2C19,3A457	pantoprazole		N06AB08	A02BC02	Selective serotonin reuptake inhibitors (N06AB)	Proton pump inhibitors (A02BC)	Antidepressants (N06A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N06AB	N06A	A02BC	A02B
6373	fluvoxamine	enhances	2C19	phenobarbital		N06AB08	N03AA02	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AA	N03A
6374	fluvoxamine	enhances	2C19,2C9	phenytoin	C	N06AB08	N03AB02	Selective serotonin reuptake inhibitors (N06AB)	Hydantoin derivatives (N03AB)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AB	N03A
6378	fluvoxamine	enhances	2C9	piroxicam	C	N06AB08	M01AC01	Selective serotonin reuptake inhibitors (N06AB)	Oxicams (M01AC)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AC	M01A
6381	fluvoxamine	enhances	2C19	primidone		N06AB08	N03AA03	Selective serotonin reuptake inhibitors (N06AB)	Barbiturates and derivatives (N03AA)	Antidepressants (N06A)	Antiepileptics (N03A)	0					N06AB	N06A	N03AA	N03A
6384	fluvoxamine	enhances	1A2,2C19,3A457	propranolol	B	N06AB08	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0					N06AB	N06A	C07AA	C07A
6385	fluvoxamine	enhances	3A457	quetiapine		N06AB08	N05AH04	Selective serotonin reuptake inhibitors (N06AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antidepressants (N06A)	Antipsychotics (N05A)	0				4692	N06AB	N06A	N05AH	N05A
6391	fluvoxamine	enhances	1A2	riluzole		N06AB08	N07XX02	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0	0				N06AB	N06A	N07XX	N07X
6392	fluvoxamine	enhances	3A457	risperidone		N06AB08	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AX	N05A
6393	fluvoxamine	enhances	3A457	ritonavir		N06AB08	J05AE03	Selective serotonin reuptake inhibitors (N06AB)	Protease inhibitors (J05AE)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AE	J05A
6394	fluvoxamine	enhances	3A457	rivaroxaban		N06AB08	B01AF01	Selective serotonin reuptake inhibitors (N06AB)	Direct factor Xa inhibitors (B01AF)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AF	B01A
6402	fluvoxamine	enhances	3A457	salmeterol		N06AB08	R03AC12	Selective serotonin reuptake inhibitors (N06AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antidepressants (N06A)	Adrenergics, inhalants (R03A)	0					N06AB	N06A	R03AC	R03A
6403	fluvoxamine	enhances	3A457	saquinavir		N06AB08	J05AE01	Selective serotonin reuptake inhibitors (N06AB)	Protease inhibitors (J05AE)	Antidepressants (N06A)	Direct acting antivirals (J05A)	0	0				N06AB	N06A	J05AE	J05A
6405	fluvoxamine	enhances	3A457	sildenafil		N06AB08	G04BE03	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in erectile dysfunction (G04BE)	Antidepressants (N06A)	Urologicals (G04B)	0	0				N06AB	N06A	G04BE	G04B
6407	fluvoxamine	enhances	3A457	simvastatin		N06AB08	C10AA01	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N06AB	N06A	C10AA	C10A
6408	fluvoxamine	enhances	3A457	sirolimus		N06AB08	L04AA10	Selective serotonin reuptake inhibitors (N06AB)	Selective immunosuppressants (L04AA)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AA	L04A
6410	fluvoxamine	enhances	3A457	sorafenib		N06AB08	L01XE05	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	1					N06AB	N06A	L01XE	L01X
6411	fluvoxamine	enhances	3A457	sunitinib		N06AB08	L01XE04	Selective serotonin reuptake inhibitors (N06AB)	 (L01XE)	Antidepressants (N06A)	Other antineoplastic agents (L01X)	1					N06AB	N06A	L01XE	L01X
6415	fluvoxamine	enhances	3A457	tacrolimus		N06AB08	L04AD02	Selective serotonin reuptake inhibitors (N06AB)	Calcineurin inhibitors (L04AD)	Antidepressants (N06A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N06AB	N06A	L04AD	L04A
6416	fluvoxamine	enhances	3A457	tadalafil		N06AB08	G04BE08	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in erectile dysfunction (G04BE)	Antidepressants (N06A)	Urologicals (G04B)	0	0				N06AB	N06A	G04BE	G04B
6417	fluvoxamine	enhances	2C9,3A457	tamoxifen		N06AB08	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AB	N06A	L02BA	L02B
6424	fluvoxamine	enhances	3A457	testosterone		N06AB08	G03BA03	Selective serotonin reuptake inhibitors (N06AB)	3-oxoandrosten (4) derivatives (G03BA)	Antidepressants (N06A)	Androgens (G03B)	0					N06AB	N06A	G03BA	G03B
6425	fluvoxamine	enhances	1A2	theophylline	D	N06AB08	R03DA04	Selective serotonin reuptake inhibitors (N06AB)	Xanthines (R03DA)	Antidepressants (N06A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				N06AB	N06A	R03DA	R03D
6426	fluvoxamine	enhances	3A457	ticagrelor		N06AB08	B01AC24	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0					N06AB	N06A	B01AC	B01A
6427	fluvoxamine	enhances	1A2	tizanidine	D	N06AB08	M03BX02	Selective serotonin reuptake inhibitors (N06AB)	Other centrally acting agents (M03BX)	Antidepressants (N06A)	Muscle relaxants, centrally acting agents (M03B)	1	0				N06AB	N06A	M03BX	M03B
6431	fluvoxamine	enhances	2C9	torasemide		N06AB08	C03CA04	Selective serotonin reuptake inhibitors (N06AB)	Sulfonamides, plain (C03CA)	Antidepressants (N06A)	High-ceiling diuretics (C03C)	0	0				N06AB	N06A	C03CA	C03C
6432	fluvoxamine	enhances	3A457	tramadol	D	N06AB08	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect		N06AB	N06A	N02AX	N02A
6433	fluvoxamine	enhances	3A457	trazodone		N06AB08	N06AX05	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3466	N06AB	N06A	N06AX	N06A
6434	fluvoxamine	enhances	1A2	triamterene		N06AB08	C03DB02	Selective serotonin reuptake inhibitors (N06AB)	Other potassium-sparing agents (C03DB)	Antidepressants (N06A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			N06AB	N06A	C03DB	C03D
6435	fluvoxamine	enhances	3A457	triazolam	B	N06AB08	N05CD05	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine derivatives (N05CD)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N06AB	N06A	N05CD	N05C
6437	fluvoxamine	enhances	2C9	valproate		N06AB08	N03AG01	Selective serotonin reuptake inhibitors (N06AB)	Fatty acid derivatives (N03AG)	Antidepressants (N06A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AG	N03A
6443	fluvoxamine	enhances	2C19,2C9,3A457	venlafaxine		N06AB08	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
6444	fluvoxamine	enhances	1A2,3A457	verapamil		N06AB08	C08DA01	Selective serotonin reuptake inhibitors (N06AB)	Phenylalkylamine derivatives (C08DA)	Antidepressants (N06A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N06AB	N06A	C08DA	C08D
6448	fluvoxamine	enhances	2C19,2C9,3A457	voriconazole		N06AB08	J02AC03	Selective serotonin reuptake inhibitors (N06AB)	Triazole derivatives (J02AC)	Antidepressants (N06A)	Antimycotics for systemic use (J02A)	0	0				N06AB	N06A	J02AC	J02A
6449	fluvoxamine	enhances	1A2,2C19,2C9	warfarin	C	N06AB08	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding			N06AB	N06A	B01AA	B01A
6451	fluvoxamine	enhances	3A457	zaleplon		N06AB08	N05CF03	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine related drugs (N05CF)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0					N06AB	N06A	N05CF	N05C
6455	fluvoxamine	enhances	3A457	zolpidem		N06AB08	N05CF02	Selective serotonin reuptake inhibitors (N06AB)	Benzodiazepine related drugs (N05CF)	Antidepressants (N06A)	Hypnotics and sedatives (N05C)	0					N06AB	N06A	N05CF	N05C
6463	gemfibrozil	enhances	2C8	repaglinide	D	C10AB04	A10BX02	Fibrates (C10AB)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Lipid modifying agents, plain (C10A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			C10AB	C10A	A10BX	A10B
6465	gemfibrozil	enhances	2C8	sorafenib		C10AB04	L01XE05	Fibrates (C10AB)	 (L01XE)	Lipid modifying agents, plain (C10A)	Other antineoplastic agents (L01X)	1					C10AB	C10A	L01XE	L01X
6466	gemfibrozil	enhances	2C8	torasemide		C10AB04	C03CA04	Fibrates (C10AB)	Sulfonamides, plain (C03CA)	Lipid modifying agents, plain (C10A)	High-ceiling diuretics (C03C)	0	0				C10AB	C10A	C03CA	C03C
6869	haloperidol	enhances	2D6	amitriptyline	D	N05AD01	N06AA09	Butyrophenone derivatives (N05AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AD	N05A	N06AA	N06A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2660	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2975	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3079	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3096	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3155	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3484	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4017	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4155	N05AD	N05A	C07AG	C07A
6874	haloperidol	enhances	2D6	carvedilol		N05AD01	C07AG02	Butyrophenone derivatives (N05AD)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7735	N05AD	N05A	C07AG	C07A
6875	haloperidol	enhances	2D6	chlorpheniramine	B	N05AD01	R06AB04	Butyrophenone derivatives (N05AD)	Substituted alkylamines (R06AB)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0	0				N05AD	N05A	R06AB	R06A
6876	haloperidol	enhances	2D6	chlorpromazine	D	N05AD01	N05AA01	Butyrophenone derivatives (N05AD)	Phenothiazines with aliphatic side-chain (N05AA)	Antipsychotics (N05A)	Antipsychotics (N05A)	0					N05AD	N05A	N05AA	N05A
6877	haloperidol	enhances	2D6	citalopram	D	N05AD01	N06AB04	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0			3047	N05AD	N05A	N06AB	N06A
6878	haloperidol	enhances	2D6	clomipramine	D	N05AD01	N06AA04	Butyrophenone derivatives (N05AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AD	N05A	N06AA	N06A
6879	haloperidol	enhances	2D6	clonidine		N05AD01	C02AC01	Butyrophenone derivatives (N05AD)	Imidazoline receptor agonists (C02AC)	Antipsychotics (N05A)	Antiadrenergic agents, centrally acting (C02A)	1					N05AD	N05A	C02AC	C02A
6884	haloperidol	enhances	2D6	dextromethorphan	B	N05AD01	R05DA09	Butyrophenone derivatives (N05AD)	Opium alkaloids and derivatives (R05DA)	Antipsychotics (N05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N05AD	N05A	R05DA	R05D
6885	haloperidol	enhances	2D6	donepezil	D	N05AD01	N06DA02	Butyrophenone derivatives (N05AD)	Anticholinesterases (N06DA)	Antipsychotics (N05A)	Anti-dementia drugs (N06D)	0					N05AD	N05A	N06DA	N06D
6887	haloperidol	enhances	2D6	duloxetine		N05AD01	N06AX21	Butyrophenone derivatives (N05AD)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4882	N05AD	N05A	N06AX	N06A
6890	haloperidol	enhances	2D6	escitalopram	D	N05AD01	N06AB10	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0				334	N05AD	N05A	N06AB	N06A
6890	haloperidol	enhances	2D6	escitalopram	D	N05AD01	N06AB10	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0				7445	N05AD	N05A	N06AB	N06A
6891	haloperidol	enhances	2D6	flecainide	D	N05AD01	C01BC04	Butyrophenone derivatives (N05AD)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N05AD	N05A	C01BC	C01B
6892	haloperidol	enhances	2D6	fluoxetine	D	N05AD01	N06AB03	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AD	N05A	N06AB	N06A
6893	haloperidol	enhances	2D6	fluvoxamine	B	N05AD01	N06AB08	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AD	N05A	N06AB	N06A
6895	haloperidol	enhances	2D6	imipramine	D	N05AD01	N06AA02	Butyrophenone derivatives (N05AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AD	N05A	N06AA	N06A
6898	haloperidol	enhances	2D6	metoclopramide	D	N05AD01	A03FA01	Butyrophenone derivatives (N05AD)	Propulsives (A03FA)	Antipsychotics (N05A)	Propulsives (A03F)	0					N05AD	N05A	A03FA	A03F
6899	haloperidol	enhances	2D6	metoprolol		N05AD01	C07AB02	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2920	N05AD	N05A	C07AB	C07A
6899	haloperidol	enhances	2D6	metoprolol		N05AD01	C07AB02	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2989	N05AD	N05A	C07AB	C07A
6899	haloperidol	enhances	2D6	metoprolol		N05AD01	C07AB02	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5423	N05AD	N05A	C07AB	C07A
6899	haloperidol	enhances	2D6	metoprolol		N05AD01	C07AB02	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7310	N05AD	N05A	C07AB	C07A
6899	haloperidol	enhances	2D6	metoprolol		N05AD01	C07AB02	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7454	N05AD	N05A	C07AB	C07A
6902	haloperidol	enhances	2D6	nebivolol		N05AD01	C07AB12	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0				975	N05AD	N05A	C07AB	C07A
6902	haloperidol	enhances	2D6	nebivolol		N05AD01	C07AB12	Butyrophenone derivatives (N05AD)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0				1092	N05AD	N05A	C07AB	C07A
6903	haloperidol	enhances	2D6	nortriptyline	D	N05AD01	N06AA10	Butyrophenone derivatives (N05AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1					N05AD	N05A	N06AA	N06A
6904	haloperidol	enhances	2D6	ondansetron	D	N05AD01	A04AA01	Butyrophenone derivatives (N05AD)	Serotonin (5HT3) antagonists (A04AA)	Antipsychotics (N05A)	Antiemetics and antinauseants (A04A)	0	0				N05AD	N05A	A04AA	A04A
6905	haloperidol	enhances	2D6	oxycodone		N05AD01	N02AA05	Butyrophenone derivatives (N05AD)	Natural opium alkaloids (N02AA)	Antipsychotics (N05A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5866	N05AD	N05A	N02AA	N02A
6907	haloperidol	enhances	2D6	paroxetine	D	N05AD01	N06AB05	Butyrophenone derivatives (N05AD)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2196	N05AD	N05A	N06AB	N06A
6915	haloperidol	enhances	2D6	promethazine	D	N05AD01	R06AD02	Butyrophenone derivatives (N05AD)	Phenothiazine derivatives (R06AD)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0				2226	N05AD	N05A	R06AD	R06A
6916	haloperidol	enhances	2D6	propafenone	D	N05AD01	C01BC03	Butyrophenone derivatives (N05AD)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N05AD	N05A	C01BC	C01B
6917	haloperidol	enhances	2D6	propranolol	C	N05AD01	C07AA05	Butyrophenone derivatives (N05AD)	Beta blocking agents, non-selective (C07AA)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0					N05AD	N05A	C07AA	C07A
6918	haloperidol	enhances	2D6	risperidone	D	N05AD01	N05AX08	Butyrophenone derivatives (N05AD)	Other antipsychotics (N05AX)	Antipsychotics (N05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	605	N05AD	N05A	N05AX	N05A
6921	haloperidol	enhances	2D6	tamoxifen	D	N05AD01	L02BA01	Butyrophenone derivatives (N05AD)	Anti-estrogens (L02BA)	Antipsychotics (N05A)	Hormone antagonists and related agents (L02B)	1	1				N05AD	N05A	L02BA	L02B
6922	haloperidol	enhances	2D6	tetrabenazine	D	N05AD01	N07XX06	Butyrophenone derivatives (N05AD)	Other nervous system drugs (N07XX)	Antipsychotics (N05A)	Other nervous system drugs (N07X)	0					N05AD	N05A	N07XX	N07X
6925	haloperidol	enhances	2D6	tramadol	D	N05AD01	N02AX02	Butyrophenone derivatives (N05AD)	Other opioids (N02AX)	Antipsychotics (N05A)	Opioids (N02A)	0	1		Reduced analgesic effect	2768	N05AD	N05A	N02AX	N02A
6925	haloperidol	enhances	2D6	tramadol	D	N05AD01	N02AX02	Butyrophenone derivatives (N05AD)	Other opioids (N02AX)	Antipsychotics (N05A)	Opioids (N02A)	0	1		Reduced analgesic effect	7310	N05AD	N05A	N02AX	N02A
6928	haloperidol	enhances	2D6	venlafaxine	D	N05AD01	N06AX16	Butyrophenone derivatives (N05AD)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AD	N05A	N06AX	N06A
6930	haloperidol	enhances	2D6	zuclopenthixol		N05AD01	N05AF05	Butyrophenone derivatives (N05AD)	Thioxanthene derivatives (N05AF)	Antipsychotics (N05A)	Antipsychotics (N05A)	0					N05AD	N05A	N05AF	N05A
6933	hydroxyzine	enhances	2D6	amitriptyline	D	N05BB01	N06AA09	Diphenylmethane derivatives (N05BB)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05BB	N05B	N06AA	N06A
6938	hydroxyzine	enhances	2D6	carvedilol		N05BB01	C07AG02	Diphenylmethane derivatives (N05BB)	Alpha and beta blocking agents (C07AG)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3639	N05BB	N05B	C07AG	C07A
6939	hydroxyzine	enhances	2D6	chlorpheniramine		N05BB01	R06AB04	Diphenylmethane derivatives (N05BB)	Substituted alkylamines (R06AB)	Anxiolytics (N05B)	Antihistamines for systemic use (R06A)	0	0				N05BB	N05B	R06AB	R06A
6940	hydroxyzine	enhances	2D6	chlorpromazine	D	N05BB01	N05AA01	Diphenylmethane derivatives (N05BB)	Phenothiazines with aliphatic side-chain (N05AA)	Anxiolytics (N05B)	Antipsychotics (N05A)	0					N05BB	N05B	N05AA	N05A
6941	hydroxyzine	enhances	2D6	citalopram	D	N05BB01	N06AB04	Diphenylmethane derivatives (N05BB)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0				N05BB	N05B	N06AB	N06A
6942	hydroxyzine	enhances	2D6	clomipramine	D	N05BB01	N06AA04	Diphenylmethane derivatives (N05BB)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05BB	N05B	N06AA	N06A
6943	hydroxyzine	enhances	2D6	clonidine		N05BB01	C02AC01	Diphenylmethane derivatives (N05BB)	Imidazoline receptor agonists (C02AC)	Anxiolytics (N05B)	Antiadrenergic agents, centrally acting (C02A)	1					N05BB	N05B	C02AC	C02A
6948	hydroxyzine	enhances	2D6	dextromethorphan		N05BB01	R05DA09	Diphenylmethane derivatives (N05BB)	Opium alkaloids and derivatives (R05DA)	Anxiolytics (N05B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N05BB	N05B	R05DA	R05D
6949	hydroxyzine	enhances	2D6	donepezil	D	N05BB01	N06DA02	Diphenylmethane derivatives (N05BB)	Anticholinesterases (N06DA)	Anxiolytics (N05B)	Anti-dementia drugs (N06D)	0					N05BB	N05B	N06DA	N06D
6951	hydroxyzine	enhances	2D6	duloxetine		N05BB01	N06AX21	Diphenylmethane derivatives (N05BB)	Other antidepressants (N06AX)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BB	N05B	N06AX	N06A
6954	hydroxyzine	enhances	2D6	escitalopram	D	N05BB01	N06AB10	Diphenylmethane derivatives (N05BB)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0				2061	N05BB	N05B	N06AB	N06A
6955	hydroxyzine	enhances	2D6	flecainide	D	N05BB01	C01BC04	Diphenylmethane derivatives (N05BB)	Antiarrhythmics, class Ic (C01BC)	Anxiolytics (N05B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		7151	N05BB	N05B	C01BC	C01B
6956	hydroxyzine	enhances	2D6	fluoxetine	D	N05BB01	N06AB03	Diphenylmethane derivatives (N05BB)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BB	N05B	N06AB	N06A
6957	hydroxyzine	enhances	2D6	fluvoxamine		N05BB01	N06AB08	Diphenylmethane derivatives (N05BB)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BB	N05B	N06AB	N06A
6958	hydroxyzine	enhances	2D6	haloperidol	D	N05BB01	N05AD01	Diphenylmethane derivatives (N05BB)	Butyrophenone derivatives (N05AD)	Anxiolytics (N05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	330	N05BB	N05B	N05AD	N05A
6958	hydroxyzine	enhances	2D6	haloperidol	D	N05BB01	N05AD01	Diphenylmethane derivatives (N05BB)	Butyrophenone derivatives (N05AD)	Anxiolytics (N05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2153	N05BB	N05B	N05AD	N05A
6958	hydroxyzine	enhances	2D6	haloperidol	D	N05BB01	N05AD01	Diphenylmethane derivatives (N05BB)	Butyrophenone derivatives (N05AD)	Anxiolytics (N05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2175	N05BB	N05B	N05AD	N05A
6960	hydroxyzine	enhances	2D6	imipramine	D	N05BB01	N06AA02	Diphenylmethane derivatives (N05BB)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05BB	N05B	N06AA	N06A
6963	hydroxyzine	enhances	2D6	metoclopramide	D	N05BB01	A03FA01	Diphenylmethane derivatives (N05BB)	Propulsives (A03FA)	Anxiolytics (N05B)	Propulsives (A03F)	0					N05BB	N05B	A03FA	A03F
6964	hydroxyzine	enhances	2D6	metoprolol		N05BB01	C07AB02	Diphenylmethane derivatives (N05BB)	Beta blocking agents, selective (C07AB)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5411	N05BB	N05B	C07AB	C07A
6967	hydroxyzine	enhances	2D6	nebivolol		N05BB01	C07AB12	Diphenylmethane derivatives (N05BB)	Beta blocking agents, selective (C07AB)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0					N05BB	N05B	C07AB	C07A
6968	hydroxyzine	enhances	2D6	nortriptyline	D	N05BB01	N06AA10	Diphenylmethane derivatives (N05BB)	Non-selective monoamine reuptake inhibitors (N06AA)	Anxiolytics (N05B)	Antidepressants (N06A)	1					N05BB	N05B	N06AA	N06A
6969	hydroxyzine	enhances	2D6	ondansetron	D	N05BB01	A04AA01	Diphenylmethane derivatives (N05BB)	Serotonin (5HT3) antagonists (A04AA)	Anxiolytics (N05B)	Antiemetics and antinauseants (A04A)	0	0				N05BB	N05B	A04AA	A04A
6970	hydroxyzine	enhances	2D6	oxycodone		N05BB01	N02AA05	Diphenylmethane derivatives (N05BB)	Natural opium alkaloids (N02AA)	Anxiolytics (N05B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N05BB	N05B	N02AA	N02A
6972	hydroxyzine	enhances	2D6	paroxetine	D	N05BB01	N06AB05	Diphenylmethane derivatives (N05BB)	Selective serotonin reuptake inhibitors (N06AB)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05BB	N05B	N06AB	N06A
6980	hydroxyzine	enhances	2D6	promethazine	D	N05BB01	R06AD02	Diphenylmethane derivatives (N05BB)	Phenothiazine derivatives (R06AD)	Anxiolytics (N05B)	Antihistamines for systemic use (R06A)	0					N05BB	N05B	R06AD	R06A
6981	hydroxyzine	enhances	2D6	propafenone	D	N05BB01	C01BC03	Diphenylmethane derivatives (N05BB)	Antiarrhythmics, class Ic (C01BC)	Anxiolytics (N05B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		367	N05BB	N05B	C01BC	C01B
6982	hydroxyzine	enhances	2D6	propranolol		N05BB01	C07AA05	Diphenylmethane derivatives (N05BB)	Beta blocking agents, non-selective (C07AA)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0				649	N05BB	N05B	C07AA	C07A
6982	hydroxyzine	enhances	2D6	propranolol		N05BB01	C07AA05	Diphenylmethane derivatives (N05BB)	Beta blocking agents, non-selective (C07AA)	Anxiolytics (N05B)	Beta blocking agents (C07A)	0				779	N05BB	N05B	C07AA	C07A
6983	hydroxyzine	enhances	2D6	risperidone	D	N05BB01	N05AX08	Diphenylmethane derivatives (N05BB)	Other antipsychotics (N05AX)	Anxiolytics (N05B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N05BB	N05B	N05AX	N05A
6986	hydroxyzine	enhances	2D6	tamoxifen	D	N05BB01	L02BA01	Diphenylmethane derivatives (N05BB)	Anti-estrogens (L02BA)	Anxiolytics (N05B)	Hormone antagonists and related agents (L02B)	1	1				N05BB	N05B	L02BA	L02B
6987	hydroxyzine	enhances	2D6	tetrabenazine	D	N05BB01	N07XX06	Diphenylmethane derivatives (N05BB)	Other nervous system drugs (N07XX)	Anxiolytics (N05B)	Other nervous system drugs (N07X)	0					N05BB	N05B	N07XX	N07X
6990	hydroxyzine	enhances	2D6	tramadol		N05BB01	N02AX02	Diphenylmethane derivatives (N05BB)	Other opioids (N02AX)	Anxiolytics (N05B)	Opioids (N02A)	0	1		Reduced analgesic effect		N05BB	N05B	N02AX	N02A
6993	hydroxyzine	enhances	2D6	venlafaxine	D	N05BB01	N06AX16	Diphenylmethane derivatives (N05BB)	Other antidepressants (N06AX)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5411	N05BB	N05B	N06AX	N06A
6993	hydroxyzine	enhances	2D6	venlafaxine	D	N05BB01	N06AX16	Diphenylmethane derivatives (N05BB)	Other antidepressants (N06AX)	Anxiolytics (N05B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7106	N05BB	N05B	N06AX	N06A
6995	hydroxyzine	enhances	2D6	zuclopenthixol		N05BB01	N05AF05	Diphenylmethane derivatives (N05BB)	Thioxanthene derivatives (N05AF)	Anxiolytics (N05B)	Antipsychotics (N05A)	0					N05BB	N05B	N05AF	N05A
7160	imatinib	enhances	3A457	alprazolam		L01XE01	N05BA12	 (L01XE)	Benzodiazepine derivatives (N05BA)	Other antineoplastic agents (L01X)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		L01XE	L01X	N05BA	N05B
7161	imatinib	enhances	3A457	amitriptyline		L01XE01	N06AA09	 (L01XE)	Non-selective monoamine reuptake inhibitors (N06AA)	Other antineoplastic agents (L01X)	Antidepressants (N06A)	1	0	Serotonin toxicity			L01XE	L01X	N06AA	N06A
7162	imatinib	enhances	3A457	amlodipine	B	L01XE01	C08CA01	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		L01XE	L01X	C08CA	C08C
7163	imatinib	enhances	3A457	apixaban		L01XE01	B01AF02	 (L01XE)	Direct factor Xa inhibitors (B01AF)	Other antineoplastic agents (L01X)	Antithrombotic agents (B01A)	0					L01XE	L01X	B01AF	B01A
7167	imatinib	enhances	3A457	atorvastatin	C	L01XE01	C10AA05	 (L01XE)	HMG CoA reductase inhibitors (C10AA)	Other antineoplastic agents (L01X)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			L01XE	L01X	C10AA	C10A
7178	imatinib	enhances	3A457	chlorpheniramine		L01XE01	R06AB04	 (L01XE)	Substituted alkylamines (R06AB)	Other antineoplastic agents (L01X)	Antihistamines for systemic use (R06A)	0	0				L01XE	L01X	R06AB	R06A
7179	imatinib	enhances	3A457	cilostazol		L01XE01	B01AC23	 (L01XE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antineoplastic agents (L01X)	Antithrombotic agents (B01A)	0					L01XE	L01X	B01AC	B01A
7181	imatinib	enhances	3A457	citalopram		L01XE01	N06AB04	 (L01XE)	Selective serotonin reuptake inhibitors (N06AB)	Other antineoplastic agents (L01X)	Antidepressants (N06A)	0	0				L01XE	L01X	N06AB	N06A
7182	imatinib	enhances	3A457	clarithromycin	D	L01XE01	J01FA09	 (L01XE)	Macrolides (J01FA)	Other antineoplastic agents (L01X)	Macrolides, lincosamides and streptogramins (J01F)	0	0				L01XE	L01X	J01FA	J01F
7183	imatinib	enhances	3A457	clopidogrel		L01XE01	B01AC04	 (L01XE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antineoplastic agents (L01X)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		L01XE	L01X	B01AC	B01A
7187	imatinib	enhances	3A457	colchicine	C	L01XE01	M04AC01	 (L01XE)	Preparations with no effect on uric acid metabolism (M04AC)	Other antineoplastic agents (L01X)	Antigout preparations (M04A)	0					L01XE	L01X	M04AC	M04A
7190	imatinib	enhances	3A457	cyclosporine	B	L01XE01	L04AD01	 (L01XE)	Calcineurin inhibitors (L04AD)	Other antineoplastic agents (L01X)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			L01XE	L01X	L04AD	L04A
7193	imatinib	enhances	3A457	deflazacort		L01XE01	H02AB13	 (L01XE)	Glucocorticoids (H02AB)	Other antineoplastic agents (L01X)	Corticosteroids for systemic use, plain (H02A)	0					L01XE	L01X	H02AB	H02A
7194	imatinib	enhances	3A457	dexamethasone	C	L01XE01	H02AB02	 (L01XE)	Glucocorticoids (H02AB)	Other antineoplastic agents (L01X)	Corticosteroids for systemic use, plain (H02A)	0					L01XE	L01X	H02AB	H02A
7195	imatinib	enhances	3A457	dextromethorphan	B	L01XE01	R05DA09	 (L01XE)	Opium alkaloids and derivatives (R05DA)	Other antineoplastic agents (L01X)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				L01XE	L01X	R05DA	R05D
7196	imatinib	enhances	3A457	diazepam	B	L01XE01	N05BA01	 (L01XE)	Benzodiazepine derivatives (N05BA)	Other antineoplastic agents (L01X)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		L01XE	L01X	N05BA	N05B
7197	imatinib	enhances	3A457	diltiazem	B	L01XE01	C08DB01	 (L01XE)	Benzothiazepine derivatives (C08DB)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			L01XE	L01X	C08DB	C08D
7200	imatinib	enhances	3A457	domperidone	C	L01XE01	A03FA03	 (L01XE)	Propulsives (A03FA)	Other antineoplastic agents (L01X)	Propulsives (A03F)	0					L01XE	L01X	A03FA	A03F
7204	imatinib	enhances	3A457	eplerenone	C	L01XE01	C03DA04	 (L01XE)	Aldosterone antagonists (C03DA)	Other antineoplastic agents (L01X)	Potassium-sparing agents (C03D)	0					L01XE	L01X	C03DA	C03D
7207	imatinib	enhances	3A457	escitalopram		L01XE01	N06AB10	 (L01XE)	Selective serotonin reuptake inhibitors (N06AB)	Other antineoplastic agents (L01X)	Antidepressants (N06A)	0					L01XE	L01X	N06AB	N06A
7208	imatinib	enhances	3A457	esomeprazole		L01XE01	A02BC05	 (L01XE)	Proton pump inhibitors (A02BC)	Other antineoplastic agents (L01X)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					L01XE	L01X	A02BC	A02B
7210	imatinib	enhances	3A457	felodipine		L01XE01	C08CA02	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		L01XE	L01X	C08CA	C08C
7214	imatinib	enhances	3A457	haloperidol	B	L01XE01	N05AD01	 (L01XE)	Butyrophenone derivatives (N05AD)	Other antineoplastic agents (L01X)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		L01XE	L01X	N05AD	N05A
7215	imatinib	enhances	3A457	hydrocortisone		L01XE01	H02AB09	 (L01XE)	Glucocorticoids (H02AB)	Other antineoplastic agents (L01X)	Corticosteroids for systemic use, plain (H02A)	0					L01XE	L01X	H02AB	H02A
7218	imatinib	enhances	3A457	indacaterol	B	L01XE01	R03AC18	 (L01XE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Other antineoplastic agents (L01X)	Adrenergics, inhalants (R03A)	0					L01XE	L01X	R03AC	R03A
7222	imatinib	enhances	3A457	ivabradine		L01XE01	C01EB17	 (L01XE)	Other cardiac preparations (C01EB)	Other antineoplastic agents (L01X)	Other cardiac preparations (C01E)	0					L01XE	L01X	C01EB	C01E
7224	imatinib	enhances	3A457	lansoprazole		L01XE01	A02BC03	 (L01XE)	Proton pump inhibitors (A02BC)	Other antineoplastic agents (L01X)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				L01XE	L01X	A02BC	A02B
7226	imatinib	enhances	3A457	lercanidipine		L01XE01	C08CA13	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					L01XE	L01X	C08CA	C08C
7230	imatinib	enhances	3A457	lovastatin	C	L01XE01	C10AA02	 (L01XE)	HMG CoA reductase inhibitors (C10AA)	Other antineoplastic agents (L01X)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			L01XE	L01X	C10AA	C10A
7232	imatinib	enhances	3A457	methadone		L01XE01	N07BC02	 (L01XE)	Drugs used in opioid dependence (N07BC)	Other antineoplastic agents (L01X)	Drugs used in addictive disorders (N07B)	0	0				L01XE	L01X	N07BC	N07B
7233	imatinib	enhances	3A457	midazolam		L01XE01	N05CD08	 (L01XE)	Benzodiazepine derivatives (N05CD)	Other antineoplastic agents (L01X)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		L01XE	L01X	N05CD	N05C
7239	imatinib	enhances	3A457	nifedipine	B	L01XE01	C08CA05	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		L01XE	L01X	C08CA	C08C
7240	imatinib	enhances	3A457	nisoldipine		L01XE01	C08CA07	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		L01XE	L01X	C08CA	C08C
7241	imatinib	enhances	3A457	nitrendipine		L01XE01	C08CA08	 (L01XE)	Dihydropyridine derivatives (C08CA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		L01XE	L01X	C08CA	C08C
7243	imatinib	enhances	3A457	omeprazole		L01XE01	A02BC01	 (L01XE)	Proton pump inhibitors (A02BC)	Other antineoplastic agents (L01X)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			819	L01XE	L01X	A02BC	A02B
7244	imatinib	enhances	3A457	ondansetron		L01XE01	A04AA01	 (L01XE)	Serotonin (5HT3) antagonists (A04AA)	Other antineoplastic agents (L01X)	Antiemetics and antinauseants (A04A)	0	0				L01XE	L01X	A04AA	A04A
7251	imatinib	enhances	3A457	pantoprazole		L01XE01	A02BC02	 (L01XE)	Proton pump inhibitors (A02BC)	Other antineoplastic agents (L01X)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				L01XE	L01X	A02BC	A02B
7258	imatinib	enhances	3A457	propranolol		L01XE01	C07AA05	 (L01XE)	Beta blocking agents, non-selective (C07AA)	Other antineoplastic agents (L01X)	Beta blocking agents (C07A)	0					L01XE	L01X	C07AA	C07A
7259	imatinib	enhances	3A457	quetiapine		L01XE01	N05AH04	 (L01XE)	Diazepines, oxazepines and thiazepines (N05AH)	Other antineoplastic agents (L01X)	Antipsychotics (N05A)	0					L01XE	L01X	N05AH	N05A
7265	imatinib	enhances	3A457	risperidone		L01XE01	N05AX08	 (L01XE)	Other antipsychotics (N05AX)	Other antineoplastic agents (L01X)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		L01XE	L01X	N05AX	N05A
7266	imatinib	enhances	3A457	ritonavir	D	L01XE01	J05AE03	 (L01XE)	Protease inhibitors (J05AE)	Other antineoplastic agents (L01X)	Direct acting antivirals (J05A)	0	0				L01XE	L01X	J05AE	J05A
7267	imatinib	enhances	3A457	rivaroxaban		L01XE01	B01AF01	 (L01XE)	Direct factor Xa inhibitors (B01AF)	Other antineoplastic agents (L01X)	Antithrombotic agents (B01A)	0					L01XE	L01X	B01AF	B01A
7273	imatinib	enhances	3A457	salmeterol		L01XE01	R03AC12	 (L01XE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Other antineoplastic agents (L01X)	Adrenergics, inhalants (R03A)	0					L01XE	L01X	R03AC	R03A
7274	imatinib	enhances	3A457	saquinavir	D	L01XE01	J05AE01	 (L01XE)	Protease inhibitors (J05AE)	Other antineoplastic agents (L01X)	Direct acting antivirals (J05A)	0	0				L01XE	L01X	J05AE	J05A
7276	imatinib	enhances	3A457	sildenafil		L01XE01	G04BE03	 (L01XE)	Drugs used in erectile dysfunction (G04BE)	Other antineoplastic agents (L01X)	Urologicals (G04B)	0	0				L01XE	L01X	G04BE	G04B
7278	imatinib	enhances	3A457	simvastatin	C	L01XE01	C10AA01	 (L01XE)	HMG CoA reductase inhibitors (C10AA)	Other antineoplastic agents (L01X)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			L01XE	L01X	C10AA	C10A
7279	imatinib	enhances	3A457	sirolimus	C	L01XE01	L04AA10	 (L01XE)	Selective immunosuppressants (L04AA)	Other antineoplastic agents (L01X)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			L01XE	L01X	L04AA	L04A
7281	imatinib	enhances	3A457	sorafenib		L01XE01	L01XE05	 (L01XE)	 (L01XE)	Other antineoplastic agents (L01X)	Other antineoplastic agents (L01X)	1					L01XE	L01X	L01XE	L01X
7282	imatinib	enhances	3A457	sunitinib		L01XE01	L01XE04	 (L01XE)	 (L01XE)	Other antineoplastic agents (L01X)	Other antineoplastic agents (L01X)	1					L01XE	L01X	L01XE	L01X
7284	imatinib	enhances	3A457	tacrolimus	B	L01XE01	L04AD02	 (L01XE)	Calcineurin inhibitors (L04AD)	Other antineoplastic agents (L01X)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			L01XE	L01X	L04AD	L04A
7285	imatinib	enhances	3A457	tadalafil	C	L01XE01	G04BE08	 (L01XE)	Drugs used in erectile dysfunction (G04BE)	Other antineoplastic agents (L01X)	Urologicals (G04B)	0	0				L01XE	L01X	G04BE	G04B
7286	imatinib	enhances	3A457	tamoxifen	B	L01XE01	L02BA01	 (L01XE)	Anti-estrogens (L02BA)	Other antineoplastic agents (L01X)	Hormone antagonists and related agents (L02B)	1	1				L01XE	L01X	L02BA	L02B
7292	imatinib	enhances	3A457	testosterone	B	L01XE01	G03BA03	 (L01XE)	3-oxoandrosten (4) derivatives (G03BA)	Other antineoplastic agents (L01X)	Androgens (G03B)	0					L01XE	L01X	G03BA	G03B
7293	imatinib	enhances	3A457	ticagrelor		L01XE01	B01AC24	 (L01XE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antineoplastic agents (L01X)	Antithrombotic agents (B01A)	0					L01XE	L01X	B01AC	B01A
7296	imatinib	enhances	3A457	tramadol		L01XE01	N02AX02	 (L01XE)	Other opioids (N02AX)	Other antineoplastic agents (L01X)	Opioids (N02A)	0	1		Reduced analgesic effect		L01XE	L01X	N02AX	N02A
7297	imatinib	enhances	3A457	trazodone	C	L01XE01	N06AX05	 (L01XE)	Other antidepressants (N06AX)	Other antineoplastic agents (L01X)	Antidepressants (N06A)	0	0	Serotonin toxicity			L01XE	L01X	N06AX	N06A
7298	imatinib	enhances	3A457	triazolam		L01XE01	N05CD05	 (L01XE)	Benzodiazepine derivatives (N05CD)	Other antineoplastic agents (L01X)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		L01XE	L01X	N05CD	N05C
7305	imatinib	enhances	3A457	venlafaxine	B	L01XE01	N06AX16	 (L01XE)	Other antidepressants (N06AX)	Other antineoplastic agents (L01X)	Antidepressants (N06A)	0	0	Serotonin toxicity			L01XE	L01X	N06AX	N06A
7306	imatinib	enhances	3A457	verapamil	B	L01XE01	C08DA01	 (L01XE)	Phenylalkylamine derivatives (C08DA)	Other antineoplastic agents (L01X)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			L01XE	L01X	C08DA	C08D
7310	imatinib	enhances	3A457	voriconazole	D	L01XE01	J02AC03	 (L01XE)	Triazole derivatives (J02AC)	Other antineoplastic agents (L01X)	Antimycotics for systemic use (J02A)	0	0				L01XE	L01X	J02AC	J02A
7311	imatinib	enhances	3A457	zaleplon		L01XE01	N05CF03	 (L01XE)	Benzodiazepine related drugs (N05CF)	Other antineoplastic agents (L01X)	Hypnotics and sedatives (N05C)	0					L01XE	L01X	N05CF	N05C
7313	imatinib	enhances	3A457	zolpidem	A	L01XE01	N05CF02	 (L01XE)	Benzodiazepine related drugs (N05CF)	Other antineoplastic agents (L01X)	Hypnotics and sedatives (N05C)	0					L01XE	L01X	N05CF	N05C
7508	isoniazid	enhances	2C19,2C9	amitriptyline		J04AC01	N06AA09	Hydrazides (J04AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AC	J04A	N06AA	N06A
7512	isoniazid	enhances	2C9	capecitabine		J04AC01	L01BC06	Hydrazides (J04AC)	Pyrimidine analogues (L01BC)	Drugs for treatment of tuberculosis (J04A)	Antimetabolites (L01B)	1					J04AC	J04A	L01BC	L01B
7514	isoniazid	enhances	2C9	celecoxib		J04AC01	M01AH01	Hydrazides (J04AC)	Coxibs (M01AH)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AC	J04A	M01AH	M01A
7516	isoniazid	enhances	2C19	citalopram	D	J04AC01	N06AB04	Hydrazides (J04AC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0				J04AC	J04A	N06AB	N06A
7517	isoniazid	enhances	2C19	clobazam		J04AC01	N05BA09	Hydrazides (J04AC)	Benzodiazepine derivatives (N05BA)	Drugs for treatment of tuberculosis (J04A)	Anxiolytics (N05B)	0					J04AC	J04A	N05BA	N05B
7518	isoniazid	enhances	2C19	clomipramine		J04AC01	N06AA04	Hydrazides (J04AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AC	J04A	N06AA	N06A
7519	isoniazid	enhances	2C19,2C9	clopidogrel		J04AC01	B01AC04	Hydrazides (J04AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J04AC	J04A	B01AC	B01A
7520	isoniazid	enhances	2C19	cyclophosphamide		J04AC01	L01AA01	Hydrazides (J04AC)	Nitrogen mustard analogues (L01AA)	Drugs for treatment of tuberculosis (J04A)	Alkylating agents (L01A)	1	1				J04AC	J04A	L01AA	L01A
7521	isoniazid	enhances	2C19	diazepam	D	J04AC01	N05BA01	Hydrazides (J04AC)	Benzodiazepine derivatives (N05BA)	Drugs for treatment of tuberculosis (J04A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J04AC	J04A	N05BA	N05B
7522	isoniazid	enhances	2C9	diclofenac		J04AC01	M01AB05	Hydrazides (J04AC)	Acetic acid derivatives and related substances (M01AB)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AC	J04A	M01AB	M01A
7524	isoniazid	enhances	2C19	escitalopram	D	J04AC01	N06AB10	Hydrazides (J04AC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0					J04AC	J04A	N06AB	N06A
7525	isoniazid	enhances	2C19	esomeprazole		J04AC01	A02BC05	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1179	J04AC	J04A	A02BC	A02B
7525	isoniazid	enhances	2C19	esomeprazole		J04AC01	A02BC05	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5122	J04AC	J04A	A02BC	A02B
7527	isoniazid	enhances	2C9	fluoxetine		J04AC01	N06AB03	Hydrazides (J04AC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AC	J04A	N06AB	N06A
7528	isoniazid	enhances	2C9	fluvastatin		J04AC01	C10AA04	Hydrazides (J04AC)	HMG CoA reductase inhibitors (C10AA)	Drugs for treatment of tuberculosis (J04A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J04AC	J04A	C10AA	C10A
7529	isoniazid	enhances	2C9	glimepiride	C	J04AC01	A10BB12	Hydrazides (J04AC)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J04AC	J04A	A10BB	A10B
7530	isoniazid	enhances	2C9	glipizide		J04AC01	A10BB07	Hydrazides (J04AC)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J04AC	J04A	A10BB	A10B
7531	isoniazid	enhances	2C9	glyburide		J04AC01	A10BB01	Hydrazides (J04AC)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J04AC	J04A	A10BB	A10B
7533	isoniazid	enhances	2C9	ibuprofen		J04AC01	M01AE01	Hydrazides (J04AC)	Propionic acid derivatives (M01AE)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AC	J04A	M01AE	M01A
7534	isoniazid	enhances	2C19	imipramine		J04AC01	N06AA02	Hydrazides (J04AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AC	J04A	N06AA	N06A
7535	isoniazid	enhances	2C19	indometacin		J04AC01	M01AB01	Hydrazides (J04AC)	Acetic acid derivatives and related substances (M01AB)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J04AC	J04A	M01AB	M01A
7536	isoniazid	enhances	2C9	irbesartan		J04AC01	C09CA04	Hydrazides (J04AC)	Angiotensin II receptor blockers, plain (C09CA)	Drugs for treatment of tuberculosis (J04A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		J04AC	J04A	C09CA	C09C
7538	isoniazid	enhances	2C19	lansoprazole		J04AC01	A02BC03	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3713	J04AC	J04A	A02BC	A02B
7541	isoniazid	enhances	2C9	losartan		J04AC01	C09CA01	Hydrazides (J04AC)	Angiotensin II receptor blockers, plain (C09CA)	Drugs for treatment of tuberculosis (J04A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		J04AC	J04A	C09CA	C09C
7542	isoniazid	enhances	2C9	meloxicam		J04AC01	M01AC06	Hydrazides (J04AC)	Oxicams (M01AC)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J04AC	J04A	M01AC	M01A
7546	isoniazid	enhances	2C9	naproxen		J04AC01	M01AE02	Hydrazides (J04AC)	Propionic acid derivatives (M01AE)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AC	J04A	M01AE	M01A
7551	isoniazid	enhances	2C19	omeprazole		J04AC01	A02BC01	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1353	J04AC	J04A	A02BC	A02B
7553	isoniazid	enhances	2C19	pantoprazole		J04AC01	A02BC02	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2225	J04AC	J04A	A02BC	A02B
7553	isoniazid	enhances	2C19	pantoprazole		J04AC01	A02BC02	Hydrazides (J04AC)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5926	J04AC	J04A	A02BC	A02B
7554	isoniazid	enhances	2C19	phenobarbital		J04AC01	N03AA02	Hydrazides (J04AC)	Barbiturates and derivatives (N03AA)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AC	J04A	N03AA	N03A
7555	isoniazid	enhances	2C19,2C9	phenytoin	B	J04AC01	N03AB02	Hydrazides (J04AC)	Hydantoin derivatives (N03AB)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AC	J04A	N03AB	N03A
7556	isoniazid	enhances	2C9	piroxicam		J04AC01	M01AC01	Hydrazides (J04AC)	Oxicams (M01AC)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AC	J04A	M01AC	M01A
7558	isoniazid	enhances	2C19	primidone		J04AC01	N03AA03	Hydrazides (J04AC)	Barbiturates and derivatives (N03AA)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	0					J04AC	J04A	N03AA	N03A
7561	isoniazid	enhances	2C19	propranolol		J04AC01	C07AA05	Hydrazides (J04AC)	Beta blocking agents, non-selective (C07AA)	Drugs for treatment of tuberculosis (J04A)	Beta blocking agents (C07A)	0					J04AC	J04A	C07AA	C07A
7566	isoniazid	enhances	2C9	tamoxifen		J04AC01	L02BA01	Hydrazides (J04AC)	Anti-estrogens (L02BA)	Drugs for treatment of tuberculosis (J04A)	Hormone antagonists and related agents (L02B)	1	1				J04AC	J04A	L02BA	L02B
7570	isoniazid	enhances	2C9	torasemide		J04AC01	C03CA04	Hydrazides (J04AC)	Sulfonamides, plain (C03CA)	Drugs for treatment of tuberculosis (J04A)	High-ceiling diuretics (C03C)	0	0				J04AC	J04A	C03CA	C03C
7571	isoniazid	enhances	2C9	valproate	C	J04AC01	N03AG01	Hydrazides (J04AC)	Fatty acid derivatives (N03AG)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AC	J04A	N03AG	N03A
7572	isoniazid	enhances	2C19,2C9	venlafaxine		J04AC01	N06AX16	Hydrazides (J04AC)	Other antidepressants (N06AX)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AC	J04A	N06AX	N06A
7574	isoniazid	enhances	2C19,2C9	voriconazole		J04AC01	J02AC03	Hydrazides (J04AC)	Triazole derivatives (J02AC)	Drugs for treatment of tuberculosis (J04A)	Antimycotics for systemic use (J02A)	0	0				J04AC	J04A	J02AC	J02A
7575	isoniazid	enhances	2C19,2C9	warfarin	B	J04AC01	B01AA03	Hydrazides (J04AC)	Vitamin K antagonists (B01AA)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	1	0	Bleeding			J04AC	J04A	B01AA	B01A
7577	isoniazid	reduces	2E1	acetaminophen	B	J04AC01	N02BE01	Hydrazides (J04AC)	Anilides (N02BE)	Drugs for treatment of tuberculosis (J04A)	Other analgesics and antipyretics (N02B)	0	0				J04AC	J04A	N02BE	N02B
7588	isoniazid	reduces	2E1	theophylline	B	J04AC01	R03DA04	Hydrazides (J04AC)	Xanthines (R03DA)	Drugs for treatment of tuberculosis (J04A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				J04AC	J04A	R03DA	R03D
7594	itraconazole	enhances	3A457	alprazolam	D	J02AC02	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05BA	N05B
7595	itraconazole	enhances	3A457	amitriptyline	D	J02AC02	N06AA09	Triazole derivatives (J02AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J02AC	J02A	N06AA	N06A
7596	itraconazole	enhances	3A457	amlodipine	B	J02AC02	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2122	J02AC	J02A	C08CA	C08C
7597	itraconazole	enhances	3A457	apixaban	D	J02AC02	B01AF02	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
7601	itraconazole	enhances	3A457	atorvastatin	D	J02AC02	C10AA05	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5298	J02AC	J02A	C10AA	C10A
7610	itraconazole	enhances	3A457	carbamazepine	D	J02AC02	N03AF01	Triazole derivatives (J02AC)	Carboxamide derivatives (N03AF)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J02AC	J02A	N03AF	N03A
7614	itraconazole	enhances	3A457	chlorpheniramine		J02AC02	R06AB04	Triazole derivatives (J02AC)	Substituted alkylamines (R06AB)	Antimycotics for systemic use (J02A)	Antihistamines for systemic use (R06A)	0	0				J02AC	J02A	R06AB	R06A
7615	itraconazole	enhances	3A457	cilostazol	D	J02AC02	B01AC23	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
7617	itraconazole	enhances	3A457	citalopram	D	J02AC02	N06AB04	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0				J02AC	J02A	N06AB	N06A
7618	itraconazole	enhances	3A457	clarithromycin	D	J02AC02	J01FA09	Triazole derivatives (J02AC)	Macrolides (J01FA)	Antimycotics for systemic use (J02A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J02AC	J02A	J01FA	J01F
7619	itraconazole	enhances	3A457	clobazam	D	J02AC02	N05BA09	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0					J02AC	J02A	N05BA	N05B
7620	itraconazole	enhances	3A457	clopidogrel		J02AC02	B01AC04	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5298	J02AC	J02A	B01AC	B01A
7624	itraconazole	enhances	3A457	colchicine		J02AC02	M04AC01	Triazole derivatives (J02AC)	Preparations with no effect on uric acid metabolism (M04AC)	Antimycotics for systemic use (J02A)	Antigout preparations (M04A)	0					J02AC	J02A	M04AC	M04A
7627	itraconazole	enhances	3A457	cyclosporine	D	J02AC02	L04AD01	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
7631	itraconazole	enhances	3A457	deflazacort		J02AC02	H02AB13	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
7632	itraconazole	enhances	3A457	dexamethasone	C	J02AC02	H02AB02	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0				5298	J02AC	J02A	H02AB	H02A
7633	itraconazole	enhances	3A457	dextromethorphan		J02AC02	R05DA09	Triazole derivatives (J02AC)	Opium alkaloids and derivatives (R05DA)	Antimycotics for systemic use (J02A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J02AC	J02A	R05DA	R05D
7634	itraconazole	enhances	3A457	diazepam	B	J02AC02	N05BA01	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05BA	N05B
7635	itraconazole	enhances	3A457	diltiazem		J02AC02	C08DB01	Triazole derivatives (J02AC)	Benzothiazepine derivatives (C08DB)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2400	J02AC	J02A	C08DB	C08D
7638	itraconazole	enhances	3A457	domperidone	D	J02AC02	A03FA03	Triazole derivatives (J02AC)	Propulsives (A03FA)	Antimycotics for systemic use (J02A)	Propulsives (A03F)	0				4897	J02AC	J02A	A03FA	A03F
7644	itraconazole	enhances	3A457	eplerenone	D	J02AC02	C03DA04	Triazole derivatives (J02AC)	Aldosterone antagonists (C03DA)	Antimycotics for systemic use (J02A)	Potassium-sparing agents (C03D)	0					J02AC	J02A	C03DA	C03D
7647	itraconazole	enhances	3A457	escitalopram	D	J02AC02	N06AB10	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0					J02AC	J02A	N06AB	N06A
7648	itraconazole	enhances	3A457	esomeprazole	B	J02AC02	A02BC05	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				794	J02AC	J02A	A02BC	A02B
7650	itraconazole	enhances	3A457	felodipine	B	J02AC02	C08CA02	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
7654	itraconazole	enhances	3A457	haloperidol	D	J02AC02	N05AD01	Triazole derivatives (J02AC)	Butyrophenone derivatives (N05AD)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J02AC	J02A	N05AD	N05A
7655	itraconazole	enhances	3A457	hydrocortisone	B	J02AC02	H02AB09	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
7658	itraconazole	enhances	3A457	imatinib	D	J02AC02	L01XE01	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	0	0				J02AC	J02A	L01XE	L01X
7659	itraconazole	enhances	3A457	indacaterol		J02AC02	R03AC18	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0					J02AC	J02A	R03AC	R03A
7663	itraconazole	enhances	3A457	ivabradine		J02AC02	C01EB17	Triazole derivatives (J02AC)	Other cardiac preparations (C01EB)	Antimycotics for systemic use (J02A)	Other cardiac preparations (C01E)	0					J02AC	J02A	C01EB	C01E
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1383	J02AC	J02A	A02BC	A02B
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2122	J02AC	J02A	A02BC	A02B
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2400	J02AC	J02A	A02BC	A02B
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4297	J02AC	J02A	A02BC	A02B
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4897	J02AC	J02A	A02BC	A02B
7665	itraconazole	enhances	3A457	lansoprazole	B	J02AC02	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5262	J02AC	J02A	A02BC	A02B
7667	itraconazole	enhances	3A457	lercanidipine	B	J02AC02	C08CA13	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J02AC	J02A	C08CA	C08C
7671	itraconazole	enhances	3A457	lovastatin	D	J02AC02	C10AA02	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J02AC	J02A	C10AA	C10A
7673	itraconazole	enhances	3A457	methadone	D	J02AC02	N07BC02	Triazole derivatives (J02AC)	Drugs used in opioid dependence (N07BC)	Antimycotics for systemic use (J02A)	Drugs used in addictive disorders (N07B)	0	0				J02AC	J02A	N07BC	N07B
7674	itraconazole	enhances	3A457	midazolam	D	J02AC02	N05CD08	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05CD	N05C
7680	itraconazole	enhances	3A457	nevirapine	C	J02AC02	J05AG01	Triazole derivatives (J02AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AG	J05A
7681	itraconazole	enhances	3A457	nifedipine	D	J02AC02	C08CA05	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3813	J02AC	J02A	C08CA	C08C
7682	itraconazole	enhances	3A457	nisoldipine	B	J02AC02	C08CA07	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
7683	itraconazole	enhances	3A457	nitrendipine	B	J02AC02	C08CA08	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
7685	itraconazole	enhances	3A457	omeprazole	B	J02AC02	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2199	J02AC	J02A	A02BC	A02B
7685	itraconazole	enhances	3A457	omeprazole	B	J02AC02	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2904	J02AC	J02A	A02BC	A02B
7685	itraconazole	enhances	3A457	omeprazole	B	J02AC02	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3813	J02AC	J02A	A02BC	A02B
7685	itraconazole	enhances	3A457	omeprazole	B	J02AC02	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6223	J02AC	J02A	A02BC	A02B
7686	itraconazole	enhances	3A457	ondansetron	D	J02AC02	A04AA01	Triazole derivatives (J02AC)	Serotonin (5HT3) antagonists (A04AA)	Antimycotics for systemic use (J02A)	Antiemetics and antinauseants (A04A)	0	0				J02AC	J02A	A04AA	A04A
7693	itraconazole	enhances	3A457	pantoprazole	D	J02AC02	A02BC02	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7135	J02AC	J02A	A02BC	A02B
7700	itraconazole	enhances	3A457	propranolol		J02AC02	C07AA05	Triazole derivatives (J02AC)	Beta blocking agents, non-selective (C07AA)	Antimycotics for systemic use (J02A)	Beta blocking agents (C07A)	0					J02AC	J02A	C07AA	C07A
7701	itraconazole	enhances	3A457	quetiapine	D	J02AC02	N05AH04	Triazole derivatives (J02AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0					J02AC	J02A	N05AH	N05A
7707	itraconazole	enhances	3A457	risperidone	D	J02AC02	N05AX08	Triazole derivatives (J02AC)	Other antipsychotics (N05AX)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J02AC	J02A	N05AX	N05A
7708	itraconazole	enhances	3A457	ritonavir	D	J02AC02	J05AE03	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
7709	itraconazole	enhances	3A457	rivaroxaban	C	J02AC02	B01AF01	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				794	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				1383	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				2122	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				2199	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				2290	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				4291	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				6223	J02AC	J02A	R03AC	R03A
7715	itraconazole	enhances	3A457	salmeterol	D	J02AC02	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0				7135	J02AC	J02A	R03AC	R03A
7716	itraconazole	enhances	3A457	saquinavir	D	J02AC02	J05AE01	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
7718	itraconazole	enhances	3A457	sildenafil	B	J02AC02	G04BE03	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
7720	itraconazole	enhances	3A457	simvastatin	D	J02AC02	C10AA01	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2122	J02AC	J02A	C10AA	C10A
7721	itraconazole	enhances	3A457	sirolimus	D	J02AC02	L04AA10	Triazole derivatives (J02AC)	Selective immunosuppressants (L04AA)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AA	L04A
7723	itraconazole	enhances	3A457	sorafenib	D	J02AC02	L01XE05	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
7724	itraconazole	enhances	3A457	sunitinib	D	J02AC02	L01XE04	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
7726	itraconazole	enhances	3A457	tacrolimus	D	J02AC02	L04AD02	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
7727	itraconazole	enhances	3A457	tadalafil		J02AC02	G04BE08	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
7728	itraconazole	enhances	3A457	tamoxifen	D	J02AC02	L02BA01	Triazole derivatives (J02AC)	Anti-estrogens (L02BA)	Antimycotics for systemic use (J02A)	Hormone antagonists and related agents (L02B)	1	1				J02AC	J02A	L02BA	L02B
7734	itraconazole	enhances	3A457	testosterone		J02AC02	G03BA03	Triazole derivatives (J02AC)	3-oxoandrosten (4) derivatives (G03BA)	Antimycotics for systemic use (J02A)	Androgens (G03B)	0					J02AC	J02A	G03BA	G03B
7735	itraconazole	enhances	3A457	ticagrelor		J02AC02	B01AC24	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
7738	itraconazole	enhances	3A457	tramadol		J02AC02	N02AX02	Triazole derivatives (J02AC)	Other opioids (N02AX)	Antimycotics for systemic use (J02A)	Opioids (N02A)	0	1		Reduced analgesic effect	7135	J02AC	J02A	N02AX	N02A
7739	itraconazole	enhances	3A457	trazodone	D	J02AC02	N06AX05	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AX	N06A
7740	itraconazole	enhances	3A457	triazolam	D	J02AC02	N05CD05	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5262	J02AC	J02A	N05CD	N05C
7747	itraconazole	enhances	3A457	venlafaxine	D	J02AC02	N06AX16	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7135	J02AC	J02A	N06AX	N06A
7748	itraconazole	enhances	3A457	verapamil	B	J02AC02	C08DA01	Triazole derivatives (J02AC)	Phenylalkylamine derivatives (C08DA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2199	J02AC	J02A	C08DA	C08D
7748	itraconazole	enhances	3A457	verapamil	B	J02AC02	C08DA01	Triazole derivatives (J02AC)	Phenylalkylamine derivatives (C08DA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4297	J02AC	J02A	C08DA	C08D
7752	itraconazole	enhances	3A457	voriconazole	D	J02AC02	J02AC03	Triazole derivatives (J02AC)	Triazole derivatives (J02AC)	Antimycotics for systemic use (J02A)	Antimycotics for systemic use (J02A)	0	0				J02AC	J02A	J02AC	J02A
7753	itraconazole	enhances	3A457	zaleplon		J02AC02	N05CF03	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0					J02AC	J02A	N05CF	N05C
7755	itraconazole	enhances	3A457	zolpidem		J02AC02	N05CF02	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0					J02AC	J02A	N05CF	N05C
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		199	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		363	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		1193	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		3081	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		4141	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		5441	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		5815	A02BC	A02B	N06AA	N06A
7943	lansoprazole	enhances	2C19	amitriptyline		A02BC03	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		6011	A02BC	A02B	N06AA	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			107	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			278	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			608	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			672	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			994	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1082	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1107	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1286	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1366	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1537	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1560	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2289	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2456	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2567	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2813	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2861	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2899	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3004	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3069	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3075	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3108	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3204	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			4135	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5242	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5486	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			6014	A02BC	A02B	N06AB	N06A
7948	lansoprazole	enhances	2C19	citalopram		A02BC03	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			6239	A02BC	A02B	N06AB	N06A
7949	lansoprazole	enhances	2C19	clobazam		A02BC03	N05BA09	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0				4598	A02BC	A02B	N05BA	N05B
7950	lansoprazole	enhances	2C19	clomipramine		A02BC03	N06AA04	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		2030	A02BC	A02B	N06AA	N06A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	59	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	69	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	619	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	714	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	837	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	994	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	998	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1076	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1188	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1449	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1564	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1578	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2065	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2162	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2267	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2315	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2410	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2442	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2679	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2819	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2908	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2912	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2976	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3002	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3004	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3165	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3181	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3215	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3383	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3437	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3461	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3546	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3610	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3611	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3675	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3830	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4114	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4133	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4200	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4296	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4476	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4513	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4665	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4668	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4721	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5134	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5154	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5210	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5223	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5241	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5242	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5312	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5341	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5423	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5445	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5456	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5691	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5820	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5830	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6091	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6144	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6184	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7119	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7145	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7245	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7508	A02BC	A02B	B01AC	B01A
7951	lansoprazole	enhances	2C19	clopidogrel	C	A02BC03	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7603	A02BC	A02B	B01AC	B01A
7952	lansoprazole	enhances	2C19	cyclophosphamide		A02BC03	L01AA01	Proton pump inhibitors (A02BC)	Nitrogen mustard analogues (L01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Alkylating agents (L01A)	1	1			3590	A02BC	A02B	L01AA	L01A
7953	lansoprazole	enhances	2C19	diazepam		A02BC03	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2456	A02BC	A02B	N05BA	N05B
7953	lansoprazole	enhances	2C19	diazepam		A02BC03	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2992	A02BC	A02B	N05BA	N05B
7953	lansoprazole	enhances	2C19	diazepam		A02BC03	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4141	A02BC	A02B	N05BA	N05B
7953	lansoprazole	enhances	2C19	diazepam		A02BC03	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5456	A02BC	A02B	N05BA	N05B
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				334	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				580	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1292	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1481	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2276	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2651	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2697	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3204	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3247	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3248	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3464	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3782	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3847	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4323	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4350	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5610	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7149	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7177	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7497	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7555	A02BC	A02B	N06AB	N06A
7955	lansoprazole	enhances	2C19	escitalopram		A02BC03	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7557	A02BC	A02B	N06AB	N06A
7956	lansoprazole	enhances	2C19	esomeprazole		A02BC03	A02BC05	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					A02BC	A02B	A02BC	A02B
7959	lansoprazole	enhances	2C19	imipramine		A02BC03	N06AA02	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BC	A02B	N06AA	N06A
7960	lansoprazole	enhances	2C19	indometacin		A02BC03	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				4066	A02BC	A02B	M01AB	M01A
7967	lansoprazole	enhances	2C19	omeprazole		A02BC03	A02BC01	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1578	A02BC	A02B	A02BC	A02B
7969	lansoprazole	enhances	2C19	pantoprazole		A02BC03	A02BC02	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3453	A02BC	A02B	A02BC	A02B
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	57	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	68	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	165	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	244	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1031	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2003	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2139	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2891	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3002	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3117	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3156	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3395	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3525	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4258	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4317	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4708	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5521	A02BC	A02B	N03AA	N03A
7970	lansoprazole	enhances	2C19	phenobarbital		A02BC03	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5828	A02BC	A02B	N03AA	N03A
7971	lansoprazole	enhances	2C19	phenytoin		A02BC03	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	796	A02BC	A02B	N03AB	N03A
7971	lansoprazole	enhances	2C19	phenytoin		A02BC03	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1596	A02BC	A02B	N03AB	N03A
7971	lansoprazole	enhances	2C19	phenytoin		A02BC03	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3066	A02BC	A02B	N03AB	N03A
7971	lansoprazole	enhances	2C19	phenytoin		A02BC03	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	7560	A02BC	A02B	N03AB	N03A
7973	lansoprazole	enhances	2C19	primidone		A02BC03	N03AA03	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	0				2864	A02BC	A02B	N03AA	N03A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				161	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				830	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1134	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1337	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1429	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1469	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2276	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2351	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2700	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2864	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3409	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3431	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3735	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3849	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3850	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4067	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4093	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4140	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5473	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5875	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5968	A02BC	A02B	C07AA	C07A
7976	lansoprazole	enhances	2C19	propranolol		A02BC03	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7110	A02BC	A02B	C07AA	C07A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		125	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		879	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1280	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2030	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3465	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3714	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4224	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5411	A02BC	A02B	N06AX	N06A
7980	lansoprazole	enhances	2C19	venlafaxine		A02BC03	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5657	A02BC	A02B	N06AX	N06A
7982	lansoprazole	enhances	2C19	voriconazole	B	A02BC03	J02AC03	Proton pump inhibitors (A02BC)	Triazole derivatives (J02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antimycotics for systemic use (J02A)	0	0				A02BC	A02B	J02AC	J02A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		52	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		56	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		69	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		109	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		117	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		165	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		185	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		219	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		278	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		572	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		637	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		669	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		703	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		711	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		714	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		838	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		868	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		909	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		945	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		954	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		956	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		957	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		983	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		991	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		993	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1007	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1023	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1029	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1080	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1295	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1320	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1333	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1346	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1370	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1483	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1548	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1592	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2024	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2035	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2046	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2069	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2145	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2190	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2259	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2261	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2266	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2355	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2400	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2441	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2446	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2454	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2491	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2548	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2577	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2605	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2656	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2741	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2770	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2846	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2861	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2928	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2995	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3001	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3018	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3036	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3108	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3179	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3181	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3239	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3242	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3291	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3339	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3421	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3464	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3603	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3644	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3645	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3680	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3685	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3709	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3737	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3741	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3744	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3780	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3831	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3946	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4097	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4101	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4135	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4168	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4212	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4229	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4233	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4297	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4377	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4442	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4456	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4479	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4488	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4521	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4555	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4584	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4669	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4700	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4743	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4792	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4891	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4934	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4935	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4939	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4949	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4961	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5112	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5219	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5241	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5244	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5265	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5310	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5320	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5329	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5435	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5455	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5492	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5493	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5656	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5657	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5692	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5793	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5817	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5968	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6013	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6014	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6091	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6243	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6283	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7046	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7145	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7310	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7390	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7455	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7498	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7556	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7587	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7590	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7718	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7724	A02BC	A02B	B01AA	B01A
7983	lansoprazole	enhances	2C19	warfarin	B	A02BC03	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7741	A02BC	A02B	B01AA	B01A
8355	levomepromazine	enhances	2D6	amitriptyline		N05AA02	N06AA09	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity		3765	N05AA	N05A	N06AA	N06A
8360	levomepromazine	enhances	2D6	carvedilol		N05AA02	C07AG02	Phenothiazines with aliphatic side-chain (N05AA)	Alpha and beta blocking agents (C07AG)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N05AA	N05A	C07AG	C07A
8361	levomepromazine	enhances	2D6	chlorpheniramine		N05AA02	R06AB04	Phenothiazines with aliphatic side-chain (N05AA)	Substituted alkylamines (R06AB)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0	0				N05AA	N05A	R06AB	R06A
8362	levomepromazine	enhances	2D6	chlorpromazine		N05AA02	N05AA01	Phenothiazines with aliphatic side-chain (N05AA)	Phenothiazines with aliphatic side-chain (N05AA)	Antipsychotics (N05A)	Antipsychotics (N05A)	0					N05AA	N05A	N05AA	N05A
8363	levomepromazine	enhances	2D6	citalopram		N05AA02	N06AB04	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0				N05AA	N05A	N06AB	N06A
8364	levomepromazine	enhances	2D6	clomipramine		N05AA02	N06AA04	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AA	N05A	N06AA	N06A
8365	levomepromazine	enhances	2D6	clonidine		N05AA02	C02AC01	Phenothiazines with aliphatic side-chain (N05AA)	Imidazoline receptor agonists (C02AC)	Antipsychotics (N05A)	Antiadrenergic agents, centrally acting (C02A)	1					N05AA	N05A	C02AC	C02A
8370	levomepromazine	enhances	2D6	dextromethorphan		N05AA02	R05DA09	Phenothiazines with aliphatic side-chain (N05AA)	Opium alkaloids and derivatives (R05DA)	Antipsychotics (N05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N05AA	N05A	R05DA	R05D
8371	levomepromazine	enhances	2D6	donepezil		N05AA02	N06DA02	Phenothiazines with aliphatic side-chain (N05AA)	Anticholinesterases (N06DA)	Antipsychotics (N05A)	Anti-dementia drugs (N06D)	0					N05AA	N05A	N06DA	N06D
8373	levomepromazine	enhances	2D6	duloxetine		N05AA02	N06AX21	Phenothiazines with aliphatic side-chain (N05AA)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity		103	N05AA	N05A	N06AX	N06A
8376	levomepromazine	enhances	2D6	escitalopram		N05AA02	N06AB10	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0					N05AA	N05A	N06AB	N06A
8377	levomepromazine	enhances	2D6	flecainide		N05AA02	C01BC04	Phenothiazines with aliphatic side-chain (N05AA)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N05AA	N05A	C01BC	C01B
8378	levomepromazine	enhances	2D6	fluoxetine		N05AA02	N06AB03	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AB	N06A
8379	levomepromazine	enhances	2D6	fluvoxamine		N05AA02	N06AB08	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AB	N06A
8380	levomepromazine	enhances	2D6	haloperidol		N05AA02	N05AD01	Phenothiazines with aliphatic side-chain (N05AA)	Butyrophenone derivatives (N05AD)	Antipsychotics (N05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N05AA	N05A	N05AD	N05A
8382	levomepromazine	enhances	2D6	imipramine		N05AA02	N06AA02	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N05AA	N05A	N06AA	N06A
8385	levomepromazine	enhances	2D6	metoclopramide		N05AA02	A03FA01	Phenothiazines with aliphatic side-chain (N05AA)	Propulsives (A03FA)	Antipsychotics (N05A)	Propulsives (A03F)	0					N05AA	N05A	A03FA	A03F
8386	levomepromazine	enhances	2D6	metoprolol		N05AA02	C07AB02	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N05AA	N05A	C07AB	C07A
8389	levomepromazine	enhances	2D6	nebivolol		N05AA02	C07AB12	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, selective (C07AB)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0					N05AA	N05A	C07AB	C07A
8390	levomepromazine	enhances	2D6	nortriptyline		N05AA02	N06AA10	Phenothiazines with aliphatic side-chain (N05AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antipsychotics (N05A)	Antidepressants (N06A)	1					N05AA	N05A	N06AA	N06A
8391	levomepromazine	enhances	2D6	ondansetron		N05AA02	A04AA01	Phenothiazines with aliphatic side-chain (N05AA)	Serotonin (5HT3) antagonists (A04AA)	Antipsychotics (N05A)	Antiemetics and antinauseants (A04A)	0	0				N05AA	N05A	A04AA	A04A
8392	levomepromazine	enhances	2D6	oxycodone		N05AA02	N02AA05	Phenothiazines with aliphatic side-chain (N05AA)	Natural opium alkaloids (N02AA)	Antipsychotics (N05A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N05AA	N05A	N02AA	N02A
8394	levomepromazine	enhances	2D6	paroxetine		N05AA02	N06AB05	Phenothiazines with aliphatic side-chain (N05AA)	Selective serotonin reuptake inhibitors (N06AB)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AB	N06A
8402	levomepromazine	enhances	2D6	promethazine		N05AA02	R06AD02	Phenothiazines with aliphatic side-chain (N05AA)	Phenothiazine derivatives (R06AD)	Antipsychotics (N05A)	Antihistamines for systemic use (R06A)	0					N05AA	N05A	R06AD	R06A
8403	levomepromazine	enhances	2D6	propafenone		N05AA02	C01BC03	Phenothiazines with aliphatic side-chain (N05AA)	Antiarrhythmics, class Ic (C01BC)	Antipsychotics (N05A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N05AA	N05A	C01BC	C01B
8404	levomepromazine	enhances	2D6	propranolol		N05AA02	C07AA05	Phenothiazines with aliphatic side-chain (N05AA)	Beta blocking agents, non-selective (C07AA)	Antipsychotics (N05A)	Beta blocking agents (C07A)	0					N05AA	N05A	C07AA	C07A
8405	levomepromazine	enhances	2D6	risperidone		N05AA02	N05AX08	Phenothiazines with aliphatic side-chain (N05AA)	Other antipsychotics (N05AX)	Antipsychotics (N05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N05AA	N05A	N05AX	N05A
8408	levomepromazine	enhances	2D6	tamoxifen		N05AA02	L02BA01	Phenothiazines with aliphatic side-chain (N05AA)	Anti-estrogens (L02BA)	Antipsychotics (N05A)	Hormone antagonists and related agents (L02B)	1	1				N05AA	N05A	L02BA	L02B
8409	levomepromazine	enhances	2D6	tetrabenazine		N05AA02	N07XX06	Phenothiazines with aliphatic side-chain (N05AA)	Other nervous system drugs (N07XX)	Antipsychotics (N05A)	Other nervous system drugs (N07X)	0					N05AA	N05A	N07XX	N07X
8412	levomepromazine	enhances	2D6	tramadol	C	N05AA02	N02AX02	Phenothiazines with aliphatic side-chain (N05AA)	Other opioids (N02AX)	Antipsychotics (N05A)	Opioids (N02A)	0	1		Reduced analgesic effect		N05AA	N05A	N02AX	N02A
8415	levomepromazine	enhances	2D6	venlafaxine		N05AA02	N06AX16	Phenothiazines with aliphatic side-chain (N05AA)	Other antidepressants (N06AX)	Antipsychotics (N05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N05AA	N05A	N06AX	N06A
8417	levomepromazine	enhances	2D6	zuclopenthixol		N05AA02	N05AF05	Phenothiazines with aliphatic side-chain (N05AA)	Thioxanthene derivatives (N05AF)	Antipsychotics (N05A)	Antipsychotics (N05A)	0					N05AA	N05A	N05AF	N05A
8694	methadone	enhances	2D6	amitriptyline	D	N07BC02	N06AA09	Drugs used in opioid dependence (N07BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N07BC	N07B	N06AA	N06A
8699	methadone	enhances	2D6	carvedilol		N07BC02	C07AG02	Drugs used in opioid dependence (N07BC)	Alpha and beta blocking agents (C07AG)	Drugs used in addictive disorders (N07B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N07BC	N07B	C07AG	C07A
8700	methadone	enhances	2D6	chlorpheniramine		N07BC02	R06AB04	Drugs used in opioid dependence (N07BC)	Substituted alkylamines (R06AB)	Drugs used in addictive disorders (N07B)	Antihistamines for systemic use (R06A)	0	0				N07BC	N07B	R06AB	R06A
8701	methadone	enhances	2D6	chlorpromazine	D	N07BC02	N05AA01	Drugs used in opioid dependence (N07BC)	Phenothiazines with aliphatic side-chain (N05AA)	Drugs used in addictive disorders (N07B)	Antipsychotics (N05A)	0					N07BC	N07B	N05AA	N05A
8702	methadone	enhances	2D6	citalopram	D	N07BC02	N06AB04	Drugs used in opioid dependence (N07BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0				N07BC	N07B	N06AB	N06A
8703	methadone	enhances	2D6	clomipramine	D	N07BC02	N06AA04	Drugs used in opioid dependence (N07BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N07BC	N07B	N06AA	N06A
8704	methadone	enhances	2D6	clonidine		N07BC02	C02AC01	Drugs used in opioid dependence (N07BC)	Imidazoline receptor agonists (C02AC)	Drugs used in addictive disorders (N07B)	Antiadrenergic agents, centrally acting (C02A)	1					N07BC	N07B	C02AC	C02A
8709	methadone	enhances	2D6	dextromethorphan	B	N07BC02	R05DA09	Drugs used in opioid dependence (N07BC)	Opium alkaloids and derivatives (R05DA)	Drugs used in addictive disorders (N07B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N07BC	N07B	R05DA	R05D
8710	methadone	enhances	2D6	donepezil	D	N07BC02	N06DA02	Drugs used in opioid dependence (N07BC)	Anticholinesterases (N06DA)	Drugs used in addictive disorders (N07B)	Anti-dementia drugs (N06D)	0					N07BC	N07B	N06DA	N06D
8712	methadone	enhances	2D6	duloxetine	D	N07BC02	N06AX21	Drugs used in opioid dependence (N07BC)	Other antidepressants (N06AX)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N07BC	N07B	N06AX	N06A
8715	methadone	enhances	2D6	escitalopram	D	N07BC02	N06AB10	Drugs used in opioid dependence (N07BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0					N07BC	N07B	N06AB	N06A
8716	methadone	enhances	2D6	flecainide	D	N07BC02	C01BC04	Drugs used in opioid dependence (N07BC)	Antiarrhythmics, class Ic (C01BC)	Drugs used in addictive disorders (N07B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N07BC	N07B	C01BC	C01B
8717	methadone	enhances	2D6	fluoxetine	D	N07BC02	N06AB03	Drugs used in opioid dependence (N07BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N07BC	N07B	N06AB	N06A
8718	methadone	enhances	2D6	fluvoxamine	C	N07BC02	N06AB08	Drugs used in opioid dependence (N07BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N07BC	N07B	N06AB	N06A
8719	methadone	enhances	2D6	haloperidol	D	N07BC02	N05AD01	Drugs used in opioid dependence (N07BC)	Butyrophenone derivatives (N05AD)	Drugs used in addictive disorders (N07B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N07BC	N07B	N05AD	N05A
8721	methadone	enhances	2D6	imipramine	D	N07BC02	N06AA02	Drugs used in opioid dependence (N07BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	1	0	Serotonin toxicity			N07BC	N07B	N06AA	N06A
8724	methadone	enhances	2D6	metoclopramide	D	N07BC02	A03FA01	Drugs used in opioid dependence (N07BC)	Propulsives (A03FA)	Drugs used in addictive disorders (N07B)	Propulsives (A03F)	0					N07BC	N07B	A03FA	A03F
8725	methadone	enhances	2D6	metoprolol		N07BC02	C07AB02	Drugs used in opioid dependence (N07BC)	Beta blocking agents, selective (C07AB)	Drugs used in addictive disorders (N07B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		N07BC	N07B	C07AB	C07A
8728	methadone	enhances	2D6	nebivolol		N07BC02	C07AB12	Drugs used in opioid dependence (N07BC)	Beta blocking agents, selective (C07AB)	Drugs used in addictive disorders (N07B)	Beta blocking agents (C07A)	0					N07BC	N07B	C07AB	C07A
8729	methadone	enhances	2D6	nortriptyline	D	N07BC02	N06AA10	Drugs used in opioid dependence (N07BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	1					N07BC	N07B	N06AA	N06A
8730	methadone	enhances	2D6	ondansetron	D	N07BC02	A04AA01	Drugs used in opioid dependence (N07BC)	Serotonin (5HT3) antagonists (A04AA)	Drugs used in addictive disorders (N07B)	Antiemetics and antinauseants (A04A)	0	0				N07BC	N07B	A04AA	A04A
8731	methadone	enhances	2D6	oxycodone		N07BC02	N02AA05	Drugs used in opioid dependence (N07BC)	Natural opium alkaloids (N02AA)	Drugs used in addictive disorders (N07B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		N07BC	N07B	N02AA	N02A
8733	methadone	enhances	2D6	paroxetine	D	N07BC02	N06AB05	Drugs used in opioid dependence (N07BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N07BC	N07B	N06AB	N06A
8741	methadone	enhances	2D6	promethazine	D	N07BC02	R06AD02	Drugs used in opioid dependence (N07BC)	Phenothiazine derivatives (R06AD)	Drugs used in addictive disorders (N07B)	Antihistamines for systemic use (R06A)	0					N07BC	N07B	R06AD	R06A
8742	methadone	enhances	2D6	propafenone	D	N07BC02	C01BC03	Drugs used in opioid dependence (N07BC)	Antiarrhythmics, class Ic (C01BC)	Drugs used in addictive disorders (N07B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N07BC	N07B	C01BC	C01B
8743	methadone	enhances	2D6	propranolol		N07BC02	C07AA05	Drugs used in opioid dependence (N07BC)	Beta blocking agents, non-selective (C07AA)	Drugs used in addictive disorders (N07B)	Beta blocking agents (C07A)	0					N07BC	N07B	C07AA	C07A
8744	methadone	enhances	2D6	risperidone	D	N07BC02	N05AX08	Drugs used in opioid dependence (N07BC)	Other antipsychotics (N05AX)	Drugs used in addictive disorders (N07B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N07BC	N07B	N05AX	N05A
8747	methadone	enhances	2D6	tamoxifen	D	N07BC02	L02BA01	Drugs used in opioid dependence (N07BC)	Anti-estrogens (L02BA)	Drugs used in addictive disorders (N07B)	Hormone antagonists and related agents (L02B)	1	1				N07BC	N07B	L02BA	L02B
8748	methadone	enhances	2D6	tetrabenazine	D	N07BC02	N07XX06	Drugs used in opioid dependence (N07BC)	Other nervous system drugs (N07XX)	Drugs used in addictive disorders (N07B)	Other nervous system drugs (N07X)	0					N07BC	N07B	N07XX	N07X
8751	methadone	enhances	2D6	tramadol	D	N07BC02	N02AX02	Drugs used in opioid dependence (N07BC)	Other opioids (N02AX)	Drugs used in addictive disorders (N07B)	Opioids (N02A)	0	1		Reduced analgesic effect		N07BC	N07B	N02AX	N02A
8754	methadone	enhances	2D6	venlafaxine	D	N07BC02	N06AX16	Drugs used in opioid dependence (N07BC)	Other antidepressants (N06AX)	Drugs used in addictive disorders (N07B)	Antidepressants (N06A)	0	0	Serotonin toxicity			N07BC	N07B	N06AX	N06A
8756	methadone	enhances	2D6	zuclopenthixol		N07BC02	N05AF05	Drugs used in opioid dependence (N07BC)	Thioxanthene derivatives (N05AF)	Drugs used in addictive disorders (N07B)	Antipsychotics (N05A)	0					N07BC	N07B	N05AF	N05A
8794	metoclopramide	enhances	2D6	amitriptyline	D	A03FA01	N06AA09	Propulsives (A03FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03F)	Antidepressants (N06A)	1	0	Serotonin toxicity			A03FA	A03F	N06AA	N06A
8799	metoclopramide	enhances	2D6	carvedilol		A03FA01	C07AG02	Propulsives (A03FA)	Alpha and beta blocking agents (C07AG)	Propulsives (A03F)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	112	A03FA	A03F	C07AG	C07A
8800	metoclopramide	enhances	2D6	chlorpheniramine		A03FA01	R06AB04	Propulsives (A03FA)	Substituted alkylamines (R06AB)	Propulsives (A03F)	Antihistamines for systemic use (R06A)	0	0			2784	A03FA	A03F	R06AB	R06A
8801	metoclopramide	enhances	2D6	chlorpromazine	D	A03FA01	N05AA01	Propulsives (A03FA)	Phenothiazines with aliphatic side-chain (N05AA)	Propulsives (A03F)	Antipsychotics (N05A)	0					A03FA	A03F	N05AA	N05A
8802	metoclopramide	enhances	2D6	citalopram	D	A03FA01	N06AB04	Propulsives (A03FA)	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03F)	Antidepressants (N06A)	0	0			3004	A03FA	A03F	N06AB	N06A
8803	metoclopramide	enhances	2D6	clomipramine	D	A03FA01	N06AA04	Propulsives (A03FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03F)	Antidepressants (N06A)	1	0	Serotonin toxicity		2030	A03FA	A03F	N06AA	N06A
8803	metoclopramide	enhances	2D6	clomipramine	D	A03FA01	N06AA04	Propulsives (A03FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03F)	Antidepressants (N06A)	1	0	Serotonin toxicity		2576	A03FA	A03F	N06AA	N06A
8804	metoclopramide	enhances	2D6	clonidine		A03FA01	C02AC01	Propulsives (A03FA)	Imidazoline receptor agonists (C02AC)	Propulsives (A03F)	Antiadrenergic agents, centrally acting (C02A)	1					A03FA	A03F	C02AC	C02A
8809	metoclopramide	enhances	2D6	dextromethorphan		A03FA01	R05DA09	Propulsives (A03FA)	Opium alkaloids and derivatives (R05DA)	Propulsives (A03F)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				A03FA	A03F	R05DA	R05D
8810	metoclopramide	enhances	2D6	donepezil	D	A03FA01	N06DA02	Propulsives (A03FA)	Anticholinesterases (N06DA)	Propulsives (A03F)	Anti-dementia drugs (N06D)	0					A03FA	A03F	N06DA	N06D
8812	metoclopramide	enhances	2D6	duloxetine	D	A03FA01	N06AX21	Propulsives (A03FA)	Other antidepressants (N06AX)	Propulsives (A03F)	Antidepressants (N06A)	0	0	Serotonin toxicity			A03FA	A03F	N06AX	N06A
8815	metoclopramide	enhances	2D6	escitalopram	D	A03FA01	N06AB10	Propulsives (A03FA)	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03F)	Antidepressants (N06A)	0				4738	A03FA	A03F	N06AB	N06A
8816	metoclopramide	enhances	2D6	flecainide	D	A03FA01	C01BC04	Propulsives (A03FA)	Antiarrhythmics, class Ic (C01BC)	Propulsives (A03F)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			A03FA	A03F	C01BC	C01B
8817	metoclopramide	enhances	2D6	fluoxetine	D	A03FA01	N06AB03	Propulsives (A03FA)	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03F)	Antidepressants (N06A)	0	0	Serotonin toxicity			A03FA	A03F	N06AB	N06A
8818	metoclopramide	enhances	2D6	fluvoxamine		A03FA01	N06AB08	Propulsives (A03FA)	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03F)	Antidepressants (N06A)	0	0	Serotonin toxicity			A03FA	A03F	N06AB	N06A
8819	metoclopramide	enhances	2D6	haloperidol	D	A03FA01	N05AD01	Propulsives (A03FA)	Butyrophenone derivatives (N05AD)	Propulsives (A03F)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A03FA	A03F	N05AD	N05A
8821	metoclopramide	enhances	2D6	imipramine	D	A03FA01	N06AA02	Propulsives (A03FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03F)	Antidepressants (N06A)	1	0	Serotonin toxicity			A03FA	A03F	N06AA	N06A
8824	metoclopramide	enhances	2D6	metoprolol		A03FA01	C07AB02	Propulsives (A03FA)	Beta blocking agents, selective (C07AB)	Propulsives (A03F)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	804	A03FA	A03F	C07AB	C07A
8824	metoclopramide	enhances	2D6	metoprolol		A03FA01	C07AB02	Propulsives (A03FA)	Beta blocking agents, selective (C07AB)	Propulsives (A03F)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3004	A03FA	A03F	C07AB	C07A
8827	metoclopramide	enhances	2D6	nebivolol		A03FA01	C07AB12	Propulsives (A03FA)	Beta blocking agents, selective (C07AB)	Propulsives (A03F)	Beta blocking agents (C07A)	0				3530	A03FA	A03F	C07AB	C07A
8828	metoclopramide	enhances	2D6	nortriptyline	D	A03FA01	N06AA10	Propulsives (A03FA)	Non-selective monoamine reuptake inhibitors (N06AA)	Propulsives (A03F)	Antidepressants (N06A)	1					A03FA	A03F	N06AA	N06A
8829	metoclopramide	enhances	2D6	ondansetron	D	A03FA01	A04AA01	Propulsives (A03FA)	Serotonin (5HT3) antagonists (A04AA)	Propulsives (A03F)	Antiemetics and antinauseants (A04A)	0	0				A03FA	A03F	A04AA	A04A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	698	A03FA	A03F	N02AA	N02A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	804	A03FA	A03F	N02AA	N02A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	3712	A03FA	A03F	N02AA	N02A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	3781	A03FA	A03F	N02AA	N02A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4738	A03FA	A03F	N02AA	N02A
8830	metoclopramide	enhances	2D6	oxycodone		A03FA01	N02AA05	Propulsives (A03FA)	Natural opium alkaloids (N02AA)	Propulsives (A03F)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5710	A03FA	A03F	N02AA	N02A
8832	metoclopramide	enhances	2D6	paroxetine	D	A03FA01	N06AB05	Propulsives (A03FA)	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03F)	Antidepressants (N06A)	0	0	Serotonin toxicity			A03FA	A03F	N06AB	N06A
8840	metoclopramide	enhances	2D6	promethazine	D	A03FA01	R06AD02	Propulsives (A03FA)	Phenothiazine derivatives (R06AD)	Propulsives (A03F)	Antihistamines for systemic use (R06A)	0					A03FA	A03F	R06AD	R06A
8841	metoclopramide	enhances	2D6	propafenone	D	A03FA01	C01BC03	Propulsives (A03FA)	Antiarrhythmics, class Ic (C01BC)	Propulsives (A03F)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			A03FA	A03F	C01BC	C01B
8842	metoclopramide	enhances	2D6	propranolol		A03FA01	C07AA05	Propulsives (A03FA)	Beta blocking agents, non-selective (C07AA)	Propulsives (A03F)	Beta blocking agents (C07A)	0					A03FA	A03F	C07AA	C07A
8843	metoclopramide	enhances	2D6	risperidone	D	A03FA01	N05AX08	Propulsives (A03FA)	Other antipsychotics (N05AX)	Propulsives (A03F)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A03FA	A03F	N05AX	N05A
8846	metoclopramide	enhances	2D6	tamoxifen	D	A03FA01	L02BA01	Propulsives (A03FA)	Anti-estrogens (L02BA)	Propulsives (A03F)	Hormone antagonists and related agents (L02B)	1	1				A03FA	A03F	L02BA	L02B
8847	metoclopramide	enhances	2D6	tetrabenazine	D	A03FA01	N07XX06	Propulsives (A03FA)	Other nervous system drugs (N07XX)	Propulsives (A03F)	Other nervous system drugs (N07X)	0					A03FA	A03F	N07XX	N07X
8850	metoclopramide	enhances	2D6	tramadol		A03FA01	N02AX02	Propulsives (A03FA)	Other opioids (N02AX)	Propulsives (A03F)	Opioids (N02A)	0	1		Reduced analgesic effect	662	A03FA	A03F	N02AX	N02A
8850	metoclopramide	enhances	2D6	tramadol		A03FA01	N02AX02	Propulsives (A03FA)	Other opioids (N02AX)	Propulsives (A03F)	Opioids (N02A)	0	1		Reduced analgesic effect	2030	A03FA	A03F	N02AX	N02A
8853	metoclopramide	enhances	2D6	venlafaxine	D	A03FA01	N06AX16	Propulsives (A03FA)	Other antidepressants (N06AX)	Propulsives (A03F)	Antidepressants (N06A)	0	0	Serotonin toxicity			A03FA	A03F	N06AX	N06A
8855	metoclopramide	enhances	2D6	zuclopenthixol		A03FA01	N05AF05	Propulsives (A03FA)	Thioxanthene derivatives (N05AF)	Propulsives (A03F)	Antipsychotics (N05A)	0					A03FA	A03F	N05AF	N05A
8856	metronidazole	enhances	2C9	amitriptyline	D	J01XD01	N06AA09	Imidazole derivatives (J01XD)	Non-selective monoamine reuptake inhibitors (N06AA)	Other antibacterials (J01X)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01XD	J01X	N06AA	N06A
8858	metronidazole	enhances	2C9	capecitabine		J01XD01	L01BC06	Imidazole derivatives (J01XD)	Pyrimidine analogues (L01BC)	Other antibacterials (J01X)	Antimetabolites (L01B)	1					J01XD	J01X	L01BC	L01B
8859	metronidazole	enhances	2C9	celecoxib		J01XD01	M01AH01	Imidazole derivatives (J01XD)	Coxibs (M01AH)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01XD	J01X	M01AH	M01A
8860	metronidazole	enhances	2C9	clopidogrel		J01XD01	B01AC04	Imidazole derivatives (J01XD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antibacterials (J01X)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4111	J01XD	J01X	B01AC	B01A
8860	metronidazole	enhances	2C9	clopidogrel		J01XD01	B01AC04	Imidazole derivatives (J01XD)	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antibacterials (J01X)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4365	J01XD	J01X	B01AC	B01A
8861	metronidazole	enhances	2C9	diclofenac	B	J01XD01	M01AB05	Imidazole derivatives (J01XD)	Acetic acid derivatives and related substances (M01AB)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01XD	J01X	M01AB	M01A
8863	metronidazole	enhances	2C9	fluoxetine	D	J01XD01	N06AB03	Imidazole derivatives (J01XD)	Selective serotonin reuptake inhibitors (N06AB)	Other antibacterials (J01X)	Antidepressants (N06A)	0	0	Serotonin toxicity		1336	J01XD	J01X	N06AB	N06A
8864	metronidazole	enhances	2C9	fluvastatin		J01XD01	C10AA04	Imidazole derivatives (J01XD)	HMG CoA reductase inhibitors (C10AA)	Other antibacterials (J01X)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J01XD	J01X	C10AA	C10A
8865	metronidazole	enhances	2C9	glimepiride	B	J01XD01	A10BB12	Imidazole derivatives (J01XD)	Sulfonylureas (A10BB)	Other antibacterials (J01X)	Blood glucose lowering drugs, excl. insulins (A10B)	0				771	J01XD	J01X	A10BB	A10B
8866	metronidazole	enhances	2C9	glipizide	C	J01XD01	A10BB07	Imidazole derivatives (J01XD)	Sulfonylureas (A10BB)	Other antibacterials (J01X)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J01XD	J01X	A10BB	A10B
8867	metronidazole	enhances	2C9	glyburide	C	J01XD01	A10BB01	Imidazole derivatives (J01XD)	Sulfonylureas (A10BB)	Other antibacterials (J01X)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J01XD	J01X	A10BB	A10B
8868	metronidazole	enhances	2C9	ibuprofen		J01XD01	M01AE01	Imidazole derivatives (J01XD)	Propionic acid derivatives (M01AE)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01XD	J01X	M01AE	M01A
8869	metronidazole	enhances	2C9	irbesartan		J01XD01	C09CA04	Imidazole derivatives (J01XD)	Angiotensin II receptor blockers, plain (C09CA)	Other antibacterials (J01X)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	2869	J01XD	J01X	C09CA	C09C
8869	metronidazole	enhances	2C9	irbesartan		J01XD01	C09CA04	Imidazole derivatives (J01XD)	Angiotensin II receptor blockers, plain (C09CA)	Other antibacterials (J01X)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3056	J01XD	J01X	C09CA	C09C
8872	metronidazole	enhances	2C9	losartan		J01XD01	C09CA01	Imidazole derivatives (J01XD)	Angiotensin II receptor blockers, plain (C09CA)	Other antibacterials (J01X)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3994	J01XD	J01X	C09CA	C09C
8872	metronidazole	enhances	2C9	losartan		J01XD01	C09CA01	Imidazole derivatives (J01XD)	Angiotensin II receptor blockers, plain (C09CA)	Other antibacterials (J01X)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4365	J01XD	J01X	C09CA	C09C
8873	metronidazole	enhances	2C9	meloxicam		J01XD01	M01AC06	Imidazole derivatives (J01XD)	Oxicams (M01AC)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J01XD	J01X	M01AC	M01A
8874	metronidazole	enhances	2C9	naproxen		J01XD01	M01AE02	Imidazole derivatives (J01XD)	Propionic acid derivatives (M01AE)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01XD	J01X	M01AE	M01A
8878	metronidazole	enhances	2C9	phenytoin	B	J01XD01	N03AB02	Imidazole derivatives (J01XD)	Hydantoin derivatives (N03AB)	Other antibacterials (J01X)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J01XD	J01X	N03AB	N03A
8879	metronidazole	enhances	2C9	piroxicam		J01XD01	M01AC01	Imidazole derivatives (J01XD)	Oxicams (M01AC)	Other antibacterials (J01X)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J01XD	J01X	M01AC	M01A
8883	metronidazole	enhances	2C9	tamoxifen	D	J01XD01	L02BA01	Imidazole derivatives (J01XD)	Anti-estrogens (L02BA)	Other antibacterials (J01X)	Hormone antagonists and related agents (L02B)	1	1				J01XD	J01X	L02BA	L02B
8885	metronidazole	enhances	2C9	torasemide	D	J01XD01	C03CA04	Imidazole derivatives (J01XD)	Sulfonamides, plain (C03CA)	Other antibacterials (J01X)	High-ceiling diuretics (C03C)	0	0				J01XD	J01X	C03CA	C03C
8886	metronidazole	enhances	2C9	valproate		J01XD01	N03AG01	Imidazole derivatives (J01XD)	Fatty acid derivatives (N03AG)	Other antibacterials (J01X)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J01XD	J01X	N03AG	N03A
8887	metronidazole	enhances	2C9	venlafaxine	D	J01XD01	N06AX16	Imidazole derivatives (J01XD)	Other antidepressants (N06AX)	Other antibacterials (J01X)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01XD	J01X	N06AX	N06A
8888	metronidazole	enhances	2C9	voriconazole	D	J01XD01	J02AC03	Imidazole derivatives (J01XD)	Triazole derivatives (J02AC)	Other antibacterials (J01X)	Antimycotics for systemic use (J02A)	0	0				J01XD	J01X	J02AC	J02A
8889	metronidazole	enhances	2C9	warfarin	B	J01XD01	B01AA03	Imidazole derivatives (J01XD)	Vitamin K antagonists (B01AA)	Other antibacterials (J01X)	Antithrombotic agents (B01A)	1	0	Bleeding		969	J01XD	J01X	B01AA	B01A
8889	metronidazole	enhances	2C9	warfarin	B	J01XD01	B01AA03	Imidazole derivatives (J01XD)	Vitamin K antagonists (B01AA)	Other antibacterials (J01X)	Antithrombotic agents (B01A)	1	0	Bleeding		7590	J01XD	J01X	B01AA	B01A
9060	midodrine	enhances	2D6	amitriptyline	D	C01CA17	N06AA09	Adrenergic and dopaminergic agents (C01CA)	Non-selective monoamine reuptake inhibitors (N06AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01CA	C01C	N06AA	N06A
9065	midodrine	enhances	2D6	carvedilol		C01CA17	C07AG02	Adrenergic and dopaminergic agents (C01CA)	Alpha and beta blocking agents (C07AG)	Cardiac stimulants excl. cardiac glycosides (C01C)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		C01CA	C01C	C07AG	C07A
9066	midodrine	enhances	2D6	chlorpheniramine		C01CA17	R06AB04	Adrenergic and dopaminergic agents (C01CA)	Substituted alkylamines (R06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antihistamines for systemic use (R06A)	0	0				C01CA	C01C	R06AB	R06A
9067	midodrine	enhances	2D6	chlorpromazine	D	C01CA17	N05AA01	Adrenergic and dopaminergic agents (C01CA)	Phenothiazines with aliphatic side-chain (N05AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antipsychotics (N05A)	0					C01CA	C01C	N05AA	N05A
9068	midodrine	enhances	2D6	citalopram	D	C01CA17	N06AB04	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0			323	C01CA	C01C	N06AB	N06A
9068	midodrine	enhances	2D6	citalopram	D	C01CA17	N06AB04	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0			4206	C01CA	C01C	N06AB	N06A
9069	midodrine	enhances	2D6	clomipramine	D	C01CA17	N06AA04	Adrenergic and dopaminergic agents (C01CA)	Non-selective monoamine reuptake inhibitors (N06AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01CA	C01C	N06AA	N06A
9070	midodrine	enhances	2D6	clonidine		C01CA17	C02AC01	Adrenergic and dopaminergic agents (C01CA)	Imidazoline receptor agonists (C02AC)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antiadrenergic agents, centrally acting (C02A)	1					C01CA	C01C	C02AC	C02A
9075	midodrine	enhances	2D6	dextromethorphan		C01CA17	R05DA09	Adrenergic and dopaminergic agents (C01CA)	Opium alkaloids and derivatives (R05DA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				C01CA	C01C	R05DA	R05D
9076	midodrine	enhances	2D6	donepezil	D	C01CA17	N06DA02	Adrenergic and dopaminergic agents (C01CA)	Anticholinesterases (N06DA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Anti-dementia drugs (N06D)	0					C01CA	C01C	N06DA	N06D
9078	midodrine	enhances	2D6	duloxetine		C01CA17	N06AX21	Adrenergic and dopaminergic agents (C01CA)	Other antidepressants (N06AX)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01CA	C01C	N06AX	N06A
9081	midodrine	enhances	2D6	escitalopram	D	C01CA17	N06AB10	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0				4077	C01CA	C01C	N06AB	N06A
9082	midodrine	enhances	2D6	flecainide	D	C01CA17	C01BC04	Adrenergic and dopaminergic agents (C01CA)	Antiarrhythmics, class Ic (C01BC)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			C01CA	C01C	C01BC	C01B
9083	midodrine	enhances	2D6	fluoxetine	D	C01CA17	N06AB03	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01CA	C01C	N06AB	N06A
9084	midodrine	enhances	2D6	fluvoxamine		C01CA17	N06AB08	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01CA	C01C	N06AB	N06A
9085	midodrine	enhances	2D6	haloperidol	D	C01CA17	N05AD01	Adrenergic and dopaminergic agents (C01CA)	Butyrophenone derivatives (N05AD)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		C01CA	C01C	N05AD	N05A
9087	midodrine	enhances	2D6	imipramine	D	C01CA17	N06AA02	Adrenergic and dopaminergic agents (C01CA)	Non-selective monoamine reuptake inhibitors (N06AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	1	0	Serotonin toxicity			C01CA	C01C	N06AA	N06A
9090	midodrine	enhances	2D6	metoclopramide	D	C01CA17	A03FA01	Adrenergic and dopaminergic agents (C01CA)	Propulsives (A03FA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Propulsives (A03F)	0					C01CA	C01C	A03FA	A03F
9091	midodrine	enhances	2D6	metoprolol		C01CA17	C07AB02	Adrenergic and dopaminergic agents (C01CA)	Beta blocking agents, selective (C07AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		C01CA	C01C	C07AB	C07A
9094	midodrine	enhances	2D6	nebivolol		C01CA17	C07AB12	Adrenergic and dopaminergic agents (C01CA)	Beta blocking agents, selective (C07AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Beta blocking agents (C07A)	0					C01CA	C01C	C07AB	C07A
9095	midodrine	enhances	2D6	nortriptyline	D	C01CA17	N06AA10	Adrenergic and dopaminergic agents (C01CA)	Non-selective monoamine reuptake inhibitors (N06AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	1					C01CA	C01C	N06AA	N06A
9096	midodrine	enhances	2D6	ondansetron	D	C01CA17	A04AA01	Adrenergic and dopaminergic agents (C01CA)	Serotonin (5HT3) antagonists (A04AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antiemetics and antinauseants (A04A)	0	0				C01CA	C01C	A04AA	A04A
9097	midodrine	enhances	2D6	oxycodone		C01CA17	N02AA05	Adrenergic and dopaminergic agents (C01CA)	Natural opium alkaloids (N02AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		C01CA	C01C	N02AA	N02A
9099	midodrine	enhances	2D6	paroxetine	D	C01CA17	N06AB05	Adrenergic and dopaminergic agents (C01CA)	Selective serotonin reuptake inhibitors (N06AB)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01CA	C01C	N06AB	N06A
9107	midodrine	enhances	2D6	promethazine	D	C01CA17	R06AD02	Adrenergic and dopaminergic agents (C01CA)	Phenothiazine derivatives (R06AD)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antihistamines for systemic use (R06A)	0					C01CA	C01C	R06AD	R06A
9108	midodrine	enhances	2D6	propafenone	D	C01CA17	C01BC03	Adrenergic and dopaminergic agents (C01CA)	Antiarrhythmics, class Ic (C01BC)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			C01CA	C01C	C01BC	C01B
9109	midodrine	enhances	2D6	propranolol		C01CA17	C07AA05	Adrenergic and dopaminergic agents (C01CA)	Beta blocking agents, non-selective (C07AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Beta blocking agents (C07A)	0				3733	C01CA	C01C	C07AA	C07A
9109	midodrine	enhances	2D6	propranolol		C01CA17	C07AA05	Adrenergic and dopaminergic agents (C01CA)	Beta blocking agents, non-selective (C07AA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Beta blocking agents (C07A)	0				3735	C01CA	C01C	C07AA	C07A
9110	midodrine	enhances	2D6	risperidone	D	C01CA17	N05AX08	Adrenergic and dopaminergic agents (C01CA)	Other antipsychotics (N05AX)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		C01CA	C01C	N05AX	N05A
9113	midodrine	enhances	2D6	tamoxifen	D	C01CA17	L02BA01	Adrenergic and dopaminergic agents (C01CA)	Anti-estrogens (L02BA)	Cardiac stimulants excl. cardiac glycosides (C01C)	Hormone antagonists and related agents (L02B)	1	1				C01CA	C01C	L02BA	L02B
9114	midodrine	enhances	2D6	tetrabenazine	D	C01CA17	N07XX06	Adrenergic and dopaminergic agents (C01CA)	Other nervous system drugs (N07XX)	Cardiac stimulants excl. cardiac glycosides (C01C)	Other nervous system drugs (N07X)	0					C01CA	C01C	N07XX	N07X
9117	midodrine	enhances	2D6	tramadol		C01CA17	N02AX02	Adrenergic and dopaminergic agents (C01CA)	Other opioids (N02AX)	Cardiac stimulants excl. cardiac glycosides (C01C)	Opioids (N02A)	0	1		Reduced analgesic effect		C01CA	C01C	N02AX	N02A
9120	midodrine	enhances	2D6	venlafaxine	D	C01CA17	N06AX16	Adrenergic and dopaminergic agents (C01CA)	Other antidepressants (N06AX)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antidepressants (N06A)	0	0	Serotonin toxicity			C01CA	C01C	N06AX	N06A
9122	midodrine	enhances	2D6	zuclopenthixol		C01CA17	N05AF05	Adrenergic and dopaminergic agents (C01CA)	Thioxanthene derivatives (N05AF)	Cardiac stimulants excl. cardiac glycosides (C01C)	Antipsychotics (N05A)	0					C01CA	C01C	N05AF	N05A
9544	montelukast	enhances	2C8	repaglinide	B	R03DC03	A10BX02	Leukotriene receptor antagonists (R03DC)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Other systemic drugs for obstructive airway diseases (R03D)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		2073	R03DC	R03D	A10BX	A10B
9546	montelukast	enhances	2C8	sorafenib		R03DC03	L01XE05	Leukotriene receptor antagonists (R03DC)	 (L01XE)	Other systemic drugs for obstructive airway diseases (R03D)	Other antineoplastic agents (L01X)	1					R03DC	R03D	L01XE	L01X
9547	montelukast	enhances	2C8	torasemide		R03DC03	C03CA04	Leukotriene receptor antagonists (R03DC)	Sulfonamides, plain (C03CA)	Other systemic drugs for obstructive airway diseases (R03D)	High-ceiling diuretics (C03C)	0	0				R03DC	R03D	C03CA	C03C
9915	nevirapine	reduces	3A457	alprazolam		J05AG01	N05BA12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05BA	N05B
9916	nevirapine	reduces	2C9,3A457	amitriptyline		J05AG01	N06AA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Non-selective monoamine reuptake inhibitors (N06AA)	Direct acting antivirals (J05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J05AG	J05A	N06AA	N06A
9917	nevirapine	reduces	3A457	amlodipine		J05AG01	C08CA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
9918	nevirapine	reduces	3A457	apixaban		J05AG01	B01AF02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AF	B01A
9922	nevirapine	reduces	3A457	atorvastatin		J05AG01	C10AA05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AG	J05A	C10AA	C10A
9929	nevirapine	reduces	2B6	bupropion		J05AG01	N06AX12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
9932	nevirapine	reduces	2C9	capecitabine		J05AG01	L01BC06	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Pyrimidine analogues (L01BC)	Direct acting antivirals (J05A)	Antimetabolites (L01B)	1					J05AG	J05A	L01BC	L01B
9933	nevirapine	reduces	3A457	carbamazepine	B	J05AG01	N03AF01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Carboxamide derivatives (N03AF)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AF	N03A
9935	nevirapine	reduces	2C9	celecoxib		J05AG01	M01AH01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Coxibs (M01AH)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AH	M01A
9937	nevirapine	reduces	3A457	chlorpheniramine		J05AG01	R06AB04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Substituted alkylamines (R06AB)	Direct acting antivirals (J05A)	Antihistamines for systemic use (R06A)	0	0				J05AG	J05A	R06AB	R06A
9938	nevirapine	reduces	3A457	cilostazol		J05AG01	B01AC23	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AC	B01A
9940	nevirapine	reduces	3A457	citalopram		J05AG01	N06AB04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0				J05AG	J05A	N06AB	N06A
9941	nevirapine	reduces	2B6,3A457	clobazam		J05AG01	N05BA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0					J05AG	J05A	N05BA	N05B
9942	nevirapine	reduces	2C9,3A457	clopidogrel		J05AG01	B01AC04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J05AG	J05A	B01AC	B01A
9946	nevirapine	reduces	3A457	colchicine		J05AG01	M04AC01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Preparations with no effect on uric acid metabolism (M04AC)	Direct acting antivirals (J05A)	Antigout preparations (M04A)	0					J05AG	J05A	M04AC	M04A
9948	nevirapine	reduces	2B6	cyclophosphamide	C	J05AG01	L01AA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Nitrogen mustard analogues (L01AA)	Direct acting antivirals (J05A)	Alkylating agents (L01A)	1	1				J05AG	J05A	L01AA	L01A
9949	nevirapine	reduces	3A457	cyclosporine		J05AG01	L04AD01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AD	L04A
9953	nevirapine	reduces	3A457	deflazacort		J05AG01	H02AB13	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
9954	nevirapine	reduces	3A457	dexamethasone		J05AG01	H02AB02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
9955	nevirapine	reduces	3A457	dextromethorphan		J05AG01	R05DA09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Opium alkaloids and derivatives (R05DA)	Direct acting antivirals (J05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J05AG	J05A	R05DA	R05D
9956	nevirapine	reduces	3A457	diazepam		J05AG01	N05BA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05BA	N05B
9957	nevirapine	reduces	2C9	diclofenac		J05AG01	M01AB05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Acetic acid derivatives and related substances (M01AB)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AB	M01A
9960	nevirapine	reduces	3A457	domperidone		J05AG01	A03FA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propulsives (A03FA)	Direct acting antivirals (J05A)	Propulsives (A03F)	0					J05AG	J05A	A03FA	A03F
9962	nevirapine	reduces	2B6	efavirenz	D	J05AG01	J05AG03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AG	J05A	J05AG	J05A
9967	nevirapine	reduces	3A457	eplerenone		J05AG01	C03DA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Aldosterone antagonists (C03DA)	Direct acting antivirals (J05A)	Potassium-sparing agents (C03D)	0					J05AG	J05A	C03DA	C03D
9969	nevirapine	reduces	3A457	escitalopram		J05AG01	N06AB10	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0					J05AG	J05A	N06AB	N06A
9971	nevirapine	reduces	3A457	felodipine		J05AG01	C08CA02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
9975	nevirapine	reduces	2C9	fluoxetine		J05AG01	N06AB03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AB	N06A
9976	nevirapine	reduces	2C9	fluvastatin		J05AG01	C10AA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AG	J05A	C10AA	C10A
9977	nevirapine	reduces	2C9	glimepiride		J05AG01	A10BB12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J05AG	J05A	A10BB	A10B
9978	nevirapine	reduces	2C9	glipizide		J05AG01	A10BB07	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J05AG	J05A	A10BB	A10B
9979	nevirapine	reduces	2C9	glyburide		J05AG01	A10BB01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonylureas (A10BB)	Direct acting antivirals (J05A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J05AG	J05A	A10BB	A10B
9980	nevirapine	reduces	3A457	haloperidol		J05AG01	N05AD01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Butyrophenone derivatives (N05AD)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AG	J05A	N05AD	N05A
9981	nevirapine	reduces	3A457	hydrocortisone		J05AG01	H02AB09	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AG	J05A	H02AB	H02A
9983	nevirapine	reduces	2C9	ibuprofen		J05AG01	M01AE01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propionic acid derivatives (M01AE)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AE	M01A
9985	nevirapine	reduces	3A457	indacaterol		J05AG01	R03AC18	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AG	J05A	R03AC	R03A
9986	nevirapine	reduces	2C9	irbesartan		J05AG01	C09CA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Angiotensin II receptor blockers, plain (C09CA)	Direct acting antivirals (J05A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		J05AG	J05A	C09CA	C09C
9989	nevirapine	reduces	3A457	ivabradine		J05AG01	C01EB17	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other cardiac preparations (C01EB)	Direct acting antivirals (J05A)	Other cardiac preparations (C01E)	0					J05AG	J05A	C01EB	C01E
9992	nevirapine	reduces	3A457	lansoprazole		J05AG01	A02BC03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AG	J05A	A02BC	A02B
9994	nevirapine	reduces	3A457	lercanidipine		J05AG01	C08CA13	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J05AG	J05A	C08CA	C08C
10000	nevirapine	reduces	2C9	losartan		J05AG01	C09CA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Angiotensin II receptor blockers, plain (C09CA)	Direct acting antivirals (J05A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		J05AG	J05A	C09CA	C09C
10001	nevirapine	reduces	3A457	lovastatin		J05AG01	C10AA02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AG	J05A	C10AA	C10A
10003	nevirapine	reduces	2C9	meloxicam		J05AG01	M01AC06	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Oxicams (M01AC)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J05AG	J05A	M01AC	M01A
10005	nevirapine	reduces	2B6,3A457	methadone	C	J05AG01	N07BC02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in opioid dependence (N07BC)	Direct acting antivirals (J05A)	Drugs used in addictive disorders (N07B)	0	0				J05AG	J05A	N07BC	N07B
10006	nevirapine	reduces	3A457	midazolam		J05AG01	N05CD08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05CD	N05C
10009	nevirapine	reduces	2C9	naproxen		J05AG01	M01AE02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Propionic acid derivatives (M01AE)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AE	M01A
10012	nevirapine	reduces	3A457	nifedipine		J05AG01	C08CA05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7356	J05AG	J05A	C08CA	C08C
10013	nevirapine	reduces	3A457	nisoldipine		J05AG01	C08CA07	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
10014	nevirapine	reduces	3A457	nitrendipine		J05AG01	C08CA08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AG	J05A	C08CA	C08C
10017	nevirapine	reduces	3A457	ondansetron		J05AG01	A04AA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Serotonin (5HT3) antagonists (A04AA)	Direct acting antivirals (J05A)	Antiemetics and antinauseants (A04A)	0	0				J05AG	J05A	A04AA	A04A
10023	nevirapine	reduces	2C9	phenytoin		J05AG01	N03AB02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Hydantoin derivatives (N03AB)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AB	N03A
10026	nevirapine	reduces	2C9	piroxicam		J05AG01	M01AC01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Oxicams (M01AC)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J05AG	J05A	M01AC	M01A
10031	nevirapine	reduces	3A457	propranolol		J05AG01	C07AA05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Beta blocking agents, non-selective (C07AA)	Direct acting antivirals (J05A)	Beta blocking agents (C07A)	0					J05AG	J05A	C07AA	C07A
10032	nevirapine	reduces	3A457	quetiapine		J05AG01	N05AH04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AG	J05A	N05AH	N05A
10036	nevirapine	reduces	3A457	risperidone		J05AG01	N05AX08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antipsychotics (N05AX)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AG	J05A	N05AX	N05A
10037	nevirapine	reduces	3A457	rivaroxaban		J05AG01	B01AF01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AF	B01A
10043	nevirapine	reduces	3A457	salmeterol		J05AG01	R03AC12	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AG	J05A	R03AC	R03A
10044	nevirapine	reduces	2B6	selegiline		J05AG01	N04BD01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Monoamine oxidase B inhibitors (N04BD)	Direct acting antivirals (J05A)	Dopaminergic agents (N04B)	0	0				J05AG	J05A	N04BD	N04B
10046	nevirapine	reduces	3A457	sildenafil		J05AG01	G04BE03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AG	J05A	G04BE	G04B
10047	nevirapine	reduces	3A457	simvastatin		J05AG01	C10AA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AG	J05A	C10AA	C10A
10048	nevirapine	reduces	3A457	sirolimus	C	J05AG01	L04AA10	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Selective immunosuppressants (L04AA)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AA	L04A
10050	nevirapine	reduces	2B6,3A457	sorafenib		J05AG01	L01XE05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AG	J05A	L01XE	L01X
10051	nevirapine	reduces	3A457	sunitinib		J05AG01	L01XE04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AG	J05A	L01XE	L01X
10054	nevirapine	reduces	3A457	tacrolimus	B	J05AG01	L04AD02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AG	J05A	L04AD	L04A
10055	nevirapine	reduces	3A457	tadalafil		J05AG01	G04BE08	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AG	J05A	G04BE	G04B
10056	nevirapine	reduces	2C9,3A457	tamoxifen		J05AG01	L02BA01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Anti-estrogens (L02BA)	Direct acting antivirals (J05A)	Hormone antagonists and related agents (L02B)	1	1				J05AG	J05A	L02BA	L02B
10060	nevirapine	reduces	3A457	testosterone		J05AG01	G03BA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	3-oxoandrosten (4) derivatives (G03BA)	Direct acting antivirals (J05A)	Androgens (G03B)	0					J05AG	J05A	G03BA	G03B
10061	nevirapine	reduces	3A457	ticagrelor		J05AG01	B01AC24	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AG	J05A	B01AC	B01A
10065	nevirapine	reduces	2C9	torasemide		J05AG01	C03CA04	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Sulfonamides, plain (C03CA)	Direct acting antivirals (J05A)	High-ceiling diuretics (C03C)	0	0				J05AG	J05A	C03CA	C03C
10066	nevirapine	reduces	2B6,3A457	tramadol		J05AG01	N02AX02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other opioids (N02AX)	Direct acting antivirals (J05A)	Opioids (N02A)	0	1		Reduced analgesic effect		J05AG	J05A	N02AX	N02A
10067	nevirapine	reduces	3A457	trazodone		J05AG01	N06AX05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
10068	nevirapine	reduces	3A457	triazolam		J05AG01	N05CD05	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AG	J05A	N05CD	N05C
10070	nevirapine	reduces	2C9	valproate		J05AG01	N03AG01	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Fatty acid derivatives (N03AG)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AG	J05A	N03AG	N03A
10076	nevirapine	reduces	2C9,3A457	venlafaxine		J05AG01	N06AX16	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AG	J05A	N06AX	N06A
10080	nevirapine	reduces	2C9	voriconazole		J05AG01	J02AC03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Triazole derivatives (J02AC)	Direct acting antivirals (J05A)	Antimycotics for systemic use (J02A)	0	0				J05AG	J05A	J02AC	J02A
10081	nevirapine	reduces	2C9	warfarin	B	J05AG01	B01AA03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Vitamin K antagonists (B01AA)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	1	0	Bleeding			J05AG	J05A	B01AA	B01A
10083	nevirapine	reduces	3A457	zaleplon		J05AG01	N05CF03	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AG	J05A	N05CF	N05C
10085	nevirapine	reduces	3A457	zolpidem		J05AG01	N05CF02	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AG	J05A	N05CF	N05C
10133	norfloxacin	enhances	3A457	alprazolam		J01MA06	N05BA12	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05BA	N05B
10134	norfloxacin	enhances	3A457	amitriptyline	D	J01MA06	N06AA09	Fluoroquinolones (J01MA)	Non-selective monoamine reuptake inhibitors (N06AA)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	1	0	Serotonin toxicity			J01MA	J01M	N06AA	N06A
10135	norfloxacin	enhances	3A457	amlodipine		J01MA06	C08CA01	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
10136	norfloxacin	enhances	3A457	apixaban		J01MA06	B01AF02	Fluoroquinolones (J01MA)	Direct factor Xa inhibitors (B01AF)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AF	B01A
10140	norfloxacin	enhances	3A457	atorvastatin		J01MA06	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		711	J01MA	J01M	C10AA	C10A
10140	norfloxacin	enhances	3A457	atorvastatin		J01MA06	C10AA05	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2468	J01MA	J01M	C10AA	C10A
10149	norfloxacin	enhances	3A457	carbamazepine		J01MA06	N03AF01	Fluoroquinolones (J01MA)	Carboxamide derivatives (N03AF)	Quinolone antibacterials (J01M)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J01MA	J01M	N03AF	N03A
10153	norfloxacin	enhances	3A457	chlorpheniramine		J01MA06	R06AB04	Fluoroquinolones (J01MA)	Substituted alkylamines (R06AB)	Quinolone antibacterials (J01M)	Antihistamines for systemic use (R06A)	0	0				J01MA	J01M	R06AB	R06A
10154	norfloxacin	enhances	3A457	cilostazol	D	J01MA06	B01AC23	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AC	B01A
10156	norfloxacin	enhances	3A457	citalopram	D	J01MA06	N06AB04	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0				J01MA	J01M	N06AB	N06A
10157	norfloxacin	enhances	3A457	clarithromycin	D	J01MA06	J01FA09	Fluoroquinolones (J01MA)	Macrolides (J01FA)	Quinolone antibacterials (J01M)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J01MA	J01M	J01FA	J01F
10158	norfloxacin	enhances	3A457	clobazam		J01MA06	N05BA09	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0					J01MA	J01M	N05BA	N05B
10159	norfloxacin	enhances	3A457	clopidogrel		J01MA06	B01AC04	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J01MA	J01M	B01AC	B01A
10163	norfloxacin	enhances	3A457	colchicine		J01MA06	M04AC01	Fluoroquinolones (J01MA)	Preparations with no effect on uric acid metabolism (M04AC)	Quinolone antibacterials (J01M)	Antigout preparations (M04A)	0					J01MA	J01M	M04AC	M04A
10166	norfloxacin	enhances	3A457	cyclosporine	B	J01MA06	L04AD01	Fluoroquinolones (J01MA)	Calcineurin inhibitors (L04AD)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01MA	J01M	L04AD	L04A
10170	norfloxacin	enhances	3A457	deflazacort	B	J01MA06	H02AB13	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0					J01MA	J01M	H02AB	H02A
10171	norfloxacin	enhances	3A457	dexamethasone	B	J01MA06	H02AB02	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0					J01MA	J01M	H02AB	H02A
10172	norfloxacin	enhances	3A457	dextromethorphan		J01MA06	R05DA09	Fluoroquinolones (J01MA)	Opium alkaloids and derivatives (R05DA)	Quinolone antibacterials (J01M)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J01MA	J01M	R05DA	R05D
10173	norfloxacin	enhances	3A457	diazepam		J01MA06	N05BA01	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05BA)	Quinolone antibacterials (J01M)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05BA	N05B
10174	norfloxacin	enhances	3A457	diltiazem		J01MA06	C08DB01	Fluoroquinolones (J01MA)	Benzothiazepine derivatives (C08DB)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J01MA	J01M	C08DB	C08D
10177	norfloxacin	enhances	3A457	domperidone	D	J01MA06	A03FA03	Fluoroquinolones (J01MA)	Propulsives (A03FA)	Quinolone antibacterials (J01M)	Propulsives (A03F)	0					J01MA	J01M	A03FA	A03F
10183	norfloxacin	enhances	3A457	eplerenone		J01MA06	C03DA04	Fluoroquinolones (J01MA)	Aldosterone antagonists (C03DA)	Quinolone antibacterials (J01M)	Potassium-sparing agents (C03D)	0					J01MA	J01M	C03DA	C03D
10186	norfloxacin	enhances	3A457	escitalopram	D	J01MA06	N06AB10	Fluoroquinolones (J01MA)	Selective serotonin reuptake inhibitors (N06AB)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0					J01MA	J01M	N06AB	N06A
10187	norfloxacin	enhances	3A457	esomeprazole		J01MA06	A02BC05	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3396	J01MA	J01M	A02BC	A02B
10189	norfloxacin	enhances	3A457	felodipine		J01MA06	C08CA02	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
10193	norfloxacin	enhances	3A457	haloperidol	D	J01MA06	N05AD01	Fluoroquinolones (J01MA)	Butyrophenone derivatives (N05AD)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J01MA	J01M	N05AD	N05A
10194	norfloxacin	enhances	3A457	hydrocortisone	C	J01MA06	H02AB09	Fluoroquinolones (J01MA)	Glucocorticoids (H02AB)	Quinolone antibacterials (J01M)	Corticosteroids for systemic use, plain (H02A)	0					J01MA	J01M	H02AB	H02A
10197	norfloxacin	enhances	3A457	imatinib		J01MA06	L01XE01	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	0	0				J01MA	J01M	L01XE	L01X
10198	norfloxacin	enhances	3A457	indacaterol		J01MA06	R03AC18	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0					J01MA	J01M	R03AC	R03A
10202	norfloxacin	enhances	3A457	ivabradine		J01MA06	C01EB17	Fluoroquinolones (J01MA)	Other cardiac preparations (C01EB)	Quinolone antibacterials (J01M)	Other cardiac preparations (C01E)	0					J01MA	J01M	C01EB	C01E
10204	norfloxacin	enhances	3A457	lansoprazole		J01MA06	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			711	J01MA	J01M	A02BC	A02B
10204	norfloxacin	enhances	3A457	lansoprazole		J01MA06	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1185	J01MA	J01M	A02BC	A02B
10204	norfloxacin	enhances	3A457	lansoprazole		J01MA06	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1469	J01MA	J01M	A02BC	A02B
10204	norfloxacin	enhances	3A457	lansoprazole		J01MA06	A02BC03	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3409	J01MA	J01M	A02BC	A02B
10206	norfloxacin	enhances	3A457	lercanidipine		J01MA06	C08CA13	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J01MA	J01M	C08CA	C08C
10210	norfloxacin	enhances	3A457	lovastatin		J01MA06	C10AA02	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J01MA	J01M	C10AA	C10A
10212	norfloxacin	enhances	3A457	methadone	D	J01MA06	N07BC02	Fluoroquinolones (J01MA)	Drugs used in opioid dependence (N07BC)	Quinolone antibacterials (J01M)	Drugs used in addictive disorders (N07B)	0	0				J01MA	J01M	N07BC	N07B
10213	norfloxacin	enhances	3A457	midazolam		J01MA06	N05CD08	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05CD)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05CD	N05C
10219	norfloxacin	enhances	3A457	nevirapine		J01MA06	J05AG01	Fluoroquinolones (J01MA)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AG	J05A
10220	norfloxacin	enhances	3A457	nifedipine		J01MA06	C08CA05	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2468	J01MA	J01M	C08CA	C08C
10221	norfloxacin	enhances	3A457	nisoldipine		J01MA06	C08CA07	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
10222	norfloxacin	enhances	3A457	nitrendipine		J01MA06	C08CA08	Fluoroquinolones (J01MA)	Dihydropyridine derivatives (C08CA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J01MA	J01M	C08CA	C08C
10224	norfloxacin	enhances	3A457	omeprazole		J01MA06	A02BC01	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J01MA	J01M	A02BC	A02B
10225	norfloxacin	enhances	3A457	ondansetron	D	J01MA06	A04AA01	Fluoroquinolones (J01MA)	Serotonin (5HT3) antagonists (A04AA)	Quinolone antibacterials (J01M)	Antiemetics and antinauseants (A04A)	0	0				J01MA	J01M	A04AA	A04A
10232	norfloxacin	enhances	3A457	pantoprazole		J01MA06	A02BC02	Fluoroquinolones (J01MA)	Proton pump inhibitors (A02BC)	Quinolone antibacterials (J01M)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J01MA	J01M	A02BC	A02B
10239	norfloxacin	enhances	3A457	propranolol		J01MA06	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				1469	J01MA	J01M	C07AA	C07A
10239	norfloxacin	enhances	3A457	propranolol		J01MA06	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				3396	J01MA	J01M	C07AA	C07A
10239	norfloxacin	enhances	3A457	propranolol		J01MA06	C07AA05	Fluoroquinolones (J01MA)	Beta blocking agents, non-selective (C07AA)	Quinolone antibacterials (J01M)	Beta blocking agents (C07A)	0				3409	J01MA	J01M	C07AA	C07A
10240	norfloxacin	enhances	3A457	quetiapine	D	J01MA06	N05AH04	Fluoroquinolones (J01MA)	Diazepines, oxazepines and thiazepines (N05AH)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0					J01MA	J01M	N05AH	N05A
10246	norfloxacin	enhances	3A457	risperidone	D	J01MA06	N05AX08	Fluoroquinolones (J01MA)	Other antipsychotics (N05AX)	Quinolone antibacterials (J01M)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J01MA	J01M	N05AX	N05A
10247	norfloxacin	enhances	3A457	ritonavir	D	J01MA06	J05AE03	Fluoroquinolones (J01MA)	Protease inhibitors (J05AE)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AE	J05A
10248	norfloxacin	enhances	3A457	rivaroxaban		J01MA06	B01AF01	Fluoroquinolones (J01MA)	Direct factor Xa inhibitors (B01AF)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AF	B01A
10254	norfloxacin	enhances	3A457	salmeterol	D	J01MA06	R03AC12	Fluoroquinolones (J01MA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Quinolone antibacterials (J01M)	Adrenergics, inhalants (R03A)	0					J01MA	J01M	R03AC	R03A
10255	norfloxacin	enhances	3A457	saquinavir	D	J01MA06	J05AE01	Fluoroquinolones (J01MA)	Protease inhibitors (J05AE)	Quinolone antibacterials (J01M)	Direct acting antivirals (J05A)	0	0				J01MA	J01M	J05AE	J05A
10257	norfloxacin	enhances	3A457	sildenafil		J01MA06	G04BE03	Fluoroquinolones (J01MA)	Drugs used in erectile dysfunction (G04BE)	Quinolone antibacterials (J01M)	Urologicals (G04B)	0	0				J01MA	J01M	G04BE	G04B
10259	norfloxacin	enhances	3A457	simvastatin		J01MA06	C10AA01	Fluoroquinolones (J01MA)	HMG CoA reductase inhibitors (C10AA)	Quinolone antibacterials (J01M)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J01MA	J01M	C10AA	C10A
10260	norfloxacin	enhances	3A457	sirolimus		J01MA06	L04AA10	Fluoroquinolones (J01MA)	Selective immunosuppressants (L04AA)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01MA	J01M	L04AA	L04A
10262	norfloxacin	enhances	3A457	sorafenib	D	J01MA06	L01XE05	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	1					J01MA	J01M	L01XE	L01X
10263	norfloxacin	enhances	3A457	sunitinib	D	J01MA06	L01XE04	Fluoroquinolones (J01MA)	 (L01XE)	Quinolone antibacterials (J01M)	Other antineoplastic agents (L01X)	1					J01MA	J01M	L01XE	L01X
10265	norfloxacin	enhances	3A457	tacrolimus	D	J01MA06	L04AD02	Fluoroquinolones (J01MA)	Calcineurin inhibitors (L04AD)	Quinolone antibacterials (J01M)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J01MA	J01M	L04AD	L04A
10266	norfloxacin	enhances	3A457	tadalafil		J01MA06	G04BE08	Fluoroquinolones (J01MA)	Drugs used in erectile dysfunction (G04BE)	Quinolone antibacterials (J01M)	Urologicals (G04B)	0	0				J01MA	J01M	G04BE	G04B
10267	norfloxacin	enhances	3A457	tamoxifen	D	J01MA06	L02BA01	Fluoroquinolones (J01MA)	Anti-estrogens (L02BA)	Quinolone antibacterials (J01M)	Hormone antagonists and related agents (L02B)	1	1				J01MA	J01M	L02BA	L02B
10273	norfloxacin	enhances	3A457	testosterone		J01MA06	G03BA03	Fluoroquinolones (J01MA)	3-oxoandrosten (4) derivatives (G03BA)	Quinolone antibacterials (J01M)	Androgens (G03B)	0					J01MA	J01M	G03BA	G03B
10274	norfloxacin	enhances	3A457	ticagrelor		J01MA06	B01AC24	Fluoroquinolones (J01MA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Quinolone antibacterials (J01M)	Antithrombotic agents (B01A)	0					J01MA	J01M	B01AC	B01A
10277	norfloxacin	enhances	3A457	tramadol		J01MA06	N02AX02	Fluoroquinolones (J01MA)	Other opioids (N02AX)	Quinolone antibacterials (J01M)	Opioids (N02A)	0	1		Reduced analgesic effect		J01MA	J01M	N02AX	N02A
10278	norfloxacin	enhances	3A457	trazodone	D	J01MA06	N06AX05	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01MA	J01M	N06AX	N06A
10279	norfloxacin	enhances	3A457	triazolam		J01MA06	N05CD05	Fluoroquinolones (J01MA)	Benzodiazepine derivatives (N05CD)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J01MA	J01M	N05CD	N05C
10286	norfloxacin	enhances	3A457	venlafaxine	D	J01MA06	N06AX16	Fluoroquinolones (J01MA)	Other antidepressants (N06AX)	Quinolone antibacterials (J01M)	Antidepressants (N06A)	0	0	Serotonin toxicity			J01MA	J01M	N06AX	N06A
10287	norfloxacin	enhances	3A457	verapamil		J01MA06	C08DA01	Fluoroquinolones (J01MA)	Phenylalkylamine derivatives (C08DA)	Quinolone antibacterials (J01M)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J01MA	J01M	C08DA	C08D
10291	norfloxacin	enhances	3A457	voriconazole	D	J01MA06	J02AC03	Fluoroquinolones (J01MA)	Triazole derivatives (J02AC)	Quinolone antibacterials (J01M)	Antimycotics for systemic use (J02A)	0	0				J01MA	J01M	J02AC	J02A
10292	norfloxacin	enhances	3A457	zaleplon		J01MA06	N05CF03	Fluoroquinolones (J01MA)	Benzodiazepine related drugs (N05CF)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0					J01MA	J01M	N05CF	N05C
10294	norfloxacin	enhances	3A457	zolpidem		J01MA06	N05CF02	Fluoroquinolones (J01MA)	Benzodiazepine related drugs (N05CF)	Quinolone antibacterials (J01M)	Hypnotics and sedatives (N05C)	0					J01MA	J01M	N05CF	N05C
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	677	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	778	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	893	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1048	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1403	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1601	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2120	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2207	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2256	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2301	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2386	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3405	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3496	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3598	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3707	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3758	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3869	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4351	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4448	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5255	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5365	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5836	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5925	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5998	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6005	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6041	A02BC	A02B	N05BA	N05B
10300	omeprazole	enhances	3A457	alprazolam		A02BC01	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7277	A02BC	A02B	N05BA	N05B
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	50	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	241	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	313	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	331	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	343	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	594	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	612	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	646	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	695	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	709	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	728	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	764	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	893	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	977	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1063	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1086	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1130	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1351	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1353	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1410	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1455	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1475	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1528	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1585	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1620	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2002	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2008	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2054	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2075	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2096	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2105	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2106	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2177	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2197	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2211	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2218	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2245	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2282	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2337	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2471	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2481	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2482	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2484	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2585	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2592	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2615	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2677	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2720	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2782	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2821	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2824	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2849	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2852	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2869	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2896	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2903	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2905	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2942	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3029	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3111	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3125	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3137	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3140	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3176	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3188	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3261	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3296	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3347	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3348	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3350	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3438	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3468	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3477	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3480	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3484	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3497	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3624	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3625	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3639	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3762	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3766	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3775	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3819	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3858	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3872	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3893	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3904	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3918	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3919	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3948	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4011	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4030	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4038	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4078	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4153	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4165	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4210	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4216	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4219	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4222	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4245	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4349	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4395	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4396	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4424	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4500	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4534	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4550	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4552	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4654	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4728	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4778	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4957	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5104	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5176	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5357	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5505	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5544	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5573	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5702	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5757	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5998	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6009	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6054	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6056	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6065	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6148	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6179	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6185	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6221	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6255	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6258	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6285	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7055	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7131	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7234	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7251	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7317	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7578	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7629	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7705	A02BC	A02B	C08CA	C08C
10301	omeprazole	enhances	3A457	amlodipine		A02BC01	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7751	A02BC	A02B	C08CA	C08C
10302	omeprazole	enhances	3A457	apixaban		A02BC01	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7510	A02BC	A02B	B01AF	B01A
10302	omeprazole	enhances	3A457	apixaban		A02BC01	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7638	A02BC	A02B	B01AF	B01A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		65	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		251	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		313	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		316	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		322	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		331	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		560	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		594	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		602	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		618	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		943	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		981	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1016	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1183	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1349	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1385	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1411	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1433	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1455	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1475	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1621	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2197	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2211	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2386	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2387	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2533	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2583	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2878	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2954	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3002	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3029	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3030	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3072	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3193	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3231	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3298	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3350	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3386	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3438	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3456	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3503	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3529	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3595	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3600	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3697	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3734	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3749	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3773	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3814	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3818	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3819	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3834	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3854	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3918	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3963	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3965	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3977	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3992	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4029	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4078	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4202	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4219	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4290	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4439	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4510	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4512	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4536	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4552	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4573	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4641	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4655	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4657	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4664	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4728	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4730	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4867	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5091	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5104	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5107	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5176	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5339	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5383	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5394	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5494	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5527	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5528	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5539	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5540	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5702	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5831	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5858	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5862	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5910	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5998	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6056	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6065	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6095	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6124	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6148	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6195	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6285	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7062	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7154	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7228	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7317	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7494	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7514	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7578	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7594	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7595	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7690	A02BC	A02B	C10AA	C10A
10307	omeprazole	enhances	3A457	atorvastatin		A02BC01	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7753	A02BC	A02B	C10AA	C10A
10320	omeprazole	enhances	3A457	chlorpheniramine		A02BC01	R06AB04	Proton pump inhibitors (A02BC)	Substituted alkylamines (R06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antihistamines for systemic use (R06A)	0	0			5026	A02BC	A02B	R06AB	R06A
10321	omeprazole	enhances	3A457	cilostazol		A02BC01	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				4709	A02BC	A02B	B01AC	B01A
10321	omeprazole	enhances	3A457	cilostazol		A02BC01	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5011	A02BC	A02B	B01AC	B01A
10321	omeprazole	enhances	3A457	cilostazol		A02BC01	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5462	A02BC	A02B	B01AC	B01A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			336	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			600	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			728	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			902	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1009	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1026	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1164	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1267	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1378	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			1581	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2521	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2899	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3298	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3477	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3503	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3656	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			4209	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5462	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5902	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5925	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			6006	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			6244	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			7251	A02BC	A02B	N06AB	N06A
10323	omeprazole	enhances	2C19,3A457	citalopram		A02BC01	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			7721	A02BC	A02B	N06AB	N06A
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			952	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			1455	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			2357	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			3819	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			4208	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5099	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5138	A02BC	A02B	J01FA	J01F
10324	omeprazole	enhances	3A457	clarithromycin		A02BC01	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5805	A02BC	A02B	J01FA	J01F
10325	omeprazole	enhances	2C19	clobazam	B	A02BC01	N05BA09	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0					A02BC	A02B	N05BA	N05B
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	39	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	65	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	249	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	251	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	602	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	646	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	782	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1016	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1198	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1578	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2256	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2386	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2390	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2583	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2653	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2721	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3072	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3225	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3264	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3386	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3438	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3477	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3504	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3597	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3686	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3732	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3818	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3904	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4213	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4439	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4510	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4552	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4561	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4778	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4874	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5636	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5702	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5786	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5890	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5990	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6009	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6054	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6065	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6255	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6282	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7154	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7610	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7721	A02BC	A02B	B01AC	B01A
10326	omeprazole	enhances	2C19,3A457	clopidogrel	C	A02BC01	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7753	A02BC	A02B	B01AC	B01A
10330	omeprazole	enhances	3A457	colchicine		A02BC01	M04AC01	Proton pump inhibitors (A02BC)	Preparations with no effect on uric acid metabolism (M04AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antigout preparations (M04A)	0				3859	A02BC	A02B	M04AC	M04A
10333	omeprazole	enhances	2C19	cyclophosphamide		A02BC01	L01AA01	Proton pump inhibitors (A02BC)	Nitrogen mustard analogues (L01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Alkylating agents (L01A)	1	1			2049	A02BC	A02B	L01AA	L01A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		1433	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		2659	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		2706	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		3166	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		4383	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		4730	A02BC	A02B	L04AD	L04A
10334	omeprazole	enhances	3A457	cyclosporine		A02BC01	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		5484	A02BC	A02B	L04AD	L04A
10337	omeprazole	enhances	3A457	deflazacort		A02BC01	H02AB13	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7086	A02BC	A02B	H02AB	H02A
10337	omeprazole	enhances	3A457	deflazacort		A02BC01	H02AB13	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7579	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				900	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				1378	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				1408	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2002	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2132	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2390	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				2484	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3574	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3712	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3758	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3963	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				4977	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5268	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5808	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5903	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				6255	A02BC	A02B	H02AB	H02A
10338	omeprazole	enhances	3A457	dexamethasone		A02BC01	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7367	A02BC	A02B	H02AB	H02A
10339	omeprazole	enhances	3A457	dextromethorphan		A02BC01	R05DA09	Proton pump inhibitors (A02BC)	Opium alkaloids and derivatives (R05DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				A02BC	A02B	R05DA	R05D
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2823	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3127	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3342	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3359	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3530	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3732	A02BC	A02B	N05BA	N05B
10340	omeprazole	enhances	2C19,3A457	diazepam	B	A02BC01	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3792	A02BC	A02B	N05BA	N05B
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		171	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		620	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		782	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		788	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1027	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1378	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1400	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1456	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2227	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2256	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2285	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2525	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2659	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2937	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2947	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3022	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3111	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3386	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3504	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3693	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4005	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4086	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4111	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4367	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4613	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4641	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4733	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4884	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5654	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5752	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5902	A02BC	A02B	C08DB	C08D
10341	omeprazole	enhances	3A457	diltiazem		A02BC01	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5903	A02BC	A02B	C08DB	C08D
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				93	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				194	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				598	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				821	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2534	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2554	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2565	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2689	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2727	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2824	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				2869	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3345	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3351	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3362	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3401	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3475	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3492	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3547	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3606	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3656	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3693	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3698	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3934	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4165	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4520	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4977	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				5175	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				5488	A02BC	A02B	A03FA	A03F
10344	omeprazole	enhances	3A457	domperidone		A02BC01	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				7685	A02BC	A02B	A03FA	A03F
10347	omeprazole	enhances	3A457	eplerenone		A02BC01	C03DA04	Proton pump inhibitors (A02BC)	Aldosterone antagonists (C03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Potassium-sparing agents (C03D)	0				4957	A02BC	A02B	C03DA	C03D
10347	omeprazole	enhances	3A457	eplerenone		A02BC01	C03DA04	Proton pump inhibitors (A02BC)	Aldosterone antagonists (C03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Potassium-sparing agents (C03D)	0				5732	A02BC	A02B	C03DA	C03D
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1237	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2061	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2120	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2482	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2501	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2653	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3072	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3166	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3453	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3782	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3834	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4077	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4323	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4351	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5365	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5381	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7086	A02BC	A02B	N06AB	N06A
10350	omeprazole	enhances	2C19,3A457	escitalopram		A02BC01	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7495	A02BC	A02B	N06AB	N06A
10351	omeprazole	enhances	2C19,3A457	esomeprazole		A02BC01	A02BC05	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					A02BC	A02B	A02BC	A02B
10352	omeprazole	enhances	3A457	felodipine		A02BC01	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2387	A02BC	A02B	C08CA	C08C
10352	omeprazole	enhances	3A457	felodipine		A02BC01	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3989	A02BC	A02B	C08CA	C08C
10352	omeprazole	enhances	3A457	felodipine		A02BC01	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4536	A02BC	A02B	C08CA	C08C
10357	omeprazole	enhances	3A457	hydrocortisone		A02BC01	H02AB09	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0					A02BC	A02B	H02AB	H02A
10360	omeprazole	enhances	3A457	imatinib		A02BC01	L01XE01	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	0	0			819	A02BC	A02B	L01XE	L01X
10361	omeprazole	enhances	3A457	indacaterol		A02BC01	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4828	A02BC	A02B	R03AC	R03A
10361	omeprazole	enhances	3A457	indacaterol		A02BC01	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7062	A02BC	A02B	R03AC	R03A
10361	omeprazole	enhances	3A457	indacaterol		A02BC01	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7381	A02BC	A02B	R03AC	R03A
10363	omeprazole	enhances	2C19	indometacin		A02BC01	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				7144	A02BC	A02B	M01AB	M01A
10366	omeprazole	enhances	3A457	ivabradine		A02BC01	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				1381	A02BC	A02B	C01EB	C01E
10366	omeprazole	enhances	3A457	ivabradine		A02BC01	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				5528	A02BC	A02B	C01EB	C01E
10369	omeprazole	enhances	2C19,3A457	lansoprazole		A02BC01	A02BC03	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1578	A02BC	A02B	A02BC	A02B
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				138	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				958	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1527	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2026	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2720	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2854	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3090	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3773	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3789	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3906	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4005	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4290	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				4664	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5011	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5104	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5367	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5925	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5990	A02BC	A02B	C08CA	C08C
10371	omeprazole	enhances	3A457	lercanidipine		A02BC01	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				7482	A02BC	A02B	C08CA	C08C
10375	omeprazole	enhances	3A457	lovastatin		A02BC01	C10AA02	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3858	A02BC	A02B	C10AA	C10A
10378	omeprazole	enhances	3A457	methadone		A02BC01	N07BC02	Proton pump inhibitors (A02BC)	Drugs used in opioid dependence (N07BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs used in addictive disorders (N07B)	0	0				A02BC	A02B	N07BC	N07B
10380	omeprazole	enhances	3A457	midazolam		A02BC01	N05CD08	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A02BC	A02B	N05CD	N05C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	120	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	607	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1054	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1169	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1216	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1450	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1623	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2280	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2840	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3231	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3254	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3543	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3813	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4509	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4785	A02BC	A02B	C08CA	C08C
10387	omeprazole	enhances	3A457	nifedipine		A02BC01	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7154	A02BC	A02B	C08CA	C08C
10389	omeprazole	enhances	3A457	nisoldipine		A02BC01	C08CA07	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5091	A02BC	A02B	C08CA	C08C
10390	omeprazole	enhances	3A457	nitrendipine		A02BC01	C08CA08	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A02BC	A02B	C08CA	C08C
10398	omeprazole	enhances	2C19,3A457	pantoprazole		A02BC01	A02BC02	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3535	A02BC	A02B	A02BC	A02B
10398	omeprazole	enhances	2C19,3A457	pantoprazole		A02BC01	A02BC02	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5505	A02BC	A02B	A02BC	A02B
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	72	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	203	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	336	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	817	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1378	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1412	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2232	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2390	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3166	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3525	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3591	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4667	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5339	A02BC	A02B	N03AA	N03A
10400	omeprazole	enhances	2C19	phenobarbital		A02BC01	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5517	A02BC	A02B	N03AA	N03A
10401	omeprazole	enhances	2C19	phenytoin	B	A02BC01	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3166	A02BC	A02B	N03AB	N03A
10405	omeprazole	enhances	2C19	primidone		A02BC01	N03AA03	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	0				2132	A02BC	A02B	N03AA	N03A
10405	omeprazole	enhances	2C19	primidone		A02BC01	N03AA03	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	0				2585	A02BC	A02B	N03AA	N03A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				602	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				1237	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				1597	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				2505	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				2877	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3310	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3458	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4910	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				5125	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7204	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7252	A02BC	A02B	N05AH	N05A
10408	omeprazole	enhances	3A457	quetiapine		A02BC01	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7317	A02BC	A02B	N05AH	N05A
10414	omeprazole	enhances	3A457	risperidone		A02BC01	N05AX08	Proton pump inhibitors (A02BC)	Other antipsychotics (N05AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	172	A02BC	A02B	N05AX	N05A
10415	omeprazole	enhances	3A457	ritonavir		A02BC01	J05AE03	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0				A02BC	A02B	J05AE	J05A
10416	omeprazole	enhances	3A457	rivaroxaban		A02BC01	B01AF01	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5925	A02BC	A02B	B01AF	B01A
10416	omeprazole	enhances	3A457	rivaroxaban		A02BC01	B01AF01	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				6041	A02BC	A02B	B01AF	B01A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				40	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				143	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				569	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				631	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				728	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1048	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1349	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1421	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1456	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1565	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1626	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2026	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2197	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2199	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2507	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2717	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2817	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2854	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2942	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2972	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3026	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3150	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3157	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3359	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3503	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3624	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3693	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3752	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3845	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3887	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4202	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4203	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4213	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4216	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4222	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4291	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4305	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4415	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4416	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4485	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4514	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4634	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4656	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4657	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4991	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5344	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5622	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5902	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6006	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6068	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6146	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6190	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6221	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6223	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6238	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7086	A02BC	A02B	R03AC	R03A
10420	omeprazole	enhances	3A457	salmeterol		A02BC01	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7494	A02BC	A02B	R03AC	R03A
10421	omeprazole	enhances	3A457	saquinavir	D	A02BC01	J05AE01	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0				A02BC	A02B	J05AE	J05A
10423	omeprazole	enhances	3A457	sildenafil		A02BC01	G04BE03	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0				A02BC	A02B	G04BE	G04B
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		20	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		51	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		135	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		171	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		172	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		275	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		612	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		620	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		677	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		728	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		922	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		977	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1026	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1057	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1063	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1169	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1198	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1326	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1378	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1403	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1411	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1527	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1542	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1578	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1585	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1620	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1623	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1641	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2207	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2233	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2280	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2285	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2482	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2596	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2660	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2677	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2721	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2822	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2852	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2902	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2935	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3022	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3264	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3305	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3343	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3484	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3494	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3497	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3543	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3631	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3689	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3732	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3792	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4085	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4125	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4165	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4221	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4349	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4395	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4448	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4509	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4667	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4709	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4756	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4837	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4953	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4977	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5381	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5462	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5484	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5485	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5544	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5573	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5690	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5699	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5737	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5786	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5878	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5932	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5990	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6019	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6041	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6049	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6054	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6255	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6258	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7055	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7233	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7234	A02BC	A02B	C10AA	C10A
10425	omeprazole	enhances	3A457	simvastatin		A02BC01	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7705	A02BC	A02B	C10AA	C10A
10426	omeprazole	enhances	3A457	sirolimus		A02BC01	L04AA10	Proton pump inhibitors (A02BC)	Selective immunosuppressants (L04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A02BC	A02B	L04AA	L04A
10428	omeprazole	enhances	3A457	sorafenib		A02BC01	L01XE05	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1				4315	A02BC	A02B	L01XE	L01X
10429	omeprazole	enhances	3A457	sunitinib		A02BC01	L01XE04	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1					A02BC	A02B	L01XE	L01X
10431	omeprazole	enhances	3A457	tacrolimus	B	A02BC01	L04AD02	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		1455	A02BC	A02B	L04AD	L04A
10431	omeprazole	enhances	3A457	tacrolimus	B	A02BC01	L04AD02	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		4868	A02BC	A02B	L04AD	L04A
10432	omeprazole	enhances	3A457	tadalafil		A02BC01	G04BE08	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0				A02BC	A02B	G04BE	G04B
10433	omeprazole	enhances	3A457	tamoxifen		A02BC01	L02BA01	Proton pump inhibitors (A02BC)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1			343	A02BC	A02B	L02BA	L02B
10433	omeprazole	enhances	3A457	tamoxifen		A02BC01	L02BA01	Proton pump inhibitors (A02BC)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1			1183	A02BC	A02B	L02BA	L02B
10439	omeprazole	enhances	3A457	testosterone		A02BC01	G03BA03	Proton pump inhibitors (A02BC)	3-oxoandrosten (4) derivatives (G03BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Androgens (G03B)	0				728	A02BC	A02B	G03BA	G03B
10440	omeprazole	enhances	3A457	ticagrelor		A02BC01	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				6195	A02BC	A02B	B01AC	B01A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	194	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	728	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1170	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1216	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1349	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1350	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1484	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2277	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2281	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2282	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2525	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2717	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2778	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3480	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3597	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3734	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4188	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4315	A02BC	A02B	N02AX	N02A
10443	omeprazole	enhances	3A457	tramadol		A02BC01	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4778	A02BC	A02B	N02AX	N02A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		90	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		607	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1258	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1378	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2168	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2476	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2727	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2822	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2877	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3466	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4378	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4383	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4613	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5488	A02BC	A02B	N06AX	N06A
10444	omeprazole	enhances	3A457	trazodone		A02BC01	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7251	A02BC	A02B	N06AX	N06A
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	275	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	594	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1033	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1048	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1475	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2168	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3724	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3734	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3819	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4830	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7408	A02BC	A02B	N05CD	N05C
10445	omeprazole	enhances	3A457	triazolam		A02BC01	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7424	A02BC	A02B	N05CD	N05C
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1255	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2208	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2386	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5365	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6220	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7424	A02BC	A02B	N06AX	N06A
10452	omeprazole	enhances	2C19,3A457	venlafaxine		A02BC01	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7705	A02BC	A02B	N06AX	N06A
10456	omeprazole	enhances	2C19,3A457	voriconazole	B	A02BC01	J02AC03	Proton pump inhibitors (A02BC)	Triazole derivatives (J02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antimycotics for systemic use (J02A)	0	0				A02BC	A02B	J02AC	J02A
10457	omeprazole	enhances	3A457	zaleplon		A02BC01	N05CF03	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0					A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				43	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				618	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				1086	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				1100	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				1157	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				2132	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				2351	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				2352	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3058	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3263	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3484	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3528	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3624	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3814	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4331	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4349	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4655	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5213	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5998	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				7387	A02BC	A02B	N05CF	N05C
10459	omeprazole	enhances	3A457	zolpidem		A02BC01	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				7559	A02BC	A02B	N05CF	N05C
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			155	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			194	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			728	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			871	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			981	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			1057	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			1157	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			1350	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			1484	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2008	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2132	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2382	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2386	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2387	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2432	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2554	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2717	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			2817	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			3308	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			3480	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			3555	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			3671	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4004	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4174	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4188	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4209	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4227	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4416	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4417	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4656	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4706	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4955	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			4977	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5028	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5268	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5460	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5505	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5548	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5699	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5834	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5862	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5932	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			5998	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7144	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7248	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7277	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7317	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7367	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7408	A02BC	A02B	N02BE	N02B
10460	omeprazole	reduces	1A2	acetaminophen		A02BC01	N02BE01	Proton pump inhibitors (A02BC)	Anilides (N02BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other analgesics and antipyretics (N02B)	0	0			7424	A02BC	A02B	N02BE	N02B
10462	omeprazole	reduces	1A2	clozapine	C	A02BC01	N05AH02	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7387	A02BC	A02B	N05AH	N05A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		103	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		728	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1027	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1048	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2283	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4520	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6185	A02BC	A02B	N06AX	N06A
10464	omeprazole	reduces	1A2	duloxetine		A02BC01	N06AX21	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7317	A02BC	A02B	N06AX	N06A
10465	omeprazole	reduces	1A2	fluvoxamine		A02BC01	N06AB08	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A02BC	A02B	N06AB	N06A
10468	omeprazole	reduces	1A2	naproxen		A02BC01	M01AE02	Proton pump inhibitors (A02BC)	Propionic acid derivatives (M01AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				A02BC	A02B	M01AE	M01A
10469	omeprazole	reduces	1A2	olanzapine		A02BC01	N05AH03	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	970	A02BC	A02B	N05AH	N05A
10469	omeprazole	reduces	1A2	olanzapine		A02BC01	N05AH03	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2617	A02BC	A02B	N05AH	N05A
10472	omeprazole	reduces	1A2	riluzole		A02BC01	N07XX02	Proton pump inhibitors (A02BC)	Other nervous system drugs (N07XX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other nervous system drugs (N07X)	0	0				A02BC	A02B	N07XX	N07X
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			297	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			569	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2211	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2829	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2942	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			3186	A02BC	A02B	R03DA	R03D
10475	omeprazole	reduces	1A2	theophylline	B	A02BC01	R03DA04	Proton pump inhibitors (A02BC)	Xanthines (R03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			4038	A02BC	A02B	R03DA	R03D
10476	omeprazole	reduces	1A2	tizanidine		A02BC01	M03BX02	Proton pump inhibitors (A02BC)	Other centrally acting agents (M03BX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Muscle relaxants, centrally acting agents (M03B)	1	0				A02BC	A02B	M03BX	M03B
10477	omeprazole	reduces	1A2	triamterene		A02BC01	C03DB02	Proton pump inhibitors (A02BC)	Other potassium-sparing agents (C03DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			A02BC	A02B	C03DB	C03D
10682	oxcarbazepine	reduces	3A457	alprazolam		N03AF02	N05BA12	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05BA	N05B
10683	oxcarbazepine	reduces	3A457	amitriptyline		N03AF02	N06AA09	Carboxamide derivatives (N03AF)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AF	N03A	N06AA	N06A
10684	oxcarbazepine	reduces	3A457	amlodipine		N03AF02	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3987	N03AF	N03A	C08CA	C08C
10684	oxcarbazepine	reduces	3A457	amlodipine		N03AF02	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4500	N03AF	N03A	C08CA	C08C
10684	oxcarbazepine	reduces	3A457	amlodipine		N03AF02	C08CA01	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7443	N03AF	N03A	C08CA	C08C
10685	oxcarbazepine	reduces	3A457	apixaban		N03AF02	B01AF02	Carboxamide derivatives (N03AF)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AF	B01A
10689	oxcarbazepine	reduces	3A457	atorvastatin	B	N03AF02	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2996	N03AF	N03A	C10AA	C10A
10689	oxcarbazepine	reduces	3A457	atorvastatin	B	N03AF02	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4029	N03AF	N03A	C10AA	C10A
10689	oxcarbazepine	reduces	3A457	atorvastatin	B	N03AF02	C10AA05	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7443	N03AF	N03A	C10AA	C10A
10698	oxcarbazepine	reduces	3A457	carbamazepine	B	N03AF02	N03AF01	Carboxamide derivatives (N03AF)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N03AF	N03A	N03AF	N03A
10702	oxcarbazepine	reduces	3A457	chlorpheniramine		N03AF02	R06AB04	Carboxamide derivatives (N03AF)	Substituted alkylamines (R06AB)	Antiepileptics (N03A)	Antihistamines for systemic use (R06A)	0	0				N03AF	N03A	R06AB	R06A
10703	oxcarbazepine	reduces	3A457	cilostazol		N03AF02	B01AC23	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AC	B01A
10705	oxcarbazepine	reduces	3A457	citalopram	C	N03AF02	N06AB04	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0				N03AF	N03A	N06AB	N06A
10706	oxcarbazepine	reduces	3A457	clarithromycin		N03AF02	J01FA09	Carboxamide derivatives (N03AF)	Macrolides (J01FA)	Antiepileptics (N03A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				N03AF	N03A	J01FA	J01F
10707	oxcarbazepine	reduces	3A457	clobazam		N03AF02	N05BA09	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0					N03AF	N03A	N05BA	N05B
10708	oxcarbazepine	reduces	3A457	clopidogrel	B	N03AF02	B01AC04	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4326	N03AF	N03A	B01AC	B01A
10712	oxcarbazepine	reduces	3A457	colchicine		N03AF02	M04AC01	Carboxamide derivatives (N03AF)	Preparations with no effect on uric acid metabolism (M04AC)	Antiepileptics (N03A)	Antigout preparations (M04A)	0				1196	N03AF	N03A	M04AC	M04A
10715	oxcarbazepine	reduces	3A457	cyclosporine	C	N03AF02	L04AD01	Carboxamide derivatives (N03AF)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AD	L04A
10719	oxcarbazepine	reduces	3A457	deflazacort		N03AF02	H02AB13	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AF	N03A	H02AB	H02A
10720	oxcarbazepine	reduces	3A457	dexamethasone		N03AF02	H02AB02	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AF	N03A	H02AB	H02A
10721	oxcarbazepine	reduces	3A457	dextromethorphan		N03AF02	R05DA09	Carboxamide derivatives (N03AF)	Opium alkaloids and derivatives (R05DA)	Antiepileptics (N03A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N03AF	N03A	R05DA	R05D
10722	oxcarbazepine	reduces	3A457	diazepam		N03AF02	N05BA01	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05BA	N05B
10723	oxcarbazepine	reduces	3A457	diltiazem		N03AF02	C08DB01	Carboxamide derivatives (N03AF)	Benzothiazepine derivatives (C08DB)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N03AF	N03A	C08DB	C08D
10726	oxcarbazepine	reduces	3A457	domperidone		N03AF02	A03FA03	Carboxamide derivatives (N03AF)	Propulsives (A03FA)	Antiepileptics (N03A)	Propulsives (A03F)	0					N03AF	N03A	A03FA	A03F
10732	oxcarbazepine	reduces	3A457	eplerenone		N03AF02	C03DA04	Carboxamide derivatives (N03AF)	Aldosterone antagonists (C03DA)	Antiepileptics (N03A)	Potassium-sparing agents (C03D)	0					N03AF	N03A	C03DA	C03D
10735	oxcarbazepine	reduces	3A457	escitalopram	C	N03AF02	N06AB10	Carboxamide derivatives (N03AF)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0					N03AF	N03A	N06AB	N06A
10736	oxcarbazepine	reduces	3A457	esomeprazole		N03AF02	A02BC05	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					N03AF	N03A	A02BC	A02B
10738	oxcarbazepine	reduces	3A457	felodipine	B	N03AF02	C08CA02	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4326	N03AF	N03A	C08CA	C08C
10742	oxcarbazepine	reduces	3A457	haloperidol		N03AF02	N05AD01	Carboxamide derivatives (N03AF)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N03AF	N03A	N05AD	N05A
10743	oxcarbazepine	reduces	3A457	hydrocortisone		N03AF02	H02AB09	Carboxamide derivatives (N03AF)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AF	N03A	H02AB	H02A
10746	oxcarbazepine	reduces	3A457	imatinib	D	N03AF02	L01XE01	Carboxamide derivatives (N03AF)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	0	0				N03AF	N03A	L01XE	L01X
10747	oxcarbazepine	reduces	3A457	indacaterol		N03AF02	R03AC18	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0					N03AF	N03A	R03AC	R03A
10751	oxcarbazepine	reduces	3A457	ivabradine		N03AF02	C01EB17	Carboxamide derivatives (N03AF)	Other cardiac preparations (C01EB)	Antiepileptics (N03A)	Other cardiac preparations (C01E)	0					N03AF	N03A	C01EB	C01E
10753	oxcarbazepine	reduces	3A457	lansoprazole		N03AF02	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1196	N03AF	N03A	A02BC	A02B
10753	oxcarbazepine	reduces	3A457	lansoprazole		N03AF02	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1231	N03AF	N03A	A02BC	A02B
10753	oxcarbazepine	reduces	3A457	lansoprazole		N03AF02	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2996	N03AF	N03A	A02BC	A02B
10753	oxcarbazepine	reduces	3A457	lansoprazole		N03AF02	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3841	N03AF	N03A	A02BC	A02B
10753	oxcarbazepine	reduces	3A457	lansoprazole		N03AF02	A02BC03	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4149	N03AF	N03A	A02BC	A02B
10755	oxcarbazepine	reduces	3A457	lercanidipine		N03AF02	C08CA13	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N03AF	N03A	C08CA	C08C
10759	oxcarbazepine	reduces	3A457	lovastatin	D	N03AF02	C10AA02	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3757	N03AF	N03A	C10AA	C10A
10761	oxcarbazepine	reduces	3A457	methadone		N03AF02	N07BC02	Carboxamide derivatives (N03AF)	Drugs used in opioid dependence (N07BC)	Antiepileptics (N03A)	Drugs used in addictive disorders (N07B)	0	0				N03AF	N03A	N07BC	N07B
10762	oxcarbazepine	reduces	3A457	midazolam		N03AF02	N05CD08	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05CD	N05C
10768	oxcarbazepine	reduces	3A457	nevirapine		N03AF02	J05AG01	Carboxamide derivatives (N03AF)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AF	N03A	J05AG	J05A
10769	oxcarbazepine	reduces	3A457	nifedipine		N03AF02	C08CA05	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
10770	oxcarbazepine	reduces	3A457	nisoldipine		N03AF02	C08CA07	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
10771	oxcarbazepine	reduces	3A457	nitrendipine		N03AF02	C08CA08	Carboxamide derivatives (N03AF)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AF	N03A	C08CA	C08C
10773	oxcarbazepine	reduces	3A457	omeprazole		N03AF02	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4029	N03AF	N03A	A02BC	A02B
10773	oxcarbazepine	reduces	3A457	omeprazole		N03AF02	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4500	N03AF	N03A	A02BC	A02B
10773	oxcarbazepine	reduces	3A457	omeprazole		N03AF02	A02BC01	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4667	N03AF	N03A	A02BC	A02B
10774	oxcarbazepine	reduces	3A457	ondansetron		N03AF02	A04AA01	Carboxamide derivatives (N03AF)	Serotonin (5HT3) antagonists (A04AA)	Antiepileptics (N03A)	Antiemetics and antinauseants (A04A)	0	0				N03AF	N03A	A04AA	A04A
10781	oxcarbazepine	reduces	3A457	pantoprazole		N03AF02	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4029	N03AF	N03A	A02BC	A02B
10781	oxcarbazepine	reduces	3A457	pantoprazole		N03AF02	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4326	N03AF	N03A	A02BC	A02B
10781	oxcarbazepine	reduces	3A457	pantoprazole		N03AF02	A02BC02	Carboxamide derivatives (N03AF)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7443	N03AF	N03A	A02BC	A02B
10788	oxcarbazepine	reduces	3A457	propranolol		N03AF02	C07AA05	Carboxamide derivatives (N03AF)	Beta blocking agents, non-selective (C07AA)	Antiepileptics (N03A)	Beta blocking agents (C07A)	0					N03AF	N03A	C07AA	C07A
10789	oxcarbazepine	reduces	3A457	quetiapine		N03AF02	N05AH04	Carboxamide derivatives (N03AF)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0					N03AF	N03A	N05AH	N05A
10795	oxcarbazepine	reduces	3A457	risperidone		N03AF02	N05AX08	Carboxamide derivatives (N03AF)	Other antipsychotics (N05AX)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N03AF	N03A	N05AX	N05A
10796	oxcarbazepine	reduces	3A457	ritonavir		N03AF02	J05AE03	Carboxamide derivatives (N03AF)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AF	N03A	J05AE	J05A
10797	oxcarbazepine	reduces	3A457	rivaroxaban		N03AF02	B01AF01	Carboxamide derivatives (N03AF)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AF	B01A
10803	oxcarbazepine	reduces	3A457	salmeterol		N03AF02	R03AC12	Carboxamide derivatives (N03AF)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				3987	N03AF	N03A	R03AC	R03A
10804	oxcarbazepine	reduces	3A457	saquinavir		N03AF02	J05AE01	Carboxamide derivatives (N03AF)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AF	N03A	J05AE	J05A
10806	oxcarbazepine	reduces	3A457	sildenafil		N03AF02	G04BE03	Carboxamide derivatives (N03AF)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AF	N03A	G04BE	G04B
10808	oxcarbazepine	reduces	3A457	simvastatin	B	N03AF02	C10AA01	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3987	N03AF	N03A	C10AA	C10A
10808	oxcarbazepine	reduces	3A457	simvastatin	B	N03AF02	C10AA01	Carboxamide derivatives (N03AF)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4667	N03AF	N03A	C10AA	C10A
10809	oxcarbazepine	reduces	3A457	sirolimus		N03AF02	L04AA10	Carboxamide derivatives (N03AF)	Selective immunosuppressants (L04AA)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AA	L04A
10811	oxcarbazepine	reduces	3A457	sorafenib		N03AF02	L01XE05	Carboxamide derivatives (N03AF)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AF	N03A	L01XE	L01X
10812	oxcarbazepine	reduces	3A457	sunitinib		N03AF02	L01XE04	Carboxamide derivatives (N03AF)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AF	N03A	L01XE	L01X
10814	oxcarbazepine	reduces	3A457	tacrolimus		N03AF02	L04AD02	Carboxamide derivatives (N03AF)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AF	N03A	L04AD	L04A
10815	oxcarbazepine	reduces	3A457	tadalafil		N03AF02	G04BE08	Carboxamide derivatives (N03AF)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AF	N03A	G04BE	G04B
10816	oxcarbazepine	reduces	3A457	tamoxifen		N03AF02	L02BA01	Carboxamide derivatives (N03AF)	Anti-estrogens (L02BA)	Antiepileptics (N03A)	Hormone antagonists and related agents (L02B)	1	1				N03AF	N03A	L02BA	L02B
10822	oxcarbazepine	reduces	3A457	testosterone		N03AF02	G03BA03	Carboxamide derivatives (N03AF)	3-oxoandrosten (4) derivatives (G03BA)	Antiepileptics (N03A)	Androgens (G03B)	0					N03AF	N03A	G03BA	G03B
10823	oxcarbazepine	reduces	3A457	ticagrelor		N03AF02	B01AC24	Carboxamide derivatives (N03AF)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AF	N03A	B01AC	B01A
10826	oxcarbazepine	reduces	3A457	tramadol		N03AF02	N02AX02	Carboxamide derivatives (N03AF)	Other opioids (N02AX)	Antiepileptics (N03A)	Opioids (N02A)	0	1		Reduced analgesic effect		N03AF	N03A	N02AX	N02A
10827	oxcarbazepine	reduces	3A457	trazodone		N03AF02	N06AX05	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3272	N03AF	N03A	N06AX	N06A
10827	oxcarbazepine	reduces	3A457	trazodone		N03AF02	N06AX05	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4149	N03AF	N03A	N06AX	N06A
10828	oxcarbazepine	reduces	3A457	triazolam		N03AF02	N05CD05	Carboxamide derivatives (N03AF)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AF	N03A	N05CD	N05C
10835	oxcarbazepine	reduces	3A457	venlafaxine		N03AF02	N06AX16	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2713	N03AF	N03A	N06AX	N06A
10835	oxcarbazepine	reduces	3A457	venlafaxine		N03AF02	N06AX16	Carboxamide derivatives (N03AF)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3272	N03AF	N03A	N06AX	N06A
10836	oxcarbazepine	reduces	3A457	verapamil	B	N03AF02	C08DA01	Carboxamide derivatives (N03AF)	Phenylalkylamine derivatives (C08DA)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N03AF	N03A	C08DA	C08D
10840	oxcarbazepine	reduces	3A457	voriconazole		N03AF02	J02AC03	Carboxamide derivatives (N03AF)	Triazole derivatives (J02AC)	Antiepileptics (N03A)	Antimycotics for systemic use (J02A)	0	0				N03AF	N03A	J02AC	J02A
10841	oxcarbazepine	reduces	3A457	zaleplon		N03AF02	N05CF03	Carboxamide derivatives (N03AF)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AF	N03A	N05CF	N05C
10843	oxcarbazepine	reduces	3A457	zolpidem		N03AF02	N05CF02	Carboxamide derivatives (N03AF)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AF	N03A	N05CF	N05C
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	133	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	693	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	937	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1219	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1533	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2597	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3357	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3464	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3482	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3561	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3653	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3873	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3896	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3939	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4333	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4401	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4448	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4461	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4544	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5396	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6042	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6044	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	6149	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7104	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7313	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7445	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7679	A02BC	A02B	N05BA	N05B
11073	pantoprazole	enhances	3A457	alprazolam		A02BC02	N05BA12	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7718	A02BC	A02B	N05BA	N05B
11074	pantoprazole	enhances	2C19,3A457	amitriptyline		A02BC02	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		1610	A02BC	A02B	N06AA	N06A
11074	pantoprazole	enhances	2C19,3A457	amitriptyline		A02BC02	N06AA09	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		5826	A02BC	A02B	N06AA	N06A
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	195	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	256	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	307	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	325	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	634	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	725	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	801	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1060	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1111	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1171	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1214	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1217	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1524	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1533	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1587	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1600	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1624	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2101	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2163	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2221	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2546	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2849	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3056	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3353	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3444	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3489	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3513	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3531	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3561	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3563	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3599	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3629	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3653	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3655	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3762	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3833	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3853	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3867	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3896	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4021	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4028	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4222	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4252	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4264	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4266	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4282	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4289	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4292	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4316	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4366	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4371	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4392	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4408	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4421	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4441	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4448	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4478	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4538	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4544	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4547	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4557	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4562	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4567	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4659	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4675	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4677	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4699	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4712	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4737	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4822	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4876	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4891	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4924	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5024	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5209	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5280	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5315	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5331	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5333	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5380	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5402	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5421	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5430	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5470	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5489	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5571	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5608	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5619	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5721	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5722	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5733	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5767	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5772	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5788	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5795	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5867	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6022	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6025	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6048	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6107	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6109	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6201	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6205	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6215	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6226	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7059	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7071	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7100	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7155	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7161	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7240	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7338	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7364	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7443	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7489	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7568	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7596	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7598	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7622	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7625	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7629	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7706	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7717	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7744	A02BC	A02B	C08CA	C08C
11075	pantoprazole	enhances	3A457	amlodipine		A02BC02	C08CA01	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7755	A02BC	A02B	C08CA	C08C
11076	pantoprazole	enhances	3A457	apixaban		A02BC02	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5421	A02BC	A02B	B01AF	B01A
11076	pantoprazole	enhances	3A457	apixaban		A02BC02	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7044	A02BC	A02B	B01AF	B01A
11076	pantoprazole	enhances	3A457	apixaban		A02BC02	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7568	A02BC	A02B	B01AF	B01A
11076	pantoprazole	enhances	3A457	apixaban		A02BC02	B01AF02	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7642	A02BC	A02B	B01AF	B01A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		316	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		634	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		706	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		811	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		839	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		937	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		982	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1162	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1178	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1210	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1414	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1432	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1435	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1488	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2332	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2386	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2878	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3056	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3443	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3501	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3515	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3519	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3562	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3662	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3762	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3764	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3853	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3870	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3881	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3883	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4091	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4148	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4196	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4282	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4344	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4352	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4414	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4440	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4461	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4470	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4562	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4627	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4655	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4699	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4740	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4775	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4776	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4822	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4869	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4876	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4891	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4924	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4933	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4944	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5001	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5106	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5120	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5156	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5173	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5205	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5227	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5333	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5383	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5489	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5526	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5531	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5664	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5695	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5696	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5721	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5730	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5733	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5736	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5740	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5761	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5783	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5796	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5887	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5929	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5934	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5989	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6110	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6149	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6184	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6189	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6226	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6229	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6233	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6245	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6250	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7034	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7043	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7106	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7137	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7196	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7214	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7217	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7235	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7318	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7366	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7415	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7443	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7445	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7484	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7485	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7489	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7592	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7594	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7622	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7625	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7706	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7743	A02BC	A02B	C10AA	C10A
11081	pantoprazole	enhances	3A457	atorvastatin		A02BC02	C10AA05	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7744	A02BC	A02B	C10AA	C10A
11095	pantoprazole	enhances	3A457	chlorpheniramine		A02BC02	R06AB04	Proton pump inhibitors (A02BC)	Substituted alkylamines (R06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antihistamines for systemic use (R06A)	0	0				A02BC	A02B	R06AB	R06A
11096	pantoprazole	enhances	3A457	cilostazol		A02BC02	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5531	A02BC	A02B	B01AC	B01A
11096	pantoprazole	enhances	3A457	cilostazol		A02BC02	B01AC23	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5856	A02BC	A02B	B01AC	B01A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			260	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			353	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			2436	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3483	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			3490	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			5033	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			7044	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			7118	A02BC	A02B	N06AB	N06A
11098	pantoprazole	enhances	2C19,3A457	citalopram		A02BC02	N06AB04	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			7513	A02BC	A02B	N06AB	N06A
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			260	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			1147	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			2597	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			3815	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			4371	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5206	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			5771	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			6046	A02BC	A02B	J01FA	J01F
11099	pantoprazole	enhances	3A457	clarithromycin		A02BC02	J01FA09	Proton pump inhibitors (A02BC)	Macrolides (J01FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Macrolides, lincosamides and streptogramins (J01F)	0	0			6048	A02BC	A02B	J01FA	J01F
11100	pantoprazole	enhances	2C19	clobazam		A02BC02	N05BA09	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0					A02BC	A02B	N05BA	N05B
11101	pantoprazole	enhances	2C19	clomipramine		A02BC02	N06AA04	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity		5761	A02BC	A02B	N06AA	N06A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	39	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	121	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	140	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	184	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	634	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	959	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1141	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1162	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1181	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1217	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1274	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1488	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2386	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2436	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3446	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3483	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3487	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3501	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3513	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3568	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3732	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3881	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3960	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4091	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4196	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4199	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4242	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4255	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4326	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4352	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4365	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4376	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4408	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4414	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4421	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4451	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4493	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4559	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4562	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4612	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4635	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4775	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4869	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4876	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4904	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4924	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5008	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5015	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5063	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5120	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5205	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5227	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5246	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5248	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5266	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5301	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5331	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5349	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5350	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5386	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5417	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5442	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5489	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5571	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5572	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5613	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5615	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5619	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5664	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5688	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5736	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5761	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5783	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5819	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5843	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5846	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6081	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6088	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6110	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6184	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6189	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6230	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6245	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7080	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7106	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7137	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7191	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7196	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7217	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7362	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7415	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7484	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7485	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7489	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7592	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7593	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7622	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7656	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7687	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7722	A02BC	A02B	B01AC	B01A
11102	pantoprazole	enhances	2C19,3A457	clopidogrel	B	A02BC02	B01AC04	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7743	A02BC	A02B	B01AC	B01A
11106	pantoprazole	enhances	3A457	colchicine		A02BC02	M04AC01	Proton pump inhibitors (A02BC)	Preparations with no effect on uric acid metabolism (M04AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antigout preparations (M04A)	0				4543	A02BC	A02B	M04AC	M04A
11106	pantoprazole	enhances	3A457	colchicine		A02BC02	M04AC01	Proton pump inhibitors (A02BC)	Preparations with no effect on uric acid metabolism (M04AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antigout preparations (M04A)	0				7489	A02BC	A02B	M04AC	M04A
11109	pantoprazole	enhances	2C19	cyclophosphamide		A02BC02	L01AA01	Proton pump inhibitors (A02BC)	Nitrogen mustard analogues (L01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Alkylating agents (L01A)	1	1				A02BC	A02B	L01AA	L01A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		178	A02BC	A02B	L04AD	L04A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		615	A02BC	A02B	L04AD	L04A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		803	A02BC	A02B	L04AD	L04A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		1434	A02BC	A02B	L04AD	L04A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		4693	A02BC	A02B	L04AD	L04A
11110	pantoprazole	enhances	3A457	cyclosporine		A02BC02	L04AD01	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		5310	A02BC	A02B	L04AD	L04A
11113	pantoprazole	enhances	3A457	deflazacort		A02BC02	H02AB13	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7404	A02BC	A02B	H02AB	H02A
11113	pantoprazole	enhances	3A457	deflazacort		A02BC02	H02AB13	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7583	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				662	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3061	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				3995	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5178	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5396	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5722	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				5859	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				6042	A02BC	A02B	H02AB	H02A
11114	pantoprazole	enhances	3A457	dexamethasone		A02BC02	H02AB02	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0				7248	A02BC	A02B	H02AB	H02A
11115	pantoprazole	enhances	3A457	dextromethorphan		A02BC02	R05DA09	Proton pump inhibitors (A02BC)	Opium alkaloids and derivatives (R05DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				A02BC	A02B	R05DA	R05D
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3732	A02BC	A02B	N05BA	N05B
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4306	A02BC	A02B	N05BA	N05B
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4933	A02BC	A02B	N05BA	N05B
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5215	A02BC	A02B	N05BA	N05B
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7366	A02BC	A02B	N05BA	N05B
11116	pantoprazole	enhances	2C19,3A457	diazepam		A02BC02	N05BA01	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7752	A02BC	A02B	N05BA	N05B
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		123	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		565	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		675	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		760	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1162	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3059	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3501	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3542	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3878	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4178	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4273	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4295	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4612	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4655	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5206	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5278	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5349	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5735	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5789	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5865	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7023	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7071	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7162	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7232	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7439	A02BC	A02B	C08DB	C08D
11117	pantoprazole	enhances	3A457	diltiazem		A02BC02	C08DB01	Proton pump inhibitors (A02BC)	Benzothiazepine derivatives (C08DB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7679	A02BC	A02B	C08DB	C08D
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				353	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				937	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3896	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3932	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				3961	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4122	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4298	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4544	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				5074	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				5781	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				6247	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				7220	A02BC	A02B	A03FA	A03F
11120	pantoprazole	enhances	3A457	domperidone		A02BC02	A03FA03	Proton pump inhibitors (A02BC)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				7400	A02BC	A02B	A03FA	A03F
11124	pantoprazole	enhances	3A457	eplerenone		A02BC02	C03DA04	Proton pump inhibitors (A02BC)	Aldosterone antagonists (C03DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Potassium-sparing agents (C03D)	0					A02BC	A02B	C03DA	C03D
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				133	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1139	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1219	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1496	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1532	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				2224	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3464	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				3939	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4316	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4401	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				4738	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5404	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5619	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5771	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				5970	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7197	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7211	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7445	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7495	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7618	A02BC	A02B	N06AB	N06A
11127	pantoprazole	enhances	2C19,3A457	escitalopram		A02BC02	N06AB10	Proton pump inhibitors (A02BC)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				7717	A02BC	A02B	N06AB	N06A
11128	pantoprazole	enhances	2C19,3A457	esomeprazole		A02BC02	A02BC05	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					A02BC	A02B	A02BC	A02B
11130	pantoprazole	enhances	3A457	felodipine		A02BC02	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2598	A02BC	A02B	C08CA	C08C
11130	pantoprazole	enhances	3A457	felodipine		A02BC02	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3412	A02BC	A02B	C08CA	C08C
11130	pantoprazole	enhances	3A457	felodipine		A02BC02	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4326	A02BC	A02B	C08CA	C08C
11130	pantoprazole	enhances	3A457	felodipine		A02BC02	C08CA02	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5030	A02BC	A02B	C08CA	C08C
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	330	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	959	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1390	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1416	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1432	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3079	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3762	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3896	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4882	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5008	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5866	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7115	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7439	A02BC	A02B	N05AD	N05A
11134	pantoprazole	enhances	3A457	haloperidol		A02BC02	N05AD01	Proton pump inhibitors (A02BC)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7735	A02BC	A02B	N05AD	N05A
11136	pantoprazole	enhances	3A457	hydrocortisone		A02BC02	H02AB09	Proton pump inhibitors (A02BC)	Glucocorticoids (H02AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Corticosteroids for systemic use, plain (H02A)	0					A02BC	A02B	H02AB	H02A
11139	pantoprazole	enhances	3A457	imatinib		A02BC02	L01XE01	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	0	0				A02BC	A02B	L01XE	L01X
11140	pantoprazole	enhances	2C19	imipramine		A02BC02	N06AA02	Proton pump inhibitors (A02BC)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BC	A02B	N06AA	N06A
11141	pantoprazole	enhances	3A457	indacaterol		A02BC02	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7023	A02BC	A02B	R03AC	R03A
11141	pantoprazole	enhances	3A457	indacaterol		A02BC02	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7613	A02BC	A02B	R03AC	R03A
11141	pantoprazole	enhances	3A457	indacaterol		A02BC02	R03AC18	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7647	A02BC	A02B	R03AC	R03A
11143	pantoprazole	enhances	2C19	indometacin		A02BC02	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				123	A02BC	A02B	M01AB	M01A
11143	pantoprazole	enhances	2C19	indometacin		A02BC02	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				195	A02BC	A02B	M01AB	M01A
11143	pantoprazole	enhances	2C19	indometacin		A02BC02	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				3943	A02BC	A02B	M01AB	M01A
11143	pantoprazole	enhances	2C19	indometacin		A02BC02	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				4292	A02BC	A02B	M01AB	M01A
11143	pantoprazole	enhances	2C19	indometacin		A02BC02	M01AB01	Proton pump inhibitors (A02BC)	Acetic acid derivatives and related substances (M01AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				6178	A02BC	A02B	M01AB	M01A
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				325	A02BC	A02B	C01EB	C01E
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				1162	A02BC	A02B	C01EB	C01E
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				4876	A02BC	A02B	C01EB	C01E
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				5843	A02BC	A02B	C01EB	C01E
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				7622	A02BC	A02B	C01EB	C01E
11146	pantoprazole	enhances	3A457	ivabradine		A02BC02	C01EB17	Proton pump inhibitors (A02BC)	Other cardiac preparations (C01EB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other cardiac preparations (C01E)	0				7743	A02BC	A02B	C01EB	C01E
11149	pantoprazole	enhances	2C19,3A457	lansoprazole		A02BC02	A02BC03	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3453	A02BC	A02B	A02BC	A02B
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				329	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				799	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				947	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1016	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1239	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1415	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				1497	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				2932	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3214	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				3815	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				5338	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				6225	A02BC	A02B	C08CA	C08C
11151	pantoprazole	enhances	3A457	lercanidipine		A02BC02	C08CA13	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0				7746	A02BC	A02B	C08CA	C08C
11155	pantoprazole	enhances	3A457	lovastatin		A02BC02	C10AA02	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3957	A02BC	A02B	C10AA	C10A
11155	pantoprazole	enhances	3A457	lovastatin		A02BC02	C10AA02	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5063	A02BC	A02B	C10AA	C10A
11155	pantoprazole	enhances	3A457	lovastatin		A02BC02	C10AA02	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7137	A02BC	A02B	C10AA	C10A
11158	pantoprazole	enhances	3A457	methadone		A02BC02	N07BC02	Proton pump inhibitors (A02BC)	Drugs used in opioid dependence (N07BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs used in addictive disorders (N07B)	0	0				A02BC	A02B	N07BC	N07B
11160	pantoprazole	enhances	3A457	midazolam		A02BC02	N05CD08	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A02BC	A02B	N05CD	N05C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	183	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	1139	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3883	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3957	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4502	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5369	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5795	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7516	A02BC	A02B	C08CA	C08C
11167	pantoprazole	enhances	3A457	nifedipine		A02BC02	C08CA05	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7614	A02BC	A02B	C08CA	C08C
11169	pantoprazole	enhances	3A457	nisoldipine		A02BC02	C08CA07	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A02BC	A02B	C08CA	C08C
11170	pantoprazole	enhances	3A457	nitrendipine		A02BC02	C08CA08	Proton pump inhibitors (A02BC)	Dihydropyridine derivatives (C08CA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A02BC	A02B	C08CA	C08C
11172	pantoprazole	enhances	2C19,3A457	omeprazole		A02BC02	A02BC01	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3535	A02BC	A02B	A02BC	A02B
11172	pantoprazole	enhances	2C19,3A457	omeprazole		A02BC02	A02BC01	Proton pump inhibitors (A02BC)	Proton pump inhibitors (A02BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5505	A02BC	A02B	A02BC	A02B
11173	pantoprazole	enhances	3A457	ondansetron		A02BC02	A04AA01	Proton pump inhibitors (A02BC)	Serotonin (5HT3) antagonists (A04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiemetics and antinauseants (A04A)	0	0			3520	A02BC	A02B	A04AA	A04A
11173	pantoprazole	enhances	3A457	ondansetron		A02BC02	A04AA01	Proton pump inhibitors (A02BC)	Serotonin (5HT3) antagonists (A04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiemetics and antinauseants (A04A)	0	0			7248	A02BC	A02B	A04AA	A04A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	121	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	817	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2139	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2332	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3513	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3774	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4292	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4293	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5008	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5031	A02BC	A02B	N03AA	N03A
11181	pantoprazole	enhances	2C19	phenobarbital		A02BC02	N03AA02	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	7115	A02BC	A02B	N03AA	N03A
11182	pantoprazole	enhances	2C19	phenytoin		A02BC02	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2240	A02BC	A02B	N03AB	N03A
11182	pantoprazole	enhances	2C19	phenytoin		A02BC02	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3092	A02BC	A02B	N03AB	N03A
11182	pantoprazole	enhances	2C19	phenytoin		A02BC02	N03AB02	Proton pump inhibitors (A02BC)	Hydantoin derivatives (N03AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4684	A02BC	A02B	N03AB	N03A
11187	pantoprazole	enhances	2C19	primidone		A02BC02	N03AA03	Proton pump inhibitors (A02BC)	Barbiturates and derivatives (N03AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiepileptics (N03A)	0					A02BC	A02B	N03AA	N03A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				735	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				801	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				817	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1283	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1549	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1610	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				2870	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3733	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3825	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3833	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4795	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4805	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4821	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4844	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				4968	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5024	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5185	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5301	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5305	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5422	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5689	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5693	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5781	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				5908	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7130	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7140	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7207	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7291	A02BC	A02B	C07AA	C07A
11190	pantoprazole	enhances	2C19,3A457	propranolol		A02BC02	C07AA05	Proton pump inhibitors (A02BC)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7526	A02BC	A02B	C07AA	C07A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				1239	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				1533	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3417	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3426	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				3816	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4079	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4910	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				4987	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				5215	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				5658	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				6181	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7420	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7593	A02BC	A02B	N05AH	N05A
11191	pantoprazole	enhances	3A457	quetiapine		A02BC02	N05AH04	Proton pump inhibitors (A02BC)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				7655	A02BC	A02B	N05AH	N05A
11197	pantoprazole	enhances	3A457	risperidone		A02BC02	N05AX08	Proton pump inhibitors (A02BC)	Other antipsychotics (N05AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A02BC	A02B	N05AX	N05A
11198	pantoprazole	enhances	3A457	ritonavir		A02BC02	J05AE03	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0				A02BC	A02B	J05AE	J05A
11199	pantoprazole	enhances	3A457	rivaroxaban		A02BC02	B01AF01	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				5248	A02BC	A02B	B01AF	B01A
11199	pantoprazole	enhances	3A457	rivaroxaban		A02BC02	B01AF01	Proton pump inhibitors (A02BC)	Direct factor Xa inhibitors (B01AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7427	A02BC	A02B	B01AF	B01A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				28	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				47	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				240	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				256	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				264	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				281	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				329	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				338	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				622	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				867	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1070	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1423	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1505	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1555	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				1595	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				2597	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3059	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3061	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3524	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3691	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3878	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3939	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				3950	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4156	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4222	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4242	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4365	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4582	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4589	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4603	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4655	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4662	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4712	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4745	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				4876	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5031	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5074	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5075	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5292	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5390	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5435	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5481	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5523	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5639	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5656	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5695	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5701	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5865	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				5930	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				6096	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7104	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7135	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7158	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7210	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7242	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7571	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7592	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7646	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7647	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7666	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7679	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7744	A02BC	A02B	R03AC	R03A
11205	pantoprazole	enhances	3A457	salmeterol		A02BC02	R03AC12	Proton pump inhibitors (A02BC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Adrenergics, inhalants (R03A)	0				7746	A02BC	A02B	R03AC	R03A
11206	pantoprazole	enhances	3A457	saquinavir	B	A02BC02	J05AE01	Proton pump inhibitors (A02BC)	Protease inhibitors (J05AE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Direct acting antivirals (J05A)	0	0				A02BC	A02B	J05AE	J05A
11208	pantoprazole	enhances	3A457	sildenafil		A02BC02	G04BE03	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0			5248	A02BC	A02B	G04BE	G04B
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		140	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		179	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		183	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		184	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		325	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		329	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		578	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		731	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		801	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		823	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1070	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1108	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1118	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1171	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1415	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1497	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1502	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1532	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2101	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2163	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2313	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2409	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2557	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2673	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		2885	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3483	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3513	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3561	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3563	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3568	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3627	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3678	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3732	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3816	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3896	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4189	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4230	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4293	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4295	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4330	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4355	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4427	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4428	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4429	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4448	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4451	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4502	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4544	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4547	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4568	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4612	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4644	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4647	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4675	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4693	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4709	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4711	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4712	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4833	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4923	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4972	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4988	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5071	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5188	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5198	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5215	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5253	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5266	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5269	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5293	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5349	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5350	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5572	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5595	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5656	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5767	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5788	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5795	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5841	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5856	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5867	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5963	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6044	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6081	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		6199	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7044	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7191	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7213	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7364	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7404	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7478	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7646	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7695	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7722	A02BC	A02B	C10AA	C10A
11210	pantoprazole	enhances	3A457	simvastatin		A02BC02	C10AA01	Proton pump inhibitors (A02BC)	HMG CoA reductase inhibitors (C10AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7752	A02BC	A02B	C10AA	C10A
11211	pantoprazole	enhances	3A457	sirolimus		A02BC02	L04AA10	Proton pump inhibitors (A02BC)	Selective immunosuppressants (L04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		5856	A02BC	A02B	L04AA	L04A
11213	pantoprazole	enhances	3A457	sorafenib		A02BC02	L01XE05	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1					A02BC	A02B	L01XE	L01X
11214	pantoprazole	enhances	3A457	sunitinib		A02BC02	L01XE04	Proton pump inhibitors (A02BC)	 (L01XE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other antineoplastic agents (L01X)	1					A02BC	A02B	L01XE	L01X
11216	pantoprazole	enhances	3A457	tacrolimus		A02BC02	L04AD02	Proton pump inhibitors (A02BC)	Calcineurin inhibitors (L04AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		5321	A02BC	A02B	L04AD	L04A
11217	pantoprazole	enhances	3A457	tadalafil		A02BC02	G04BE08	Proton pump inhibitors (A02BC)	Drugs used in erectile dysfunction (G04BE)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Urologicals (G04B)	0	0				A02BC	A02B	G04BE	G04B
11218	pantoprazole	enhances	3A457	tamoxifen		A02BC02	L02BA01	Proton pump inhibitors (A02BC)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1			4475	A02BC	A02B	L02BA	L02B
11218	pantoprazole	enhances	3A457	tamoxifen		A02BC02	L02BA01	Proton pump inhibitors (A02BC)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1			5305	A02BC	A02B	L02BA	L02B
11225	pantoprazole	enhances	3A457	testosterone		A02BC02	G03BA03	Proton pump inhibitors (A02BC)	3-oxoandrosten (4) derivatives (G03BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Androgens (G03B)	0				4833	A02BC	A02B	G03BA	G03B
11226	pantoprazole	enhances	3A457	ticagrelor		A02BC02	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				6214	A02BC	A02B	B01AC	B01A
11226	pantoprazole	enhances	3A457	ticagrelor		A02BC02	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7043	A02BC	A02B	B01AC	B01A
11226	pantoprazole	enhances	3A457	ticagrelor		A02BC02	B01AC24	Proton pump inhibitors (A02BC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	0				7706	A02BC	A02B	B01AC	B01A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	307	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	662	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	693	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	760	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	1072	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2045	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2064	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	2684	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3867	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3905	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	3995	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4557	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	4696	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	5020	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	5863	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	7135	A02BC	A02B	N02AX	N02A
11229	pantoprazole	enhances	3A457	tramadol		A02BC02	N02AX02	Proton pump inhibitors (A02BC)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	7197	A02BC	A02B	N02AX	N02A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		126	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		565	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		937	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1367	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2619	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3520	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3705	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		4936	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5020	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5278	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5293	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5421	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5422	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5589	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5781	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5865	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5930	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7364	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7718	A02BC	A02B	N06AX	N06A
11230	pantoprazole	enhances	3A457	trazodone		A02BC02	N06AX05	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7735	A02BC	A02B	N06AX	N06A
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1127	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1274	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1374	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3881	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5033	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5253	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5266	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5796	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7085	A02BC	A02B	N05CD	N05C
11231	pantoprazole	enhances	3A457	triazolam		A02BC02	N05CD05	Proton pump inhibitors (A02BC)	Benzodiazepine derivatives (N05CD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	7579	A02BC	A02B	N05CD	N05C
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1274	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		1482	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		2163	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		3357	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		5471	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7106	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7135	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7451	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7489	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7614	A02BC	A02B	N06AX	N06A
11238	pantoprazole	enhances	2C19,3A457	venlafaxine		A02BC02	N06AX16	Proton pump inhibitors (A02BC)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		7655	A02BC	A02B	N06AX	N06A
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		28	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		123	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1391	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2692	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2985	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3568	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4603	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4620	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4723	A02BC	A02B	C08DA	C08D
11239	pantoprazole	enhances	3A457	verapamil		A02BC02	C08DA01	Proton pump inhibitors (A02BC)	Phenylalkylamine derivatives (C08DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7093	A02BC	A02B	C08DA	C08D
11243	pantoprazole	enhances	2C19,3A457	voriconazole	B	A02BC02	J02AC03	Proton pump inhibitors (A02BC)	Triazole derivatives (J02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antimycotics for systemic use (J02A)	0	0				A02BC	A02B	J02AC	J02A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		28	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		147	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		148	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		179	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		565	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		662	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		731	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		839	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		947	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1108	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1256	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1367	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1392	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1423	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1482	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1497	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1533	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1572	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		1600	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2332	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2673	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2849	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		2873	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3235	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3357	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3412	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3444	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3464	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3519	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3561	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3562	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3563	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3632	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3662	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3739	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3764	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3870	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3902	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		3932	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4000	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4063	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4101	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4178	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4199	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4252	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4255	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4282	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4289	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4293	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4295	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4333	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4441	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4461	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4470	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4475	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4544	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4592	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4603	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4644	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4679	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4722	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4777	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4797	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4829	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4833	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4834	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4842	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4860	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4891	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4930	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4937	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		4944	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5024	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5031	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5106	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5120	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5153	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5156	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5172	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5198	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5205	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5207	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5209	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5278	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5310	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5380	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5383	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5404	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5435	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5531	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5572	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5591	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5696	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5701	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5735	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5754	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5843	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5846	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5855	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5866	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		5929	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6044	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6189	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6213	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6233	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6237	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6247	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		6250	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7023	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7066	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7088	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7140	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7210	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7232	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7291	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7366	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7439	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7513	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7614	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7646	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7729	A02BC	A02B	B01AA	B01A
11244	pantoprazole	enhances	2C19	warfarin	B	A02BC02	B01AA03	Proton pump inhibitors (A02BC)	Vitamin K antagonists (B01AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antithrombotic agents (B01A)	1	0	Bleeding		7744	A02BC	A02B	B01AA	B01A
11245	pantoprazole	enhances	3A457	zaleplon		A02BC02	N05CF03	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0					A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				133	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				344	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3426	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3490	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				3979	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4252	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4365	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4557	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4655	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				4929	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5364	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				5865	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				7592	A02BC	A02B	N05CF	N05C
11247	pantoprazole	enhances	3A457	zolpidem		A02BC02	N05CF02	Proton pump inhibitors (A02BC)	Benzodiazepine related drugs (N05CF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hypnotics and sedatives (N05C)	0				7596	A02BC	A02B	N05CF	N05C
11250	paroxetine	enhances	2C9,2D6	amitriptyline	D	N06AB05	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity		4702	N06AB	N06A	N06AA	N06A
11255	paroxetine	enhances	2C9	capecitabine		N06AB05	L01BC06	Selective serotonin reuptake inhibitors (N06AB)	Pyrimidine analogues (L01BC)	Antidepressants (N06A)	Antimetabolites (L01B)	1					N06AB	N06A	L01BC	L01B
11257	paroxetine	enhances	2D6	carvedilol		N06AB05	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2502	N06AB	N06A	C07AG	C07A
11257	paroxetine	enhances	2D6	carvedilol		N06AB05	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3250	N06AB	N06A	C07AG	C07A
11257	paroxetine	enhances	2D6	carvedilol		N06AB05	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4993	N06AB	N06A	C07AG	C07A
11257	paroxetine	enhances	2D6	carvedilol		N06AB05	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5474	N06AB	N06A	C07AG	C07A
11257	paroxetine	enhances	2D6	carvedilol		N06AB05	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7138	N06AB	N06A	C07AG	C07A
11258	paroxetine	enhances	2C9	celecoxib	C	N06AB05	M01AH01	Selective serotonin reuptake inhibitors (N06AB)	Coxibs (M01AH)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AH	M01A
11259	paroxetine	enhances	2D6	chlorpheniramine		N06AB05	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
11260	paroxetine	enhances	2D6	chlorpromazine	D	N06AB05	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0				4265	N06AB	N06A	N05AA	N05A
11261	paroxetine	enhances	2D6	citalopram	D	N06AB05	N06AB04	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AB	N06A	N06AB	N06A
11262	paroxetine	enhances	2D6	clomipramine	D	N06AB05	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
11263	paroxetine	enhances	2D6	clonidine		N06AB05	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				5272	N06AB	N06A	C02AC	C02A
11263	paroxetine	enhances	2D6	clonidine		N06AB05	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				7405	N06AB	N06A	C02AC	C02A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3513	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4242	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4668	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4718	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	6091	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7113	N06AB	N06A	B01AC	B01A
11264	paroxetine	enhances	2C9	clopidogrel	B	N06AB05	B01AC04	Selective serotonin reuptake inhibitors (N06AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antidepressants (N06A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7473	N06AB	N06A	B01AC	B01A
11269	paroxetine	enhances	2D6	dextromethorphan	D	N06AB05	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
11270	paroxetine	enhances	2C9	diclofenac	C	N06AB05	M01AB05	Selective serotonin reuptake inhibitors (N06AB)	Acetic acid derivatives and related substances (M01AB)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AB	M01A
11271	paroxetine	enhances	2D6	donepezil	D	N06AB05	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				4120	N06AB	N06A	N06DA	N06D
11271	paroxetine	enhances	2D6	donepezil	D	N06AB05	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				5980	N06AB	N06A	N06DA	N06D
11273	paroxetine	enhances	2D6	duloxetine	C	N06AB05	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
11276	paroxetine	enhances	2D6	escitalopram	D	N06AB05	N06AB10	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AB	N06A	N06AB	N06A
11277	paroxetine	enhances	2D6	flecainide	D	N06AB05	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			N06AB	N06A	C01BC	C01B
11278	paroxetine	enhances	2C9,2D6	fluoxetine	D	N06AB05	N06AB03	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
11279	paroxetine	enhances	2C9	fluvastatin		N06AB05	C10AA04	Selective serotonin reuptake inhibitors (N06AB)	HMG CoA reductase inhibitors (C10AA)	Antidepressants (N06A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N06AB	N06A	C10AA	C10A
11280	paroxetine	enhances	2D6	fluvoxamine		N06AB05	N06AB08	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
11281	paroxetine	enhances	2C9	glimepiride		N06AB05	A10BB12	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				2868	N06AB	N06A	A10BB	A10B
11281	paroxetine	enhances	2C9	glimepiride		N06AB05	A10BB12	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0				7473	N06AB	N06A	A10BB	A10B
11282	paroxetine	enhances	2C9	glipizide		N06AB05	A10BB07	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N06AB	N06A	A10BB	A10B
11283	paroxetine	enhances	2C9	glyburide		N06AB05	A10BB01	Selective serotonin reuptake inhibitors (N06AB)	Sulfonylureas (A10BB)	Antidepressants (N06A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N06AB	N06A	A10BB	A10B
11284	paroxetine	enhances	2D6	haloperidol	D	N06AB05	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2196	N06AB	N06A	N05AD	N05A
11286	paroxetine	enhances	2C9	ibuprofen	C	N06AB05	M01AE01	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			3528	N06AB	N06A	M01AE	M01A
11286	paroxetine	enhances	2C9	ibuprofen	C	N06AB05	M01AE01	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			4102	N06AB	N06A	M01AE	M01A
11287	paroxetine	enhances	2D6	imipramine	D	N06AB05	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
11288	paroxetine	enhances	2C9	irbesartan		N06AB05	C09CA04	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	1281	N06AB	N06A	C09CA	C09C
11288	paroxetine	enhances	2C9	irbesartan		N06AB05	C09CA04	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	3075	N06AB	N06A	C09CA	C09C
11288	paroxetine	enhances	2C9	irbesartan		N06AB05	C09CA04	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	4542	N06AB	N06A	C09CA	C09C
11288	paroxetine	enhances	2C9	irbesartan		N06AB05	C09CA04	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect	5863	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	326	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3528	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4005	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4993	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7104	N06AB	N06A	C09CA	C09C
11293	paroxetine	enhances	2C9	losartan		N06AB05	C09CA01	Selective serotonin reuptake inhibitors (N06AB)	Angiotensin II receptor blockers, plain (C09CA)	Antidepressants (N06A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	7138	N06AB	N06A	C09CA	C09C
11294	paroxetine	enhances	2C9	meloxicam	C	N06AB05	M01AC06	Selective serotonin reuptake inhibitors (N06AB)	Oxicams (M01AC)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N06AB	N06A	M01AC	M01A
11295	paroxetine	enhances	2D6	metoclopramide	D	N06AB05	A03FA01	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0					N06AB	N06A	A03FA	A03F
11296	paroxetine	enhances	2D6	metoprolol	D	N06AB05	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4542	N06AB	N06A	C07AB	C07A
11299	paroxetine	enhances	2C9	naproxen	C	N06AB05	M01AE02	Selective serotonin reuptake inhibitors (N06AB)	Propionic acid derivatives (M01AE)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AE	M01A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				1406	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2699	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2897	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				3250	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				4448	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				4631	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				5706	N06AB	N06A	C07AB	C07A
11301	paroxetine	enhances	2D6	nebivolol		N06AB05	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				7740	N06AB	N06A	C07AB	C07A
11302	paroxetine	enhances	2D6	nortriptyline	D	N06AB05	N06AA10	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1					N06AB	N06A	N06AA	N06A
11304	paroxetine	enhances	2D6	ondansetron	D	N06AB05	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0				N06AB	N06A	A04AA	A04A
11306	paroxetine	enhances	2D6	oxycodone		N06AB05	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	1281	N06AB	N06A	N02AA	N02A
11306	paroxetine	enhances	2D6	oxycodone		N06AB05	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4423	N06AB	N06A	N02AA	N02A
11306	paroxetine	enhances	2D6	oxycodone		N06AB05	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7104	N06AB	N06A	N02AA	N02A
11312	paroxetine	enhances	2C9	phenytoin	B	N06AB05	N03AB02	Selective serotonin reuptake inhibitors (N06AB)	Hydantoin derivatives (N03AB)	Antidepressants (N06A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N06AB	N06A	N03AB	N03A
11314	paroxetine	enhances	2C9	piroxicam	C	N06AB05	M01AC01	Selective serotonin reuptake inhibitors (N06AB)	Oxicams (M01AC)	Antidepressants (N06A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N06AB	N06A	M01AC	M01A
11317	paroxetine	enhances	2D6	promethazine	D	N06AB05	R06AD02	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AB	N06A	R06AD	R06A
11318	paroxetine	enhances	2D6	propafenone	D	N06AB05	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			N06AB	N06A	C01BC	C01B
11319	paroxetine	enhances	2D6	propranolol	D	N06AB05	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2549	N06AB	N06A	C07AA	C07A
11319	paroxetine	enhances	2D6	propranolol	D	N06AB05	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				3294	N06AB	N06A	C07AA	C07A
11320	paroxetine	enhances	2D6	risperidone	D	N06AB05	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AX	N05A
11326	paroxetine	enhances	2C9,2D6	tamoxifen	D	N06AB05	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AB	N06A	L02BA	L02B
11327	paroxetine	enhances	2D6	tetrabenazine	D	N06AB05	N07XX06	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AB	N06A	N07XX	N07X
11331	paroxetine	enhances	2C9	torasemide	D	N06AB05	C03CA04	Selective serotonin reuptake inhibitors (N06AB)	Sulfonamides, plain (C03CA)	Antidepressants (N06A)	High-ceiling diuretics (C03C)	0	0			213	N06AB	N06A	C03CA	C03C
11331	paroxetine	enhances	2C9	torasemide	D	N06AB05	C03CA04	Selective serotonin reuptake inhibitors (N06AB)	Sulfonamides, plain (C03CA)	Antidepressants (N06A)	High-ceiling diuretics (C03C)	0	0			850	N06AB	N06A	C03CA	C03C
11331	paroxetine	enhances	2C9	torasemide	D	N06AB05	C03CA04	Selective serotonin reuptake inhibitors (N06AB)	Sulfonamides, plain (C03CA)	Antidepressants (N06A)	High-ceiling diuretics (C03C)	0	0			4542	N06AB	N06A	C03CA	C03C
11332	paroxetine	enhances	2D6	tramadol	D	N06AB05	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	5863	N06AB	N06A	N02AX	N02A
11335	paroxetine	enhances	2C9	valproate		N06AB05	N03AG01	Selective serotonin reuptake inhibitors (N06AB)	Fatty acid derivatives (N03AG)	Antidepressants (N06A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1281	N06AB	N06A	N03AG	N03A
11336	paroxetine	enhances	2C9,2D6	venlafaxine	D	N06AB05	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
11338	paroxetine	enhances	2C9	voriconazole	D	N06AB05	J02AC03	Selective serotonin reuptake inhibitors (N06AB)	Triazole derivatives (J02AC)	Antidepressants (N06A)	Antimycotics for systemic use (J02A)	0	0				N06AB	N06A	J02AC	J02A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		711	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		2035	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		3598	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		4542	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		5493	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		6091	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		7405	N06AB	N06A	B01AA	B01A
11339	paroxetine	enhances	2C9	warfarin	B	N06AB05	B01AA03	Selective serotonin reuptake inhibitors (N06AB)	Vitamin K antagonists (B01AA)	Antidepressants (N06A)	Antithrombotic agents (B01A)	1	0	Bleeding		7587	N06AB	N06A	B01AA	B01A
11341	paroxetine	enhances	2D6	zuclopenthixol	C	N06AB05	N05AF05	Selective serotonin reuptake inhibitors (N06AB)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AF	N05A
11582	phenobarbital	reduces	3A457	alprazolam	C	N03AA02	N05BA12	Barbiturates and derivatives (N03AA)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3324	N03AA	N03A	N05BA	N05B
11583	phenobarbital	reduces	2C9,3A457	amitriptyline	A	N03AA02	N06AA09	Barbiturates and derivatives (N03AA)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AA	N03A	N06AA	N06A
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	165	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	203	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2419	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3513	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3525	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4292	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4725	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5095	N03AA	N03A	C08CA	C08C
11584	phenobarbital	reduces	3A457	amlodipine		N03AA02	C08CA01	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6062	N03AA	N03A	C08CA	C08C
11585	phenobarbital	reduces	3A457	apixaban	B	N03AA02	B01AF02	Barbiturates and derivatives (N03AA)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AA	N03A	B01AF	B01A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2332	N03AA	N03A	C10AA	C10A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2787	N03AA	N03A	C10AA	C10A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4726	N03AA	N03A	C10AA	C10A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4911	N03AA	N03A	C10AA	C10A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5339	N03AA	N03A	C10AA	C10A
11590	phenobarbital	reduces	3A457	atorvastatin		N03AA02	C10AA05	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5828	N03AA	N03A	C10AA	C10A
11598	phenobarbital	reduces	2B6	bupropion	A	N03AA02	N06AX12	Barbiturates and derivatives (N03AA)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AA	N03A	N06AX	N06A
11601	phenobarbital	reduces	2C9	capecitabine		N03AA02	L01BC06	Barbiturates and derivatives (N03AA)	Pyrimidine analogues (L01BC)	Antiepileptics (N03A)	Antimetabolites (L01B)	1					N03AA	N03A	L01BC	L01B
11602	phenobarbital	reduces	3A457	carbamazepine	B	N03AA02	N03AF01	Barbiturates and derivatives (N03AA)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	192	N03AA	N03A	N03AF	N03A
11602	phenobarbital	reduces	3A457	carbamazepine	B	N03AA02	N03AF01	Barbiturates and derivatives (N03AA)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	776	N03AA	N03A	N03AF	N03A
11602	phenobarbital	reduces	3A457	carbamazepine	B	N03AA02	N03AF01	Barbiturates and derivatives (N03AA)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2003	N03AA	N03A	N03AF	N03A
11602	phenobarbital	reduces	3A457	carbamazepine	B	N03AA02	N03AF01	Barbiturates and derivatives (N03AA)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4317	N03AA	N03A	N03AF	N03A
11602	phenobarbital	reduces	3A457	carbamazepine	B	N03AA02	N03AF01	Barbiturates and derivatives (N03AA)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4667	N03AA	N03A	N03AF	N03A
11604	phenobarbital	reduces	2C9	celecoxib		N03AA02	M01AH01	Barbiturates and derivatives (N03AA)	Coxibs (M01AH)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AA	N03A	M01AH	M01A
11607	phenobarbital	reduces	3A457	chlorpheniramine		N03AA02	R06AB04	Barbiturates and derivatives (N03AA)	Substituted alkylamines (R06AB)	Antiepileptics (N03A)	Antihistamines for systemic use (R06A)	0	0				N03AA	N03A	R06AB	R06A
11608	phenobarbital	reduces	3A457	cilostazol		N03AA02	B01AC23	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AA	N03A	B01AC	B01A
11610	phenobarbital	reduces	3A457	citalopram		N03AA02	N06AB04	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0			336	N03AA	N03A	N06AB	N06A
11610	phenobarbital	reduces	3A457	citalopram		N03AA02	N06AB04	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0			1163	N03AA	N03A	N06AB	N06A
11610	phenobarbital	reduces	3A457	citalopram		N03AA02	N06AB04	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0			1378	N03AA	N03A	N06AB	N06A
11610	phenobarbital	reduces	3A457	citalopram		N03AA02	N06AB04	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0			3324	N03AA	N03A	N06AB	N06A
11611	phenobarbital	reduces	3A457	clarithromycin		N03AA02	J01FA09	Barbiturates and derivatives (N03AA)	Macrolides (J01FA)	Antiepileptics (N03A)	Macrolides, lincosamides and streptogramins (J01F)	0	0			4317	N03AA	N03A	J01FA	J01F
11612	phenobarbital	reduces	2B6,3A457	clobazam	C	N03AA02	N05BA09	Barbiturates and derivatives (N03AA)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0					N03AA	N03A	N05BA	N05B
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	121	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1388	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2390	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3002	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3513	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5008	N03AA	N03A	B01AC	B01A
11613	phenobarbital	reduces	2C9,3A457	clopidogrel		N03AA02	B01AC04	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5249	N03AA	N03A	B01AC	B01A
11617	phenobarbital	reduces	3A457	colchicine		N03AA02	M04AC01	Barbiturates and derivatives (N03AA)	Preparations with no effect on uric acid metabolism (M04AC)	Antiepileptics (N03A)	Antigout preparations (M04A)	0					N03AA	N03A	M04AC	M04A
11620	phenobarbital	reduces	2B6	cyclophosphamide	B	N03AA02	L01AA01	Barbiturates and derivatives (N03AA)	Nitrogen mustard analogues (L01AA)	Antiepileptics (N03A)	Alkylating agents (L01A)	1	1				N03AA	N03A	L01AA	L01A
11621	phenobarbital	reduces	3A457	cyclosporine	C	N03AA02	L04AD01	Barbiturates and derivatives (N03AA)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		3166	N03AA	N03A	L04AD	L04A
11625	phenobarbital	reduces	3A457	deflazacort	B	N03AA02	H02AB13	Barbiturates and derivatives (N03AA)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AA	N03A	H02AB	H02A
11626	phenobarbital	reduces	3A457	dexamethasone	B	N03AA02	H02AB02	Barbiturates and derivatives (N03AA)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0				1378	N03AA	N03A	H02AB	H02A
11626	phenobarbital	reduces	3A457	dexamethasone	B	N03AA02	H02AB02	Barbiturates and derivatives (N03AA)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0				2390	N03AA	N03A	H02AB	H02A
11626	phenobarbital	reduces	3A457	dexamethasone	B	N03AA02	H02AB02	Barbiturates and derivatives (N03AA)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0				3395	N03AA	N03A	H02AB	H02A
11627	phenobarbital	reduces	3A457	dextromethorphan		N03AA02	R05DA09	Barbiturates and derivatives (N03AA)	Opium alkaloids and derivatives (R05DA)	Antiepileptics (N03A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N03AA	N03A	R05DA	R05D
11628	phenobarbital	reduces	3A457	diazepam	C	N03AA02	N05BA01	Barbiturates and derivatives (N03AA)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AA	N03A	N05BA	N05B
11629	phenobarbital	reduces	2C9	diclofenac	B	N03AA02	M01AB05	Barbiturates and derivatives (N03AA)	Acetic acid derivatives and related substances (M01AB)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0			336	N03AA	N03A	M01AB	M01A
11630	phenobarbital	reduces	3A457	diltiazem		N03AA02	C08DB01	Barbiturates and derivatives (N03AA)	Benzothiazepine derivatives (C08DB)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		192	N03AA	N03A	C08DB	C08D
11630	phenobarbital	reduces	3A457	diltiazem		N03AA02	C08DB01	Barbiturates and derivatives (N03AA)	Benzothiazepine derivatives (C08DB)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5828	N03AA	N03A	C08DB	C08D
11633	phenobarbital	reduces	3A457	domperidone		N03AA02	A03FA03	Barbiturates and derivatives (N03AA)	Propulsives (A03FA)	Antiepileptics (N03A)	Propulsives (A03F)	0				4725	N03AA	N03A	A03FA	A03F
11635	phenobarbital	reduces	2B6	efavirenz	B	N03AA02	J05AG03	Barbiturates and derivatives (N03AA)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AA	N03A	J05AG	J05A
11640	phenobarbital	reduces	3A457	eplerenone		N03AA02	C03DA04	Barbiturates and derivatives (N03AA)	Aldosterone antagonists (C03DA)	Antiepileptics (N03A)	Potassium-sparing agents (C03D)	0					N03AA	N03A	C03DA	C03D
11643	phenobarbital	reduces	3A457	escitalopram		N03AA02	N06AB10	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				3166	N03AA	N03A	N06AB	N06A
11644	phenobarbital	reduces	3A457	esomeprazole		N03AA02	A02BC05	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2326	N03AA	N03A	A02BC	A02B
11644	phenobarbital	reduces	3A457	esomeprazole		N03AA02	A02BC05	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2787	N03AA	N03A	A02BC	A02B
11644	phenobarbital	reduces	3A457	esomeprazole		N03AA02	A02BC05	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3320	N03AA	N03A	A02BC	A02B
11644	phenobarbital	reduces	3A457	esomeprazole		N03AA02	A02BC05	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4947	N03AA	N03A	A02BC	A02B
11646	phenobarbital	reduces	3A457	felodipine	B	N03AA02	C08CA02	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AA	N03A	C08CA	C08C
11650	phenobarbital	reduces	2C9	fluoxetine		N03AA02	N06AB03	Barbiturates and derivatives (N03AA)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AA	N03A	N06AB	N06A
11651	phenobarbital	reduces	2C9	fluvastatin		N03AA02	C10AA04	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			N03AA	N03A	C10AA	C10A
11652	phenobarbital	reduces	2C9	glimepiride		N03AA02	A10BB12	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					N03AA	N03A	A10BB	A10B
11653	phenobarbital	reduces	2C9	glipizide		N03AA02	A10BB07	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			N03AA	N03A	A10BB	A10B
11654	phenobarbital	reduces	2C9	glyburide		N03AA02	A10BB01	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		121	N03AA	N03A	A10BB	A10B
11654	phenobarbital	reduces	2C9	glyburide		N03AA02	A10BB01	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		2390	N03AA	N03A	A10BB	A10B
11654	phenobarbital	reduces	2C9	glyburide		N03AA02	A10BB01	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		3092	N03AA	N03A	A10BB	A10B
11654	phenobarbital	reduces	2C9	glyburide		N03AA02	A10BB01	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4258	N03AA	N03A	A10BB	A10B
11654	phenobarbital	reduces	2C9	glyburide		N03AA02	A10BB01	Barbiturates and derivatives (N03AA)	Sulfonylureas (A10BB)	Antiepileptics (N03A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia		4911	N03AA	N03A	A10BB	A10B
11655	phenobarbital	reduces	3A457	haloperidol		N03AA02	N05AD01	Barbiturates and derivatives (N03AA)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3216	N03AA	N03A	N05AD	N05A
11655	phenobarbital	reduces	3A457	haloperidol		N03AA02	N05AD01	Barbiturates and derivatives (N03AA)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4258	N03AA	N03A	N05AD	N05A
11655	phenobarbital	reduces	3A457	haloperidol		N03AA02	N05AD01	Barbiturates and derivatives (N03AA)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5008	N03AA	N03A	N05AD	N05A
11655	phenobarbital	reduces	3A457	haloperidol		N03AA02	N05AD01	Barbiturates and derivatives (N03AA)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7115	N03AA	N03A	N05AD	N05A
11656	phenobarbital	reduces	3A457	hydrocortisone	B	N03AA02	H02AB09	Barbiturates and derivatives (N03AA)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AA	N03A	H02AB	H02A
11658	phenobarbital	reduces	2C9	ibuprofen		N03AA02	M01AE01	Barbiturates and derivatives (N03AA)	Propionic acid derivatives (M01AE)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AA	N03A	M01AE	M01A
11661	phenobarbital	reduces	3A457	imatinib	D	N03AA02	L01XE01	Barbiturates and derivatives (N03AA)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	0	0				N03AA	N03A	L01XE	L01X
11662	phenobarbital	reduces	3A457	indacaterol		N03AA02	R03AC18	Barbiturates and derivatives (N03AA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0					N03AA	N03A	R03AC	R03A
11664	phenobarbital	reduces	2C9	irbesartan		N03AA02	C09CA04	Barbiturates and derivatives (N03AA)	Angiotensin II receptor blockers, plain (C09CA)	Antiepileptics (N03A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		N03AA	N03A	C09CA	C09C
11667	phenobarbital	reduces	3A457	ivabradine		N03AA02	C01EB17	Barbiturates and derivatives (N03AA)	Other cardiac preparations (C01EB)	Antiepileptics (N03A)	Other cardiac preparations (C01E)	0					N03AA	N03A	C01EB	C01E
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			57	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			68	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			165	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			244	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1031	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2003	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2891	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3002	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3117	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3156	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3395	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3525	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4258	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4317	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4708	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5521	N03AA	N03A	A02BC	A02B
11670	phenobarbital	reduces	3A457	lansoprazole		N03AA02	A02BC03	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5828	N03AA	N03A	A02BC	A02B
11672	phenobarbital	reduces	3A457	lercanidipine		N03AA02	C08CA13	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N03AA	N03A	C08CA	C08C
11678	phenobarbital	reduces	2C9	losartan	A	N03AA02	C09CA01	Barbiturates and derivatives (N03AA)	Angiotensin II receptor blockers, plain (C09CA)	Antiepileptics (N03A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	3166	N03AA	N03A	C09CA	C09C
11679	phenobarbital	reduces	3A457	lovastatin		N03AA02	C10AA02	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N03AA	N03A	C10AA	C10A
11681	phenobarbital	reduces	2C9	meloxicam		N03AA02	M01AC06	Barbiturates and derivatives (N03AA)	Oxicams (M01AC)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N03AA	N03A	M01AC	M01A
11683	phenobarbital	reduces	2B6,3A457	methadone	C	N03AA02	N07BC02	Barbiturates and derivatives (N03AA)	Drugs used in opioid dependence (N07BC)	Antiepileptics (N03A)	Drugs used in addictive disorders (N07B)	0	0				N03AA	N03A	N07BC	N07B
11684	phenobarbital	reduces	3A457	midazolam	C	N03AA02	N05CD08	Barbiturates and derivatives (N03AA)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AA	N03A	N05CD	N05C
11687	phenobarbital	reduces	2C9	naproxen	C	N03AA02	M01AE02	Barbiturates and derivatives (N03AA)	Propionic acid derivatives (M01AE)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AA	N03A	M01AE	M01A
11691	phenobarbital	reduces	2B6,3A457	nevirapine		N03AA02	J05AG01	Barbiturates and derivatives (N03AA)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AA	N03A	J05AG	J05A
11692	phenobarbital	reduces	3A457	nifedipine	D	N03AA02	C08CA05	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AA	N03A	C08CA	C08C
11693	phenobarbital	reduces	3A457	nisoldipine	D	N03AA02	C08CA07	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AA	N03A	C08CA	C08C
11694	phenobarbital	reduces	3A457	nitrendipine	D	N03AA02	C08CA08	Barbiturates and derivatives (N03AA)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AA	N03A	C08CA	C08C
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			72	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			203	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			336	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			817	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1378	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1412	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2232	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2390	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3166	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3525	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3591	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4667	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5339	N03AA	N03A	A02BC	A02B
11697	phenobarbital	reduces	3A457	omeprazole		N03AA02	A02BC01	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5517	N03AA	N03A	A02BC	A02B
11698	phenobarbital	reduces	3A457	ondansetron		N03AA02	A04AA01	Barbiturates and derivatives (N03AA)	Serotonin (5HT3) antagonists (A04AA)	Antiepileptics (N03A)	Antiemetics and antinauseants (A04A)	0	0				N03AA	N03A	A04AA	A04A
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			121	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			817	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2332	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3513	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3774	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4292	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4293	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5008	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5031	N03AA	N03A	A02BC	A02B
11705	phenobarbital	reduces	3A457	pantoprazole		N03AA02	A02BC02	Barbiturates and derivatives (N03AA)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7115	N03AA	N03A	A02BC	A02B
11707	phenobarbital	reduces	2C9	phenytoin	B	N03AA02	N03AB02	Barbiturates and derivatives (N03AA)	Hydantoin derivatives (N03AB)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3166	N03AA	N03A	N03AB	N03A
11707	phenobarbital	reduces	2C9	phenytoin	B	N03AA02	N03AB02	Barbiturates and derivatives (N03AA)	Hydantoin derivatives (N03AB)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	7407	N03AA	N03A	N03AB	N03A
11710	phenobarbital	reduces	2C9	piroxicam		N03AA02	M01AC01	Barbiturates and derivatives (N03AA)	Oxicams (M01AC)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				N03AA	N03A	M01AC	M01A
11715	phenobarbital	reduces	3A457	propranolol	B	N03AA02	C07AA05	Barbiturates and derivatives (N03AA)	Beta blocking agents, non-selective (C07AA)	Antiepileptics (N03A)	Beta blocking agents (C07A)	0				817	N03AA	N03A	C07AA	C07A
11716	phenobarbital	reduces	3A457	quetiapine	C	N03AA02	N05AH04	Barbiturates and derivatives (N03AA)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				2552	N03AA	N03A	N05AH	N05A
11716	phenobarbital	reduces	3A457	quetiapine	C	N03AA02	N05AH04	Barbiturates and derivatives (N03AA)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				3320	N03AA	N03A	N05AH	N05A
11722	phenobarbital	reduces	3A457	risperidone	B	N03AA02	N05AX08	Barbiturates and derivatives (N03AA)	Other antipsychotics (N05AX)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	6062	N03AA	N03A	N05AX	N05A
11723	phenobarbital	reduces	3A457	ritonavir		N03AA02	J05AE03	Barbiturates and derivatives (N03AA)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AA	N03A	J05AE	J05A
11724	phenobarbital	reduces	3A457	rivaroxaban		N03AA02	B01AF01	Barbiturates and derivatives (N03AA)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AA	N03A	B01AF	B01A
11731	phenobarbital	reduces	3A457	salmeterol		N03AA02	R03AC12	Barbiturates and derivatives (N03AA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				1388	N03AA	N03A	R03AC	R03A
11731	phenobarbital	reduces	3A457	salmeterol		N03AA02	R03AC12	Barbiturates and derivatives (N03AA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				3324	N03AA	N03A	R03AC	R03A
11731	phenobarbital	reduces	3A457	salmeterol		N03AA02	R03AC12	Barbiturates and derivatives (N03AA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				5031	N03AA	N03A	R03AC	R03A
11731	phenobarbital	reduces	3A457	salmeterol		N03AA02	R03AC12	Barbiturates and derivatives (N03AA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				5521	N03AA	N03A	R03AC	R03A
11732	phenobarbital	reduces	3A457	saquinavir	B	N03AA02	J05AE01	Barbiturates and derivatives (N03AA)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AA	N03A	J05AE	J05A
11733	phenobarbital	reduces	2B6	selegiline		N03AA02	N04BD01	Barbiturates and derivatives (N03AA)	Monoamine oxidase B inhibitors (N04BD)	Antiepileptics (N03A)	Dopaminergic agents (N04B)	0	0				N03AA	N03A	N04BD	N04B
11735	phenobarbital	reduces	3A457	sildenafil	D	N03AA02	G04BE03	Barbiturates and derivatives (N03AA)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AA	N03A	G04BE	G04B
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		68	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1378	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		1521	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3324	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3513	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4293	N03AA	N03A	C10AA	C10A
11737	phenobarbital	reduces	3A457	simvastatin		N03AA02	C10AA01	Barbiturates and derivatives (N03AA)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4667	N03AA	N03A	C10AA	C10A
11738	phenobarbital	reduces	3A457	sirolimus	B	N03AA02	L04AA10	Barbiturates and derivatives (N03AA)	Selective immunosuppressants (L04AA)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AA	N03A	L04AA	L04A
11740	phenobarbital	reduces	2B6,3A457	sorafenib	B	N03AA02	L01XE05	Barbiturates and derivatives (N03AA)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AA	N03A	L01XE	L01X
11741	phenobarbital	reduces	3A457	sunitinib	D	N03AA02	L01XE04	Barbiturates and derivatives (N03AA)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AA	N03A	L01XE	L01X
11744	phenobarbital	reduces	3A457	tacrolimus	C	N03AA02	L04AD02	Barbiturates and derivatives (N03AA)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AA	N03A	L04AD	L04A
11745	phenobarbital	reduces	3A457	tadalafil		N03AA02	G04BE08	Barbiturates and derivatives (N03AA)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AA	N03A	G04BE	G04B
11746	phenobarbital	reduces	2C9,3A457	tamoxifen		N03AA02	L02BA01	Barbiturates and derivatives (N03AA)	Anti-estrogens (L02BA)	Antiepileptics (N03A)	Hormone antagonists and related agents (L02B)	1	1				N03AA	N03A	L02BA	L02B
11752	phenobarbital	reduces	3A457	testosterone		N03AA02	G03BA03	Barbiturates and derivatives (N03AA)	3-oxoandrosten (4) derivatives (G03BA)	Antiepileptics (N03A)	Androgens (G03B)	0					N03AA	N03A	G03BA	G03B
11753	phenobarbital	reduces	3A457	ticagrelor		N03AA02	B01AC24	Barbiturates and derivatives (N03AA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AA	N03A	B01AC	B01A
11757	phenobarbital	reduces	2C9	torasemide		N03AA02	C03CA04	Barbiturates and derivatives (N03AA)	Sulfonamides, plain (C03CA)	Antiepileptics (N03A)	High-ceiling diuretics (C03C)	0	0			817	N03AA	N03A	C03CA	C03C
11758	phenobarbital	reduces	2B6,3A457	tramadol		N03AA02	N02AX02	Barbiturates and derivatives (N03AA)	Other opioids (N02AX)	Antiepileptics (N03A)	Opioids (N02A)	0	1		Reduced analgesic effect		N03AA	N03A	N02AX	N02A
11759	phenobarbital	reduces	3A457	trazodone		N03AA02	N06AX05	Barbiturates and derivatives (N03AA)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		165	N03AA	N03A	N06AX	N06A
11759	phenobarbital	reduces	3A457	trazodone		N03AA02	N06AX05	Barbiturates and derivatives (N03AA)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		1378	N03AA	N03A	N06AX	N06A
11760	phenobarbital	reduces	3A457	triazolam	C	N03AA02	N05CD05	Barbiturates and derivatives (N03AA)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	68	N03AA	N03A	N05CD	N05C
11762	phenobarbital	reduces	2C9	valproate	B	N03AA02	N03AG01	Barbiturates and derivatives (N03AA)	Fatty acid derivatives (N03AG)	Antiepileptics (N03A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N03AA	N03A	N03AG	N03A
11768	phenobarbital	reduces	2C9,3A457	venlafaxine	B	N03AA02	N06AX16	Barbiturates and derivatives (N03AA)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2031	N03AA	N03A	N06AX	N06A
11769	phenobarbital	reduces	3A457	verapamil	B	N03AA02	C08DA01	Barbiturates and derivatives (N03AA)	Phenylalkylamine derivatives (C08DA)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3591	N03AA	N03A	C08DA	C08D
11773	phenobarbital	reduces	2C9,3A457	voriconazole	D	N03AA02	J02AC03	Barbiturates and derivatives (N03AA)	Triazole derivatives (J02AC)	Antiepileptics (N03A)	Antimycotics for systemic use (J02A)	0	0				N03AA	N03A	J02AC	J02A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		165	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		1163	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		1405	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		2332	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		3092	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		3216	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		3591	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		4293	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		4911	N03AA	N03A	B01AA	B01A
11774	phenobarbital	reduces	2C9	warfarin	B	N03AA02	B01AA03	Barbiturates and derivatives (N03AA)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		5031	N03AA	N03A	B01AA	B01A
11776	phenobarbital	reduces	3A457	zaleplon	D	N03AA02	N05CF03	Barbiturates and derivatives (N03AA)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AA	N03A	N05CF	N05C
11778	phenobarbital	reduces	3A457	zolpidem	D	N03AA02	N05CF02	Barbiturates and derivatives (N03AA)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AA	N03A	N05CF	N05C
11819	phenytoin	reduces	3A457	alprazolam		N03AB02	N05BA12	Hydantoin derivatives (N03AB)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AB	N03A	N05BA	N05B
11820	phenytoin	reduces	3A457	amitriptyline	B	N03AB02	N06AA09	Hydantoin derivatives (N03AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AB	N03A	N06AA	N06A
11821	phenytoin	reduces	3A457	amlodipine		N03AB02	C08CA01	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AB	N03A	C08CA	C08C
11822	phenytoin	reduces	3A457	apixaban	B	N03AB02	B01AF02	Hydantoin derivatives (N03AB)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AB	N03A	B01AF	B01A
11827	phenytoin	reduces	3A457	atorvastatin	B	N03AB02	C10AA05	Hydantoin derivatives (N03AB)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		930	N03AB	N03A	C10AA	C10A
11834	phenytoin	reduces	2B6	bupropion	B	N03AB02	N06AX12	Hydantoin derivatives (N03AB)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AB	N03A	N06AX	N06A
11837	phenytoin	reduces	3A457	carbamazepine	B	N03AB02	N03AF01	Hydantoin derivatives (N03AB)	Carboxamide derivatives (N03AF)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	930	N03AB	N03A	N03AF	N03A
11841	phenytoin	reduces	3A457	chlorpheniramine	B	N03AB02	R06AB04	Hydantoin derivatives (N03AB)	Substituted alkylamines (R06AB)	Antiepileptics (N03A)	Antihistamines for systemic use (R06A)	0	0				N03AB	N03A	R06AB	R06A
11842	phenytoin	reduces	3A457	cilostazol		N03AB02	B01AC23	Hydantoin derivatives (N03AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AB	N03A	B01AC	B01A
11844	phenytoin	reduces	3A457	citalopram		N03AB02	N06AB04	Hydantoin derivatives (N03AB)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0				N03AB	N03A	N06AB	N06A
11845	phenytoin	reduces	3A457	clarithromycin	B	N03AB02	J01FA09	Hydantoin derivatives (N03AB)	Macrolides (J01FA)	Antiepileptics (N03A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				N03AB	N03A	J01FA	J01F
11846	phenytoin	reduces	2B6,3A457	clobazam	B	N03AB02	N05BA09	Hydantoin derivatives (N03AB)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0					N03AB	N03A	N05BA	N05B
11847	phenytoin	reduces	3A457	clopidogrel		N03AB02	B01AC04	Hydantoin derivatives (N03AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		N03AB	N03A	B01AC	B01A
11851	phenytoin	reduces	3A457	colchicine		N03AB02	M04AC01	Hydantoin derivatives (N03AB)	Preparations with no effect on uric acid metabolism (M04AC)	Antiepileptics (N03A)	Antigout preparations (M04A)	0					N03AB	N03A	M04AC	M04A
11854	phenytoin	reduces	2B6	cyclophosphamide	C	N03AB02	L01AA01	Hydantoin derivatives (N03AB)	Nitrogen mustard analogues (L01AA)	Antiepileptics (N03A)	Alkylating agents (L01A)	1	1				N03AB	N03A	L01AA	L01A
11855	phenytoin	reduces	3A457	cyclosporine	C	N03AB02	L04AD01	Hydantoin derivatives (N03AB)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity		3166	N03AB	N03A	L04AD	L04A
11859	phenytoin	reduces	3A457	deflazacort	B	N03AB02	H02AB13	Hydantoin derivatives (N03AB)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AB	N03A	H02AB	H02A
11860	phenytoin	reduces	3A457	dexamethasone	B	N03AB02	H02AB02	Hydantoin derivatives (N03AB)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AB	N03A	H02AB	H02A
11861	phenytoin	reduces	3A457	dextromethorphan		N03AB02	R05DA09	Hydantoin derivatives (N03AB)	Opium alkaloids and derivatives (R05DA)	Antiepileptics (N03A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N03AB	N03A	R05DA	R05D
11862	phenytoin	reduces	3A457	diazepam	B	N03AB02	N05BA01	Hydantoin derivatives (N03AB)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AB	N03A	N05BA	N05B
11863	phenytoin	reduces	3A457	diltiazem	B	N03AB02	C08DB01	Hydantoin derivatives (N03AB)	Benzothiazepine derivatives (C08DB)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			N03AB	N03A	C08DB	C08D
11866	phenytoin	reduces	3A457	domperidone		N03AB02	A03FA03	Hydantoin derivatives (N03AB)	Propulsives (A03FA)	Antiepileptics (N03A)	Propulsives (A03F)	0					N03AB	N03A	A03FA	A03F
11868	phenytoin	reduces	2B6	efavirenz		N03AB02	J05AG03	Hydantoin derivatives (N03AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AB	N03A	J05AG	J05A
11873	phenytoin	reduces	3A457	eplerenone	D	N03AB02	C03DA04	Hydantoin derivatives (N03AB)	Aldosterone antagonists (C03DA)	Antiepileptics (N03A)	Potassium-sparing agents (C03D)	0					N03AB	N03A	C03DA	C03D
11876	phenytoin	reduces	3A457	escitalopram		N03AB02	N06AB10	Hydantoin derivatives (N03AB)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0				3166	N03AB	N03A	N06AB	N06A
11877	phenytoin	reduces	3A457	esomeprazole		N03AB02	A02BC05	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					N03AB	N03A	A02BC	A02B
11879	phenytoin	reduces	3A457	felodipine	B	N03AB02	C08CA02	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AB	N03A	C08CA	C08C
11883	phenytoin	reduces	3A457	haloperidol		N03AB02	N05AD01	Hydantoin derivatives (N03AB)	Butyrophenone derivatives (N05AD)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3121	N03AB	N03A	N05AD	N05A
11884	phenytoin	reduces	3A457	hydrocortisone	B	N03AB02	H02AB09	Hydantoin derivatives (N03AB)	Glucocorticoids (H02AB)	Antiepileptics (N03A)	Corticosteroids for systemic use, plain (H02A)	0					N03AB	N03A	H02AB	H02A
11888	phenytoin	reduces	3A457	imatinib	D	N03AB02	L01XE01	Hydantoin derivatives (N03AB)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	0	0				N03AB	N03A	L01XE	L01X
11889	phenytoin	reduces	3A457	indacaterol		N03AB02	R03AC18	Hydantoin derivatives (N03AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0					N03AB	N03A	R03AC	R03A
11893	phenytoin	reduces	3A457	ivabradine		N03AB02	C01EB17	Hydantoin derivatives (N03AB)	Other cardiac preparations (C01EB)	Antiepileptics (N03A)	Other cardiac preparations (C01E)	0					N03AB	N03A	C01EB	C01E
11896	phenytoin	reduces	3A457	lansoprazole		N03AB02	A02BC03	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			796	N03AB	N03A	A02BC	A02B
11896	phenytoin	reduces	3A457	lansoprazole		N03AB02	A02BC03	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1596	N03AB	N03A	A02BC	A02B
11896	phenytoin	reduces	3A457	lansoprazole		N03AB02	A02BC03	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3066	N03AB	N03A	A02BC	A02B
11896	phenytoin	reduces	3A457	lansoprazole		N03AB02	A02BC03	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7560	N03AB	N03A	A02BC	A02B
11898	phenytoin	reduces	3A457	lercanidipine		N03AB02	C08CA13	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					N03AB	N03A	C08CA	C08C
11902	phenytoin	reduces	3A457	lovastatin	D	N03AB02	C10AA02	Hydantoin derivatives (N03AB)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N03AB	N03A	C10AA	C10A
11905	phenytoin	reduces	2B6,3A457	methadone	C	N03AB02	N07BC02	Hydantoin derivatives (N03AB)	Drugs used in opioid dependence (N07BC)	Antiepileptics (N03A)	Drugs used in addictive disorders (N07B)	0	0				N03AB	N03A	N07BC	N07B
11906	phenytoin	reduces	3A457	midazolam	B	N03AB02	N05CD08	Hydantoin derivatives (N03AB)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AB	N03A	N05CD	N05C
11912	phenytoin	reduces	2B6,3A457	nevirapine		N03AB02	J05AG01	Hydantoin derivatives (N03AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AB	N03A	J05AG	J05A
11913	phenytoin	reduces	3A457	nifedipine	D	N03AB02	C08CA05	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AB	N03A	C08CA	C08C
11914	phenytoin	reduces	3A457	nisoldipine	D	N03AB02	C08CA07	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AB	N03A	C08CA	C08C
11915	phenytoin	reduces	3A457	nitrendipine	D	N03AB02	C08CA08	Hydantoin derivatives (N03AB)	Dihydropyridine derivatives (C08CA)	Antiepileptics (N03A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		N03AB	N03A	C08CA	C08C
11917	phenytoin	reduces	3A457	omeprazole	B	N03AB02	A02BC01	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3166	N03AB	N03A	A02BC	A02B
11918	phenytoin	reduces	3A457	ondansetron	B	N03AB02	A04AA01	Hydantoin derivatives (N03AB)	Serotonin (5HT3) antagonists (A04AA)	Antiepileptics (N03A)	Antiemetics and antinauseants (A04A)	0	0				N03AB	N03A	A04AA	A04A
11925	phenytoin	reduces	3A457	pantoprazole		N03AB02	A02BC02	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2240	N03AB	N03A	A02BC	A02B
11925	phenytoin	reduces	3A457	pantoprazole		N03AB02	A02BC02	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3092	N03AB	N03A	A02BC	A02B
11925	phenytoin	reduces	3A457	pantoprazole		N03AB02	A02BC02	Hydantoin derivatives (N03AB)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4684	N03AB	N03A	A02BC	A02B
11933	phenytoin	reduces	3A457	propranolol		N03AB02	C07AA05	Hydantoin derivatives (N03AB)	Beta blocking agents, non-selective (C07AA)	Antiepileptics (N03A)	Beta blocking agents (C07A)	0					N03AB	N03A	C07AA	C07A
11934	phenytoin	reduces	3A457	quetiapine	C	N03AB02	N05AH04	Hydantoin derivatives (N03AB)	Diazepines, oxazepines and thiazepines (N05AH)	Antiepileptics (N03A)	Antipsychotics (N05A)	0				1596	N03AB	N03A	N05AH	N05A
11940	phenytoin	reduces	3A457	risperidone	C	N03AB02	N05AX08	Hydantoin derivatives (N03AB)	Other antipsychotics (N05AX)	Antiepileptics (N03A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N03AB	N03A	N05AX	N05A
11941	phenytoin	reduces	3A457	ritonavir	B	N03AB02	J05AE03	Hydantoin derivatives (N03AB)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AB	N03A	J05AE	J05A
11942	phenytoin	reduces	3A457	rivaroxaban	C	N03AB02	B01AF01	Hydantoin derivatives (N03AB)	Direct factor Xa inhibitors (B01AF)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AB	N03A	B01AF	B01A
11948	phenytoin	reduces	3A457	salmeterol		N03AB02	R03AC12	Hydantoin derivatives (N03AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antiepileptics (N03A)	Adrenergics, inhalants (R03A)	0				796	N03AB	N03A	R03AC	R03A
11949	phenytoin	reduces	3A457	saquinavir	B	N03AB02	J05AE01	Hydantoin derivatives (N03AB)	Protease inhibitors (J05AE)	Antiepileptics (N03A)	Direct acting antivirals (J05A)	0	0				N03AB	N03A	J05AE	J05A
11950	phenytoin	reduces	2B6	selegiline		N03AB02	N04BD01	Hydantoin derivatives (N03AB)	Monoamine oxidase B inhibitors (N04BD)	Antiepileptics (N03A)	Dopaminergic agents (N04B)	0	0				N03AB	N03A	N04BD	N04B
11952	phenytoin	reduces	3A457	sildenafil	D	N03AB02	G04BE03	Hydantoin derivatives (N03AB)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AB	N03A	G04BE	G04B
11954	phenytoin	reduces	3A457	simvastatin	B	N03AB02	C10AA01	Hydantoin derivatives (N03AB)	HMG CoA reductase inhibitors (C10AA)	Antiepileptics (N03A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			N03AB	N03A	C10AA	C10A
11955	phenytoin	reduces	3A457	sirolimus	D	N03AB02	L04AA10	Hydantoin derivatives (N03AB)	Selective immunosuppressants (L04AA)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AB	N03A	L04AA	L04A
11957	phenytoin	reduces	2B6,3A457	sorafenib	B	N03AB02	L01XE05	Hydantoin derivatives (N03AB)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AB	N03A	L01XE	L01X
11958	phenytoin	reduces	3A457	sunitinib	D	N03AB02	L01XE04	Hydantoin derivatives (N03AB)	 (L01XE)	Antiepileptics (N03A)	Other antineoplastic agents (L01X)	1					N03AB	N03A	L01XE	L01X
11960	phenytoin	reduces	3A457	tacrolimus	C	N03AB02	L04AD02	Hydantoin derivatives (N03AB)	Calcineurin inhibitors (L04AD)	Antiepileptics (N03A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			N03AB	N03A	L04AD	L04A
11961	phenytoin	reduces	3A457	tadalafil	B	N03AB02	G04BE08	Hydantoin derivatives (N03AB)	Drugs used in erectile dysfunction (G04BE)	Antiepileptics (N03A)	Urologicals (G04B)	0	0				N03AB	N03A	G04BE	G04B
11962	phenytoin	reduces	3A457	tamoxifen		N03AB02	L02BA01	Hydantoin derivatives (N03AB)	Anti-estrogens (L02BA)	Antiepileptics (N03A)	Hormone antagonists and related agents (L02B)	1	1				N03AB	N03A	L02BA	L02B
11968	phenytoin	reduces	3A457	testosterone		N03AB02	G03BA03	Hydantoin derivatives (N03AB)	3-oxoandrosten (4) derivatives (G03BA)	Antiepileptics (N03A)	Androgens (G03B)	0					N03AB	N03A	G03BA	G03B
11969	phenytoin	reduces	3A457	ticagrelor		N03AB02	B01AC24	Hydantoin derivatives (N03AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0					N03AB	N03A	B01AC	B01A
11972	phenytoin	reduces	2B6,3A457	tramadol		N03AB02	N02AX02	Hydantoin derivatives (N03AB)	Other opioids (N02AX)	Antiepileptics (N03A)	Opioids (N02A)	0	1		Reduced analgesic effect		N03AB	N03A	N02AX	N02A
11973	phenytoin	reduces	3A457	trazodone	B	N03AB02	N06AX05	Hydantoin derivatives (N03AB)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity		1596	N03AB	N03A	N06AX	N06A
11974	phenytoin	reduces	3A457	triazolam		N03AB02	N05CD05	Hydantoin derivatives (N03AB)	Benzodiazepine derivatives (N05CD)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AB	N03A	N05CD	N05C
11981	phenytoin	reduces	3A457	venlafaxine		N03AB02	N06AX16	Hydantoin derivatives (N03AB)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AB	N03A	N06AX	N06A
11982	phenytoin	reduces	3A457	verapamil	B	N03AB02	C08DA01	Hydantoin derivatives (N03AB)	Phenylalkylamine derivatives (C08DA)	Antiepileptics (N03A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		3268	N03AB	N03A	C08DA	C08D
11986	phenytoin	reduces	3A457	voriconazole	D	N03AB02	J02AC03	Hydantoin derivatives (N03AB)	Triazole derivatives (J02AC)	Antiepileptics (N03A)	Antimycotics for systemic use (J02A)	0	0				N03AB	N03A	J02AC	J02A
11987	phenytoin	reduces	3A457	zaleplon	D	N03AB02	N05CF03	Hydantoin derivatives (N03AB)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AB	N03A	N05CF	N05C
11989	phenytoin	reduces	3A457	zolpidem	D	N03AB02	N05CF02	Hydantoin derivatives (N03AB)	Benzodiazepine related drugs (N05CF)	Antiepileptics (N03A)	Hypnotics and sedatives (N05C)	0					N03AB	N03A	N05CF	N05C
11995	pioglitazone	reduces	3A457	alprazolam		A10BG03	N05BA12	Thiazolidinediones (A10BG)	Benzodiazepine derivatives (N05BA)	Blood glucose lowering drugs, excl. insulins (A10B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A10BG	A10B	N05BA	N05B
11996	pioglitazone	reduces	3A457	amitriptyline		A10BG03	N06AA09	Thiazolidinediones (A10BG)	Non-selective monoamine reuptake inhibitors (N06AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A10BG	A10B	N06AA	N06A
11997	pioglitazone	reduces	3A457	amlodipine		A10BG03	C08CA01	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2481	A10BG	A10B	C08CA	C08C
11997	pioglitazone	reduces	3A457	amlodipine		A10BG03	C08CA01	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	4438	A10BG	A10B	C08CA	C08C
11997	pioglitazone	reduces	3A457	amlodipine		A10BG03	C08CA01	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6095	A10BG	A10B	C08CA	C08C
11997	pioglitazone	reduces	3A457	amlodipine		A10BG03	C08CA01	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7606	A10BG	A10B	C08CA	C08C
11998	pioglitazone	reduces	3A457	apixaban		A10BG03	B01AF02	Thiazolidinediones (A10BG)	Direct factor Xa inhibitors (B01AF)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0					A10BG	A10B	B01AF	B01A
12002	pioglitazone	reduces	3A457	atorvastatin	B	A10BG03	C10AA05	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2192	A10BG	A10B	C10AA	C10A
12002	pioglitazone	reduces	3A457	atorvastatin	B	A10BG03	C10AA05	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4438	A10BG	A10B	C10AA	C10A
12002	pioglitazone	reduces	3A457	atorvastatin	B	A10BG03	C10AA05	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5173	A10BG	A10B	C10AA	C10A
12002	pioglitazone	reduces	3A457	atorvastatin	B	A10BG03	C10AA05	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6095	A10BG	A10B	C10AA	C10A
12002	pioglitazone	reduces	3A457	atorvastatin	B	A10BG03	C10AA05	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7154	A10BG	A10B	C10AA	C10A
12011	pioglitazone	reduces	3A457	carbamazepine		A10BG03	N03AF01	Thiazolidinediones (A10BG)	Carboxamide derivatives (N03AF)	Blood glucose lowering drugs, excl. insulins (A10B)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		A10BG	A10B	N03AF	N03A
12015	pioglitazone	reduces	3A457	chlorpheniramine		A10BG03	R06AB04	Thiazolidinediones (A10BG)	Substituted alkylamines (R06AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Antihistamines for systemic use (R06A)	0	0				A10BG	A10B	R06AB	R06A
12016	pioglitazone	reduces	3A457	cilostazol		A10BG03	B01AC23	Thiazolidinediones (A10BG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0					A10BG	A10B	B01AC	B01A
12018	pioglitazone	reduces	3A457	citalopram		A10BG03	N06AB04	Thiazolidinediones (A10BG)	Selective serotonin reuptake inhibitors (N06AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Antidepressants (N06A)	0	0				A10BG	A10B	N06AB	N06A
12019	pioglitazone	reduces	3A457	clarithromycin		A10BG03	J01FA09	Thiazolidinediones (A10BG)	Macrolides (J01FA)	Blood glucose lowering drugs, excl. insulins (A10B)	Macrolides, lincosamides and streptogramins (J01F)	0	0				A10BG	A10B	J01FA	J01F
12020	pioglitazone	reduces	3A457	clobazam		A10BG03	N05BA09	Thiazolidinediones (A10BG)	Benzodiazepine derivatives (N05BA)	Blood glucose lowering drugs, excl. insulins (A10B)	Anxiolytics (N05B)	0					A10BG	A10B	N05BA	N05B
12021	pioglitazone	reduces	3A457	clopidogrel		A10BG03	B01AC04	Thiazolidinediones (A10BG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	38	A10BG	A10B	B01AC	B01A
12021	pioglitazone	reduces	3A457	clopidogrel		A10BG03	B01AC04	Thiazolidinediones (A10BG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4493	A10BG	A10B	B01AC	B01A
12021	pioglitazone	reduces	3A457	clopidogrel		A10BG03	B01AC04	Thiazolidinediones (A10BG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7245	A10BG	A10B	B01AC	B01A
12025	pioglitazone	reduces	3A457	colchicine		A10BG03	M04AC01	Thiazolidinediones (A10BG)	Preparations with no effect on uric acid metabolism (M04AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antigout preparations (M04A)	0					A10BG	A10B	M04AC	M04A
12028	pioglitazone	reduces	3A457	cyclosporine		A10BG03	L04AD01	Thiazolidinediones (A10BG)	Calcineurin inhibitors (L04AD)	Blood glucose lowering drugs, excl. insulins (A10B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A10BG	A10B	L04AD	L04A
12032	pioglitazone	reduces	3A457	deflazacort		A10BG03	H02AB13	Thiazolidinediones (A10BG)	Glucocorticoids (H02AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Corticosteroids for systemic use, plain (H02A)	0					A10BG	A10B	H02AB	H02A
12033	pioglitazone	reduces	3A457	dexamethasone		A10BG03	H02AB02	Thiazolidinediones (A10BG)	Glucocorticoids (H02AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Corticosteroids for systemic use, plain (H02A)	0					A10BG	A10B	H02AB	H02A
12034	pioglitazone	reduces	3A457	dextromethorphan		A10BG03	R05DA09	Thiazolidinediones (A10BG)	Opium alkaloids and derivatives (R05DA)	Blood glucose lowering drugs, excl. insulins (A10B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				A10BG	A10B	R05DA	R05D
12035	pioglitazone	reduces	3A457	diazepam	B	A10BG03	N05BA01	Thiazolidinediones (A10BG)	Benzodiazepine derivatives (N05BA)	Blood glucose lowering drugs, excl. insulins (A10B)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A10BG	A10B	N05BA	N05B
12036	pioglitazone	reduces	3A457	diltiazem		A10BG03	C08DB01	Thiazolidinediones (A10BG)	Benzothiazepine derivatives (C08DB)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			A10BG	A10B	C08DB	C08D
12039	pioglitazone	reduces	3A457	domperidone		A10BG03	A03FA03	Thiazolidinediones (A10BG)	Propulsives (A03FA)	Blood glucose lowering drugs, excl. insulins (A10B)	Propulsives (A03F)	0					A10BG	A10B	A03FA	A03F
12045	pioglitazone	reduces	3A457	eplerenone		A10BG03	C03DA04	Thiazolidinediones (A10BG)	Aldosterone antagonists (C03DA)	Blood glucose lowering drugs, excl. insulins (A10B)	Potassium-sparing agents (C03D)	0					A10BG	A10B	C03DA	C03D
12048	pioglitazone	reduces	3A457	escitalopram		A10BG03	N06AB10	Thiazolidinediones (A10BG)	Selective serotonin reuptake inhibitors (N06AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Antidepressants (N06A)	0					A10BG	A10B	N06AB	N06A
12049	pioglitazone	reduces	3A457	esomeprazole		A10BG03	A02BC05	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4438	A10BG	A10B	A02BC	A02B
12051	pioglitazone	reduces	3A457	felodipine		A10BG03	C08CA02	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A10BG	A10B	C08CA	C08C
12055	pioglitazone	reduces	3A457	haloperidol		A10BG03	N05AD01	Thiazolidinediones (A10BG)	Butyrophenone derivatives (N05AD)	Blood glucose lowering drugs, excl. insulins (A10B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A10BG	A10B	N05AD	N05A
12056	pioglitazone	reduces	3A457	hydrocortisone	A	A10BG03	H02AB09	Thiazolidinediones (A10BG)	Glucocorticoids (H02AB)	Blood glucose lowering drugs, excl. insulins (A10B)	Corticosteroids for systemic use, plain (H02A)	0					A10BG	A10B	H02AB	H02A
12059	pioglitazone	reduces	3A457	imatinib		A10BG03	L01XE01	Thiazolidinediones (A10BG)	 (L01XE)	Blood glucose lowering drugs, excl. insulins (A10B)	Other antineoplastic agents (L01X)	0	0				A10BG	A10B	L01XE	L01X
12060	pioglitazone	reduces	3A457	indacaterol		A10BG03	R03AC18	Thiazolidinediones (A10BG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Adrenergics, inhalants (R03A)	0					A10BG	A10B	R03AC	R03A
12064	pioglitazone	reduces	3A457	ivabradine		A10BG03	C01EB17	Thiazolidinediones (A10BG)	Other cardiac preparations (C01EB)	Blood glucose lowering drugs, excl. insulins (A10B)	Other cardiac preparations (C01E)	0				7245	A10BG	A10B	C01EB	C01E
12066	pioglitazone	reduces	3A457	lansoprazole		A10BG03	A02BC03	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4098	A10BG	A10B	A02BC	A02B
12066	pioglitazone	reduces	3A457	lansoprazole		A10BG03	A02BC03	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7245	A10BG	A10B	A02BC	A02B
12066	pioglitazone	reduces	3A457	lansoprazole		A10BG03	A02BC03	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7606	A10BG	A10B	A02BC	A02B
12068	pioglitazone	reduces	3A457	lercanidipine		A10BG03	C08CA13	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					A10BG	A10B	C08CA	C08C
12072	pioglitazone	reduces	3A457	lovastatin	B	A10BG03	C10AA02	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			A10BG	A10B	C10AA	C10A
12074	pioglitazone	reduces	3A457	methadone		A10BG03	N07BC02	Thiazolidinediones (A10BG)	Drugs used in opioid dependence (N07BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs used in addictive disorders (N07B)	0	0				A10BG	A10B	N07BC	N07B
12075	pioglitazone	reduces	3A457	midazolam		A10BG03	N05CD08	Thiazolidinediones (A10BG)	Benzodiazepine derivatives (N05CD)	Blood glucose lowering drugs, excl. insulins (A10B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A10BG	A10B	N05CD	N05C
12081	pioglitazone	reduces	3A457	nevirapine		A10BG03	J05AG01	Thiazolidinediones (A10BG)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Blood glucose lowering drugs, excl. insulins (A10B)	Direct acting antivirals (J05A)	0	0				A10BG	A10B	J05AG	J05A
12082	pioglitazone	reduces	3A457	nifedipine		A10BG03	C08CA05	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7154	A10BG	A10B	C08CA	C08C
12083	pioglitazone	reduces	3A457	nisoldipine		A10BG03	C08CA07	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A10BG	A10B	C08CA	C08C
12084	pioglitazone	reduces	3A457	nitrendipine		A10BG03	C08CA08	Thiazolidinediones (A10BG)	Dihydropyridine derivatives (C08CA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		A10BG	A10B	C08CA	C08C
12086	pioglitazone	reduces	3A457	omeprazole		A10BG03	A02BC01	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2481	A10BG	A10B	A02BC	A02B
12086	pioglitazone	reduces	3A457	omeprazole		A10BG03	A02BC01	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6095	A10BG	A10B	A02BC	A02B
12086	pioglitazone	reduces	3A457	omeprazole		A10BG03	A02BC01	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6220	A10BG	A10B	A02BC	A02B
12086	pioglitazone	reduces	3A457	omeprazole		A10BG03	A02BC01	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7154	A10BG	A10B	A02BC	A02B
12087	pioglitazone	reduces	3A457	ondansetron		A10BG03	A04AA01	Thiazolidinediones (A10BG)	Serotonin (5HT3) antagonists (A04AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Antiemetics and antinauseants (A04A)	0	0				A10BG	A10B	A04AA	A04A
12094	pioglitazone	reduces	3A457	pantoprazole		A10BG03	A02BC02	Thiazolidinediones (A10BG)	Proton pump inhibitors (A02BC)	Blood glucose lowering drugs, excl. insulins (A10B)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4493	A10BG	A10B	A02BC	A02B
12101	pioglitazone	reduces	3A457	propranolol	B	A10BG03	C07AA05	Thiazolidinediones (A10BG)	Beta blocking agents, non-selective (C07AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Beta blocking agents (C07A)	0					A10BG	A10B	C07AA	C07A
12102	pioglitazone	reduces	3A457	quetiapine		A10BG03	N05AH04	Thiazolidinediones (A10BG)	Diazepines, oxazepines and thiazepines (N05AH)	Blood glucose lowering drugs, excl. insulins (A10B)	Antipsychotics (N05A)	0					A10BG	A10B	N05AH	N05A
12108	pioglitazone	reduces	3A457	risperidone		A10BG03	N05AX08	Thiazolidinediones (A10BG)	Other antipsychotics (N05AX)	Blood glucose lowering drugs, excl. insulins (A10B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A10BG	A10B	N05AX	N05A
12109	pioglitazone	reduces	3A457	ritonavir		A10BG03	J05AE03	Thiazolidinediones (A10BG)	Protease inhibitors (J05AE)	Blood glucose lowering drugs, excl. insulins (A10B)	Direct acting antivirals (J05A)	0	0				A10BG	A10B	J05AE	J05A
12110	pioglitazone	reduces	3A457	rivaroxaban		A10BG03	B01AF01	Thiazolidinediones (A10BG)	Direct factor Xa inhibitors (B01AF)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0					A10BG	A10B	B01AF	B01A
12116	pioglitazone	reduces	3A457	salmeterol		A10BG03	R03AC12	Thiazolidinediones (A10BG)	Selective beta-2-adrenoreceptor agonists (R03AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Adrenergics, inhalants (R03A)	0				7245	A10BG	A10B	R03AC	R03A
12117	pioglitazone	reduces	3A457	saquinavir		A10BG03	J05AE01	Thiazolidinediones (A10BG)	Protease inhibitors (J05AE)	Blood glucose lowering drugs, excl. insulins (A10B)	Direct acting antivirals (J05A)	0	0				A10BG	A10B	J05AE	J05A
12119	pioglitazone	reduces	3A457	sildenafil		A10BG03	G04BE03	Thiazolidinediones (A10BG)	Drugs used in erectile dysfunction (G04BE)	Blood glucose lowering drugs, excl. insulins (A10B)	Urologicals (G04B)	0	0				A10BG	A10B	G04BE	G04B
12121	pioglitazone	reduces	3A457	simvastatin		A10BG03	C10AA01	Thiazolidinediones (A10BG)	HMG CoA reductase inhibitors (C10AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			A10BG	A10B	C10AA	C10A
12122	pioglitazone	reduces	3A457	sirolimus		A10BG03	L04AA10	Thiazolidinediones (A10BG)	Selective immunosuppressants (L04AA)	Blood glucose lowering drugs, excl. insulins (A10B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A10BG	A10B	L04AA	L04A
12124	pioglitazone	reduces	3A457	sorafenib	B	A10BG03	L01XE05	Thiazolidinediones (A10BG)	 (L01XE)	Blood glucose lowering drugs, excl. insulins (A10B)	Other antineoplastic agents (L01X)	1					A10BG	A10B	L01XE	L01X
12125	pioglitazone	reduces	3A457	sunitinib		A10BG03	L01XE04	Thiazolidinediones (A10BG)	 (L01XE)	Blood glucose lowering drugs, excl. insulins (A10B)	Other antineoplastic agents (L01X)	1					A10BG	A10B	L01XE	L01X
12127	pioglitazone	reduces	3A457	tacrolimus		A10BG03	L04AD02	Thiazolidinediones (A10BG)	Calcineurin inhibitors (L04AD)	Blood glucose lowering drugs, excl. insulins (A10B)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			A10BG	A10B	L04AD	L04A
12128	pioglitazone	reduces	3A457	tadalafil		A10BG03	G04BE08	Thiazolidinediones (A10BG)	Drugs used in erectile dysfunction (G04BE)	Blood glucose lowering drugs, excl. insulins (A10B)	Urologicals (G04B)	0	0				A10BG	A10B	G04BE	G04B
12129	pioglitazone	reduces	3A457	tamoxifen		A10BG03	L02BA01	Thiazolidinediones (A10BG)	Anti-estrogens (L02BA)	Blood glucose lowering drugs, excl. insulins (A10B)	Hormone antagonists and related agents (L02B)	1	1				A10BG	A10B	L02BA	L02B
12135	pioglitazone	reduces	3A457	testosterone		A10BG03	G03BA03	Thiazolidinediones (A10BG)	3-oxoandrosten (4) derivatives (G03BA)	Blood glucose lowering drugs, excl. insulins (A10B)	Androgens (G03B)	0					A10BG	A10B	G03BA	G03B
12136	pioglitazone	reduces	3A457	ticagrelor		A10BG03	B01AC24	Thiazolidinediones (A10BG)	Platelet aggregation inhibitors excl. heparin (B01AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antithrombotic agents (B01A)	0					A10BG	A10B	B01AC	B01A
12139	pioglitazone	reduces	3A457	tramadol		A10BG03	N02AX02	Thiazolidinediones (A10BG)	Other opioids (N02AX)	Blood glucose lowering drugs, excl. insulins (A10B)	Opioids (N02A)	0	1		Reduced analgesic effect		A10BG	A10B	N02AX	N02A
12140	pioglitazone	reduces	3A457	trazodone		A10BG03	N06AX05	Thiazolidinediones (A10BG)	Other antidepressants (N06AX)	Blood glucose lowering drugs, excl. insulins (A10B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A10BG	A10B	N06AX	N06A
12141	pioglitazone	reduces	3A457	triazolam		A10BG03	N05CD05	Thiazolidinediones (A10BG)	Benzodiazepine derivatives (N05CD)	Blood glucose lowering drugs, excl. insulins (A10B)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		A10BG	A10B	N05CD	N05C
12148	pioglitazone	reduces	3A457	venlafaxine		A10BG03	N06AX16	Thiazolidinediones (A10BG)	Other antidepressants (N06AX)	Blood glucose lowering drugs, excl. insulins (A10B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6220	A10BG	A10B	N06AX	N06A
12149	pioglitazone	reduces	3A457	verapamil		A10BG03	C08DA01	Thiazolidinediones (A10BG)	Phenylalkylamine derivatives (C08DA)	Blood glucose lowering drugs, excl. insulins (A10B)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		6095	A10BG	A10B	C08DA	C08D
12153	pioglitazone	reduces	3A457	voriconazole		A10BG03	J02AC03	Thiazolidinediones (A10BG)	Triazole derivatives (J02AC)	Blood glucose lowering drugs, excl. insulins (A10B)	Antimycotics for systemic use (J02A)	0	0				A10BG	A10B	J02AC	J02A
12154	pioglitazone	reduces	3A457	zaleplon		A10BG03	N05CF03	Thiazolidinediones (A10BG)	Benzodiazepine related drugs (N05CF)	Blood glucose lowering drugs, excl. insulins (A10B)	Hypnotics and sedatives (N05C)	0					A10BG	A10B	N05CF	N05C
12156	pioglitazone	reduces	3A457	zolpidem		A10BG03	N05CF02	Thiazolidinediones (A10BG)	Benzodiazepine related drugs (N05CF)	Blood glucose lowering drugs, excl. insulins (A10B)	Hypnotics and sedatives (N05C)	0					A10BG	A10B	N05CF	N05C
12157	prednisone	reduces	2C19	amitriptyline		H02AB07	N06AA09	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity		1561	H02AB	H02A	N06AA	N06A
12162	prednisone	reduces	2C19	citalopram		H02AB07	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			260	H02AB	H02A	N06AB	N06A
12162	prednisone	reduces	2C19	citalopram		H02AB07	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			278	H02AB	H02A	N06AB	N06A
12162	prednisone	reduces	2C19	citalopram		H02AB07	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			336	H02AB	H02A	N06AB	N06A
12162	prednisone	reduces	2C19	citalopram		H02AB07	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			353	H02AB	H02A	N06AB	N06A
12162	prednisone	reduces	2C19	citalopram		H02AB07	N06AB04	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0			3047	H02AB	H02A	N06AB	N06A
12163	prednisone	reduces	2C19	clobazam		H02AB07	N05BA09	Glucocorticoids (H02AB)	Benzodiazepine derivatives (N05BA)	Corticosteroids for systemic use, plain (H02A)	Anxiolytics (N05B)	0					H02AB	H02A	N05BA	N05B
12164	prednisone	reduces	2C19	clomipramine		H02AB07	N06AA04	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			H02AB	H02A	N06AA	N06A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	184	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	251	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	995	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3438	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3732	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3826	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4133	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4200	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4391	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4775	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5350	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5842	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	5957	H02AB	H02A	B01AC	B01A
12165	prednisone	reduces	2C19	clopidogrel		H02AB07	B01AC04	Glucocorticoids (H02AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7489	H02AB	H02A	B01AC	B01A
12166	prednisone	reduces	2C19	cyclophosphamide		H02AB07	L01AA01	Glucocorticoids (H02AB)	Nitrogen mustard analogues (L01AA)	Corticosteroids for systemic use, plain (H02A)	Alkylating agents (L01A)	1	1			321	H02AB	H02A	L01AA	L01A
12166	prednisone	reduces	2C19	cyclophosphamide		H02AB07	L01AA01	Glucocorticoids (H02AB)	Nitrogen mustard analogues (L01AA)	Corticosteroids for systemic use, plain (H02A)	Alkylating agents (L01A)	1	1			2049	H02AB	H02A	L01AA	L01A
12166	prednisone	reduces	2C19	cyclophosphamide		H02AB07	L01AA01	Glucocorticoids (H02AB)	Nitrogen mustard analogues (L01AA)	Corticosteroids for systemic use, plain (H02A)	Alkylating agents (L01A)	1	1			4469	H02AB	H02A	L01AA	L01A
12167	prednisone	reduces	2C19	diazepam		H02AB07	N05BA01	Glucocorticoids (H02AB)	Benzodiazepine derivatives (N05BA)	Corticosteroids for systemic use, plain (H02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3732	H02AB	H02A	N05BA	N05B
12167	prednisone	reduces	2C19	diazepam		H02AB07	N05BA01	Glucocorticoids (H02AB)	Benzodiazepine derivatives (N05BA)	Corticosteroids for systemic use, plain (H02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4549	H02AB	H02A	N05BA	N05B
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				897	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				1481	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				2120	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				4077	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				5610	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				7039	H02AB	H02A	N06AB	N06A
12169	prednisone	reduces	2C19	escitalopram		H02AB07	N06AB10	Glucocorticoids (H02AB)	Selective serotonin reuptake inhibitors (N06AB)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0				7618	H02AB	H02A	N06AB	N06A
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				278	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				356	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				678	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				757	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				794	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				870	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				897	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1212	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1293	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1362	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1459	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2058	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2347	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2348	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2437	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2510	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2648	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2672	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2715	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2732	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2872	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2960	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2979	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3777	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4002	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4061	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4394	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4434	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4683	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4864	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4947	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5122	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5461	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5730	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5865	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5931	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5957	H02AB	H02A	A02BC	A02B
12170	prednisone	reduces	2C19	esomeprazole		H02AB07	A02BC05	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5973	H02AB	H02A	A02BC	A02B
12173	prednisone	reduces	2C19	imipramine		H02AB07	N06AA02	Glucocorticoids (H02AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			H02AB	H02A	N06AA	N06A
12174	prednisone	reduces	2C19	indometacin		H02AB07	M01AB01	Glucocorticoids (H02AB)	Acetic acid derivatives and related substances (M01AB)	Corticosteroids for systemic use, plain (H02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					H02AB	H02A	M01AB	M01A
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			56	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			57	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			164	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			174	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			278	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			299	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			315	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			340	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			717	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			835	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			879	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			883	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			904	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			940	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			941	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			957	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			989	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1009	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1036	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1134	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1196	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1287	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1376	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1383	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1450	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1481	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1525	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1550	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1555	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1593	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1596	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1608	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1618	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2034	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2037	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2071	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2072	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2107	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2122	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2145	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2148	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2190	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2201	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2400	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2487	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2492	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2682	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2711	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2783	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2813	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2846	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2903	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2911	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2996	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3018	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3049	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3181	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3194	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3498	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3641	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3709	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3713	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3843	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3884	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3985	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4040	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4081	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4133	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4200	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4259	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4265	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4271	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4332	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4360	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4385	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4420	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4425	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4426	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4471	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4523	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4587	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4714	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4935	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4973	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5109	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5118	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5342	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5454	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5475	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5487	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5503	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5610	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5656	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5661	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5692	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5817	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5818	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5869	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5924	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5950	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6016	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6028	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6038	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6091	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7025	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7440	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7505	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7607	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7702	H02AB	H02A	A02BC	A02B
12176	prednisone	reduces	2C19	lansoprazole		H02AB07	A02BC03	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7740	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			93	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			138	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			143	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			172	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			180	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			194	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			245	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			246	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			336	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			598	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			609	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			636	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			720	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			824	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			979	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1104	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1110	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1134	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1170	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1204	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1258	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1358	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1379	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1433	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1455	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1512	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1632	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2049	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2120	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2128	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2138	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2199	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2200	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2202	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2206	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2281	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2282	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2335	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2382	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2432	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2544	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2564	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2580	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2659	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2733	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2824	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2831	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2854	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2867	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2869	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2903	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2942	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2947	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2972	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2980	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3150	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3351	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3354	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3405	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3438	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3458	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3508	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3582	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3591	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3681	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3682	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3698	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3752	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3759	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3767	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3859	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3897	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3918	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4004	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4074	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4077	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4108	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4111	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4125	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4202	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4204	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4244	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4248	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4276	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4363	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4383	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4416	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4495	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4520	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4655	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4656	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4730	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5102	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5271	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5373	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5394	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5488	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5505	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5529	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5536	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5836	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5903	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6068	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6136	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6223	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7131	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7159	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7494	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7559	H02AB	H02A	A02BC	A02B
12182	prednisone	reduces	2C19	omeprazole		H02AB07	A02BC01	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7597	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			184	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			240	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			260	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			281	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			353	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			803	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			823	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			839	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1018	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1595	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1600	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2029	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2139	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2487	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2580	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2873	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3061	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3482	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3489	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3652	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3662	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3678	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3732	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3815	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3826	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3884	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3957	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4028	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4189	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4264	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4363	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4508	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4543	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4582	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4603	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4646	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4662	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4693	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4719	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4740	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4775	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4826	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4842	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4896	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4929	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5031	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5153	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5206	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5236	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5315	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5321	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5350	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5415	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5431	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5470	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5481	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5505	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5586	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5695	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5745	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5855	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5856	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5863	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5865	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6046	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6048	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6247	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7088	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7151	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7158	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7161	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7240	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7242	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7319	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7489	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7516	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7579	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7613	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7618	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7635	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7655	H02AB	H02A	A02BC	A02B
12184	prednisone	reduces	2C19	pantoprazole		H02AB07	A02BC02	Glucocorticoids (H02AB)	Proton pump inhibitors (A02BC)	Corticosteroids for systemic use, plain (H02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7716	H02AB	H02A	A02BC	A02B
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	57	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	336	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1521	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2139	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2141	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3591	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3771	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4947	H02AB	H02A	N03AA	N03A
12185	prednisone	reduces	2C19	phenobarbital	B	H02AB07	N03AA02	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	5031	H02AB	H02A	N03AA	N03A
12186	prednisone	reduces	2C19	phenytoin	B	H02AB07	N03AB02	Glucocorticoids (H02AB)	Hydantoin derivatives (N03AB)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1596	H02AB	H02A	N03AB	N03A
12186	prednisone	reduces	2C19	phenytoin	B	H02AB07	N03AB02	Glucocorticoids (H02AB)	Hydantoin derivatives (N03AB)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	3121	H02AB	H02A	N03AB	N03A
12188	prednisone	reduces	2C19	primidone	B	H02AB07	N03AA03	Glucocorticoids (H02AB)	Barbiturates and derivatives (N03AA)	Corticosteroids for systemic use, plain (H02A)	Antiepileptics (N03A)	0					H02AB	H02A	N03AA	N03A
12191	prednisone	reduces	2C19	propranolol		H02AB07	C07AA05	Glucocorticoids (H02AB)	Beta blocking agents, non-selective (C07AA)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0				124	H02AB	H02A	C07AA	C07A
12191	prednisone	reduces	2C19	propranolol		H02AB07	C07AA05	Glucocorticoids (H02AB)	Beta blocking agents, non-selective (C07AA)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0				1134	H02AB	H02A	C07AA	C07A
12191	prednisone	reduces	2C19	propranolol		H02AB07	C07AA05	Glucocorticoids (H02AB)	Beta blocking agents, non-selective (C07AA)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0				2938	H02AB	H02A	C07AA	C07A
12191	prednisone	reduces	2C19	propranolol		H02AB07	C07AA05	Glucocorticoids (H02AB)	Beta blocking agents, non-selective (C07AA)	Corticosteroids for systemic use, plain (H02A)	Beta blocking agents (C07A)	0				5488	H02AB	H02A	C07AA	C07A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		879	H02AB	H02A	N06AX	N06A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		1280	H02AB	H02A	N06AX	N06A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2438	H02AB	H02A	N06AX	N06A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7072	H02AB	H02A	N06AX	N06A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7489	H02AB	H02A	N06AX	N06A
12195	prednisone	reduces	2C19	venlafaxine		H02AB07	N06AX16	Glucocorticoids (H02AB)	Other antidepressants (N06AX)	Corticosteroids for systemic use, plain (H02A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7655	H02AB	H02A	N06AX	N06A
12197	prednisone	reduces	2C19	voriconazole		H02AB07	J02AC03	Glucocorticoids (H02AB)	Triazole derivatives (J02AC)	Corticosteroids for systemic use, plain (H02A)	Antimycotics for systemic use (J02A)	0	0			2126	H02AB	H02A	J02AC	J02A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		56	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		110	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		124	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		278	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		561	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		606	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		839	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		957	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		969	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		1146	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		1204	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		1272	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		1600	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2058	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2145	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2190	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2400	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2672	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2733	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2831	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2846	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2872	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2873	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2979	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		2980	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3018	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3181	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3405	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3434	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3591	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3608	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3662	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		3709	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4002	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4383	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4603	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4683	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4730	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4841	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4864	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		4935	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5031	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5153	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5373	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5443	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5656	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5692	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5817	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		5855	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		6091	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		6247	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		7088	H02AB	H02A	B01AA	B01A
12198	prednisone	reduces	2C19	warfarin	B	H02AB07	B01AA03	Glucocorticoids (H02AB)	Vitamin K antagonists (B01AA)	Corticosteroids for systemic use, plain (H02A)	Antithrombotic agents (B01A)	1	0	Bleeding		7723	H02AB	H02A	B01AA	B01A
12201	promethazine	enhances	2D6	amitriptyline	D	R06AD02	N06AA09	Phenothiazine derivatives (R06AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AD	R06A	N06AA	N06A
12206	promethazine	enhances	2D6	carvedilol		R06AD02	C07AG02	Phenothiazine derivatives (R06AD)	Alpha and beta blocking agents (C07AG)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2228	R06AD	R06A	C07AG	C07A
12207	promethazine	enhances	2D6	chlorpheniramine		R06AD02	R06AB04	Phenothiazine derivatives (R06AD)	Substituted alkylamines (R06AB)	Antihistamines for systemic use (R06A)	Antihistamines for systemic use (R06A)	0	0				R06AD	R06A	R06AB	R06A
12208	promethazine	enhances	2D6	chlorpromazine	D	R06AD02	N05AA01	Phenothiazine derivatives (R06AD)	Phenothiazines with aliphatic side-chain (N05AA)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0				96	R06AD	R06A	N05AA	N05A
12209	promethazine	enhances	2D6	citalopram	D	R06AD02	N06AB04	Phenothiazine derivatives (R06AD)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0			2173	R06AD	R06A	N06AB	N06A
12210	promethazine	enhances	2D6	clomipramine	D	R06AD02	N06AA04	Phenothiazine derivatives (R06AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AD	R06A	N06AA	N06A
12211	promethazine	enhances	2D6	clonidine		R06AD02	C02AC01	Phenothiazine derivatives (R06AD)	Imidazoline receptor agonists (C02AC)	Antihistamines for systemic use (R06A)	Antiadrenergic agents, centrally acting (C02A)	1					R06AD	R06A	C02AC	C02A
12216	promethazine	enhances	2D6	dextromethorphan		R06AD02	R05DA09	Phenothiazine derivatives (R06AD)	Opium alkaloids and derivatives (R05DA)	Antihistamines for systemic use (R06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				R06AD	R06A	R05DA	R05D
12217	promethazine	enhances	2D6	donepezil	D	R06AD02	N06DA02	Phenothiazine derivatives (R06AD)	Anticholinesterases (N06DA)	Antihistamines for systemic use (R06A)	Anti-dementia drugs (N06D)	0					R06AD	R06A	N06DA	N06D
12219	promethazine	enhances	2D6	duloxetine	C	R06AD02	N06AX21	Phenothiazine derivatives (R06AD)	Other antidepressants (N06AX)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AD	R06A	N06AX	N06A
12222	promethazine	enhances	2D6	escitalopram	D	R06AD02	N06AB10	Phenothiazine derivatives (R06AD)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0					R06AD	R06A	N06AB	N06A
12223	promethazine	enhances	2D6	flecainide	D	R06AD02	C01BC04	Phenothiazine derivatives (R06AD)	Antiarrhythmics, class Ic (C01BC)	Antihistamines for systemic use (R06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			R06AD	R06A	C01BC	C01B
12224	promethazine	enhances	2D6	fluoxetine	D	R06AD02	N06AB03	Phenothiazine derivatives (R06AD)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AD	R06A	N06AB	N06A
12225	promethazine	enhances	2D6	fluvoxamine		R06AD02	N06AB08	Phenothiazine derivatives (R06AD)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity		96	R06AD	R06A	N06AB	N06A
12226	promethazine	enhances	2D6	haloperidol	D	R06AD02	N05AD01	Phenothiazine derivatives (R06AD)	Butyrophenone derivatives (N05AD)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2226	R06AD	R06A	N05AD	N05A
12228	promethazine	enhances	2D6	imipramine	D	R06AD02	N06AA02	Phenothiazine derivatives (R06AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			R06AD	R06A	N06AA	N06A
12231	promethazine	enhances	2D6	metoclopramide	D	R06AD02	A03FA01	Phenothiazine derivatives (R06AD)	Propulsives (A03FA)	Antihistamines for systemic use (R06A)	Propulsives (A03F)	0					R06AD	R06A	A03FA	A03F
12232	promethazine	enhances	2D6	metoprolol		R06AD02	C07AB02	Phenothiazine derivatives (R06AD)	Beta blocking agents, selective (C07AB)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		R06AD	R06A	C07AB	C07A
12235	promethazine	enhances	2D6	nebivolol		R06AD02	C07AB12	Phenothiazine derivatives (R06AD)	Beta blocking agents, selective (C07AB)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0					R06AD	R06A	C07AB	C07A
12236	promethazine	enhances	2D6	nortriptyline	D	R06AD02	N06AA10	Phenothiazine derivatives (R06AD)	Non-selective monoamine reuptake inhibitors (N06AA)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	1					R06AD	R06A	N06AA	N06A
12237	promethazine	enhances	2D6	ondansetron	D	R06AD02	A04AA01	Phenothiazine derivatives (R06AD)	Serotonin (5HT3) antagonists (A04AA)	Antihistamines for systemic use (R06A)	Antiemetics and antinauseants (A04A)	0	0				R06AD	R06A	A04AA	A04A
12238	promethazine	enhances	2D6	oxycodone	D	R06AD02	N02AA05	Phenothiazine derivatives (R06AD)	Natural opium alkaloids (N02AA)	Antihistamines for systemic use (R06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		R06AD	R06A	N02AA	N02A
12240	promethazine	enhances	2D6	paroxetine	D	R06AD02	N06AB05	Phenothiazine derivatives (R06AD)	Selective serotonin reuptake inhibitors (N06AB)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AD	R06A	N06AB	N06A
12248	promethazine	enhances	2D6	propafenone	D	R06AD02	C01BC03	Phenothiazine derivatives (R06AD)	Antiarrhythmics, class Ic (C01BC)	Antihistamines for systemic use (R06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			R06AD	R06A	C01BC	C01B
12249	promethazine	enhances	2D6	propranolol		R06AD02	C07AA05	Phenothiazine derivatives (R06AD)	Beta blocking agents, non-selective (C07AA)	Antihistamines for systemic use (R06A)	Beta blocking agents (C07A)	0					R06AD	R06A	C07AA	C07A
12250	promethazine	enhances	2D6	risperidone	D	R06AD02	N05AX08	Phenothiazine derivatives (R06AD)	Other antipsychotics (N05AX)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		R06AD	R06A	N05AX	N05A
12253	promethazine	enhances	2D6	tamoxifen	D	R06AD02	L02BA01	Phenothiazine derivatives (R06AD)	Anti-estrogens (L02BA)	Antihistamines for systemic use (R06A)	Hormone antagonists and related agents (L02B)	1	1				R06AD	R06A	L02BA	L02B
12254	promethazine	enhances	2D6	tetrabenazine	D	R06AD02	N07XX06	Phenothiazine derivatives (R06AD)	Other nervous system drugs (N07XX)	Antihistamines for systemic use (R06A)	Other nervous system drugs (N07X)	0					R06AD	R06A	N07XX	N07X
12257	promethazine	enhances	2D6	tramadol	D	R06AD02	N02AX02	Phenothiazine derivatives (R06AD)	Other opioids (N02AX)	Antihistamines for systemic use (R06A)	Opioids (N02A)	0	1		Reduced analgesic effect		R06AD	R06A	N02AX	N02A
12260	promethazine	enhances	2D6	venlafaxine	D	R06AD02	N06AX16	Phenothiazine derivatives (R06AD)	Other antidepressants (N06AX)	Antihistamines for systemic use (R06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			R06AD	R06A	N06AX	N06A
12262	promethazine	enhances	2D6	zuclopenthixol		R06AD02	N05AF05	Phenothiazine derivatives (R06AD)	Thioxanthene derivatives (N05AF)	Antihistamines for systemic use (R06A)	Antipsychotics (N05A)	0					R06AD	R06A	N05AF	N05A
12330	ranitidine	enhances	2D6	amitriptyline		A02BA02	N06AA09	H2-receptor antagonists (A02BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BA	A02B	N06AA	N06A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	8	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	766	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	770	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	963	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	995	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1178	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3519	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4801	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5923	A02BA	A02B	C07AG	C07A
12335	ranitidine	enhances	2D6	carvedilol		A02BA02	C07AG02	H2-receptor antagonists (A02BA)	Alpha and beta blocking agents (C07AG)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7230	A02BA	A02B	C07AG	C07A
12336	ranitidine	enhances	2D6	chlorpheniramine		A02BA02	R06AB04	H2-receptor antagonists (A02BA)	Substituted alkylamines (R06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antihistamines for systemic use (R06A)	0	0			4299	A02BA	A02B	R06AB	R06A
12337	ranitidine	enhances	2D6	chlorpromazine		A02BA02	N05AA01	H2-receptor antagonists (A02BA)	Phenothiazines with aliphatic side-chain (N05AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0					A02BA	A02B	N05AA	N05A
12338	ranitidine	enhances	2D6	citalopram		A02BA02	N06AB04	H2-receptor antagonists (A02BA)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0			770	A02BA	A02B	N06AB	N06A
12339	ranitidine	enhances	2D6	clomipramine		A02BA02	N06AA04	H2-receptor antagonists (A02BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BA	A02B	N06AA	N06A
12340	ranitidine	enhances	2D6	clonidine		A02BA02	C02AC01	H2-receptor antagonists (A02BA)	Imidazoline receptor agonists (C02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiadrenergic agents, centrally acting (C02A)	1				851	A02BA	A02B	C02AC	C02A
12340	ranitidine	enhances	2D6	clonidine		A02BA02	C02AC01	H2-receptor antagonists (A02BA)	Imidazoline receptor agonists (C02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiadrenergic agents, centrally acting (C02A)	1				4676	A02BA	A02B	C02AC	C02A
12340	ranitidine	enhances	2D6	clonidine		A02BA02	C02AC01	H2-receptor antagonists (A02BA)	Imidazoline receptor agonists (C02AC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiadrenergic agents, centrally acting (C02A)	1				7230	A02BA	A02B	C02AC	C02A
12345	ranitidine	enhances	2D6	dextromethorphan		A02BA02	R05DA09	H2-receptor antagonists (A02BA)	Opium alkaloids and derivatives (R05DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				A02BA	A02B	R05DA	R05D
12346	ranitidine	enhances	2D6	donepezil		A02BA02	N06DA02	H2-receptor antagonists (A02BA)	Anticholinesterases (N06DA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Anti-dementia drugs (N06D)	0					A02BA	A02B	N06DA	N06D
12348	ranitidine	enhances	2D6	duloxetine		A02BA02	N06AX21	H2-receptor antagonists (A02BA)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A02BA	A02B	N06AX	N06A
12351	ranitidine	enhances	2D6	escitalopram		A02BA02	N06AB10	H2-receptor antagonists (A02BA)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0				1219	A02BA	A02B	N06AB	N06A
12352	ranitidine	enhances	2D6	flecainide		A02BA02	C01BC04	H2-receptor antagonists (A02BA)	Antiarrhythmics, class Ic (C01BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		1219	A02BA	A02B	C01BC	C01B
12352	ranitidine	enhances	2D6	flecainide		A02BA02	C01BC04	H2-receptor antagonists (A02BA)	Antiarrhythmics, class Ic (C01BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		3599	A02BA	A02B	C01BC	C01B
12353	ranitidine	enhances	2D6	fluoxetine		A02BA02	N06AB03	H2-receptor antagonists (A02BA)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A02BA	A02B	N06AB	N06A
12354	ranitidine	enhances	2D6	fluvoxamine		A02BA02	N06AB08	H2-receptor antagonists (A02BA)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A02BA	A02B	N06AB	N06A
12355	ranitidine	enhances	2D6	haloperidol		A02BA02	N05AD01	H2-receptor antagonists (A02BA)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	1165	A02BA	A02B	N05AD	N05A
12355	ranitidine	enhances	2D6	haloperidol		A02BA02	N05AD01	H2-receptor antagonists (A02BA)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2547	A02BA	A02B	N05AD	N05A
12355	ranitidine	enhances	2D6	haloperidol		A02BA02	N05AD01	H2-receptor antagonists (A02BA)	Butyrophenone derivatives (N05AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5261	A02BA	A02B	N05AD	N05A
12357	ranitidine	enhances	2D6	imipramine		A02BA02	N06AA02	H2-receptor antagonists (A02BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1	0	Serotonin toxicity			A02BA	A02B	N06AA	N06A
12360	ranitidine	enhances	2D6	metoclopramide		A02BA02	A03FA01	H2-receptor antagonists (A02BA)	Propulsives (A03FA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Propulsives (A03F)	0				4238	A02BA	A02B	A03FA	A03F
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	274	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	679	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	701	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1359	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1360	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2647	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2702	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2983	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3592	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3937	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3951	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4134	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4835	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4981	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5369	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6094	A02BA	A02B	C07AB	C07A
12361	ranitidine	enhances	2D6	metoprolol		A02BA02	C07AB02	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7652	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1015	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1083	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1373	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				1612	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3975	A02BA	A02B	C07AB	C07A
12364	ranitidine	enhances	2D6	nebivolol		A02BA02	C07AB12	H2-receptor antagonists (A02BA)	Beta blocking agents, selective (C07AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				7485	A02BA	A02B	C07AB	C07A
12365	ranitidine	enhances	2D6	nortriptyline		A02BA02	N06AA10	H2-receptor antagonists (A02BA)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	1					A02BA	A02B	N06AA	N06A
12366	ranitidine	enhances	2D6	ondansetron		A02BA02	A04AA01	H2-receptor antagonists (A02BA)	Serotonin (5HT3) antagonists (A04AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiemetics and antinauseants (A04A)	0	0				A02BA	A02B	A04AA	A04A
12367	ranitidine	enhances	2D6	oxycodone		A02BA02	N02AA05	H2-receptor antagonists (A02BA)	Natural opium alkaloids (N02AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	7079	A02BA	A02B	N02AA	N02A
12369	ranitidine	enhances	2D6	paroxetine		A02BA02	N06AB05	H2-receptor antagonists (A02BA)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity			A02BA	A02B	N06AB	N06A
12377	ranitidine	enhances	2D6	promethazine		A02BA02	R06AD02	H2-receptor antagonists (A02BA)	Phenothiazine derivatives (R06AD)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antihistamines for systemic use (R06A)	0					A02BA	A02B	R06AD	R06A
12378	ranitidine	enhances	2D6	propafenone		A02BA02	C01BC03	H2-receptor antagonists (A02BA)	Antiarrhythmics, class Ic (C01BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		2603	A02BA	A02B	C01BC	C01B
12378	ranitidine	enhances	2D6	propafenone		A02BA02	C01BC03	H2-receptor antagonists (A02BA)	Antiarrhythmics, class Ic (C01BC)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		7168	A02BA	A02B	C01BC	C01B
12379	ranitidine	enhances	2D6	propranolol		A02BA02	C07AA05	H2-receptor antagonists (A02BA)	Beta blocking agents, non-selective (C07AA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Beta blocking agents (C07A)	0				3042	A02BA	A02B	C07AA	C07A
12380	ranitidine	enhances	2D6	risperidone		A02BA02	N05AX08	H2-receptor antagonists (A02BA)	Other antipsychotics (N05AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		A02BA	A02B	N05AX	N05A
12383	ranitidine	enhances	2D6	tamoxifen		A02BA02	L02BA01	H2-receptor antagonists (A02BA)	Anti-estrogens (L02BA)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Hormone antagonists and related agents (L02B)	1	1				A02BA	A02B	L02BA	L02B
12384	ranitidine	enhances	2D6	tetrabenazine		A02BA02	N07XX06	H2-receptor antagonists (A02BA)	Other nervous system drugs (N07XX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Other nervous system drugs (N07X)	0					A02BA	A02B	N07XX	N07X
12387	ranitidine	enhances	2D6	tramadol		A02BA02	N02AX02	H2-receptor antagonists (A02BA)	Other opioids (N02AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Opioids (N02A)	0	1		Reduced analgesic effect	8	A02BA	A02B	N02AX	N02A
12390	ranitidine	enhances	2D6	venlafaxine		A02BA02	N06AX16	H2-receptor antagonists (A02BA)	Other antidepressants (N06AX)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antidepressants (N06A)	0	0	Serotonin toxicity		6066	A02BA	A02B	N06AX	N06A
12392	ranitidine	enhances	2D6	zuclopenthixol		A02BA02	N05AF05	H2-receptor antagonists (A02BA)	Thioxanthene derivatives (N05AF)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	Antipsychotics (N05A)	0				2336	A02BA	A02B	N05AF	N05A
12914	rifampin	reduces	1A2	acetaminophen	A	J04AB02	N02BE01	Antibiotics (J04AB)	Anilides (N02BE)	Drugs for treatment of tuberculosis (J04A)	Other analgesics and antipyretics (N02B)	0	0				J04AB	J04A	N02BE	N02B
12917	rifampin	reduces	3A457	alprazolam		J04AB02	N05BA12	Antibiotics (J04AB)	Benzodiazepine derivatives (N05BA)	Drugs for treatment of tuberculosis (J04A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J04AB	J04A	N05BA	N05B
12920	rifampin	reduces	1A2,2C19,2C9,2D6,3A457	amitriptyline		J04AB02	N06AA09	Antibiotics (J04AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AB	J04A	N06AA	N06A
12921	rifampin	reduces	3A457	amlodipine	B	J04AB02	C08CA01	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	358	J04AB	J04A	C08CA	C08C
12923	rifampin	reduces	3A457	apixaban	B	J04AB02	B01AF02	Antibiotics (J04AB)	Direct factor Xa inhibitors (B01AF)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0					J04AB	J04A	B01AF	B01A
12930	rifampin	reduces	3A457	atorvastatin	B	J04AB02	C10AA05	Antibiotics (J04AB)	HMG CoA reductase inhibitors (C10AA)	Drugs for treatment of tuberculosis (J04A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J04AB	J04A	C10AA	C10A
12939	rifampin	reduces	2B6	bupropion		J04AB02	N06AX12	Antibiotics (J04AB)	Other antidepressants (N06AX)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AX	N06A
12942	rifampin	reduces	2C9	capecitabine		J04AB02	L01BC06	Antibiotics (J04AB)	Pyrimidine analogues (L01BC)	Drugs for treatment of tuberculosis (J04A)	Antimetabolites (L01B)	1					J04AB	J04A	L01BC	L01B
12943	rifampin	reduces	3A457	carbamazepine	C	J04AB02	N03AF01	Antibiotics (J04AB)	Carboxamide derivatives (N03AF)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AB	J04A	N03AF	N03A
12946	rifampin	reduces	2D6	carvedilol		J04AB02	C07AG02	Antibiotics (J04AB)	Alpha and beta blocking agents (C07AG)	Drugs for treatment of tuberculosis (J04A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		J04AB	J04A	C07AG	C07A
12947	rifampin	reduces	2C9	celecoxib		J04AB02	M01AH01	Antibiotics (J04AB)	Coxibs (M01AH)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AB	J04A	M01AH	M01A
12951	rifampin	reduces	2D6,3A457	chlorpheniramine		J04AB02	R06AB04	Antibiotics (J04AB)	Substituted alkylamines (R06AB)	Drugs for treatment of tuberculosis (J04A)	Antihistamines for systemic use (R06A)	0	0				J04AB	J04A	R06AB	R06A
12952	rifampin	reduces	2D6	chlorpromazine	B	J04AB02	N05AA01	Antibiotics (J04AB)	Phenothiazines with aliphatic side-chain (N05AA)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0					J04AB	J04A	N05AA	N05A
12953	rifampin	reduces	3A457	cilostazol		J04AB02	B01AC23	Antibiotics (J04AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0					J04AB	J04A	B01AC	B01A
12955	rifampin	reduces	2C19,2D6,3A457	citalopram		J04AB02	N06AB04	Antibiotics (J04AB)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0				J04AB	J04A	N06AB	N06A
12956	rifampin	reduces	3A457	clarithromycin		J04AB02	J01FA09	Antibiotics (J04AB)	Macrolides (J01FA)	Drugs for treatment of tuberculosis (J04A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J04AB	J04A	J01FA	J01F
12957	rifampin	reduces	2B6,2C19,3A457	clobazam		J04AB02	N05BA09	Antibiotics (J04AB)	Benzodiazepine derivatives (N05BA)	Drugs for treatment of tuberculosis (J04A)	Anxiolytics (N05B)	0					J04AB	J04A	N05BA	N05B
12958	rifampin	reduces	1A2,2C19,2D6	clomipramine		J04AB02	N06AA04	Antibiotics (J04AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AB	J04A	N06AA	N06A
12959	rifampin	reduces	2D6	clonidine		J04AB02	C02AC01	Antibiotics (J04AB)	Imidazoline receptor agonists (C02AC)	Drugs for treatment of tuberculosis (J04A)	Antiadrenergic agents, centrally acting (C02A)	1				358	J04AB	J04A	C02AC	C02A
12960	rifampin	reduces	2C19,2C9,3A457	clopidogrel		J04AB02	B01AC04	Antibiotics (J04AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4365	J04AB	J04A	B01AC	B01A
12961	rifampin	reduces	1A2	clozapine	B	J04AB02	N05AH02	Antibiotics (J04AB)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J04AB	J04A	N05AH	N05A
12965	rifampin	reduces	3A457	colchicine		J04AB02	M04AC01	Antibiotics (J04AB)	Preparations with no effect on uric acid metabolism (M04AC)	Drugs for treatment of tuberculosis (J04A)	Antigout preparations (M04A)	0					J04AB	J04A	M04AC	M04A
12969	rifampin	reduces	2B6,2C19	cyclophosphamide		J04AB02	L01AA01	Antibiotics (J04AB)	Nitrogen mustard analogues (L01AA)	Drugs for treatment of tuberculosis (J04A)	Alkylating agents (L01A)	1	1				J04AB	J04A	L01AA	L01A
12970	rifampin	reduces	3A457	cyclosporine	C	J04AB02	L04AD01	Antibiotics (J04AB)	Calcineurin inhibitors (L04AD)	Drugs for treatment of tuberculosis (J04A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J04AB	J04A	L04AD	L04A
12975	rifampin	reduces	3A457	deflazacort		J04AB02	H02AB13	Antibiotics (J04AB)	Glucocorticoids (H02AB)	Drugs for treatment of tuberculosis (J04A)	Corticosteroids for systemic use, plain (H02A)	0					J04AB	J04A	H02AB	H02A
12977	rifampin	reduces	3A457	dexamethasone	B	J04AB02	H02AB02	Antibiotics (J04AB)	Glucocorticoids (H02AB)	Drugs for treatment of tuberculosis (J04A)	Corticosteroids for systemic use, plain (H02A)	0					J04AB	J04A	H02AB	H02A
12979	rifampin	reduces	2D6,3A457	dextromethorphan		J04AB02	R05DA09	Antibiotics (J04AB)	Opium alkaloids and derivatives (R05DA)	Drugs for treatment of tuberculosis (J04A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J04AB	J04A	R05DA	R05D
12980	rifampin	reduces	2C19,3A457	diazepam	D	J04AB02	N05BA01	Antibiotics (J04AB)	Benzodiazepine derivatives (N05BA)	Drugs for treatment of tuberculosis (J04A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J04AB	J04A	N05BA	N05B
12981	rifampin	reduces	2C9	diclofenac	B	J04AB02	M01AB05	Antibiotics (J04AB)	Acetic acid derivatives and related substances (M01AB)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AB	J04A	M01AB	M01A
12982	rifampin	reduces	3A457	diltiazem	B	J04AB02	C08DB01	Antibiotics (J04AB)	Benzothiazepine derivatives (C08DB)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		1179	J04AB	J04A	C08DB	C08D
12985	rifampin	reduces	3A457	domperidone		J04AB02	A03FA03	Antibiotics (J04AB)	Propulsives (A03FA)	Drugs for treatment of tuberculosis (J04A)	Propulsives (A03F)	0					J04AB	J04A	A03FA	A03F
12986	rifampin	reduces	2D6	donepezil	D	J04AB02	N06DA02	Antibiotics (J04AB)	Anticholinesterases (N06DA)	Drugs for treatment of tuberculosis (J04A)	Anti-dementia drugs (N06D)	0					J04AB	J04A	N06DA	N06D
12988	rifampin	reduces	1A2,2D6	duloxetine		J04AB02	N06AX21	Antibiotics (J04AB)	Other antidepressants (N06AX)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AX	N06A
12989	rifampin	reduces	2B6	efavirenz	C	J04AB02	J05AG03	Antibiotics (J04AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs for treatment of tuberculosis (J04A)	Direct acting antivirals (J05A)	0	0				J04AB	J04A	J05AG	J05A
12995	rifampin	reduces	3A457	eplerenone	D	J04AB02	C03DA04	Antibiotics (J04AB)	Aldosterone antagonists (C03DA)	Drugs for treatment of tuberculosis (J04A)	Potassium-sparing agents (C03D)	0					J04AB	J04A	C03DA	C03D
12998	rifampin	reduces	2C19,2D6,3A457	escitalopram		J04AB02	N06AB10	Antibiotics (J04AB)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0					J04AB	J04A	N06AB	N06A
12999	rifampin	reduces	2C19,3A457	esomeprazole		J04AB02	A02BC05	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1179	J04AB	J04A	A02BC	A02B
13001	rifampin	reduces	3A457	felodipine	B	J04AB02	C08CA02	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J04AB	J04A	C08CA	C08C
13004	rifampin	reduces	2D6	flecainide	B	J04AB02	C01BC04	Antibiotics (J04AB)	Antiarrhythmics, class Ic (C01BC)	Drugs for treatment of tuberculosis (J04A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			J04AB	J04A	C01BC	C01B
13006	rifampin	reduces	2C9,2D6	fluoxetine		J04AB02	N06AB03	Antibiotics (J04AB)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AB	N06A
13007	rifampin	reduces	2C9	fluvastatin	B	J04AB02	C10AA04	Antibiotics (J04AB)	HMG CoA reductase inhibitors (C10AA)	Drugs for treatment of tuberculosis (J04A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J04AB	J04A	C10AA	C10A
13008	rifampin	reduces	1A2,2D6	fluvoxamine		J04AB02	N06AB08	Antibiotics (J04AB)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AB	N06A
13009	rifampin	reduces	2C9	glimepiride	B	J04AB02	A10BB12	Antibiotics (J04AB)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J04AB	J04A	A10BB	A10B
13010	rifampin	reduces	2C9	glipizide	B	J04AB02	A10BB07	Antibiotics (J04AB)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J04AB	J04A	A10BB	A10B
13011	rifampin	reduces	2C9	glyburide	B	J04AB02	A10BB01	Antibiotics (J04AB)	Sulfonylureas (A10BB)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J04AB	J04A	A10BB	A10B
13012	rifampin	reduces	1A2,2D6,3A457	haloperidol	B	J04AB02	N05AD01	Antibiotics (J04AB)	Butyrophenone derivatives (N05AD)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J04AB	J04A	N05AD	N05A
13014	rifampin	reduces	3A457	hydrocortisone	B	J04AB02	H02AB09	Antibiotics (J04AB)	Glucocorticoids (H02AB)	Drugs for treatment of tuberculosis (J04A)	Corticosteroids for systemic use, plain (H02A)	0					J04AB	J04A	H02AB	H02A
13016	rifampin	reduces	2C9	ibuprofen		J04AB02	M01AE01	Antibiotics (J04AB)	Propionic acid derivatives (M01AE)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AB	J04A	M01AE	M01A
13019	rifampin	reduces	3A457	imatinib	D	J04AB02	L01XE01	Antibiotics (J04AB)	 (L01XE)	Drugs for treatment of tuberculosis (J04A)	Other antineoplastic agents (L01X)	0	0				J04AB	J04A	L01XE	L01X
13020	rifampin	reduces	1A2,2C19,2D6	imipramine		J04AB02	N06AA02	Antibiotics (J04AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J04AB	J04A	N06AA	N06A
13021	rifampin	reduces	3A457	indacaterol		J04AB02	R03AC18	Antibiotics (J04AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for treatment of tuberculosis (J04A)	Adrenergics, inhalants (R03A)	0					J04AB	J04A	R03AC	R03A
13023	rifampin	reduces	2C19	indometacin		J04AB02	M01AB01	Antibiotics (J04AB)	Acetic acid derivatives and related substances (M01AB)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J04AB	J04A	M01AB	M01A
13024	rifampin	reduces	2C9	irbesartan		J04AB02	C09CA04	Antibiotics (J04AB)	Angiotensin II receptor blockers, plain (C09CA)	Drugs for treatment of tuberculosis (J04A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		J04AB	J04A	C09CA	C09C
13027	rifampin	reduces	3A457	ivabradine		J04AB02	C01EB17	Antibiotics (J04AB)	Other cardiac preparations (C01EB)	Drugs for treatment of tuberculosis (J04A)	Other cardiac preparations (C01E)	0					J04AB	J04A	C01EB	C01E
13031	rifampin	reduces	2C19,3A457	lansoprazole		J04AB02	A02BC03	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			358	J04AB	J04A	A02BC	A02B
13033	rifampin	reduces	3A457	lercanidipine	B	J04AB02	C08CA13	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J04AB	J04A	C08CA	C08C
13040	rifampin	reduces	2C9	losartan	B	J04AB02	C09CA01	Antibiotics (J04AB)	Angiotensin II receptor blockers, plain (C09CA)	Drugs for treatment of tuberculosis (J04A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect	4365	J04AB	J04A	C09CA	C09C
13041	rifampin	reduces	3A457	lovastatin	D	J04AB02	C10AA02	Antibiotics (J04AB)	HMG CoA reductase inhibitors (C10AA)	Drugs for treatment of tuberculosis (J04A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J04AB	J04A	C10AA	C10A
13043	rifampin	reduces	2C9	meloxicam		J04AB02	M01AC06	Antibiotics (J04AB)	Oxicams (M01AC)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J04AB	J04A	M01AC	M01A
13046	rifampin	reduces	2B6,3A457	methadone	C	J04AB02	N07BC02	Antibiotics (J04AB)	Drugs used in opioid dependence (N07BC)	Drugs for treatment of tuberculosis (J04A)	Drugs used in addictive disorders (N07B)	0	0				J04AB	J04A	N07BC	N07B
13048	rifampin	reduces	2D6	metoclopramide		J04AB02	A03FA01	Antibiotics (J04AB)	Propulsives (A03FA)	Drugs for treatment of tuberculosis (J04A)	Propulsives (A03F)	0					J04AB	J04A	A03FA	A03F
13049	rifampin	reduces	2D6	metoprolol		J04AB02	C07AB02	Antibiotics (J04AB)	Beta blocking agents, selective (C07AB)	Drugs for treatment of tuberculosis (J04A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		J04AB	J04A	C07AB	C07A
13051	rifampin	reduces	3A457	midazolam		J04AB02	N05CD08	Antibiotics (J04AB)	Benzodiazepine derivatives (N05CD)	Drugs for treatment of tuberculosis (J04A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J04AB	J04A	N05CD	N05C
13057	rifampin	reduces	1A2,2C9	naproxen		J04AB02	M01AE02	Antibiotics (J04AB)	Propionic acid derivatives (M01AE)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AB	J04A	M01AE	M01A
13059	rifampin	reduces	2D6	nebivolol		J04AB02	C07AB12	Antibiotics (J04AB)	Beta blocking agents, selective (C07AB)	Drugs for treatment of tuberculosis (J04A)	Beta blocking agents (C07A)	0				358	J04AB	J04A	C07AB	C07A
13062	rifampin	reduces	2B6,3A457	nevirapine	D	J04AB02	J05AG01	Antibiotics (J04AB)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Drugs for treatment of tuberculosis (J04A)	Direct acting antivirals (J05A)	0	0				J04AB	J04A	J05AG	J05A
13063	rifampin	reduces	3A457	nifedipine	B	J04AB02	C08CA05	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J04AB	J04A	C08CA	C08C
13065	rifampin	reduces	3A457	nisoldipine	D	J04AB02	C08CA07	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J04AB	J04A	C08CA	C08C
13066	rifampin	reduces	3A457	nitrendipine	D	J04AB02	C08CA08	Antibiotics (J04AB)	Dihydropyridine derivatives (C08CA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J04AB	J04A	C08CA	C08C
13067	rifampin	reduces	2D6	nortriptyline		J04AB02	N06AA10	Antibiotics (J04AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	1					J04AB	J04A	N06AA	N06A
13068	rifampin	reduces	1A2	olanzapine		J04AB02	N05AH03	Antibiotics (J04AB)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J04AB	J04A	N05AH	N05A
13071	rifampin	reduces	2C19,3A457	omeprazole		J04AB02	A02BC01	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J04AB	J04A	A02BC	A02B
13072	rifampin	reduces	1A2,2D6,3A457	ondansetron		J04AB02	A04AA01	Antibiotics (J04AB)	Serotonin (5HT3) antagonists (A04AA)	Drugs for treatment of tuberculosis (J04A)	Antiemetics and antinauseants (A04A)	0	0				J04AB	J04A	A04AA	A04A
13075	rifampin	reduces	2D6	oxycodone		J04AB02	N02AA05	Antibiotics (J04AB)	Natural opium alkaloids (N02AA)	Drugs for treatment of tuberculosis (J04A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		J04AB	J04A	N02AA	N02A
13080	rifampin	reduces	2C19,3A457	pantoprazole		J04AB02	A02BC02	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2225	J04AB	J04A	A02BC	A02B
13080	rifampin	reduces	2C19,3A457	pantoprazole		J04AB02	A02BC02	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4365	J04AB	J04A	A02BC	A02B
13080	rifampin	reduces	2C19,3A457	pantoprazole		J04AB02	A02BC02	Antibiotics (J04AB)	Proton pump inhibitors (A02BC)	Drugs for treatment of tuberculosis (J04A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5926	J04AB	J04A	A02BC	A02B
13081	rifampin	reduces	2D6	paroxetine		J04AB02	N06AB05	Antibiotics (J04AB)	Selective serotonin reuptake inhibitors (N06AB)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AB	N06A
13087	rifampin	reduces	2C19	phenobarbital		J04AB02	N03AA02	Antibiotics (J04AB)	Barbiturates and derivatives (N03AA)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AB	J04A	N03AA	N03A
13088	rifampin	reduces	2C19,2C9	phenytoin	C	J04AB02	N03AB02	Antibiotics (J04AB)	Hydantoin derivatives (N03AB)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AB	J04A	N03AB	N03A
13092	rifampin	reduces	2C9	piroxicam		J04AB02	M01AC01	Antibiotics (J04AB)	Oxicams (M01AC)	Drugs for treatment of tuberculosis (J04A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J04AB	J04A	M01AC	M01A
13095	rifampin	reduces	2C19	primidone		J04AB02	N03AA03	Antibiotics (J04AB)	Barbiturates and derivatives (N03AA)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	0					J04AB	J04A	N03AA	N03A
13098	rifampin	reduces	2D6	promethazine		J04AB02	R06AD02	Antibiotics (J04AB)	Phenothiazine derivatives (R06AD)	Drugs for treatment of tuberculosis (J04A)	Antihistamines for systemic use (R06A)	0					J04AB	J04A	R06AD	R06A
13099	rifampin	reduces	2D6	propafenone	B	J04AB02	C01BC03	Antibiotics (J04AB)	Antiarrhythmics, class Ic (C01BC)	Drugs for treatment of tuberculosis (J04A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			J04AB	J04A	C01BC	C01B
13101	rifampin	reduces	1A2,2C19,2D6,3A457	propranolol	B	J04AB02	C07AA05	Antibiotics (J04AB)	Beta blocking agents, non-selective (C07AA)	Drugs for treatment of tuberculosis (J04A)	Beta blocking agents (C07A)	0					J04AB	J04A	C07AA	C07A
13102	rifampin	reduces	3A457	quetiapine	C	J04AB02	N05AH04	Antibiotics (J04AB)	Diazepines, oxazepines and thiazepines (N05AH)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0				5724	J04AB	J04A	N05AH	N05A
13106	rifampin	reduces	2C8	repaglinide		J04AB02	A10BX02	Antibiotics (J04AB)	Other blood glucose lowering drugs, excl. insulins (A10BX)	Drugs for treatment of tuberculosis (J04A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J04AB	J04A	A10BX	A10B
13109	rifampin	reduces	1A2	riluzole		J04AB02	N07XX02	Antibiotics (J04AB)	Other nervous system drugs (N07XX)	Drugs for treatment of tuberculosis (J04A)	Other nervous system drugs (N07X)	0	0				J04AB	J04A	N07XX	N07X
13110	rifampin	reduces	2D6,3A457	risperidone		J04AB02	N05AX08	Antibiotics (J04AB)	Other antipsychotics (N05AX)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J04AB	J04A	N05AX	N05A
13111	rifampin	reduces	3A457	ritonavir	C	J04AB02	J05AE03	Antibiotics (J04AB)	Protease inhibitors (J05AE)	Drugs for treatment of tuberculosis (J04A)	Direct acting antivirals (J05A)	0	0				J04AB	J04A	J05AE	J05A
13112	rifampin	reduces	3A457	rivaroxaban	C	J04AB02	B01AF01	Antibiotics (J04AB)	Direct factor Xa inhibitors (B01AF)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0					J04AB	J04A	B01AF	B01A
13120	rifampin	reduces	3A457	salmeterol		J04AB02	R03AC12	Antibiotics (J04AB)	Selective beta-2-adrenoreceptor agonists (R03AC)	Drugs for treatment of tuberculosis (J04A)	Adrenergics, inhalants (R03A)	0				4365	J04AB	J04A	R03AC	R03A
13121	rifampin	reduces	3A457	saquinavir	C	J04AB02	J05AE01	Antibiotics (J04AB)	Protease inhibitors (J05AE)	Drugs for treatment of tuberculosis (J04A)	Direct acting antivirals (J05A)	0	0				J04AB	J04A	J05AE	J05A
13122	rifampin	reduces	2B6	selegiline		J04AB02	N04BD01	Antibiotics (J04AB)	Monoamine oxidase B inhibitors (N04BD)	Drugs for treatment of tuberculosis (J04A)	Dopaminergic agents (N04B)	0	0				J04AB	J04A	N04BD	N04B
13124	rifampin	reduces	3A457	sildenafil	D	J04AB02	G04BE03	Antibiotics (J04AB)	Drugs used in erectile dysfunction (G04BE)	Drugs for treatment of tuberculosis (J04A)	Urologicals (G04B)	0	0				J04AB	J04A	G04BE	G04B
13126	rifampin	reduces	3A457	simvastatin	B	J04AB02	C10AA01	Antibiotics (J04AB)	HMG CoA reductase inhibitors (C10AA)	Drugs for treatment of tuberculosis (J04A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J04AB	J04A	C10AA	C10A
13127	rifampin	reduces	3A457	sirolimus	D	J04AB02	L04AA10	Antibiotics (J04AB)	Selective immunosuppressants (L04AA)	Drugs for treatment of tuberculosis (J04A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J04AB	J04A	L04AA	L04A
13129	rifampin	reduces	2B6,2C8,3A457	sorafenib	B	J04AB02	L01XE05	Antibiotics (J04AB)	 (L01XE)	Drugs for treatment of tuberculosis (J04A)	Other antineoplastic agents (L01X)	1					J04AB	J04A	L01XE	L01X
13131	rifampin	reduces	3A457	sunitinib	D	J04AB02	L01XE04	Antibiotics (J04AB)	 (L01XE)	Drugs for treatment of tuberculosis (J04A)	Other antineoplastic agents (L01X)	1					J04AB	J04A	L01XE	L01X
13135	rifampin	reduces	3A457	tacrolimus	C	J04AB02	L04AD02	Antibiotics (J04AB)	Calcineurin inhibitors (L04AD)	Drugs for treatment of tuberculosis (J04A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J04AB	J04A	L04AD	L04A
13136	rifampin	reduces	3A457	tadalafil		J04AB02	G04BE08	Antibiotics (J04AB)	Drugs used in erectile dysfunction (G04BE)	Drugs for treatment of tuberculosis (J04A)	Urologicals (G04B)	0	0				J04AB	J04A	G04BE	G04B
13137	rifampin	reduces	2C9,2D6,3A457	tamoxifen	C	J04AB02	L02BA01	Antibiotics (J04AB)	Anti-estrogens (L02BA)	Drugs for treatment of tuberculosis (J04A)	Hormone antagonists and related agents (L02B)	1	1				J04AB	J04A	L02BA	L02B
13144	rifampin	reduces	3A457	testosterone		J04AB02	G03BA03	Antibiotics (J04AB)	3-oxoandrosten (4) derivatives (G03BA)	Drugs for treatment of tuberculosis (J04A)	Androgens (G03B)	0					J04AB	J04A	G03BA	G03B
13145	rifampin	reduces	2D6	tetrabenazine		J04AB02	N07XX06	Antibiotics (J04AB)	Other nervous system drugs (N07XX)	Drugs for treatment of tuberculosis (J04A)	Other nervous system drugs (N07X)	0					J04AB	J04A	N07XX	N07X
13146	rifampin	reduces	1A2	theophylline	B	J04AB02	R03DA04	Antibiotics (J04AB)	Xanthines (R03DA)	Drugs for treatment of tuberculosis (J04A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0				J04AB	J04A	R03DA	R03D
13148	rifampin	reduces	3A457	ticagrelor		J04AB02	B01AC24	Antibiotics (J04AB)	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	0					J04AB	J04A	B01AC	B01A
13150	rifampin	reduces	1A2	tizanidine		J04AB02	M03BX02	Antibiotics (J04AB)	Other centrally acting agents (M03BX)	Drugs for treatment of tuberculosis (J04A)	Muscle relaxants, centrally acting agents (M03B)	1	0				J04AB	J04A	M03BX	M03B
13154	rifampin	reduces	2C8,2C9	torasemide		J04AB02	C03CA04	Antibiotics (J04AB)	Sulfonamides, plain (C03CA)	Drugs for treatment of tuberculosis (J04A)	High-ceiling diuretics (C03C)	0	0				J04AB	J04A	C03CA	C03C
13155	rifampin	reduces	2B6,2D6,3A457	tramadol	D	J04AB02	N02AX02	Antibiotics (J04AB)	Other opioids (N02AX)	Drugs for treatment of tuberculosis (J04A)	Opioids (N02A)	0	1		Reduced analgesic effect	603	J04AB	J04A	N02AX	N02A
13156	rifampin	reduces	3A457	trazodone		J04AB02	N06AX05	Antibiotics (J04AB)	Other antidepressants (N06AX)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AX	N06A
13157	rifampin	reduces	1A2	triamterene		J04AB02	C03DB02	Antibiotics (J04AB)	Other potassium-sparing agents (C03DB)	Drugs for treatment of tuberculosis (J04A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			J04AB	J04A	C03DB	C03D
13158	rifampin	reduces	3A457	triazolam		J04AB02	N05CD05	Antibiotics (J04AB)	Benzodiazepine derivatives (N05CD)	Drugs for treatment of tuberculosis (J04A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J04AB	J04A	N05CD	N05C
13162	rifampin	reduces	2C9	valproate	B	J04AB02	N03AG01	Antibiotics (J04AB)	Fatty acid derivatives (N03AG)	Drugs for treatment of tuberculosis (J04A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J04AB	J04A	N03AG	N03A
13168	rifampin	reduces	2C19,2C9,2D6,3A457	venlafaxine		J04AB02	N06AX16	Antibiotics (J04AB)	Other antidepressants (N06AX)	Drugs for treatment of tuberculosis (J04A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J04AB	J04A	N06AX	N06A
13169	rifampin	reduces	1A2,3A457	verapamil	B	J04AB02	C08DA01	Antibiotics (J04AB)	Phenylalkylamine derivatives (C08DA)	Drugs for treatment of tuberculosis (J04A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J04AB	J04A	C08DA	C08D
13173	rifampin	reduces	2C19,2C9,3A457	voriconazole	D	J04AB02	J02AC03	Antibiotics (J04AB)	Triazole derivatives (J02AC)	Drugs for treatment of tuberculosis (J04A)	Antimycotics for systemic use (J02A)	0	0				J04AB	J04A	J02AC	J02A
13174	rifampin	reduces	1A2,2C19,2C9	warfarin	C	J04AB02	B01AA03	Antibiotics (J04AB)	Vitamin K antagonists (B01AA)	Drugs for treatment of tuberculosis (J04A)	Antithrombotic agents (B01A)	1	0	Bleeding			J04AB	J04A	B01AA	B01A
13176	rifampin	reduces	3A457	zaleplon	B	J04AB02	N05CF03	Antibiotics (J04AB)	Benzodiazepine related drugs (N05CF)	Drugs for treatment of tuberculosis (J04A)	Hypnotics and sedatives (N05C)	0					J04AB	J04A	N05CF	N05C
13180	rifampin	reduces	3A457	zolpidem	D	J04AB02	N05CF02	Antibiotics (J04AB)	Benzodiazepine related drugs (N05CF)	Drugs for treatment of tuberculosis (J04A)	Hypnotics and sedatives (N05C)	0				4365	J04AB	J04A	N05CF	N05C
13181	rifampin	reduces	2D6	zuclopenthixol		J04AB02	N05AF05	Antibiotics (J04AB)	Thioxanthene derivatives (N05AF)	Drugs for treatment of tuberculosis (J04A)	Antipsychotics (N05A)	0					J04AB	J04A	N05AF	N05A
13187	ritonavir	enhances	3A457	alprazolam	D	J05AE03	N05BA12	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05BA	N05B
13190	ritonavir	enhances	3A457	amlodipine	B	J05AE03	C08CA01	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13191	ritonavir	enhances	3A457	apixaban	D	J05AE03	B01AF02	Protease inhibitors (J05AE)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AF	B01A
13195	ritonavir	enhances	3A457	atorvastatin	C	J05AE03	C10AA05	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AE	J05A	C10AA	C10A
13204	ritonavir	enhances	2D6	carvedilol		J05AE03	C07AG02	Protease inhibitors (J05AE)	Alpha and beta blocking agents (C07AG)	Direct acting antivirals (J05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		J05AE	J05A	C07AG	C07A
13207	ritonavir	enhances	2D6,3A457	chlorpheniramine		J05AE03	R06AB04	Protease inhibitors (J05AE)	Substituted alkylamines (R06AB)	Direct acting antivirals (J05A)	Antihistamines for systemic use (R06A)	0	0				J05AE	J05A	R06AB	R06A
13208	ritonavir	enhances	2D6	chlorpromazine	D	J05AE03	N05AA01	Protease inhibitors (J05AE)	Phenothiazines with aliphatic side-chain (N05AA)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AE	J05A	N05AA	N05A
13209	ritonavir	enhances	3A457	cilostazol	D	J05AE03	B01AC23	Protease inhibitors (J05AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AC	B01A
13211	ritonavir	enhances	3A457	clarithromycin	D	J05AE03	J01FA09	Protease inhibitors (J05AE)	Macrolides (J01FA)	Direct acting antivirals (J05A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J05AE	J05A	J01FA	J01F
13212	ritonavir	enhances	2D6	clonidine		J05AE03	C02AC01	Protease inhibitors (J05AE)	Imidazoline receptor agonists (C02AC)	Direct acting antivirals (J05A)	Antiadrenergic agents, centrally acting (C02A)	1					J05AE	J05A	C02AC	C02A
13216	ritonavir	enhances	3A457	colchicine	D	J05AE03	M04AC01	Protease inhibitors (J05AE)	Preparations with no effect on uric acid metabolism (M04AC)	Direct acting antivirals (J05A)	Antigout preparations (M04A)	0					J05AE	J05A	M04AC	M04A
13219	ritonavir	enhances	3A457	cyclosporine	C	J05AE03	L04AD01	Protease inhibitors (J05AE)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AD	L04A
13223	ritonavir	enhances	3A457	deflazacort		J05AE03	H02AB13	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13225	ritonavir	enhances	3A457	dexamethasone	B	J05AE03	H02AB02	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13227	ritonavir	enhances	2D6,3A457	dextromethorphan		J05AE03	R05DA09	Protease inhibitors (J05AE)	Opium alkaloids and derivatives (R05DA)	Direct acting antivirals (J05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J05AE	J05A	R05DA	R05D
13228	ritonavir	enhances	3A457	diltiazem	B	J05AE03	C08DB01	Protease inhibitors (J05AE)	Benzothiazepine derivatives (C08DB)	Direct acting antivirals (J05A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J05AE	J05A	C08DB	C08D
13231	ritonavir	enhances	3A457	domperidone	D	J05AE03	A03FA03	Protease inhibitors (J05AE)	Propulsives (A03FA)	Direct acting antivirals (J05A)	Propulsives (A03F)	0					J05AE	J05A	A03FA	A03F
13232	ritonavir	enhances	2D6	donepezil	D	J05AE03	N06DA02	Protease inhibitors (J05AE)	Anticholinesterases (N06DA)	Direct acting antivirals (J05A)	Anti-dementia drugs (N06D)	0					J05AE	J05A	N06DA	N06D
13233	ritonavir	enhances	2D6	duloxetine		J05AE03	N06AX21	Protease inhibitors (J05AE)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AX	N06A
13237	ritonavir	enhances	3A457	eplerenone	D	J05AE03	C03DA04	Protease inhibitors (J05AE)	Aldosterone antagonists (C03DA)	Direct acting antivirals (J05A)	Potassium-sparing agents (C03D)	0					J05AE	J05A	C03DA	C03D
13241	ritonavir	enhances	3A457	felodipine	B	J05AE03	C08CA02	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13244	ritonavir	enhances	2D6	flecainide	D	J05AE03	C01BC04	Protease inhibitors (J05AE)	Antiarrhythmics, class Ic (C01BC)	Direct acting antivirals (J05A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation			J05AE	J05A	C01BC	C01B
13245	ritonavir	enhances	2D6	fluoxetine	D	J05AE03	N06AB03	Protease inhibitors (J05AE)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AB	N06A
13246	ritonavir	enhances	2D6	fluvoxamine		J05AE03	N06AB08	Protease inhibitors (J05AE)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AB	N06A
13247	ritonavir	enhances	2D6,3A457	haloperidol	D	J05AE03	N05AD01	Protease inhibitors (J05AE)	Butyrophenone derivatives (N05AD)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AE	J05A	N05AD	N05A
13248	ritonavir	enhances	3A457	hydrocortisone		J05AE03	H02AB09	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13251	ritonavir	enhances	3A457	imatinib	D	J05AE03	L01XE01	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	0	0				J05AE	J05A	L01XE	L01X
13252	ritonavir	enhances	3A457	indacaterol		J05AE03	R03AC18	Protease inhibitors (J05AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AE	J05A	R03AC	R03A
13256	ritonavir	enhances	3A457	ivabradine		J05AE03	C01EB17	Protease inhibitors (J05AE)	Other cardiac preparations (C01EB)	Direct acting antivirals (J05A)	Other cardiac preparations (C01E)	0					J05AE	J05A	C01EB	C01E
13259	ritonavir	enhances	3A457	lercanidipine	B	J05AE03	C08CA13	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J05AE	J05A	C08CA	C08C
13264	ritonavir	enhances	3A457	lovastatin	D	J05AE03	C10AA02	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AE	J05A	C10AA	C10A
13266	ritonavir	enhances	3A457	methadone	D	J05AE03	N07BC02	Protease inhibitors (J05AE)	Drugs used in opioid dependence (N07BC)	Direct acting antivirals (J05A)	Drugs used in addictive disorders (N07B)	0	0				J05AE	J05A	N07BC	N07B
13267	ritonavir	enhances	2D6	metoclopramide	D	J05AE03	A03FA01	Protease inhibitors (J05AE)	Propulsives (A03FA)	Direct acting antivirals (J05A)	Propulsives (A03F)	0					J05AE	J05A	A03FA	A03F
13268	ritonavir	enhances	2D6	metoprolol	B	J05AE03	C07AB02	Protease inhibitors (J05AE)	Beta blocking agents, selective (C07AB)	Direct acting antivirals (J05A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect		J05AE	J05A	C07AB	C07A
13270	ritonavir	enhances	3A457	midazolam	D	J05AE03	N05CD08	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05CD	N05C
13275	ritonavir	enhances	2D6	nebivolol		J05AE03	C07AB12	Protease inhibitors (J05AE)	Beta blocking agents, selective (C07AB)	Direct acting antivirals (J05A)	Beta blocking agents (C07A)	0					J05AE	J05A	C07AB	C07A
13277	ritonavir	enhances	3A457	nifedipine	B	J05AE03	C08CA05	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13278	ritonavir	enhances	3A457	nisoldipine	B	J05AE03	C08CA07	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13279	ritonavir	enhances	3A457	nitrendipine	B	J05AE03	C08CA08	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13280	ritonavir	enhances	2D6	nortriptyline	D	J05AE03	N06AA10	Protease inhibitors (J05AE)	Non-selective monoamine reuptake inhibitors (N06AA)	Direct acting antivirals (J05A)	Antidepressants (N06A)	1					J05AE	J05A	N06AA	N06A
13282	ritonavir	enhances	2D6,3A457	ondansetron	D	J05AE03	A04AA01	Protease inhibitors (J05AE)	Serotonin (5HT3) antagonists (A04AA)	Direct acting antivirals (J05A)	Antiemetics and antinauseants (A04A)	0	0				J05AE	J05A	A04AA	A04A
13284	ritonavir	enhances	2D6	oxycodone	D	J05AE03	N02AA05	Protease inhibitors (J05AE)	Natural opium alkaloids (N02AA)	Direct acting antivirals (J05A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect		J05AE	J05A	N02AA	N02A
13289	ritonavir	enhances	2D6	paroxetine	D	J05AE03	N06AB05	Protease inhibitors (J05AE)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AB	N06A
13298	ritonavir	enhances	2D6	promethazine	D	J05AE03	R06AD02	Protease inhibitors (J05AE)	Phenothiazine derivatives (R06AD)	Direct acting antivirals (J05A)	Antihistamines for systemic use (R06A)	0					J05AE	J05A	R06AD	R06A
13299	ritonavir	enhances	2D6	propafenone	D	J05AE03	C01BC03	Protease inhibitors (J05AE)	Antiarrhythmics, class Ic (C01BC)	Direct acting antivirals (J05A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation			J05AE	J05A	C01BC	C01B
13300	ritonavir	enhances	3A457	quetiapine	D	J05AE03	N05AH04	Protease inhibitors (J05AE)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AE	J05A	N05AH	N05A
13306	ritonavir	enhances	2D6,3A457	risperidone	D	J05AE03	N05AX08	Protease inhibitors (J05AE)	Other antipsychotics (N05AX)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AE	J05A	N05AX	N05A
13307	ritonavir	enhances	3A457	rivaroxaban	D	J05AE03	B01AF01	Protease inhibitors (J05AE)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AF	B01A
13313	ritonavir	enhances	3A457	salmeterol	D	J05AE03	R03AC12	Protease inhibitors (J05AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0				7342	J05AE	J05A	R03AC	R03A
13314	ritonavir	enhances	3A457	saquinavir	D	J05AE03	J05AE01	Protease inhibitors (J05AE)	Protease inhibitors (J05AE)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AE	J05A	J05AE	J05A
13316	ritonavir	enhances	3A457	sildenafil	C	J05AE03	G04BE03	Protease inhibitors (J05AE)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AE	J05A	G04BE	G04B
13318	ritonavir	enhances	3A457	simvastatin	D	J05AE03	C10AA01	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AE	J05A	C10AA	C10A
13319	ritonavir	enhances	3A457	sirolimus	D	J05AE03	L04AA10	Protease inhibitors (J05AE)	Selective immunosuppressants (L04AA)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AA	L04A
13321	ritonavir	enhances	3A457	sorafenib	D	J05AE03	L01XE05	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AE	J05A	L01XE	L01X
13323	ritonavir	enhances	3A457	sunitinib	D	J05AE03	L01XE04	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AE	J05A	L01XE	L01X
13324	ritonavir	enhances	3A457	tacrolimus	D	J05AE03	L04AD02	Protease inhibitors (J05AE)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AD	L04A
13325	ritonavir	enhances	3A457	tadalafil	C	J05AE03	G04BE08	Protease inhibitors (J05AE)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0			7330	J05AE	J05A	G04BE	G04B
13326	ritonavir	enhances	2D6,3A457	tamoxifen	D	J05AE03	L02BA01	Protease inhibitors (J05AE)	Anti-estrogens (L02BA)	Direct acting antivirals (J05A)	Hormone antagonists and related agents (L02B)	1	1				J05AE	J05A	L02BA	L02B
13332	ritonavir	enhances	3A457	testosterone		J05AE03	G03BA03	Protease inhibitors (J05AE)	3-oxoandrosten (4) derivatives (G03BA)	Direct acting antivirals (J05A)	Androgens (G03B)	0					J05AE	J05A	G03BA	G03B
13333	ritonavir	enhances	2D6	tetrabenazine	D	J05AE03	N07XX06	Protease inhibitors (J05AE)	Other nervous system drugs (N07XX)	Direct acting antivirals (J05A)	Other nervous system drugs (N07X)	0					J05AE	J05A	N07XX	N07X
13335	ritonavir	enhances	3A457	ticagrelor		J05AE03	B01AC24	Protease inhibitors (J05AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AC	B01A
13338	ritonavir	enhances	2D6,3A457	tramadol	C	J05AE03	N02AX02	Protease inhibitors (J05AE)	Other opioids (N02AX)	Direct acting antivirals (J05A)	Opioids (N02A)	0	1		Reduced analgesic effect		J05AE	J05A	N02AX	N02A
13339	ritonavir	enhances	3A457	trazodone	D	J05AE03	N06AX05	Protease inhibitors (J05AE)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AX	N06A
13340	ritonavir	enhances	3A457	triazolam	D	J05AE03	N05CD05	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05CD	N05C
13348	ritonavir	enhances	3A457	verapamil	B	J05AE03	C08DA01	Protease inhibitors (J05AE)	Phenylalkylamine derivatives (C08DA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J05AE	J05A	C08DA	C08D
13351	ritonavir	enhances	3A457	zaleplon		J05AE03	N05CF03	Protease inhibitors (J05AE)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AE	J05A	N05CF	N05C
13353	ritonavir	enhances	3A457	zolpidem	B	J05AE03	N05CF02	Protease inhibitors (J05AE)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AE	J05A	N05CF	N05C
13354	ritonavir	enhances	2D6	zuclopenthixol	D	J05AE03	N05AF05	Protease inhibitors (J05AE)	Thioxanthene derivatives (N05AF)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AE	J05A	N05AF	N05A
13358	ritonavir	reduces	2C19	cyclophosphamide		J05AE03	L01AA01	Protease inhibitors (J05AE)	Nitrogen mustard analogues (L01AA)	Direct acting antivirals (J05A)	Alkylating agents (L01A)	1	1				J05AE	J05A	L01AA	L01A
13360	ritonavir	reduces	2C19	indometacin		J05AE03	M01AB01	Protease inhibitors (J05AE)	Acetic acid derivatives and related substances (M01AB)	Direct acting antivirals (J05A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J05AE	J05A	M01AB	M01A
13366	ritonavir	reduces	2C19	phenobarbital		J05AE03	N03AA02	Protease inhibitors (J05AE)	Barbiturates and derivatives (N03AA)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AE	J05A	N03AA	N03A
13367	ritonavir	reduces	2C19	phenytoin	B	J05AE03	N03AB02	Protease inhibitors (J05AE)	Hydantoin derivatives (N03AB)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J05AE	J05A	N03AB	N03A
13368	ritonavir	reduces	2C19	primidone		J05AE03	N03AA03	Protease inhibitors (J05AE)	Barbiturates and derivatives (N03AA)	Direct acting antivirals (J05A)	Antiepileptics (N03A)	0					J05AE	J05A	N03AA	N03A
13371	ritonavir	reduces	2C19	warfarin	B	J05AE03	B01AA03	Protease inhibitors (J05AE)	Vitamin K antagonists (B01AA)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	1	0	Bleeding			J05AE	J05A	B01AA	B01A
13627	saquinavir	enhances	3A457	alprazolam	D	J05AE01	N05BA12	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05BA	N05B
13628	saquinavir	enhances	3A457	amitriptyline	D	J05AE01	N06AA09	Protease inhibitors (J05AE)	Non-selective monoamine reuptake inhibitors (N06AA)	Direct acting antivirals (J05A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J05AE	J05A	N06AA	N06A
13629	saquinavir	enhances	3A457	amlodipine	B	J05AE01	C08CA01	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13630	saquinavir	enhances	3A457	apixaban		J05AE01	B01AF02	Protease inhibitors (J05AE)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AF	B01A
13634	saquinavir	enhances	3A457	atorvastatin	C	J05AE01	C10AA05	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J05AE	J05A	C10AA	C10A
13645	saquinavir	enhances	3A457	chlorpheniramine		J05AE01	R06AB04	Protease inhibitors (J05AE)	Substituted alkylamines (R06AB)	Direct acting antivirals (J05A)	Antihistamines for systemic use (R06A)	0	0				J05AE	J05A	R06AB	R06A
13646	saquinavir	enhances	3A457	cilostazol	D	J05AE01	B01AC23	Protease inhibitors (J05AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AC	B01A
13648	saquinavir	enhances	3A457	citalopram	D	J05AE01	N06AB04	Protease inhibitors (J05AE)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0				J05AE	J05A	N06AB	N06A
13649	saquinavir	enhances	3A457	clarithromycin	D	J05AE01	J01FA09	Protease inhibitors (J05AE)	Macrolides (J01FA)	Direct acting antivirals (J05A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J05AE	J05A	J01FA	J01F
13650	saquinavir	enhances	3A457	clopidogrel		J05AE01	B01AC04	Protease inhibitors (J05AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J05AE	J05A	B01AC	B01A
13654	saquinavir	enhances	3A457	colchicine	D	J05AE01	M04AC01	Protease inhibitors (J05AE)	Preparations with no effect on uric acid metabolism (M04AC)	Direct acting antivirals (J05A)	Antigout preparations (M04A)	0					J05AE	J05A	M04AC	M04A
13657	saquinavir	enhances	3A457	cyclosporine	D	J05AE01	L04AD01	Protease inhibitors (J05AE)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AD	L04A
13660	saquinavir	enhances	3A457	deflazacort		J05AE01	H02AB13	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13661	saquinavir	enhances	3A457	dexamethasone	C	J05AE01	H02AB02	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13662	saquinavir	enhances	3A457	dextromethorphan		J05AE01	R05DA09	Protease inhibitors (J05AE)	Opium alkaloids and derivatives (R05DA)	Direct acting antivirals (J05A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J05AE	J05A	R05DA	R05D
13663	saquinavir	enhances	3A457	diazepam	D	J05AE01	N05BA01	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05BA)	Direct acting antivirals (J05A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05BA	N05B
13664	saquinavir	enhances	3A457	diltiazem	B	J05AE01	C08DB01	Protease inhibitors (J05AE)	Benzothiazepine derivatives (C08DB)	Direct acting antivirals (J05A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J05AE	J05A	C08DB	C08D
13667	saquinavir	enhances	3A457	domperidone	D	J05AE01	A03FA03	Protease inhibitors (J05AE)	Propulsives (A03FA)	Direct acting antivirals (J05A)	Propulsives (A03F)	0					J05AE	J05A	A03FA	A03F
13671	saquinavir	enhances	3A457	eplerenone	D	J05AE01	C03DA04	Protease inhibitors (J05AE)	Aldosterone antagonists (C03DA)	Direct acting antivirals (J05A)	Potassium-sparing agents (C03D)	0					J05AE	J05A	C03DA	C03D
13674	saquinavir	enhances	3A457	escitalopram	D	J05AE01	N06AB10	Protease inhibitors (J05AE)	Selective serotonin reuptake inhibitors (N06AB)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0					J05AE	J05A	N06AB	N06A
13675	saquinavir	enhances	3A457	esomeprazole	B	J05AE01	A02BC05	Protease inhibitors (J05AE)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					J05AE	J05A	A02BC	A02B
13677	saquinavir	enhances	3A457	felodipine	B	J05AE01	C08CA02	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13681	saquinavir	enhances	3A457	haloperidol	D	J05AE01	N05AD01	Protease inhibitors (J05AE)	Butyrophenone derivatives (N05AD)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AE	J05A	N05AD	N05A
13682	saquinavir	enhances	3A457	hydrocortisone		J05AE01	H02AB09	Protease inhibitors (J05AE)	Glucocorticoids (H02AB)	Direct acting antivirals (J05A)	Corticosteroids for systemic use, plain (H02A)	0					J05AE	J05A	H02AB	H02A
13685	saquinavir	enhances	3A457	imatinib	D	J05AE01	L01XE01	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	0	0				J05AE	J05A	L01XE	L01X
13686	saquinavir	enhances	3A457	indacaterol		J05AE01	R03AC18	Protease inhibitors (J05AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AE	J05A	R03AC	R03A
13690	saquinavir	enhances	3A457	ivabradine		J05AE01	C01EB17	Protease inhibitors (J05AE)	Other cardiac preparations (C01EB)	Direct acting antivirals (J05A)	Other cardiac preparations (C01E)	0					J05AE	J05A	C01EB	C01E
13692	saquinavir	enhances	3A457	lansoprazole		J05AE01	A02BC03	Protease inhibitors (J05AE)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AE	J05A	A02BC	A02B
13694	saquinavir	enhances	3A457	lercanidipine		J05AE01	C08CA13	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J05AE	J05A	C08CA	C08C
13698	saquinavir	enhances	3A457	lovastatin	D	J05AE01	C10AA02	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AE	J05A	C10AA	C10A
13700	saquinavir	enhances	3A457	methadone	D	J05AE01	N07BC02	Protease inhibitors (J05AE)	Drugs used in opioid dependence (N07BC)	Direct acting antivirals (J05A)	Drugs used in addictive disorders (N07B)	0	0				J05AE	J05A	N07BC	N07B
13701	saquinavir	enhances	3A457	midazolam	D	J05AE01	N05CD08	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05CD	N05C
13707	saquinavir	enhances	3A457	nifedipine	B	J05AE01	C08CA05	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13708	saquinavir	enhances	3A457	nisoldipine	B	J05AE01	C08CA07	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13709	saquinavir	enhances	3A457	nitrendipine	B	J05AE01	C08CA08	Protease inhibitors (J05AE)	Dihydropyridine derivatives (C08CA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J05AE	J05A	C08CA	C08C
13711	saquinavir	enhances	3A457	omeprazole	D	J05AE01	A02BC01	Protease inhibitors (J05AE)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AE	J05A	A02BC	A02B
13712	saquinavir	enhances	3A457	ondansetron	D	J05AE01	A04AA01	Protease inhibitors (J05AE)	Serotonin (5HT3) antagonists (A04AA)	Direct acting antivirals (J05A)	Antiemetics and antinauseants (A04A)	0	0				J05AE	J05A	A04AA	A04A
13719	saquinavir	enhances	3A457	pantoprazole	B	J05AE01	A02BC02	Protease inhibitors (J05AE)	Proton pump inhibitors (A02BC)	Direct acting antivirals (J05A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J05AE	J05A	A02BC	A02B
13726	saquinavir	enhances	3A457	propranolol		J05AE01	C07AA05	Protease inhibitors (J05AE)	Beta blocking agents, non-selective (C07AA)	Direct acting antivirals (J05A)	Beta blocking agents (C07A)	0					J05AE	J05A	C07AA	C07A
13727	saquinavir	enhances	3A457	quetiapine	D	J05AE01	N05AH04	Protease inhibitors (J05AE)	Diazepines, oxazepines and thiazepines (N05AH)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0					J05AE	J05A	N05AH	N05A
13733	saquinavir	enhances	3A457	risperidone	D	J05AE01	N05AX08	Protease inhibitors (J05AE)	Other antipsychotics (N05AX)	Direct acting antivirals (J05A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J05AE	J05A	N05AX	N05A
13734	saquinavir	enhances	3A457	ritonavir	D	J05AE01	J05AE03	Protease inhibitors (J05AE)	Protease inhibitors (J05AE)	Direct acting antivirals (J05A)	Direct acting antivirals (J05A)	0	0				J05AE	J05A	J05AE	J05A
13735	saquinavir	enhances	3A457	rivaroxaban		J05AE01	B01AF01	Protease inhibitors (J05AE)	Direct factor Xa inhibitors (B01AF)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AF	B01A
13741	saquinavir	enhances	3A457	salmeterol	D	J05AE01	R03AC12	Protease inhibitors (J05AE)	Selective beta-2-adrenoreceptor agonists (R03AC)	Direct acting antivirals (J05A)	Adrenergics, inhalants (R03A)	0					J05AE	J05A	R03AC	R03A
13743	saquinavir	enhances	3A457	sildenafil	D	J05AE01	G04BE03	Protease inhibitors (J05AE)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AE	J05A	G04BE	G04B
13745	saquinavir	enhances	3A457	simvastatin	D	J05AE01	C10AA01	Protease inhibitors (J05AE)	HMG CoA reductase inhibitors (C10AA)	Direct acting antivirals (J05A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J05AE	J05A	C10AA	C10A
13746	saquinavir	enhances	3A457	sirolimus	D	J05AE01	L04AA10	Protease inhibitors (J05AE)	Selective immunosuppressants (L04AA)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AA	L04A
13748	saquinavir	enhances	3A457	sorafenib	D	J05AE01	L01XE05	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AE	J05A	L01XE	L01X
13749	saquinavir	enhances	3A457	sunitinib	D	J05AE01	L01XE04	Protease inhibitors (J05AE)	 (L01XE)	Direct acting antivirals (J05A)	Other antineoplastic agents (L01X)	1					J05AE	J05A	L01XE	L01X
13751	saquinavir	enhances	3A457	tacrolimus	D	J05AE01	L04AD02	Protease inhibitors (J05AE)	Calcineurin inhibitors (L04AD)	Direct acting antivirals (J05A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J05AE	J05A	L04AD	L04A
13752	saquinavir	enhances	3A457	tadalafil		J05AE01	G04BE08	Protease inhibitors (J05AE)	Drugs used in erectile dysfunction (G04BE)	Direct acting antivirals (J05A)	Urologicals (G04B)	0	0				J05AE	J05A	G04BE	G04B
13753	saquinavir	enhances	3A457	tamoxifen	D	J05AE01	L02BA01	Protease inhibitors (J05AE)	Anti-estrogens (L02BA)	Direct acting antivirals (J05A)	Hormone antagonists and related agents (L02B)	1	1				J05AE	J05A	L02BA	L02B
13759	saquinavir	enhances	3A457	testosterone		J05AE01	G03BA03	Protease inhibitors (J05AE)	3-oxoandrosten (4) derivatives (G03BA)	Direct acting antivirals (J05A)	Androgens (G03B)	0					J05AE	J05A	G03BA	G03B
13760	saquinavir	enhances	3A457	ticagrelor		J05AE01	B01AC24	Protease inhibitors (J05AE)	Platelet aggregation inhibitors excl. heparin (B01AC)	Direct acting antivirals (J05A)	Antithrombotic agents (B01A)	0					J05AE	J05A	B01AC	B01A
13763	saquinavir	enhances	3A457	tramadol		J05AE01	N02AX02	Protease inhibitors (J05AE)	Other opioids (N02AX)	Direct acting antivirals (J05A)	Opioids (N02A)	0	1		Reduced analgesic effect		J05AE	J05A	N02AX	N02A
13764	saquinavir	enhances	3A457	trazodone	D	J05AE01	N06AX05	Protease inhibitors (J05AE)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AX	N06A
13765	saquinavir	enhances	3A457	triazolam	D	J05AE01	N05CD05	Protease inhibitors (J05AE)	Benzodiazepine derivatives (N05CD)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J05AE	J05A	N05CD	N05C
13772	saquinavir	enhances	3A457	venlafaxine	D	J05AE01	N06AX16	Protease inhibitors (J05AE)	Other antidepressants (N06AX)	Direct acting antivirals (J05A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J05AE	J05A	N06AX	N06A
13773	saquinavir	enhances	3A457	verapamil	B	J05AE01	C08DA01	Protease inhibitors (J05AE)	Phenylalkylamine derivatives (C08DA)	Direct acting antivirals (J05A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J05AE	J05A	C08DA	C08D
13777	saquinavir	enhances	3A457	voriconazole	D	J05AE01	J02AC03	Protease inhibitors (J05AE)	Triazole derivatives (J02AC)	Direct acting antivirals (J05A)	Antimycotics for systemic use (J02A)	0	0				J05AE	J05A	J02AC	J02A
13778	saquinavir	enhances	3A457	zaleplon		J05AE01	N05CF03	Protease inhibitors (J05AE)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AE	J05A	N05CF	N05C
13780	saquinavir	enhances	3A457	zolpidem		J05AE01	N05CF02	Protease inhibitors (J05AE)	Benzodiazepine related drugs (N05CF)	Direct acting antivirals (J05A)	Hypnotics and sedatives (N05C)	0					J05AE	J05A	N05CF	N05C
13818	sertraline	enhances	2D6	amitriptyline	D	N06AB06	N06AA09	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	667	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	981	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1328	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1376	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2520	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2689	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3869	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4389	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5455	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5456	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5748	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5780	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5811	N06AB	N06A	C07AG	C07A
13823	sertraline	enhances	2D6	carvedilol		N06AB06	C07AG02	Selective serotonin reuptake inhibitors (N06AB)	Alpha and beta blocking agents (C07AG)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5999	N06AB	N06A	C07AG	C07A
13824	sertraline	enhances	2D6	chlorpheniramine	B	N06AB06	R06AB04	Selective serotonin reuptake inhibitors (N06AB)	Substituted alkylamines (R06AB)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0	0				N06AB	N06A	R06AB	R06A
13825	sertraline	enhances	2D6	chlorpromazine	D	N06AB06	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0				163	N06AB	N06A	N05AA	N05A
13825	sertraline	enhances	2D6	chlorpromazine	D	N06AB06	N05AA01	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazines with aliphatic side-chain (N05AA)	Antidepressants (N06A)	Antipsychotics (N05A)	0				3520	N06AB	N06A	N05AA	N05A
13826	sertraline	enhances	2D6	citalopram	D	N06AB06	N06AB04	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0				N06AB	N06A	N06AB	N06A
13827	sertraline	enhances	2D6	clomipramine	D	N06AB06	N06AA04	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
13828	sertraline	enhances	2D6	clonidine		N06AB06	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				956	N06AB	N06A	C02AC	C02A
13828	sertraline	enhances	2D6	clonidine		N06AB06	C02AC01	Selective serotonin reuptake inhibitors (N06AB)	Imidazoline receptor agonists (C02AC)	Antidepressants (N06A)	Antiadrenergic agents, centrally acting (C02A)	1				5999	N06AB	N06A	C02AC	C02A
13833	sertraline	enhances	2D6	dextromethorphan	D	N06AB06	R05DA09	Selective serotonin reuptake inhibitors (N06AB)	Opium alkaloids and derivatives (R05DA)	Antidepressants (N06A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				N06AB	N06A	R05DA	R05D
13834	sertraline	enhances	2D6	donepezil	D	N06AB06	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				244	N06AB	N06A	N06DA	N06D
13834	sertraline	enhances	2D6	donepezil	D	N06AB06	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				345	N06AB	N06A	N06DA	N06D
13834	sertraline	enhances	2D6	donepezil	D	N06AB06	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				2815	N06AB	N06A	N06DA	N06D
13834	sertraline	enhances	2D6	donepezil	D	N06AB06	N06DA02	Selective serotonin reuptake inhibitors (N06AB)	Anticholinesterases (N06DA)	Antidepressants (N06A)	Anti-dementia drugs (N06D)	0				7383	N06AB	N06A	N06DA	N06D
13836	sertraline	enhances	2D6	duloxetine	D	N06AB06	N06AX21	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
13839	sertraline	enhances	2D6	escitalopram	D	N06AB06	N06AB10	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0					N06AB	N06A	N06AB	N06A
13840	sertraline	enhances	2D6	flecainide	D	N06AB06	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2596	N06AB	N06A	C01BC	C01B
13840	sertraline	enhances	2D6	flecainide	D	N06AB06	C01BC04	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		5796	N06AB	N06A	C01BC	C01B
13841	sertraline	enhances	2D6	fluoxetine	D	N06AB06	N06AB03	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
13842	sertraline	enhances	2D6	fluvoxamine	D	N06AB06	N06AB08	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
13843	sertraline	enhances	2D6	haloperidol	D	N06AB06	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	959	N06AB	N06A	N05AD	N05A
13843	sertraline	enhances	2D6	haloperidol	D	N06AB06	N05AD01	Selective serotonin reuptake inhibitors (N06AB)	Butyrophenone derivatives (N05AD)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3762	N06AB	N06A	N05AD	N05A
13845	sertraline	enhances	2D6	imipramine	D	N06AB06	N06AA02	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N06AB	N06A	N06AA	N06A
13848	sertraline	enhances	2D6	metoclopramide	D	N06AB06	A03FA01	Selective serotonin reuptake inhibitors (N06AB)	Propulsives (A03FA)	Antidepressants (N06A)	Propulsives (A03F)	0				7718	N06AB	N06A	A03FA	A03F
13849	sertraline	enhances	2D6	metoprolol	B	N06AB06	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1029	N06AB	N06A	C07AB	C07A
13849	sertraline	enhances	2D6	metoprolol	B	N06AB06	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4048	N06AB	N06A	C07AB	C07A
13849	sertraline	enhances	2D6	metoprolol	B	N06AB06	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5493	N06AB	N06A	C07AB	C07A
13849	sertraline	enhances	2D6	metoprolol	B	N06AB06	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6044	N06AB	N06A	C07AB	C07A
13849	sertraline	enhances	2D6	metoprolol	B	N06AB06	C07AB02	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7032	N06AB	N06A	C07AB	C07A
13852	sertraline	enhances	2D6	nebivolol		N06AB06	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				2707	N06AB	N06A	C07AB	C07A
13852	sertraline	enhances	2D6	nebivolol		N06AB06	C07AB12	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, selective (C07AB)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				5492	N06AB	N06A	C07AB	C07A
13853	sertraline	enhances	2D6	nortriptyline	D	N06AB06	N06AA10	Selective serotonin reuptake inhibitors (N06AB)	Non-selective monoamine reuptake inhibitors (N06AA)	Antidepressants (N06A)	Antidepressants (N06A)	1				5364	N06AB	N06A	N06AA	N06A
13854	sertraline	enhances	2D6	ondansetron	D	N06AB06	A04AA01	Selective serotonin reuptake inhibitors (N06AB)	Serotonin (5HT3) antagonists (A04AA)	Antidepressants (N06A)	Antiemetics and antinauseants (A04A)	0	0			3520	N06AB	N06A	A04AA	A04A
13855	sertraline	enhances	2D6	oxycodone	C	N06AB06	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	780	N06AB	N06A	N02AA	N02A
13855	sertraline	enhances	2D6	oxycodone	C	N06AB06	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4935	N06AB	N06A	N02AA	N02A
13855	sertraline	enhances	2D6	oxycodone	C	N06AB06	N02AA05	Selective serotonin reuptake inhibitors (N06AB)	Natural opium alkaloids (N02AA)	Antidepressants (N06A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	5282	N06AB	N06A	N02AA	N02A
13857	sertraline	enhances	2D6	paroxetine	D	N06AB06	N06AB05	Selective serotonin reuptake inhibitors (N06AB)	Selective serotonin reuptake inhibitors (N06AB)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AB	N06A
13865	sertraline	enhances	2D6	promethazine	D	N06AB06	R06AD02	Selective serotonin reuptake inhibitors (N06AB)	Phenothiazine derivatives (R06AD)	Antidepressants (N06A)	Antihistamines for systemic use (R06A)	0					N06AB	N06A	R06AD	R06A
13866	sertraline	enhances	2D6	propafenone	D	N06AB06	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		293	N06AB	N06A	C01BC	C01B
13866	sertraline	enhances	2D6	propafenone	D	N06AB06	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		2394	N06AB	N06A	C01BC	C01B
13866	sertraline	enhances	2D6	propafenone	D	N06AB06	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		2830	N06AB	N06A	C01BC	C01B
13866	sertraline	enhances	2D6	propafenone	D	N06AB06	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3259	N06AB	N06A	C01BC	C01B
13866	sertraline	enhances	2D6	propafenone	D	N06AB06	C01BC03	Selective serotonin reuptake inhibitors (N06AB)	Antiarrhythmics, class Ic (C01BC)	Antidepressants (N06A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		6201	N06AB	N06A	C01BC	C01B
13867	sertraline	enhances	2D6	propranolol		N06AB06	C07AA05	Selective serotonin reuptake inhibitors (N06AB)	Beta blocking agents, non-selective (C07AA)	Antidepressants (N06A)	Beta blocking agents (C07A)	0				4402	N06AB	N06A	C07AA	C07A
13868	sertraline	enhances	2D6	risperidone	D	N06AB06	N05AX08	Selective serotonin reuptake inhibitors (N06AB)	Other antipsychotics (N05AX)	Antidepressants (N06A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		N06AB	N06A	N05AX	N05A
13871	sertraline	enhances	2D6	tamoxifen	D	N06AB06	L02BA01	Selective serotonin reuptake inhibitors (N06AB)	Anti-estrogens (L02BA)	Antidepressants (N06A)	Hormone antagonists and related agents (L02B)	1	1				N06AB	N06A	L02BA	L02B
13872	sertraline	enhances	2D6	tetrabenazine	D	N06AB06	N07XX06	Selective serotonin reuptake inhibitors (N06AB)	Other nervous system drugs (N07XX)	Antidepressants (N06A)	Other nervous system drugs (N07X)	0					N06AB	N06A	N07XX	N07X
13875	sertraline	enhances	2D6	tramadol	D	N06AB06	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	163	N06AB	N06A	N02AX	N02A
13875	sertraline	enhances	2D6	tramadol	D	N06AB06	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	756	N06AB	N06A	N02AX	N02A
13875	sertraline	enhances	2D6	tramadol	D	N06AB06	N02AX02	Selective serotonin reuptake inhibitors (N06AB)	Other opioids (N02AX)	Antidepressants (N06A)	Opioids (N02A)	0	1		Reduced analgesic effect	4048	N06AB	N06A	N02AX	N02A
13878	sertraline	enhances	2D6	venlafaxine	D	N06AB06	N06AX16	Selective serotonin reuptake inhibitors (N06AB)	Other antidepressants (N06AX)	Antidepressants (N06A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N06AB	N06A	N06AX	N06A
13880	sertraline	enhances	2D6	zuclopenthixol		N06AB06	N05AF05	Selective serotonin reuptake inhibitors (N06AB)	Thioxanthene derivatives (N05AF)	Antidepressants (N06A)	Antipsychotics (N05A)	0					N06AB	N06A	N05AF	N05A
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			2037	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			2737	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			3798	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			4122	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			4322	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			4648	B01AC	B01A	N02BE	N02B
14912	ticlopidine	enhances	1A2	acetaminophen		B01AC05	N02BE01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anilides (N02BE)	Antithrombotic agents (B01A)	Other analgesics and antipyretics (N02B)	0	0			7058	B01AC	B01A	N02BE	N02B
14915	ticlopidine	enhances	1A2,2C19,2D6	amitriptyline		B01AC05	N06AA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1	0	Serotonin toxicity		1193	B01AC	B01A	N06AA	N06A
14915	ticlopidine	enhances	1A2,2C19,2D6	amitriptyline		B01AC05	N06AA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1	0	Serotonin toxicity		3506	B01AC	B01A	N06AA	N06A
14915	ticlopidine	enhances	1A2,2C19,2D6	amitriptyline		B01AC05	N06AA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1	0	Serotonin toxicity		5176	B01AC	B01A	N06AA	N06A
14922	ticlopidine	enhances	2B6	bupropion	B	B01AC05	N06AX12	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			B01AC	B01A	N06AX	N06A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	14	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	205	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	304	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	725	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	750	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	768	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	770	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	810	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1139	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1195	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1537	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1620	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2151	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2300	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2389	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2392	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2410	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2420	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2454	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2519	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2533	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2615	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3155	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3173	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3485	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3535	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3560	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3663	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3798	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4022	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4050	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4155	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4187	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4397	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4712	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4896	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5614	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5811	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5923	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6007	B01AC	B01A	C07AG	C07A
14926	ticlopidine	enhances	2D6	carvedilol		B01AC05	C07AG02	Platelet aggregation inhibitors excl. heparin (B01AC)	Alpha and beta blocking agents (C07AG)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	6229	B01AC	B01A	C07AG	C07A
14928	ticlopidine	enhances	2D6	chlorpheniramine		B01AC05	R06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Substituted alkylamines (R06AB)	Antithrombotic agents (B01A)	Antihistamines for systemic use (R06A)	0	0			3798	B01AC	B01A	R06AB	R06A
14929	ticlopidine	enhances	2D6	chlorpromazine		B01AC05	N05AA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenothiazines with aliphatic side-chain (N05AA)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0				3792	B01AC	B01A	N05AA	N05A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			727	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			770	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			1537	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			2456	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			2865	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			3046	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			3228	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			3503	B01AC	B01A	N06AB	N06A
14930	ticlopidine	enhances	2C19,2D6	citalopram		B01AC05	N06AB04	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0			5925	B01AC	B01A	N06AB	N06A
14931	ticlopidine	enhances	2B6,2C19	clobazam	B	B01AC05	N05BA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Benzodiazepine derivatives (N05BA)	Antithrombotic agents (B01A)	Anxiolytics (N05B)	0					B01AC	B01A	N05BA	N05B
14932	ticlopidine	enhances	1A2,2C19,2D6	clomipramine		B01AC05	N06AA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1	0	Serotonin toxicity			B01AC	B01A	N06AA	N06A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				1216	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				1413	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				2279	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				2300	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				2352	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3078	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3173	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3286	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3293	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3512	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				3658	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				6071	B01AC	B01A	C02AC	C02A
14933	ticlopidine	enhances	2D6	clonidine		B01AC05	C02AC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Imidazoline receptor agonists (C02AC)	Antithrombotic agents (B01A)	Antiadrenergic agents, centrally acting (C02A)	1				7045	B01AC	B01A	C02AC	C02A
14934	ticlopidine	enhances	2C19	clopidogrel		B01AC05	B01AC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		B01AC	B01A	B01AC	B01A
14935	ticlopidine	enhances	1A2	clozapine		B01AC05	N05AH02	Platelet aggregation inhibitors excl. heparin (B01AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		B01AC	B01A	N05AH	N05A
14938	ticlopidine	enhances	2B6,2C19	cyclophosphamide		B01AC05	L01AA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Nitrogen mustard analogues (L01AA)	Antithrombotic agents (B01A)	Alkylating agents (L01A)	1	1				B01AC	B01A	L01AA	L01A
14942	ticlopidine	enhances	2D6	dextromethorphan		B01AC05	R05DA09	Platelet aggregation inhibitors excl. heparin (B01AC)	Opium alkaloids and derivatives (R05DA)	Antithrombotic agents (B01A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				B01AC	B01A	R05DA	R05D
14943	ticlopidine	enhances	2C19	diazepam		B01AC05	N05BA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Benzodiazepine derivatives (N05BA)	Antithrombotic agents (B01A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	304	B01AC	B01A	N05BA	N05B
14943	ticlopidine	enhances	2C19	diazepam		B01AC05	N05BA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Benzodiazepine derivatives (N05BA)	Antithrombotic agents (B01A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	2456	B01AC	B01A	N05BA	N05B
14943	ticlopidine	enhances	2C19	diazepam		B01AC05	N05BA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Benzodiazepine derivatives (N05BA)	Antithrombotic agents (B01A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3792	B01AC	B01A	N05BA	N05B
14944	ticlopidine	enhances	2D6	donepezil		B01AC05	N06DA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Anticholinesterases (N06DA)	Antithrombotic agents (B01A)	Anti-dementia drugs (N06D)	0				345	B01AC	B01A	N06DA	N06D
14944	ticlopidine	enhances	2D6	donepezil		B01AC05	N06DA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Anticholinesterases (N06DA)	Antithrombotic agents (B01A)	Anti-dementia drugs (N06D)	0				3282	B01AC	B01A	N06DA	N06D
14944	ticlopidine	enhances	2D6	donepezil		B01AC05	N06DA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Anticholinesterases (N06DA)	Antithrombotic agents (B01A)	Anti-dementia drugs (N06D)	0				4736	B01AC	B01A	N06DA	N06D
14946	ticlopidine	enhances	1A2,2D6	duloxetine	C	B01AC05	N06AX21	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3791	B01AC	B01A	N06AX	N06A
14946	ticlopidine	enhances	1A2,2D6	duloxetine	C	B01AC05	N06AX21	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4882	B01AC	B01A	N06AX	N06A
14946	ticlopidine	enhances	1A2,2D6	duloxetine	C	B01AC05	N06AX21	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4904	B01AC	B01A	N06AX	N06A
14947	ticlopidine	enhances	2B6	efavirenz		B01AC05	J05AG03	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antithrombotic agents (B01A)	Direct acting antivirals (J05A)	0	0				B01AC	B01A	J05AG	J05A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				133	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				1139	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				1219	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				1237	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				1496	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				2536	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				3248	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				3286	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				3939	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				3969	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				4077	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				4401	B01AC	B01A	N06AB	N06A
14950	ticlopidine	enhances	2C19,2D6	escitalopram		B01AC05	N06AB10	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0				7445	B01AC	B01A	N06AB	N06A
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				266	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				767	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				896	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1617	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2073	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2117	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2197	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2296	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2396	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2439	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2599	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2679	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2776	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3078	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3472	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3766	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3791	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3972	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4144	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4288	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4303	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4394	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4704	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5205	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5604	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				6034	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				6129	B01AC	B01A	A02BC	A02B
14951	ticlopidine	enhances	2C19	esomeprazole		B01AC05	A02BC05	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7416	B01AC	B01A	A02BC	A02B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		787	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		1219	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2015	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2124	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2138	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2702	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		2851	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		3512	B01AC	B01A	C01BC	C01B
14953	ticlopidine	enhances	2D6	flecainide		B01AC05	C01BC04	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	1	0	QT interval prolongation		3599	B01AC	B01A	C01BC	C01B
14955	ticlopidine	enhances	2D6	fluoxetine		B01AC05	N06AB03	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			B01AC	B01A	N06AB	N06A
14956	ticlopidine	enhances	1A2,2D6	fluvoxamine	C	B01AC05	N06AB08	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity			B01AC	B01A	N06AB	N06A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	974	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3155	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3175	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	3819	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4092	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4155	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4258	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4882	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	5490	B01AC	B01A	N05AD	N05A
14957	ticlopidine	enhances	1A2,2D6	haloperidol		B01AC05	N05AD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Butyrophenone derivatives (N05AD)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	7445	B01AC	B01A	N05AD	N05A
14961	ticlopidine	enhances	1A2,2C19,2D6	imipramine		B01AC05	N06AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1	0	Serotonin toxicity			B01AC	B01A	N06AA	N06A
14962	ticlopidine	enhances	2C19	indometacin	C	B01AC05	M01AB01	Platelet aggregation inhibitors excl. heparin (B01AC)	Acetic acid derivatives and related substances (M01AB)	Antithrombotic agents (B01A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0				4303	B01AC	B01A	M01AB	M01A
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			68	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			125	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			205	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			211	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			309	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			344	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			345	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			584	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			619	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			635	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			682	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			715	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			768	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			772	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			787	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			792	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			810	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			852	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1031	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1137	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1139	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1193	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1195	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1238	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1383	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1425	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1506	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1537	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1555	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1590	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2015	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2028	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2037	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2099	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2107	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2122	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2174	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2238	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2300	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2317	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2352	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2375	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2429	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2439	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2444	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2454	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2456	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2478	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2494	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2516	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2551	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2568	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2615	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2711	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2812	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2835	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2902	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2982	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3015	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3098	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3173	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3191	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3242	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3248	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3252	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3332	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3392	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3609	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3670	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3672	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3694	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3741	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3805	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3842	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3946	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4035	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4256	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4258	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4261	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4317	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4322	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4769	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4904	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5109	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5411	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5506	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5811	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5832	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5924	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6039	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6071	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6207	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7060	B01AC	B01A	A02BC	A02B
14965	ticlopidine	enhances	2C19	lansoprazole		B01AC05	A02BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7238	B01AC	B01A	A02BC	A02B
14970	ticlopidine	enhances	2B6	methadone		B01AC05	N07BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Drugs used in opioid dependence (N07BC)	Antithrombotic agents (B01A)	Drugs used in addictive disorders (N07B)	0	0				B01AC	B01A	N07BC	N07B
14972	ticlopidine	enhances	2D6	metoclopramide		B01AC05	A03FA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Propulsives (A03FA)	Antithrombotic agents (B01A)	Propulsives (A03F)	0				7350	B01AC	B01A	A03FA	A03F
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1090	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	1137	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2208	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2269	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2456	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2481	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2536	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2538	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2702	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2704	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	2835	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3472	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3497	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3609	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	3814	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4055	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4208	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	4250	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	5411	B01AC	B01A	C07AB	C07A
14973	ticlopidine	enhances	2D6	metoprolol		B01AC05	C07AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0	0		Reduced antihypertensive effect	7238	B01AC	B01A	C07AB	C07A
14978	ticlopidine	enhances	1A2	naproxen	C	B01AC05	M01AE02	Platelet aggregation inhibitors excl. heparin (B01AC)	Propionic acid derivatives (M01AE)	Antithrombotic agents (B01A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				B01AC	B01A	M01AE	M01A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				1456	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				1496	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				1504	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				2396	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				2897	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				3683	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				5411	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				5573	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				5706	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				6129	B01AC	B01A	C07AB	C07A
14979	ticlopidine	enhances	2D6	nebivolol		B01AC05	C07AB12	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, selective (C07AB)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0				7487	B01AC	B01A	C07AB	C07A
14981	ticlopidine	enhances	2B6	nevirapine		B01AC05	J05AG01	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antithrombotic agents (B01A)	Direct acting antivirals (J05A)	0	0				B01AC	B01A	J05AG	J05A
14983	ticlopidine	enhances	2D6	nortriptyline		B01AC05	N06AA10	Platelet aggregation inhibitors excl. heparin (B01AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antithrombotic agents (B01A)	Antidepressants (N06A)	1				3972	B01AC	B01A	N06AA	N06A
14984	ticlopidine	enhances	1A2	olanzapine		B01AC05	N05AH03	Platelet aggregation inhibitors excl. heparin (B01AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		B01AC	B01A	N05AH	N05A
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			203	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			309	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			569	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			594	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			682	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			843	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1054	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1064	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1086	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1197	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1216	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1237	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1403	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1411	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1413	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1456	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1597	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1601	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1620	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2026	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2075	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2138	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2208	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2250	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2282	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2352	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2373	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2410	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2481	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2533	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2544	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2615	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2616	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2720	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2782	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2902	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2935	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3002	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3137	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3176	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3186	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3296	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3497	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3503	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3504	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3535	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3631	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3763	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3766	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3789	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3792	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3814	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3819	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3918	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3949	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4011	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4022	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4077	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4208	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4221	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4318	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4512	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4910	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5176	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5367	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5573	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5925	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6009	B01AC	B01A	A02BC	A02B
14985	ticlopidine	enhances	2C19	omeprazole		B01AC05	A02BC01	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7487	B01AC	B01A	A02BC	A02B
14986	ticlopidine	enhances	1A2,2D6	ondansetron		B01AC05	A04AA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Serotonin (5HT3) antagonists (A04AA)	Antithrombotic agents (B01A)	Antiemetics and antinauseants (A04A)	0	0				B01AC	B01A	A04AA	A04A
14988	ticlopidine	enhances	2D6	oxycodone		B01AC05	N02AA05	Platelet aggregation inhibitors excl. heparin (B01AC)	Natural opium alkaloids (N02AA)	Antithrombotic agents (B01A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	1403	B01AC	B01A	N02AA	N02A
14988	ticlopidine	enhances	2D6	oxycodone		B01AC05	N02AA05	Platelet aggregation inhibitors excl. heparin (B01AC)	Natural opium alkaloids (N02AA)	Antithrombotic agents (B01A)	Opioids (N02A)	0	0	Sedation and respiratory depression	Reduced analgesic effect	4322	B01AC	B01A	N02AA	N02A
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			133	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			281	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			325	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			344	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			725	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1070	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1108	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1139	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1211	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1214	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1219	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1496	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2101	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2225	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2463	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2597	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2705	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3056	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3426	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3535	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3599	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3672	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3883	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3939	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3979	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4050	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4122	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4250	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4355	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4401	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4547	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4651	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4662	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4686	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4712	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4771	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4882	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4886	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4896	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5001	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5406	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5856	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5963	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6207	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6226	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6229	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7023	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7045	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7170	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7445	B01AC	B01A	A02BC	A02B
14990	ticlopidine	enhances	2C19	pantoprazole		B01AC05	A02BC02	Platelet aggregation inhibitors excl. heparin (B01AC)	Proton pump inhibitors (A02BC)	Antithrombotic agents (B01A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7651	B01AC	B01A	A02BC	A02B
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		33	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2474	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2720	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2897	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3672	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		3725	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4102	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		5706	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7447	B01AC	B01A	N06AB	N06A
14991	ticlopidine	enhances	2D6	paroxetine		B01AC05	N06AB05	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective serotonin reuptake inhibitors (N06AB)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7511	B01AC	B01A	N06AB	N06A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	68	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	203	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	776	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	1031	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2141	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2332	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4258	B01AC	B01A	N03AA	N03A
14996	ticlopidine	enhances	2C19	phenobarbital		B01AC05	N03AA02	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	4317	B01AC	B01A	N03AA	N03A
14997	ticlopidine	enhances	2C19	phenytoin	B	B01AC05	N03AB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Hydantoin derivatives (N03AB)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect	2230	B01AC	B01A	N03AB	N03A
15002	ticlopidine	enhances	2C19	primidone		B01AC05	N03AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Barbiturates and derivatives (N03AA)	Antithrombotic agents (B01A)	Antiepileptics (N03A)	0					B01AC	B01A	N03AA	N03A
15005	ticlopidine	enhances	2D6	promethazine		B01AC05	R06AD02	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenothiazine derivatives (R06AD)	Antithrombotic agents (B01A)	Antihistamines for systemic use (R06A)	0				2222	B01AC	B01A	R06AD	R06A
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		133	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		367	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		2296	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		2603	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3185	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3242	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3503	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		3534	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		4904	B01AC	B01A	C01BC	C01B
15006	ticlopidine	enhances	2D6	propafenone		B01AC05	C01BC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiarrhythmics, class Ic (C01BC)	Antithrombotic agents (B01A)	Antiarrhythmics, class i and iii (C01B)	0	0	QT interval prolongation		6207	B01AC	B01A	C01BC	C01B
15008	ticlopidine	enhances	1A2,2C19,2D6	propranolol		B01AC05	C07AA05	Platelet aggregation inhibitors excl. heparin (B01AC)	Beta blocking agents, non-selective (C07AA)	Antithrombotic agents (B01A)	Beta blocking agents (C07A)	0					B01AC	B01A	C07AA	C07A
15009	ticlopidine	enhances	1A2	riluzole		B01AC05	N07XX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other nervous system drugs (N07XX)	Antithrombotic agents (B01A)	Other nervous system drugs (N07X)	0	0				B01AC	B01A	N07XX	N07X
15010	ticlopidine	enhances	2D6	risperidone		B01AC05	N05AX08	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antipsychotics (N05AX)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	2187	B01AC	B01A	N05AX	N05A
15014	ticlopidine	enhances	2B6	selegiline		B01AC05	N04BD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Monoamine oxidase B inhibitors (N04BD)	Antithrombotic agents (B01A)	Dopaminergic agents (N04B)	0	0			3725	B01AC	B01A	N04BD	N04B
15014	ticlopidine	enhances	2B6	selegiline		B01AC05	N04BD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Monoamine oxidase B inhibitors (N04BD)	Antithrombotic agents (B01A)	Dopaminergic agents (N04B)	0	0			4085	B01AC	B01A	N04BD	N04B
15014	ticlopidine	enhances	2B6	selegiline		B01AC05	N04BD01	Platelet aggregation inhibitors excl. heparin (B01AC)	Monoamine oxidase B inhibitors (N04BD)	Antithrombotic agents (B01A)	Dopaminergic agents (N04B)	0	0			4757	B01AC	B01A	N04BD	N04B
15015	ticlopidine	enhances	2B6	sorafenib		B01AC05	L01XE05	Platelet aggregation inhibitors excl. heparin (B01AC)	 (L01XE)	Antithrombotic agents (B01A)	Other antineoplastic agents (L01X)	1					B01AC	B01A	L01XE	L01X
15019	ticlopidine	enhances	2D6	tamoxifen		B01AC05	L02BA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Anti-estrogens (L02BA)	Antithrombotic agents (B01A)	Hormone antagonists and related agents (L02B)	1	1				B01AC	B01A	L02BA	L02B
15022	ticlopidine	enhances	2D6	tetrabenazine		B01AC05	N07XX06	Platelet aggregation inhibitors excl. heparin (B01AC)	Other nervous system drugs (N07XX)	Antithrombotic agents (B01A)	Other nervous system drugs (N07X)	0					B01AC	B01A	N07XX	N07X
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			569	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			1383	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2195	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2536	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2725	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			2940	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			3186	B01AC	B01A	R03DA	R03D
15023	ticlopidine	enhances	1A2	theophylline	B	B01AC05	R03DA04	Platelet aggregation inhibitors excl. heparin (B01AC)	Xanthines (R03DA)	Antithrombotic agents (B01A)	Other systemic drugs for obstructive airway diseases (R03D)	1	0			3599	B01AC	B01A	R03DA	R03D
15026	ticlopidine	enhances	1A2	tizanidine	B	B01AC05	M03BX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other centrally acting agents (M03BX)	Antithrombotic agents (B01A)	Muscle relaxants, centrally acting agents (M03B)	1	0				B01AC	B01A	M03BX	M03B
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	1216	B01AC	B01A	N02AX	N02A
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	2282	B01AC	B01A	N02AX	N02A
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	2494	B01AC	B01A	N02AX	N02A
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	4882	B01AC	B01A	N02AX	N02A
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	6071	B01AC	B01A	N02AX	N02A
15028	ticlopidine	enhances	2B6,2D6	tramadol		B01AC05	N02AX02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other opioids (N02AX)	Antithrombotic agents (B01A)	Opioids (N02A)	0	1		Reduced analgesic effect	7058	B01AC	B01A	N02AX	N02A
15029	ticlopidine	enhances	1A2	triamterene		B01AC05	C03DB02	Platelet aggregation inhibitors excl. heparin (B01AC)	Other potassium-sparing agents (C03DB)	Antithrombotic agents (B01A)	Potassium-sparing agents (C03D)	0	0	Hyperkaliemia			B01AC	B01A	C03DB	C03D
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		125	B01AC	B01A	N06AX	N06A
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		1327	B01AC	B01A	N06AX	N06A
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		2208	B01AC	B01A	N06AX	N06A
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		4505	B01AC	B01A	N06AX	N06A
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		5411	B01AC	B01A	N06AX	N06A
15033	ticlopidine	enhances	2C19,2D6	venlafaxine	C	B01AC05	N06AX16	Platelet aggregation inhibitors excl. heparin (B01AC)	Other antidepressants (N06AX)	Antithrombotic agents (B01A)	Antidepressants (N06A)	0	0	Serotonin toxicity		7416	B01AC	B01A	N06AX	N06A
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		309	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		579	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		690	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		2957	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4757	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4769	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		4952	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5370	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		5880	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		6071	B01AC	B01A	C08DA	C08D
15034	ticlopidine	enhances	1A2	verapamil		B01AC05	C08DA01	Platelet aggregation inhibitors excl. heparin (B01AC)	Phenylalkylamine derivatives (C08DA)	Antithrombotic agents (B01A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension		7609	B01AC	B01A	C08DA	C08D
15036	ticlopidine	enhances	2C19	voriconazole		B01AC05	J02AC03	Platelet aggregation inhibitors excl. heparin (B01AC)	Triazole derivatives (J02AC)	Antithrombotic agents (B01A)	Antimycotics for systemic use (J02A)	0	0				B01AC	B01A	J02AC	J02A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		1108	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		1411	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		2332	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		2454	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		3242	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		3946	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		4429	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		5205	B01AC	B01A	B01AA	B01A
15037	ticlopidine	enhances	1A2,2C19	warfarin	C	B01AC05	B01AA03	Platelet aggregation inhibitors excl. heparin (B01AC)	Vitamin K antagonists (B01AA)	Antithrombotic agents (B01A)	Antithrombotic agents (B01A)	1	0	Bleeding		7023	B01AC	B01A	B01AA	B01A
15040	ticlopidine	enhances	2D6	zuclopenthixol		B01AC05	N05AF05	Platelet aggregation inhibitors excl. heparin (B01AC)	Thioxanthene derivatives (N05AF)	Antithrombotic agents (B01A)	Antipsychotics (N05A)	0					B01AC	B01A	N05AF	N05A
15076	topiramate	enhances	2C19	amitriptyline	B	N03AX11	N06AA09	Other antiepileptics (N03AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AX	N03A	N06AA	N06A
15081	topiramate	enhances	2C19	citalopram	C	N03AX11	N06AB04	Other antiepileptics (N03AX)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0				N03AX	N03A	N06AB	N06A
15082	topiramate	enhances	2C19	clobazam		N03AX11	N05BA09	Other antiepileptics (N03AX)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0					N03AX	N03A	N05BA	N05B
15083	topiramate	enhances	2C19	clomipramine		N03AX11	N06AA04	Other antiepileptics (N03AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AX	N03A	N06AA	N06A
15084	topiramate	enhances	2C19	clopidogrel		N03AX11	B01AC04	Other antiepileptics (N03AX)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		N03AX	N03A	B01AC	B01A
15085	topiramate	enhances	2C19	cyclophosphamide		N03AX11	L01AA01	Other antiepileptics (N03AX)	Nitrogen mustard analogues (L01AA)	Antiepileptics (N03A)	Alkylating agents (L01A)	1	1				N03AX	N03A	L01AA	L01A
15086	topiramate	enhances	2C19	diazepam		N03AX11	N05BA01	Other antiepileptics (N03AX)	Benzodiazepine derivatives (N05BA)	Antiepileptics (N03A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		N03AX	N03A	N05BA	N05B
15088	topiramate	enhances	2C19	escitalopram	C	N03AX11	N06AB10	Other antiepileptics (N03AX)	Selective serotonin reuptake inhibitors (N06AB)	Antiepileptics (N03A)	Antidepressants (N06A)	0					N03AX	N03A	N06AB	N06A
15089	topiramate	enhances	2C19	esomeprazole		N03AX11	A02BC05	Other antiepileptics (N03AX)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					N03AX	N03A	A02BC	A02B
15092	topiramate	enhances	2C19	imipramine		N03AX11	N06AA02	Other antiepileptics (N03AX)	Non-selective monoamine reuptake inhibitors (N06AA)	Antiepileptics (N03A)	Antidepressants (N06A)	1	0	Serotonin toxicity			N03AX	N03A	N06AA	N06A
15093	topiramate	enhances	2C19	indometacin		N03AX11	M01AB01	Other antiepileptics (N03AX)	Acetic acid derivatives and related substances (M01AB)	Antiepileptics (N03A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					N03AX	N03A	M01AB	M01A
15095	topiramate	enhances	2C19	lansoprazole		N03AX11	A02BC03	Other antiepileptics (N03AX)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			108	N03AX	N03A	A02BC	A02B
15101	topiramate	enhances	2C19	omeprazole		N03AX11	A02BC01	Other antiepileptics (N03AX)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N03AX	N03A	A02BC	A02B
15103	topiramate	enhances	2C19	pantoprazole		N03AX11	A02BC02	Other antiepileptics (N03AX)	Proton pump inhibitors (A02BC)	Antiepileptics (N03A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				N03AX	N03A	A02BC	A02B
15104	topiramate	enhances	2C19	phenobarbital	B	N03AX11	N03AA02	Other antiepileptics (N03AX)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N03AX	N03A	N03AA	N03A
15105	topiramate	enhances	2C19	phenytoin	B	N03AX11	N03AB02	Other antiepileptics (N03AX)	Hydantoin derivatives (N03AB)	Antiepileptics (N03A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		N03AX	N03A	N03AB	N03A
15107	topiramate	enhances	2C19	primidone		N03AX11	N03AA03	Other antiepileptics (N03AX)	Barbiturates and derivatives (N03AA)	Antiepileptics (N03A)	Antiepileptics (N03A)	0					N03AX	N03A	N03AA	N03A
15110	topiramate	enhances	2C19	propranolol		N03AX11	C07AA05	Other antiepileptics (N03AX)	Beta blocking agents, non-selective (C07AA)	Antiepileptics (N03A)	Beta blocking agents (C07A)	0					N03AX	N03A	C07AA	C07A
15114	topiramate	enhances	2C19	venlafaxine		N03AX11	N06AX16	Other antiepileptics (N03AX)	Other antidepressants (N06AX)	Antiepileptics (N03A)	Antidepressants (N06A)	0	0	Serotonin toxicity			N03AX	N03A	N06AX	N06A
15116	topiramate	enhances	2C19	voriconazole		N03AX11	J02AC03	Other antiepileptics (N03AX)	Triazole derivatives (J02AC)	Antiepileptics (N03A)	Antimycotics for systemic use (J02A)	0	0				N03AX	N03A	J02AC	J02A
15117	topiramate	enhances	2C19	warfarin		N03AX11	B01AA03	Other antiepileptics (N03AX)	Vitamin K antagonists (B01AA)	Antiepileptics (N03A)	Antithrombotic agents (B01A)	1	0	Bleeding		2023	N03AX	N03A	B01AA	B01A
15792	verapamil	enhances	3A457	alprazolam	C	C08DA01	N05BA12	Phenylalkylamine derivatives (C08DA)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	3405	C08DA	C08D	N05BA	N05B
15792	verapamil	enhances	3A457	alprazolam	C	C08DA01	N05BA12	Phenylalkylamine derivatives (C08DA)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	5556	C08DA	C08D	N05BA	N05B
15793	verapamil	enhances	3A457	amitriptyline		C08DA01	N06AA09	Phenylalkylamine derivatives (C08DA)	Non-selective monoamine reuptake inhibitors (N06AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	1	0	Serotonin toxicity		1275	C08DA	C08D	N06AA	N06A
15793	verapamil	enhances	3A457	amitriptyline		C08DA01	N06AA09	Phenylalkylamine derivatives (C08DA)	Non-selective monoamine reuptake inhibitors (N06AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	1	0	Serotonin toxicity		1561	C08DA	C08D	N06AA	N06A
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	181	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	705	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2039	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	2779	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3479	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	3777	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	5556	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	6227	C08DA	C08D	C08CA	C08C
15794	verapamil	enhances	3A457	amlodipine		C08DA01	C08CA01	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect	7470	C08DA	C08D	C08CA	C08C
15795	verapamil	enhances	3A457	apixaban	B	C08DA01	B01AF02	Phenylalkylamine derivatives (C08DA)	Direct factor Xa inhibitors (B01AF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0				5775	C08DA	C08D	B01AF	B01A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		560	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		705	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1016	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1275	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1356	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		1458	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		2051	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		3854	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4243	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4927	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		4943	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5286	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		5730	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		6095	C08DA	C08D	C10AA	C10A
15799	verapamil	enhances	3A457	atorvastatin	C	C08DA01	C10AA05	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	0	Myopathy		7690	C08DA	C08D	C10AA	C10A
15810	verapamil	enhances	3A457	chlorpheniramine		C08DA01	R06AB04	Phenylalkylamine derivatives (C08DA)	Substituted alkylamines (R06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antihistamines for systemic use (R06A)	0	0				C08DA	C08D	R06AB	R06A
15811	verapamil	enhances	3A457	cilostazol		C08DA01	B01AC23	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0					C08DA	C08D	B01AC	B01A
15813	verapamil	enhances	3A457	citalopram		C08DA01	N06AB04	Phenylalkylamine derivatives (C08DA)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0			5638	C08DA	C08D	N06AB	N06A
15814	verapamil	enhances	3A457	clarithromycin	C	C08DA01	J01FA09	Phenylalkylamine derivatives (C08DA)	Macrolides (J01FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Macrolides, lincosamides and streptogramins (J01F)	0	0			4748	C08DA	C08D	J01FA	J01F
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	564	C08DA	C08D	B01AC	B01A
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	1016	C08DA	C08D	B01AC	B01A
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	2627	C08DA	C08D	B01AC	B01A
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	3568	C08DA	C08D	B01AC	B01A
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	4128	C08DA	C08D	B01AC	B01A
15815	verapamil	enhances	3A457	clopidogrel		C08DA01	B01AC04	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect	7119	C08DA	C08D	B01AC	B01A
15819	verapamil	enhances	3A457	colchicine		C08DA01	M04AC01	Phenylalkylamine derivatives (C08DA)	Preparations with no effect on uric acid metabolism (M04AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antigout preparations (M04A)	0					C08DA	C08D	M04AC	M04A
15822	verapamil	enhances	3A457	cyclosporine	B	C08DA01	L04AD01	Phenylalkylamine derivatives (C08DA)	Calcineurin inhibitors (L04AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C08DA	C08D	L04AD	L04A
15825	verapamil	enhances	3A457	deflazacort		C08DA01	H02AB13	Phenylalkylamine derivatives (C08DA)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0					C08DA	C08D	H02AB	H02A
15826	verapamil	enhances	3A457	dexamethasone		C08DA01	H02AB02	Phenylalkylamine derivatives (C08DA)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0					C08DA	C08D	H02AB	H02A
15827	verapamil	enhances	3A457	dextromethorphan		C08DA01	R05DA09	Phenylalkylamine derivatives (C08DA)	Opium alkaloids and derivatives (R05DA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				C08DA	C08D	R05DA	R05D
15828	verapamil	enhances	3A457	diazepam	B	C08DA01	N05BA01	Phenylalkylamine derivatives (C08DA)	Benzodiazepine derivatives (N05BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	4549	C08DA	C08D	N05BA	N05B
15829	verapamil	enhances	3A457	diltiazem	B	C08DA01	C08DB01	Phenylalkylamine derivatives (C08DA)	Benzothiazepine derivatives (C08DB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			C08DA	C08D	C08DB	C08D
15832	verapamil	enhances	3A457	domperidone		C08DA01	A03FA03	Phenylalkylamine derivatives (C08DA)	Propulsives (A03FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Propulsives (A03F)	0				3073	C08DA	C08D	A03FA	A03F
15832	verapamil	enhances	3A457	domperidone		C08DA01	A03FA03	Phenylalkylamine derivatives (C08DA)	Propulsives (A03FA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Propulsives (A03F)	0				4757	C08DA	C08D	A03FA	A03F
15836	verapamil	enhances	3A457	eplerenone	C	C08DA01	C03DA04	Phenylalkylamine derivatives (C08DA)	Aldosterone antagonists (C03DA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Potassium-sparing agents (C03D)	0					C08DA	C08D	C03DA	C03D
15839	verapamil	enhances	3A457	escitalopram		C08DA01	N06AB10	Phenylalkylamine derivatives (C08DA)	Selective serotonin reuptake inhibitors (N06AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0				4873	C08DA	C08D	N06AB	N06A
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				1579	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2039	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				2123	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3481	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3549	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				3777	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4746	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				4873	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5556	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5601	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				5730	C08DA	C08D	A02BC	A02B
15840	verapamil	enhances	3A457	esomeprazole		C08DA01	A02BC05	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0				7639	C08DA	C08D	A02BC	A02B
15842	verapamil	enhances	3A457	felodipine		C08DA01	C08CA02	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DA	C08D	C08CA	C08C
15846	verapamil	enhances	3A457	haloperidol		C08DA01	N05AD01	Phenylalkylamine derivatives (C08DA)	Butyrophenone derivatives (N05AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect	4373	C08DA	C08D	N05AD	N05A
15847	verapamil	enhances	3A457	hydrocortisone		C08DA01	H02AB09	Phenylalkylamine derivatives (C08DA)	Glucocorticoids (H02AB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Corticosteroids for systemic use, plain (H02A)	0					C08DA	C08D	H02AB	H02A
15850	verapamil	enhances	3A457	imatinib	B	C08DA01	L01XE01	Phenylalkylamine derivatives (C08DA)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	0	0				C08DA	C08D	L01XE	L01X
15851	verapamil	enhances	3A457	indacaterol		C08DA01	R03AC18	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				7609	C08DA	C08D	R03AC	R03A
15855	verapamil	enhances	3A457	ivabradine		C08DA01	C01EB17	Phenylalkylamine derivatives (C08DA)	Other cardiac preparations (C01EB)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other cardiac preparations (C01E)	0				1458	C08DA	C08D	C01EB	C01E
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			206	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			309	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			568	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			654	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			868	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1021	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2258	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2338	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3062	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3333	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4071	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4297	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4769	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5118	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5983	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6071	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7119	C08DA	C08D	A02BC	A02B
15857	verapamil	enhances	3A457	lansoprazole		C08DA01	A02BC03	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7470	C08DA	C08D	A02BC	A02B
15859	verapamil	enhances	3A457	lercanidipine		C08DA01	C08CA13	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					C08DA	C08D	C08CA	C08C
15863	verapamil	enhances	3A457	lovastatin	C	C08DA01	C10AA02	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			C08DA	C08D	C10AA	C10A
15865	verapamil	enhances	3A457	methadone	B	C08DA01	N07BC02	Phenylalkylamine derivatives (C08DA)	Drugs used in opioid dependence (N07BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs used in addictive disorders (N07B)	0	0				C08DA	C08D	N07BC	N07B
15866	verapamil	enhances	3A457	midazolam	C	C08DA01	N05CD08	Phenylalkylamine derivatives (C08DA)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		C08DA	C08D	N05CD	N05C
15872	verapamil	enhances	3A457	nifedipine		C08DA01	C08CA05	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DA	C08D	C08CA	C08C
15873	verapamil	enhances	3A457	nisoldipine		C08DA01	C08CA07	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DA	C08D	C08CA	C08C
15874	verapamil	enhances	3A457	nitrendipine		C08DA01	C08CA08	Phenylalkylamine derivatives (C08DA)	Dihydropyridine derivatives (C08CA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		C08DA	C08D	C08CA	C08C
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			131	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			560	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			654	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			802	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1016	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1204	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1356	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2199	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2236	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2257	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2258	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3058	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3405	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3591	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3854	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4626	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			5601	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			6095	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7056	C08DA	C08D	A02BC	A02B
15876	verapamil	enhances	3A457	omeprazole		C08DA01	A02BC01	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7690	C08DA	C08D	A02BC	A02B
15877	verapamil	enhances	3A457	ondansetron		C08DA01	A04AA01	Phenylalkylamine derivatives (C08DA)	Serotonin (5HT3) antagonists (A04AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antiemetics and antinauseants (A04A)	0	0				C08DA	C08D	A04AA	A04A
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			28	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			123	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			1391	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2692	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			2985	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			3568	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4603	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4620	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			4723	C08DA	C08D	A02BC	A02B
15884	verapamil	enhances	3A457	pantoprazole		C08DA01	A02BC02	Phenylalkylamine derivatives (C08DA)	Proton pump inhibitors (A02BC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0			7093	C08DA	C08D	A02BC	A02B
15891	verapamil	enhances	3A457	propranolol	D	C08DA01	C07AA05	Phenylalkylamine derivatives (C08DA)	Beta blocking agents, non-selective (C07AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Beta blocking agents (C07A)	0					C08DA	C08D	C07AA	C07A
15892	verapamil	enhances	3A457	quetiapine		C08DA01	N05AH04	Phenylalkylamine derivatives (C08DA)	Diazepines, oxazepines and thiazepines (N05AH)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0				6227	C08DA	C08D	N05AH	N05A
15892	verapamil	enhances	3A457	quetiapine		C08DA01	N05AH04	Phenylalkylamine derivatives (C08DA)	Diazepines, oxazepines and thiazepines (N05AH)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0				7470	C08DA	C08D	N05AH	N05A
15898	verapamil	enhances	3A457	risperidone		C08DA01	N05AX08	Phenylalkylamine derivatives (C08DA)	Other antipsychotics (N05AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		C08DA	C08D	N05AX	N05A
15899	verapamil	enhances	3A457	ritonavir	B	C08DA01	J05AE03	Phenylalkylamine derivatives (C08DA)	Protease inhibitors (J05AE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Direct acting antivirals (J05A)	0	0				C08DA	C08D	J05AE	J05A
15900	verapamil	enhances	3A457	rivaroxaban		C08DA01	B01AF01	Phenylalkylamine derivatives (C08DA)	Direct factor Xa inhibitors (B01AF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0					C08DA	C08D	B01AF	B01A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				28	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				255	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				1177	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				2199	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				2997	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3481	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3809	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				3925	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				4243	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				4603	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				4746	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				4748	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5370	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				5491	C08DA	C08D	R03AC	R03A
15906	verapamil	enhances	3A457	salmeterol		C08DA01	R03AC12	Phenylalkylamine derivatives (C08DA)	Selective beta-2-adrenoreceptor agonists (R03AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Adrenergics, inhalants (R03A)	0				7038	C08DA	C08D	R03AC	R03A
15907	verapamil	enhances	3A457	saquinavir	B	C08DA01	J05AE01	Phenylalkylamine derivatives (C08DA)	Protease inhibitors (J05AE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Direct acting antivirals (J05A)	0	0				C08DA	C08D	J05AE	J05A
15909	verapamil	enhances	3A457	sildenafil		C08DA01	G04BE03	Phenylalkylamine derivatives (C08DA)	Drugs used in erectile dysfunction (G04BE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Urologicals (G04B)	0	0				C08DA	C08D	G04BE	G04B
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		206	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		255	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		579	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		3568	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4128	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4748	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		4757	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5370	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		5983	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7119	C08DA	C08D	C10AA	C10A
15911	verapamil	enhances	3A457	simvastatin	C	C08DA01	C10AA01	Phenylalkylamine derivatives (C08DA)	HMG CoA reductase inhibitors (C10AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Lipid modifying agents, plain (C10A)	0	1	Myopathy		7609	C08DA	C08D	C10AA	C10A
15912	verapamil	enhances	3A457	sirolimus	C	C08DA01	L04AA10	Phenylalkylamine derivatives (C08DA)	Selective immunosuppressants (L04AA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C08DA	C08D	L04AA	L04A
15914	verapamil	enhances	3A457	sorafenib		C08DA01	L01XE05	Phenylalkylamine derivatives (C08DA)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	1					C08DA	C08D	L01XE	L01X
15915	verapamil	enhances	3A457	sunitinib		C08DA01	L01XE04	Phenylalkylamine derivatives (C08DA)	 (L01XE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Other antineoplastic agents (L01X)	1					C08DA	C08D	L01XE	L01X
15917	verapamil	enhances	3A457	tacrolimus	B	C08DA01	L04AD02	Phenylalkylamine derivatives (C08DA)	Calcineurin inhibitors (L04AD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			C08DA	C08D	L04AD	L04A
15918	verapamil	enhances	3A457	tadalafil		C08DA01	G04BE08	Phenylalkylamine derivatives (C08DA)	Drugs used in erectile dysfunction (G04BE)	Selective calcium channel blockers with direct cardiac effects (C08D)	Urologicals (G04B)	0	0				C08DA	C08D	G04BE	G04B
15919	verapamil	enhances	3A457	tamoxifen		C08DA01	L02BA01	Phenylalkylamine derivatives (C08DA)	Anti-estrogens (L02BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hormone antagonists and related agents (L02B)	1	1			4071	C08DA	C08D	L02BA	L02B
15919	verapamil	enhances	3A457	tamoxifen		C08DA01	L02BA01	Phenylalkylamine derivatives (C08DA)	Anti-estrogens (L02BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hormone antagonists and related agents (L02B)	1	1			4873	C08DA	C08D	L02BA	L02B
15925	verapamil	enhances	3A457	testosterone		C08DA01	G03BA03	Phenylalkylamine derivatives (C08DA)	3-oxoandrosten (4) derivatives (G03BA)	Selective calcium channel blockers with direct cardiac effects (C08D)	Androgens (G03B)	0					C08DA	C08D	G03BA	G03B
15926	verapamil	enhances	3A457	ticagrelor		C08DA01	B01AC24	Phenylalkylamine derivatives (C08DA)	Platelet aggregation inhibitors excl. heparin (B01AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antithrombotic agents (B01A)	0					C08DA	C08D	B01AC	B01A
15929	verapamil	enhances	3A457	tramadol		C08DA01	N02AX02	Phenylalkylamine derivatives (C08DA)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	255	C08DA	C08D	N02AX	N02A
15929	verapamil	enhances	3A457	tramadol		C08DA01	N02AX02	Phenylalkylamine derivatives (C08DA)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	1458	C08DA	C08D	N02AX	N02A
15929	verapamil	enhances	3A457	tramadol		C08DA01	N02AX02	Phenylalkylamine derivatives (C08DA)	Other opioids (N02AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Opioids (N02A)	0	1		Reduced analgesic effect	6071	C08DA	C08D	N02AX	N02A
15930	verapamil	enhances	3A457	trazodone		C08DA01	N06AX05	Phenylalkylamine derivatives (C08DA)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		3520	C08DA	C08D	N06AX	N06A
15930	verapamil	enhances	3A457	trazodone		C08DA01	N06AX05	Phenylalkylamine derivatives (C08DA)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		5867	C08DA	C08D	N06AX	N06A
15930	verapamil	enhances	3A457	trazodone		C08DA01	N06AX05	Phenylalkylamine derivatives (C08DA)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		7038	C08DA	C08D	N06AX	N06A
15931	verapamil	enhances	3A457	triazolam	C	C08DA01	N05CD05	Phenylalkylamine derivatives (C08DA)	Benzodiazepine derivatives (N05CD)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect	1275	C08DA	C08D	N05CD	N05C
15938	verapamil	enhances	3A457	venlafaxine		C08DA01	N06AX16	Phenylalkylamine derivatives (C08DA)	Other antidepressants (N06AX)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antidepressants (N06A)	0	0	Serotonin toxicity		5867	C08DA	C08D	N06AX	N06A
15942	verapamil	enhances	3A457	voriconazole	B	C08DA01	J02AC03	Phenylalkylamine derivatives (C08DA)	Triazole derivatives (J02AC)	Selective calcium channel blockers with direct cardiac effects (C08D)	Antimycotics for systemic use (J02A)	0	0				C08DA	C08D	J02AC	J02A
15943	verapamil	enhances	3A457	zaleplon		C08DA01	N05CF03	Phenylalkylamine derivatives (C08DA)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0					C08DA	C08D	N05CF	N05C
15945	verapamil	enhances	3A457	zolpidem		C08DA01	N05CF02	Phenylalkylamine derivatives (C08DA)	Benzodiazepine related drugs (N05CF)	Selective calcium channel blockers with direct cardiac effects (C08D)	Hypnotics and sedatives (N05C)	0				3058	C08DA	C08D	N05CF	N05C
15951	voriconazole	enhances	3A457	alprazolam	D	J02AC03	N05BA12	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05BA	N05B
15952	voriconazole	enhances	2C19,2C9,3A457	amitriptyline	D	J02AC03	N06AA09	Triazole derivatives (J02AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J02AC	J02A	N06AA	N06A
15953	voriconazole	enhances	3A457	amlodipine	C	J02AC03	C08CA01	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
15954	voriconazole	enhances	3A457	apixaban	D	J02AC03	B01AF02	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
15960	voriconazole	enhances	3A457	atorvastatin	D	J02AC03	C10AA05	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J02AC	J02A	C10AA	C10A
15968	voriconazole	enhances	2B6	bupropion		J02AC03	N06AX12	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AX	N06A
15971	voriconazole	enhances	2C9	capecitabine		J02AC03	L01BC06	Triazole derivatives (J02AC)	Pyrimidine analogues (L01BC)	Antimycotics for systemic use (J02A)	Antimetabolites (L01B)	1					J02AC	J02A	L01BC	L01B
15974	voriconazole	enhances	2C9	celecoxib		J02AC03	M01AH01	Triazole derivatives (J02AC)	Coxibs (M01AH)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AH	M01A
15978	voriconazole	enhances	3A457	chlorpheniramine		J02AC03	R06AB04	Triazole derivatives (J02AC)	Substituted alkylamines (R06AB)	Antimycotics for systemic use (J02A)	Antihistamines for systemic use (R06A)	0	0				J02AC	J02A	R06AB	R06A
15979	voriconazole	enhances	3A457	cilostazol	D	J02AC03	B01AC23	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
15981	voriconazole	enhances	2C19,3A457	citalopram	D	J02AC03	N06AB04	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0				J02AC	J02A	N06AB	N06A
15982	voriconazole	enhances	3A457	clarithromycin	D	J02AC03	J01FA09	Triazole derivatives (J02AC)	Macrolides (J01FA)	Antimycotics for systemic use (J02A)	Macrolides, lincosamides and streptogramins (J01F)	0	0				J02AC	J02A	J01FA	J01F
15983	voriconazole	enhances	2B6,2C19	clobazam	D	J02AC03	N05BA09	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0					J02AC	J02A	N05BA	N05B
15984	voriconazole	enhances	2C19	clomipramine	D	J02AC03	N06AA04	Triazole derivatives (J02AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J02AC	J02A	N06AA	N06A
15985	voriconazole	enhances	2C19,2C9,3A457	clopidogrel		J02AC03	B01AC04	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0	1		Reduced anticoagulant effect		J02AC	J02A	B01AC	B01A
15989	voriconazole	enhances	3A457	colchicine		J02AC03	M04AC01	Triazole derivatives (J02AC)	Preparations with no effect on uric acid metabolism (M04AC)	Antimycotics for systemic use (J02A)	Antigout preparations (M04A)	0					J02AC	J02A	M04AC	M04A
15992	voriconazole	enhances	2B6,2C19	cyclophosphamide		J02AC03	L01AA01	Triazole derivatives (J02AC)	Nitrogen mustard analogues (L01AA)	Antimycotics for systemic use (J02A)	Alkylating agents (L01A)	1	1				J02AC	J02A	L01AA	L01A
15993	voriconazole	enhances	3A457	cyclosporine	D	J02AC03	L04AD01	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
15996	voriconazole	enhances	3A457	deflazacort		J02AC03	H02AB13	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
15997	voriconazole	enhances	3A457	dexamethasone		J02AC03	H02AB02	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
15998	voriconazole	enhances	3A457	dextromethorphan		J02AC03	R05DA09	Triazole derivatives (J02AC)	Opium alkaloids and derivatives (R05DA)	Antimycotics for systemic use (J02A)	Cough suppressants, excl. combinations with expectorants (R05D)	0	1				J02AC	J02A	R05DA	R05D
15999	voriconazole	enhances	2C19,3A457	diazepam	D	J02AC03	N05BA01	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05BA)	Antimycotics for systemic use (J02A)	Anxiolytics (N05B)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05BA	N05B
16000	voriconazole	enhances	2C9	diclofenac		J02AC03	M01AB05	Triazole derivatives (J02AC)	Acetic acid derivatives and related substances (M01AB)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AB	M01A
16001	voriconazole	enhances	3A457	diltiazem	B	J02AC03	C08DB01	Triazole derivatives (J02AC)	Benzothiazepine derivatives (C08DB)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J02AC	J02A	C08DB	C08D
16004	voriconazole	enhances	3A457	domperidone	D	J02AC03	A03FA03	Triazole derivatives (J02AC)	Propulsives (A03FA)	Antimycotics for systemic use (J02A)	Propulsives (A03F)	0					J02AC	J02A	A03FA	A03F
16006	voriconazole	enhances	2B6	efavirenz	B	J02AC03	J05AG03	Triazole derivatives (J02AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AG	J05A
16009	voriconazole	enhances	3A457	eplerenone	D	J02AC03	C03DA04	Triazole derivatives (J02AC)	Aldosterone antagonists (C03DA)	Antimycotics for systemic use (J02A)	Potassium-sparing agents (C03D)	0					J02AC	J02A	C03DA	C03D
16012	voriconazole	enhances	2C19,3A457	escitalopram	D	J02AC03	N06AB10	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0					J02AC	J02A	N06AB	N06A
16013	voriconazole	enhances	2C19,3A457	esomeprazole	B	J02AC03	A02BC05	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0					J02AC	J02A	A02BC	A02B
16015	voriconazole	enhances	3A457	felodipine	B	J02AC03	C08CA02	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
16019	voriconazole	enhances	2C9	fluoxetine	D	J02AC03	N06AB03	Triazole derivatives (J02AC)	Selective serotonin reuptake inhibitors (N06AB)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AB	N06A
16020	voriconazole	enhances	2C9	fluvastatin		J02AC03	C10AA04	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	0	Myopathy			J02AC	J02A	C10AA	C10A
16021	voriconazole	enhances	2C9	glimepiride	B	J02AC03	A10BB12	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0					J02AC	J02A	A10BB	A10B
16022	voriconazole	enhances	2C9	glipizide	B	J02AC03	A10BB07	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J02AC	J02A	A10BB	A10B
16023	voriconazole	enhances	2C9	glyburide	B	J02AC03	A10BB01	Triazole derivatives (J02AC)	Sulfonylureas (A10BB)	Antimycotics for systemic use (J02A)	Blood glucose lowering drugs, excl. insulins (A10B)	0	0	Hypoglycemia			J02AC	J02A	A10BB	A10B
16024	voriconazole	enhances	3A457	haloperidol	D	J02AC03	N05AD01	Triazole derivatives (J02AC)	Butyrophenone derivatives (N05AD)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J02AC	J02A	N05AD	N05A
16026	voriconazole	enhances	3A457	hydrocortisone		J02AC03	H02AB09	Triazole derivatives (J02AC)	Glucocorticoids (H02AB)	Antimycotics for systemic use (J02A)	Corticosteroids for systemic use, plain (H02A)	0					J02AC	J02A	H02AB	H02A
16028	voriconazole	enhances	2C9	ibuprofen		J02AC03	M01AE01	Triazole derivatives (J02AC)	Propionic acid derivatives (M01AE)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AE	M01A
16031	voriconazole	enhances	3A457	imatinib	D	J02AC03	L01XE01	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	0	0				J02AC	J02A	L01XE	L01X
16032	voriconazole	enhances	2C19	imipramine	D	J02AC03	N06AA02	Triazole derivatives (J02AC)	Non-selective monoamine reuptake inhibitors (N06AA)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	1	0	Serotonin toxicity			J02AC	J02A	N06AA	N06A
16033	voriconazole	enhances	3A457	indacaterol		J02AC03	R03AC18	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0					J02AC	J02A	R03AC	R03A
16035	voriconazole	enhances	2C19	indometacin		J02AC03	M01AB01	Triazole derivatives (J02AC)	Acetic acid derivatives and related substances (M01AB)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J02AC	J02A	M01AB	M01A
16036	voriconazole	enhances	2C9	irbesartan		J02AC03	C09CA04	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	0		Reduced antihypertensive effect		J02AC	J02A	C09CA	C09C
16039	voriconazole	enhances	3A457	ivabradine		J02AC03	C01EB17	Triazole derivatives (J02AC)	Other cardiac preparations (C01EB)	Antimycotics for systemic use (J02A)	Other cardiac preparations (C01E)	0					J02AC	J02A	C01EB	C01E
16043	voriconazole	enhances	2C19,3A457	lansoprazole	B	J02AC03	A02BC03	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J02AC	J02A	A02BC	A02B
16045	voriconazole	enhances	3A457	lercanidipine	B	J02AC03	C08CA13	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0					J02AC	J02A	C08CA	C08C
16051	voriconazole	enhances	2C9	losartan		J02AC03	C09CA01	Triazole derivatives (J02AC)	Angiotensin II receptor blockers, plain (C09CA)	Antimycotics for systemic use (J02A)	Angiotensin ii receptor blockers (arbs), plain (C09C)	0	1		Reduced antihypertensive effect		J02AC	J02A	C09CA	C09C
16052	voriconazole	enhances	3A457	lovastatin	D	J02AC03	C10AA02	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J02AC	J02A	C10AA	C10A
16054	voriconazole	enhances	2C9	meloxicam	B	J02AC03	M01AC06	Triazole derivatives (J02AC)	Oxicams (M01AC)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0					J02AC	J02A	M01AC	M01A
16057	voriconazole	enhances	2B6,3A457	methadone	D	J02AC03	N07BC02	Triazole derivatives (J02AC)	Drugs used in opioid dependence (N07BC)	Antimycotics for systemic use (J02A)	Drugs used in addictive disorders (N07B)	0	0				J02AC	J02A	N07BC	N07B
16059	voriconazole	enhances	3A457	midazolam	D	J02AC03	N05CD08	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05CD	N05C
16063	voriconazole	enhances	2C9	naproxen	B	J02AC03	M01AE02	Triazole derivatives (J02AC)	Propionic acid derivatives (M01AE)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AE	M01A
16067	voriconazole	enhances	2B6	nevirapine		J02AC03	J05AG01	Triazole derivatives (J02AC)	Non-nucleoside reverse transcriptase inhibitors (J05AG)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AG	J05A
16068	voriconazole	enhances	3A457	nifedipine	B	J02AC03	C08CA05	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
16070	voriconazole	enhances	3A457	nisoldipine	B	J02AC03	C08CA07	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
16071	voriconazole	enhances	3A457	nitrendipine	B	J02AC03	C08CA08	Triazole derivatives (J02AC)	Dihydropyridine derivatives (C08CA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with mainly vascular effects (C08C)	0	0	Hypotension	Reduced antihypertensive effect		J02AC	J02A	C08CA	C08C
16074	voriconazole	enhances	2C19,3A457	omeprazole	B	J02AC03	A02BC01	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J02AC	J02A	A02BC	A02B
16075	voriconazole	enhances	3A457	ondansetron	D	J02AC03	A04AA01	Triazole derivatives (J02AC)	Serotonin (5HT3) antagonists (A04AA)	Antimycotics for systemic use (J02A)	Antiemetics and antinauseants (A04A)	0	0				J02AC	J02A	A04AA	A04A
16082	voriconazole	enhances	2C19,3A457	pantoprazole	B	J02AC03	A02BC02	Triazole derivatives (J02AC)	Proton pump inhibitors (A02BC)	Antimycotics for systemic use (J02A)	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	0	0				J02AC	J02A	A02BC	A02B
16084	voriconazole	enhances	2C19	phenobarbital	D	J02AC03	N03AA02	Triazole derivatives (J02AC)	Barbiturates and derivatives (N03AA)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J02AC	J02A	N03AA	N03A
16085	voriconazole	enhances	2C19,2C9	phenytoin	D	J02AC03	N03AB02	Triazole derivatives (J02AC)	Hydantoin derivatives (N03AB)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	1	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J02AC	J02A	N03AB	N03A
16088	voriconazole	enhances	2C9	piroxicam		J02AC03	M01AC01	Triazole derivatives (J02AC)	Oxicams (M01AC)	Antimycotics for systemic use (J02A)	Antiinflammatory and antirheumatic products, non-steroids (M01A)	0	0				J02AC	J02A	M01AC	M01A
16091	voriconazole	enhances	2C19	primidone		J02AC03	N03AA03	Triazole derivatives (J02AC)	Barbiturates and derivatives (N03AA)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	0					J02AC	J02A	N03AA	N03A
16095	voriconazole	enhances	2C19,3A457	propranolol		J02AC03	C07AA05	Triazole derivatives (J02AC)	Beta blocking agents, non-selective (C07AA)	Antimycotics for systemic use (J02A)	Beta blocking agents (C07A)	0					J02AC	J02A	C07AA	C07A
16096	voriconazole	enhances	3A457	quetiapine	D	J02AC03	N05AH04	Triazole derivatives (J02AC)	Diazepines, oxazepines and thiazepines (N05AH)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0					J02AC	J02A	N05AH	N05A
16102	voriconazole	enhances	3A457	risperidone	D	J02AC03	N05AX08	Triazole derivatives (J02AC)	Other antipsychotics (N05AX)	Antimycotics for systemic use (J02A)	Antipsychotics (N05A)	0	0		Reduced antipsychotic effect		J02AC	J02A	N05AX	N05A
16103	voriconazole	enhances	3A457	ritonavir	D	J02AC03	J05AE03	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
16104	voriconazole	enhances	3A457	rivaroxaban	B	J02AC03	B01AF01	Triazole derivatives (J02AC)	Direct factor Xa inhibitors (B01AF)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AF	B01A
16111	voriconazole	enhances	3A457	salmeterol	D	J02AC03	R03AC12	Triazole derivatives (J02AC)	Selective beta-2-adrenoreceptor agonists (R03AC)	Antimycotics for systemic use (J02A)	Adrenergics, inhalants (R03A)	0					J02AC	J02A	R03AC	R03A
16112	voriconazole	enhances	3A457	saquinavir	D	J02AC03	J05AE01	Triazole derivatives (J02AC)	Protease inhibitors (J05AE)	Antimycotics for systemic use (J02A)	Direct acting antivirals (J05A)	0	0				J02AC	J02A	J05AE	J05A
16113	voriconazole	enhances	2B6	selegiline		J02AC03	N04BD01	Triazole derivatives (J02AC)	Monoamine oxidase B inhibitors (N04BD)	Antimycotics for systemic use (J02A)	Dopaminergic agents (N04B)	0	0				J02AC	J02A	N04BD	N04B
16115	voriconazole	enhances	3A457	sildenafil		J02AC03	G04BE03	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
16117	voriconazole	enhances	3A457	simvastatin	D	J02AC03	C10AA01	Triazole derivatives (J02AC)	HMG CoA reductase inhibitors (C10AA)	Antimycotics for systemic use (J02A)	Lipid modifying agents, plain (C10A)	0	1	Myopathy			J02AC	J02A	C10AA	C10A
16118	voriconazole	enhances	3A457	sirolimus	D	J02AC03	L04AA10	Triazole derivatives (J02AC)	Selective immunosuppressants (L04AA)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AA	L04A
16120	voriconazole	enhances	2B6,3A457	sorafenib	D	J02AC03	L01XE05	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
16121	voriconazole	enhances	3A457	sunitinib	D	J02AC03	L01XE04	Triazole derivatives (J02AC)	 (L01XE)	Antimycotics for systemic use (J02A)	Other antineoplastic agents (L01X)	1					J02AC	J02A	L01XE	L01X
16124	voriconazole	enhances	3A457	tacrolimus	D	J02AC03	L04AD02	Triazole derivatives (J02AC)	Calcineurin inhibitors (L04AD)	Antimycotics for systemic use (J02A)	Immunosuppressants (L04A)	1	0	Immunosuppressant toxicity			J02AC	J02A	L04AD	L04A
16125	voriconazole	enhances	3A457	tadalafil		J02AC03	G04BE08	Triazole derivatives (J02AC)	Drugs used in erectile dysfunction (G04BE)	Antimycotics for systemic use (J02A)	Urologicals (G04B)	0	0				J02AC	J02A	G04BE	G04B
16126	voriconazole	enhances	2C9,3A457	tamoxifen	D	J02AC03	L02BA01	Triazole derivatives (J02AC)	Anti-estrogens (L02BA)	Antimycotics for systemic use (J02A)	Hormone antagonists and related agents (L02B)	1	1				J02AC	J02A	L02BA	L02B
16133	voriconazole	enhances	3A457	testosterone		J02AC03	G03BA03	Triazole derivatives (J02AC)	3-oxoandrosten (4) derivatives (G03BA)	Antimycotics for systemic use (J02A)	Androgens (G03B)	0					J02AC	J02A	G03BA	G03B
16134	voriconazole	enhances	3A457	ticagrelor		J02AC03	B01AC24	Triazole derivatives (J02AC)	Platelet aggregation inhibitors excl. heparin (B01AC)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	0					J02AC	J02A	B01AC	B01A
16138	voriconazole	enhances	2C9	torasemide	D	J02AC03	C03CA04	Triazole derivatives (J02AC)	Sulfonamides, plain (C03CA)	Antimycotics for systemic use (J02A)	High-ceiling diuretics (C03C)	0	0				J02AC	J02A	C03CA	C03C
16139	voriconazole	enhances	2B6,3A457	tramadol		J02AC03	N02AX02	Triazole derivatives (J02AC)	Other opioids (N02AX)	Antimycotics for systemic use (J02A)	Opioids (N02A)	0	1		Reduced analgesic effect		J02AC	J02A	N02AX	N02A
16140	voriconazole	enhances	3A457	trazodone	D	J02AC03	N06AX05	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AX	N06A
16141	voriconazole	enhances	3A457	triazolam	D	J02AC03	N05CD05	Triazole derivatives (J02AC)	Benzodiazepine derivatives (N05CD)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0	0	Benzodiazepine toxicity	Reduced benzodiazepine effect		J02AC	J02A	N05CD	N05C
16143	voriconazole	enhances	2C9	valproate		J02AC03	N03AG01	Triazole derivatives (J02AC)	Fatty acid derivatives (N03AG)	Antimycotics for systemic use (J02A)	Antiepileptics (N03A)	0	0	Antiepileptic toxicity	Reduced anti-epileptic effect		J02AC	J02A	N03AG	N03A
16149	voriconazole	enhances	2C19,2C9,3A457	venlafaxine	D	J02AC03	N06AX16	Triazole derivatives (J02AC)	Other antidepressants (N06AX)	Antimycotics for systemic use (J02A)	Antidepressants (N06A)	0	0	Serotonin toxicity			J02AC	J02A	N06AX	N06A
16150	voriconazole	enhances	3A457	verapamil	B	J02AC03	C08DA01	Triazole derivatives (J02AC)	Phenylalkylamine derivatives (C08DA)	Antimycotics for systemic use (J02A)	Selective calcium channel blockers with direct cardiac effects (C08D)	0	0	AV block, bradycardia, hypotension			J02AC	J02A	C08DA	C08D
16154	voriconazole	enhances	2C19,2C9	warfarin	C	J02AC03	B01AA03	Triazole derivatives (J02AC)	Vitamin K antagonists (B01AA)	Antimycotics for systemic use (J02A)	Antithrombotic agents (B01A)	1	0	Bleeding			J02AC	J02A	B01AA	B01A
16156	voriconazole	enhances	3A457	zaleplon		J02AC03	N05CF03	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0					J02AC	J02A	N05CF	N05C
16158	voriconazole	enhances	3A457	zolpidem		J02AC03	N05CF02	Triazole derivatives (J02AC)	Benzodiazepine related drugs (N05CF)	Antimycotics for systemic use (J02A)	Hypnotics and sedatives (N05C)	0					J02AC	J02A	N05CF	N05C
